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Background: Loss of arm function is common after stroke. Robot-assisted training may improve
arm outcomes.
Objective: The objectives were to determine the clinical effectiveness and cost-effectiveness of
robot-assisted training, compared with an enhanced upper limb therapy programme and with usual care.
Design: This was a pragmatic, observer-blind, multicentre randomised controlled trial with embedded
health economic and process evaluations.
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Setting: The trial was set in four NHS trial centres.
Participants: Patients with moderate or severe upper limb functional limitation, between 1 week
and 5 years following first stroke, were recruited.
Interventions: Robot-assisted training using the Massachusetts Institute of Technology-Manus robotic
gym system (InMotion commercial version, Interactive Motion Technologies, Inc., Watertown, MA, USA),
an enhanced upper limb therapy programme comprising repetitive functional task practice, and usual care.
Main outcome measures: The primary outcome was upper limb functional recovery ‘success’ (assessed
using the Action Research Arm Test) at 3 months. Secondary outcomes at 3 and 6 months were the
Action Research Arm Test results, upper limb impairment (measured using the Fugl-Meyer Assessment),
activities of daily living (measured using the Barthel Activities of Daily Living Index), quality of life
(measured using the Stroke Impact Scale), resource use costs and quality-adjusted life-years.
Results: A total of 770 participants were randomised (robot-assisted training, n = 257; enhanced upper
limb therapy, n = 259; usual care, n = 254). Upper limb functional recovery ‘success’ was achieved in
the robot-assisted training [103/232 (44%)], enhanced upper limb therapy [118/234 (50%)] and usual
care groups [85/203 (42%)]. These differences were not statistically significant; the adjusted odds
ratios were as follows: robot-assisted training versus usual care, 1.2 (98.33% confidence interval
0.7 to 2.0); enhanced upper limb therapy versus usual care, 1.5 (98.33% confidence interval 0.9 to 2.5);
and robot-assisted training versus enhanced upper limb therapy, 0.8 (98.33% confidence interval
0.5 to 1.3). The robot-assisted training group had less upper limb impairment (as measured by the
Fugl-Meyer Assessment motor subscale) than the usual care group at 3 and 6 months. The enhanced
upper limb therapy group had less upper limb impairment (as measured by the Fugl-Meyer Assessment
motor subscale), better mobility (as measured by the Stroke Impact Scale mobility domain) and better
performance in activities of daily living (as measured by the Stroke Impact Scale activities of daily living
domain) than the usual care group, at 3 months. The robot-assisted training group performed less well
in activities of daily living (as measured by the Stroke Impact Scale activities of daily living domain) than
the enhanced upper limb therapy group at 3 months. No other differences were clinically important and
statistically significant. Participants found the robot-assisted training and the enhanced upper limb
therapy group programmes acceptable. Neither intervention, as provided in this trial, was cost-effective
at current National Institute for Health and Care Excellence willingness-to-pay thresholds for a quality-
adjusted life-year.
Conclusions: Robot-assisted training did not improve upper limb function compared with usual care.
Although robot-assisted training improved upper limb impairment, this did not translate into
improvements in other outcomes. Enhanced upper limb therapy resulted in potentially important
improvements on upper limb impairment, in performance of activities of daily living, and in mobility.
Neither intervention was cost-effective.
Future work: Further research is needed to find ways to translate the improvements in upper limb
impairment seen with robot-assisted training into improvements in upper limb function and activities
of daily living. Innovations to make rehabilitation programmes more cost-effective are required.
Limitations: Pragmatic inclusion criteria led to the recruitment of some participants with little prospect
of recovery. The attrition rate was higher in the usual care group than in the robot-assisted training or
enhanced upper limb therapy groups, and differential attrition is a potential source of bias. Obtaining
accurate information about the usual care that participants were receiving was a challenge.
Trial registration: Current Controlled Trials ISRCTN69371850.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 54. See the NIHR Journals Library website for further project information.
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Plain English summary
Many people who have arm weakness following a stroke feel that insufficient attention is paid byrehabilitation services to recovery of their arm. Unfortunately, it is currently unclear how best
to provide rehabilitation to optimise recovery, but robot-assisted training and therapy programmes that
focus on practising functional tasks are promising and require further evaluation.
The Robot-Assisted Training for the Upper Limb after Stroke (RATULS) trial evaluated three approaches
to rehabilitation for people with moderate or severe difficulty using their arm. These approaches were
robot-assisted training using the Massachusetts Institute of Technology-Manus robotic gym system
(InMotion commercial version, Interactive Motion Technologies, Inc., Watertown, MA, USA), an enhanced
upper limb therapy programme based on repetitive practice of functional tasks and usual care. Robot-
assisted training and the enhanced upper limb therapy programme were provided in an outpatient setting
for 45 minutes per session, three times per week, for 12 weeks, in addition to usual care.
The Massachusetts Institute of Technology-Manus robotic gym system was selected as it was felt
to be the best available technology. The participant sits at a table, places their affected arm onto the
Massachusetts Institute of Technology-Manus arm support and attempts to move their arm to play a
game on the computer screen. Movements are assisted by the Massachusetts Institute of Technology-
Manus if the patient cannot perform the movements themselves.
The results of the RATULS trial show that robot-assisted training did not result in additional improvement
in stroke survivors’ arm use when compared with the enhanced upper limb therapy programme or usual
care. Stroke survivors who received enhanced upper limb therapy experienced meaningful improvements
in undertaking activities of daily living, when compared with those participants who received either robot-
assisted training or usual care. Participants who received enhanced upper limb therapy also experienced
benefits in their mobility, compared with usual care participants.
Participants and therapists found both therapies acceptable, and described various benefits. A health
economic analysis found that neither robot-assisted training nor the enhanced upper limb therapy
programme was a cost-effective treatment for the NHS.
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Scientific summary
Parts of this scientific summary have been reproduced from Rodgers H, Bosomworth H, Krebs HI,Van Wijck F, Howel D, Wilson N, et al. Robot Assisted Training for the Upper Limb after Stroke
(RATULS): a multicentre randomised controlled trial. Lancet 2019;394:51–62. This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The text below includes minor additions and formatting changes to the original text.
Parts of this scientific summary have also been reproduced from Rodgers H, Shaw L, Bosomworth H,
Aird L, Alvarado N, Andole S, et al. Robot Assisted Training for the Upper Limb after Stroke (RATULS):
study protocol for a randomised controlled trial. Trials 2017;18:340. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Background
Upper limb problems occur in approximately 80% of people who have experienced an acute stroke, and
50% of stroke survivors continue to have upper limb motor impairment 4 years post stroke. This can
cause difficulties with activities of daily living, such as washing and dressing, and lowers quality of life.
Improving upper limb function post stroke is a top 10 research priority for stroke survivors, carers
and clinicians.
It is unclear how to optimise stroke patients’ upper limb recovery. Systematic reviews suggest that
patients benefit from therapy programmes in which they repeatedly practise functional tasks.
A Cochrane overview of systematic reviews (Pollock A, Farmer SE, Brady MC, Langhorne P, Mead GE,
Mehrholz J, Van Wijck F. Interventions for improving upper limb function after stroke. Cochrane
Database Syst Rev 2014;11:CD010820) found moderate-quality evidence that arm function after a
stroke can be improved by the provision of at least 20 hours of additional repetitive task training.
Robot-assisted training enables patients to perform repetitive task training and is a promising treatment
for improving arm function after stroke. However, to date, studies vary in patient characteristics, devices
used, duration and amount of training, control group and outcome measures used. Currently, there is
no clear evidence for the benefit of robot-assisted arm training over conventional therapy when delivered
at the same frequency and duration.
The Robot-Assisted Training for the Upper Limb after Stroke (RATULS) randomised controlled trial
evaluated robot-assisted training, compared with an enhanced upper limb therapy programme of the
same frequency and duration, and with usual post stroke care.
Aim and objectives
The aim of the RATULS trial was to determine whether or not robot-assisted training with the
Massachusetts Institute of Technology-Manus robotic gym system (InMotion commercial version,
Interactive Motion Technologies, Inc., Watertown, MA, USA) improved upper limb function post stroke.
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The objectives were to:
l determine whether or not robot-assisted training improved upper limb function post stroke,
compared with an enhanced upper limb therapy programme or usual care
l determine whether or not robot-assisted training improved upper limb impairment, activities of daily
living and quality of life, compared with an enhanced upper limb therapy programme or usual care
l model costs of robot-assisted training, compared with an enhanced upper limb therapy programme
or usual care
l seek the views and experiences of patients and health service professionals about the upper limb
rehabilitation that they received or provided, and about factors affecting the implementation of
the trial
l explore the time pattern of upper limb recovery of participants in each treatment group, and the
impact of the severity of baseline upper limb function and time since stroke on the effectiveness of
the interventions.
Methods
This was a three-group, pragmatic, observer-blind, multicentre randomised controlled trial with an
embedded economic analysis and process evaluation.
Setting
The trial was conducted in four NHS centres in the UK. Each centre comprised a hub site, which was a
stroke service in an NHS hospital with a Massachusetts Institute of Technology-Manus robotic gym
system, plus several participant identification spoke sites, which were stroke services in adjacent NHS
trusts and community services.
Participants
Adults with a first-ever stroke were eligible to take part if they were between 1 week and 5 years post
stroke and had moderate or severe upper limb functional limitation (Action Research Arm Test score
of 0–39) due to their stroke.
Randomisation
A central independent web-based service hosted by Newcastle University Clinical Trials Unit was used.
Participants were stratified according to trial centre, time since stroke (< 3 months, 3–12 months
or > 12 months) and severity of upper limb functional limitation (Action Research Arm Test score:
0–7, 8–13, 14–19 and 20–39), and randomised, using permuted block sequences, 1 : 1 : 1 to receive
robot-assisted training, the enhanced upper limb therapy programme or usual care.
Trial intervention treatments
Robot-assisted training
This was delivered using the Massachusetts Institute of Technology-Manus robotic gym. Robot-assisted
training involved 45 minutes of face-to-face therapy per day, within a 1-hour session, 3 days per week
for 12 weeks, and was in addition to usual care.
The enhanced upper limb therapy programme
The enhanced upper limb therapy programme was based on best evidence using repetitive functional
task practice to work towards patient-centred goals. Enhanced upper limb therapy involved 45 minutes
of face-to-face therapy per day, within a 1-hour session, 3 days per week for 12 weeks, and was in
addition to usual care.
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Trial control treatment
The control treatment was usual post-stroke NHS care.
Data collection and outcome measures
Eligibility was assessed at a screening assessment, during which the following data were collected:
demography, stroke details and upper limb function (measured using the Action Research Arm Test).
The following baseline assessments were completed for patients fulfilling the eligibility criteria: stroke
severity (measured using the National Institutes for Health Stroke Scale), cognitive function (measured
using the Montreal Cognitive Assessment), language skills (measured using the Sheffield Screening Test
for Acquired Language Disorders), upper limb impairment [measured using the Fugl-Meyer Assessment
(total upper extremity score)], activities of daily living (measured using the Barthel Activities of Daily
Living Index), quality of life (measured using the EuroQol-5 Dimensions, five-level version), upper
limb pain (measured using a numeric rating scale) and current upper limb rehabilitation treatments.
Participants were given a self-completion questionnaire containing pre-trial resource use questions
(an adaption of the Client Services Receipt Inventory).
Outcome data were collected at 3 and 6 months post randomisation, and collection was undertaken in
two stages:
l Stage 1 was a self-completion postal questionnaire consisting of the Stroke Impact Scale
(at both 3 and 6 months), and the adapted Client Services Receipt Inventory resource use
questions (at 6 months only).
l Stage 2 was a face-to-face assessment by a researcher masked to the randomisation group who
collected the following data: Action Research Arm Test, Fugl-Meyer Assessment (total upper
extremity score), Barthel Activities of Daily Living Index, EuroQol-5 Dimensions, five-level version,
upper limb pain and adverse events. At the end of the 6-month stage 2 assessment, participants
were given a further self-completion questionnaire that included time and travel resource use
questions, and were asked to return this by post.
Sample size
The target sample size was 762 participants (254 per group). Responses from 216 participants in
each randomisation group would provide 80% power (significance level of 5% ÷ 3 = 1.67% because
of multiple comparisons) to detect a 15% difference in upper limb functional recovery ‘success’
(assessed using the Action Research Arm Test) between each of the three pairs of treatments
(robot-assisted training, enhanced upper limb therapy and usual care). The baseline estimate of
‘success’ was estimated as 30% based on outcomes in the National Institute for Health Research
Health Technology Assessment programme Botulinum Toxin for the Upper Limb after Stroke trial
[Shaw L, Rodgers H, Price C, Van Wijck F, Shackley P, Steen N, et al. BoTULS: a multicentre randomised
controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb
spasticity due to stroke with botulinum toxin type A. Health Technol Assess 2010;14(26)], with a
difference of between 45% and 30% corresponding to an odds ratio of 1.9. The sample size was
increased during the course of the trial to allow for higher attrition.
Statistical analysis
Analyses were carried out on an intention-to-treat basis, retaining participants in their randomisation
groups and including all participants who were not missing data on scale totals or subtotals after
simple imputation. Logistic regression was used to compare upper limb functional recovery ‘success’
(the primary outcome) between the three randomisation groups at 3 months, adjusting for time since
stroke, baseline upper limb function (Action Research Arm Test) and trial centre. The secondary outcome
of upper limb functional recovery ‘success’ at 6 months was analysed as for the primary outcome.
Numeric secondary outcomes were analysed at 3 and 6 months using linear regression, adjusting for
time since stroke, baseline score and trial centre. Bias-corrected and accelerated confidence
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intervals (100,000 bootstrap intervals) are presented for all numerical secondary outcomes because
of the distribution of the data. The coverage of the confidence intervals was adjusted to account for
the three paired comparisons between the randomisation groups. Because the trial was powered on a
significance level of 1.67%, the confidence interval coverage used was 98.33% (100% – 1.67%).
Health economic analysis
A within-trial cost–utility analysis was conducted to assess the incremental cost per quality-adjusted
life-year gained. The economic valuation took the perspective of the NHS and Personal Social Services,
and all costs were reported using 2018 values. Costs were based on the use of primary care, secondary
care and social care services over the 6-month trial period. Quality-adjusted life-years were derived
from responses to the EuroQol-5 Dimensions, five-level version, questionnaire administered at baseline
and at 3 and 6 months. The incremental cost per quality-adjusted life-year for each participant at
6 months was calculated.
A longer-term model was conducted to extrapolate the mean costs and quality-adjusted life-years to
12 months, based on the results of the trial.
Process evaluation
The process evaluation used semistructured interviews to seek the views and experiences of both
participants and health service professionals about the upper limb rehabilitation (i.e. robot-assisted
training, enhanced upper limb therapy and usual care) that they received or provided, and about factors
affecting the implementation of the trial. An inductive thematic analysis of the data was undertaken.
Results
A total of 770 stroke survivors were randomised to the trial: robot-assisted training, n = 257; enhanced
upper limb therapy, n = 259; and usual care, n = 254. Baseline demographics and stroke characteristics
were balanced between the groups. The mean age of participants was 61 years (standard deviation
14 years), 468 (61%) participants were men and the median time from stroke to randomisation was
240 days (interquartile range 109–549 days).
Robot-assisted training participants attended a median of 35 (interquartile range 31–36) of the
intended 36 sessions. Enhanced upper limb therapy participants attended a median of 34 (interquartile
range 29–36) of the intended 36 sessions. The median duration of face-to-face therapy for each
attended session was 41 minutes (interquartile range 35–47 minutes) for robot-assisted training and
45 minutes (interquartile range 45–45 minutes) for enhanced upper limb therapy.
Primary outcome
At 3 months, 103 out of 232 (44%) participants in the robot-assisted training group, 118 out of 234
(50%) in the enhanced upper limb therapy group and 85 out of 203 (42%) in the usual care group
achieved upper limb functional recovery ‘success’. There was little evidence of a difference between
the randomisation groups [adjusted odds ratio: robot-assisted training vs. usual care, 1.2 (98.33%
confidence interval 0.7 to 2.0); enhanced upper limb therapy vs. usual care, 1.5 (98.33% confidence
interval 0.9 to 2.5); and robot-assisted training vs. enhanced upper limb therapy, 0.8 (98.33% confidence
interval 0.5 to 1.3)].
Secondary outcomes
At 6 months, 103 out of 221 (47%) participants in the robot-assisted training group, 118 out of
218 (54%) in the enhanced upper limb therapy group and 81 out of 185 (44%) in the usual care group
achieved upper limb functional recovery ‘success’.
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Some of the many comparisons between pairs of groups on each outcome at 3 and 6 months showed
evidence of differences between randomisation groups that were considered to be clinically important:
l Robot-assisted training participants had less upper limb impairment on the Fugl-Meyer Assessment
motor subscale than usual care participants at 3 months (adjusted mean difference 2.8, 98.33%
confidence interval 0.7 to 5.0), and the difference was sustained at 6 months (adjusted mean
difference 2.5, 98.33% confidence interval 0.1 to 5.1).
l Robot-assisted training participants performed less well in the Stroke Impact Scale activities of daily
living domain at 3 months than enhanced upper limb therapy participants (adjusted mean difference
–4.8, 98.33% confidence interval –9.5 to –0.1).
l Enhanced upper limb therapy participants had less upper limb impairment on the Fugl-Meyer
Assessment total upper extremity score and Fugl-Meyer Assessment motor subscale score than
usual care participants at 3 months [adjusted mean difference 3.7 (98.33% confidence interval 0.5
to 6.8) and 3.0 (98.33% confidence interval 0.9 to 5.0), respectively]. Enhanced upper limb therapy
participants also performed better in Stroke Impact Scale mobility (adjusted mean difference 5.8,
98.33% confidence interval 0.4 to 11.2) and Stroke Impact Scale activities of daily living (adjusted
mean difference 5.6, 98.33% confidence interval 0.9 to 10.2) domains at 3 months than usual
care participants.
The following results showed statistical evidence of a difference, but were not considered to be
clinically important, as the confidence interval did not include the minimum clinically important
difference of the scale:
l Participants in the robot-assisted training group performed less well in the Barthel Activities of
Daily Living Index at 3 months than participants in the enhanced upper limb therapy group
(adjusted mean difference –0.5, 98.33% confidence interval –1.0 to –0.0).
l Participants in the enhanced upper limb therapy group had better upper limb function on the Action
Research Arm Test total score (adjusted mean difference 2.5, 98.33% confidence interval 0.0 to 5.1)
and performed better on the Stroke Impact Scale hand function domain (adjusted mean difference
7.9, 98.33% confidence interval 2.2 to 13.5) than participants in the usual care group at 3 months.
Participants in the enhanced upper limb therapy group also scored higher than usual care
participants on the Barthel Activities of Daily Living Index [adjusted mean difference was 0.7
(98.33% confidence interval 0.2 to 1.2) at 3 months and 0.9 (98.33% confidence interval 0.3 to 1.5)
at 6 months].
No difference was seen in the pain numeric rating scale tests between all three randomisation groups.
Forty-three serious adverse events were reported for 39 participants in the robot-assisted training
group, 42 were reported for 33 participants in the enhanced upper limb therapy group and 29 were
reported for 20 participants in the usual care group. None of the serious adverse events was considered
to be related to a trial intervention.
Health economic evaluation
The unadjusted results of the economic analysis suggest that, on average, usual care was the least
costly option at 6 months, at £3785 per participant (standard deviation £5437), with robot-assisted
training being the most costly, at £5387 per participant (standard deviation £4054). The mean cost per
participant of enhanced upper limb therapy was £4451 (standard deviation £6033). Enhanced upper
limb therapy had a higher quality-adjusted life-year gain [0.23 (standard deviation 0.10)] than usual
care [0.21 (standard deviation 0.11)] or robot-assisted training [0.21 (standard deviation 0.12)] at 6 months.
The incremental cost per quality-adjusted life-year at 6 months for participants in the enhanced upper limb
therapy group, compared with those in the usual care group, was £74,100, with a 19% chance of being
cost-effective at the £20,000 willingness-to-pay threshold. Throughout the analysis, results suggested
that robot-assisted training was more costly than usual care and enhanced upper limb therapy, and was
no more effective than enhanced upper limb therapy or usual care.
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Process evaluation
Forty-four participants and 35 professionals were interviewed. Despite the intensity of the RATULS
trial therapies, participants in both the robot-assisted training and the enhanced upper limb therapy
groups generally found the therapies to be acceptable, and were able to complete their therapy
programmes. Participants reported a range of benefits in both therapy programmes, and many
reported (self-judged) maintenance of some benefits at 6 months.
Delivering the RATULS trial required continuous investment of effort by trial centres and the
co-ordinating centre, with high levels of engagement from the professional staff involved. At times,
flexibility and adaptation of some of the processes, within the constraints of the trial protocol, were
necessary to support continued engagement of participants and professionals.
Conclusion
The RATULS trial did not find evidence that robot-assisted training using the Massachusetts Institute
of Technology-Manus robotic gym improved upper limb function after a stroke when compared with
an enhanced upper limb therapy programme of the same frequency and duration, or with usual care.
Robot-assisted training led to improvement in upper limb impairment, but this did not translate into
improvements in other outcomes. However, enhanced upper limb therapy led to potentially clinically
important improvements in upper limb impairment, mobility and performance in activities of daily living
at the end of the intervention period. Neither robot-assisted training nor enhanced upper limb therapy
were cost-effective.
Implications for health care
The results of the RATULS trial do not support the routine use of robot-assisted training (as provided
in this trial) for patients with moderate or severe upper limb functional limitation resulting from stroke.
There is evidence of potential benefit of enhanced upper limb therapy, although, as delivered in this
trial, it is unlikely to be cost-effective at the current standard of willingness to pay for a quality-adjusted
life-year (i.e. £20,000).
Implications for research
The RATULS trial has demonstrated that it is feasible to undertake large multicentre trials to evaluate
new rehabilitation technologies. Further research is needed to find ways to translate the improvements
in upper limb impairment seen with robot-assisted training into improvements in upper limb function
and activities of daily living. This might involve combining robot-assisted training with more
functionally orientated therapy strategies. Innovations to make enhanced rehabilitation programmes
more clinically effective and cost-effective are needed.
Trial registration
This trial is registered as ISRCTN69371850.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 54.
See the NIHR Journals Library website for further project information.
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distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
In 2011, the National Institute for Health Research (NIHR) Health Technology Assessment (HTA)
programme commissioned a call for proposals3 to determine the clinical effectiveness of robot-assisted
training for upper limb recovery following a stroke: are robot-assisted training devices clinically
effective for upper limb disability in post-stroke patients?
l Technology: robotics or ‘electromechanical devices’. Researchers should justify the choice of
machine, using the patient group and setting to inform their decision.
l Patient group: post-stroke adults with moderate/severe paretic upper limb impairment. Researchers
to define and justify which time point in the patient pathway.
l Setting: community or hospital based.
l Control or comparator treatment: treatment as usual (researchers to justify choice of control).
l Design: three-arm efficacy randomised controlled trial (RCT): (1) treatment as usual, (2) enhanced
physiotherapy and (3) robotic device. Researchers should undertake simple modelling of costs
(comprehensive cost-effectiveness evaluation is not required).
l Important outcomes: hand function, arm function and costs (including societal).
l Other outcomes: rate of recovery, adverse events (pain or musculoskeletal injury), activities of daily
living (ADL) and quality of life.
l Minimum duration of follow-up: 6 months.
This report describes the findings of the Robot-Assisted Training for the Upper Limb after Stroke
(RATULS) trial, which was commissioned to undertake this work.
Problems after stroke
Stroke is the commonest cause of complex disability in the UK.4 The potential consequences of stroke
are broad and include problems with mobility, arm and hand function, speech, cognition, vision,
swallowing, continence, mood, pain and fatigue.5 There are 1.2 million stroke survivors in the UK
and > 100,000 people have a stroke each year.6 Almost two-thirds of stroke survivors leave hospital
with a disability.6
Upper limb problems after stroke
Upper limb problems frequently occur following stroke, comprising loss of movement, co-ordination,
sensation and dexterity, which lead to difficulties with everyday activities. Approximately 80% of
people with acute stroke have upper limb motor impairment, and, of those with limited arm function
early after stroke, 50% still experience problems after 4 years.7 The strongest predictor of recovery is
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severity of initial neurological deficit; patients with severe initial upper limb impairment are unlikely to
fully recover their arm function, with a clear impact on their quality of life.8 Patients report that loss of
arm function is one of the most distressing long-term consequences of stroke. Improving upper limb
function has been identified as a research priority by stroke survivors, carers and clinicians.9
Repetitive functional task practice to improve upper limb recovery
At the time of designing the RATULS trial, a systematic review7 reported that treatments that focused
on increased intensity and repetitive task-specific practice showed promise for improving motor recovery.
Since then, the body of evidence has increased, with a 2014 Cochrane overview of systematic reviews10
reporting moderate-quality Grading of Recommendations Assessment, Development and Evaluation
evidence showing that arm function following a stroke can be improved by the provision of at least
20 extra hours of repetitive task training. In addition, a 2016 Cochrane review11 found that repetitive
functional task practice for stroke patients was associated with improved arm function [standardised
mean difference (SMD) 0.25, 95% confidence interval (CI) 0.01 to 0.49], hand function (SMD 0.25,
95% CI 0.00 to 0.51) and ADL (SMD 0.28, 95% CI 0.10 to 0.45).
Robot-assisted training for upper limb recovery
First proposed in the late 1980s, robot-assisted training enables stroke patients with moderate or
severe upper limb impairment to perform repetitive tasks in a highly consistent manner, tailored to
their motor abilities. At the time of designing the RATULS trial, the most recent (2008) Cochrane
review12 of electromechanical and robot-assisted arm training after stroke reported outcomes from
328 patients who participated in 11 trials. The largest study had 55 participants13 and four of the
11 studies evaluated the Massachusetts Institute of Technology (MIT)-Manus robotic gym system
(InMotion commercial version, Interactive Motion Technologies, Inc., Watertown, MA, USA).13–16 The
systematic review12 reported improvements with electromechanical and robot-assisted arm training in
terms of arm motor function (SMD 0.68, 95% CI 0.24 to 1.11) and motor strength (SMD 1.03, 95% CI
0.29 to 1.78), but no improvement in ADL (SMD 0.29, 95% CI –0.47 to 1.06).
In 2010, the Veterans Affairs (VA) RCT was published evaluating the MIT-Manus in four centres in
the USA.17 This trial was the largest trial of robot-assisted training at the time, recruiting 127 patients
with moderate or severe upper limb impairment who were ≥ 6 months after stroke. Participants
were randomised to receive robot-assisted training, intensive comparison therapy or usual care.
Robot-assisted training and intensive comparison therapy both consisted of 36 sessions, each lasting
1 hour, over 12 weeks. The trial found that robot-assisted training did not improve upper limb motor
function at 12 weeks compared with intensive therapy or usual care (the primary outcome). However,
participants who received robot-assisted training had significantly better results at 12 weeks on the
Stroke Impact Scale (SIS) than those who received usual care. In secondary analyses, improvements
were seen in motor function for those who received robot-assisted training compared with those
who received usual care, but not compared with those who received intensive comparison therapy, at
36 weeks. The added costs of delivering robot-assisted training or intensive comparison therapy were
compensated for by the fact that the health-care costs were lower than for usual care.18
The Robot-Assisted Training for the Upper Limb after Stroke trial
The RATULS trial evaluated robot-assisted training using the MIT-Manus robotic gym system. This was
compared with an upper limb therapy programme [named the enhanced upper limb therapy (EULT)
programme] of the same frequency and duration, and with usual post-stroke care. Robot-assisted training
and the EULT programme involved repetitive task practice and were provided in addition to usual care.
INTRODUCTION
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Chapter 2 Methods
Parts of this chapter have been reproduced from Rodgers et al.2 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Trial aim and objectives
Aim
The aim was to determine whether or not robot-assisted training with the MIT-Manus robotic gym
system improved upper limb function post stroke.
Objectives
l To determine whether or not robot-assisted training improved upper limb function post stroke,
compared with an EULT programme or usual care.
l To determine whether or not robot-assisted training improved upper limb impairment, ADL and
quality of life, compared with an EULT programme or usual care.
l To model the costs of robot-assisted training, compared with an EULT programme or usual care.
l To seek the views and experiences of patients and health service professionals about the upper limb
rehabilitation that they received or provided, and about factors affecting the implementation of
the trial.
l To explore:
¢ the time pattern of upper limb recovery of participants in each treatment group
¢ the impact of the severity of baseline upper limb function and time since stroke on the
effectiveness of the interventions.
Trial design
The RATULS trial was a three-group, pragmatic, observer-blind, multicentre RCT with an embedded
economic analysis and a process evaluation. Participants were randomised to receive one of the
following: robot-assisted training (in addition to usual NHS care), an EULT programme (in addition to
usual NHS care) or usual NHS care in accordance with local clinical practice.
Trial setting
The trial was conducted in four NHS centres in the UK. Each centre comprised a hub site, which was a
stroke service in an NHS hospital (Queen’s Hospital, Barking, Havering and Redbridge University Hospitals
NHS Trust; Northwick Park Hospital, London North West University Healthcare NHS Trust; Queen
Elizabeth University Hospital, NHS Greater Glasgow and Clyde; and North Tyneside General Hospital,
Northumbria Healthcare NHS Foundation Trust) with a MIT-Manus robotic gym system, plus several spoke
sites (a total of 18), which were stroke services in adjacent NHS trusts and community services.
Participants who were randomised to receive robot-assisted training or EULT travelled to a hub stroke
unit to receive these interventions. Participants who were randomised to usual care were treated by
their local stroke service.
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Trial participants
Adults with a first-ever stroke who fulfilled the following criteria were eligible to participate in the
RATULS trial.
Inclusion criteria
l Age ≥ 18 years.
l Clinical diagnosis of stroke (cerebral infarction, primary intracerebral haemorrhage,
subarachnoid haemorrhage).
l Between 1 week and 5 years since stroke.
l Moderate or severe upper limb functional limitation [i.e. Action Research Arm Test (ARAT) score of
0–39]19 due to stroke.
l Able to provide consent to take part in the trial and to comply with the requirements of the protocol.
Exclusion criteria
l More than one stroke (patients who had had a previous transient ischaemic attack could be invited
to participate).
l Other current significant impairment of the upper limb affected by stroke (e.g. fixed contracture,
frozen shoulder, severe arthritis, recent fracture).
l Diagnosis likely to interfere with rehabilitation or outcome assessments (e.g. registered blind).
l Previous use of the MIT-Manus robotic gym system or other arm rehabilitation robot.
l Current participation in a rehabilitation trial evaluating upper limb rehabilitation after stroke.
l Previous enrolment in the RATULS trial.
Case ascertainment, recruitment and consent
Participants were recruited from both incident and prevalent stroke populations. Participants were sought
from a number of settings in primary and secondary care, including stroke units, outpatient clinics, day
hospitals, community rehabilitation services and general practices.The trial aimed to recruit similar numbers of
participants within 3 months of stroke, > 3–12 months after stroke and > 12 months to 5 years after stroke.
Potential participants from secondary care
In secondary care, potential participants were identified by local clinicians and/or staff from the NIHR
Local Clinical Research Network (LCRN). Staff approached potentially eligible patients, discussed the
trial and provided a trial information leaflet. After allowing sufficient time for the information to be
considered, staff asked the patient if they were potentially interested in taking part in the trial.
Potential participants were also identified from hospital stroke discharge summaries/clinic letters. If
this method was used, potential participants were approached by letter. A short RATULS trial leaflet,
a patient information sheet, a RATULS trial reply slip and a pre-paid envelope were enclosed with the
letter. Interested patients could make contact by telephone or by return of the RATULS trial reply slip.
Following a few short questions to confirm potential eligibility, a face-to-face appointment for further
discussion was arranged, if appropriate.
Potential participants from primary care
To identify potential participants from primary care, general practices performed a database search
using the trial inclusion/exclusion criteria. A general practitioner (GP) screened the list of potentially
eligible participants to approve the issue of an invitation letter. This letter was accompanied by the
same information that was sent to individuals identified from secondary care records. The invitation
letter detailed the main trial eligibility criteria and asked interested patients to contact their trial
METHODS
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centre for further information. Following a few short telephone questions to confirm potential
eligibility, a face-to-face appointment for further discussion was arranged, if appropriate.
Potential participants from other sources
Local community stroke clubs and day centres were also given information about the trial. In addition,
some individuals heard about the trial from press releases or saw information about the trial on a
poster or a RATULS trial leaflet. Interested individuals were able to contact the trial centres directly
for further information about the trial.
Consent
Individuals who were interested and potentially eligible to take part in the trial were given an appointment
for further discussion and consent. This was conducted by a local trial co-ordinator or NIHR LCRN staff.
Written informed consent was obtained if a patient wished to take part in the RATULS trial.
Screening assessment
Once informed consent was obtained, a screening assessment was performed by the local trial centre
co-ordinator or NIHR LCRN staff. The following data were collected: demography, stroke details,
comorbidity and upper limb function (ARAT score19,20). If a patient fulfilled the trial inclusion and
exclusion criteria, the local trial co-ordinator/NIHR LCRN staff proceeded with the baseline assessment.
If it was not possible to complete the baseline assessment on the same day as the screening assessment,
eligibility for the trial was reconfirmed on the day of the baseline assessment.
Baseline assessment
The following baseline data were collected: stroke severity (measured using the National Institutes of
Health Stroke Scale21), cognitive function (measured using the Montreal Cognitive Assessment22),
language skills (measured using the Sheffield Screening Test for Acquired Language Disorders23),
upper limb impairment [measured using the Fugl-Meyer Assessment (FMA)20,24 (motor and sensory arm
sections)], ADL (measured using the Barthel ADL Index25), quality of life [measured using the EuroQol-5
Dimensions, five-level version (EQ-5D-5L)26], upper limb pain (measured using a numeric rating scale27)
and current upper limb rehabilitation treatments.
In addition, patients were given a self-completion questionnaire containing pre-trial resource use
questions [an adaption of the Client Services Receipt Inventory (CSRI)28–30].
Randomisation
Randomisation was conducted by the local trial co-ordinator/NIHR LCRN staff following completion of
the baseline assessment. A central independent web-based service, hosted by Newcastle University
Clinical Trials Unit, was used. Participants were stratified according to trial centre, time since stroke
(< 3 months, 3–12 months, > 12 months) and severity of upper limb functional limitation (ARAT score
categories:19 0–7, 8–13, 14–19 and 20–39), and randomised, using permuted block sequences, 1 : 1 : 1
to receive robot-assisted training, EULT or usual care. The sequences were prepared by an independent
statistician prior to the start of enrolment.
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Randomisation groups
Robot-assisted training using the MIT-Manus robotic gym system
This was delivered using the MIT-Manus robotic gym, which was specifically designed for clinical
rehabilitation applications.31–33
The robot-assisted training programme consisted of 45 minutes of face-to-face therapy during a 1-hour
session, 3 days per week for 12 weeks, in addition to usual care. A detailed description of the robot-
assisted training programme is provided in Chapter 4, and a completed Template for Intervention
Description and Replication (TIDieR) checklist34 is provided in Appendix 1, Table 27. The MIT-Manus
robotic gym recorded data on the robot-assisted training sessions content.
The enhanced upper limb therapy programme
The EULT programme aimed to match the frequency and duration of the robot-assisted training
programme sessions. It was developed from the upper limb therapy programmes used in the NIHR
HTA Botulinum Toxin for the Upper Limb after Stroke (BoTULS) trial35–37 and the Repetitive Arm
Functional Tasks after Stroke (RAFTAS) project.38 Using the principles of person-centred goal-setting
and repetitive functional task practice, the EULT programme aimed to drive neuroplasticity and motor
recovery after stroke.
The EULT programme consisted of 45 minutes of face-to-face therapy during a 1-hour session, 3 days
per week for 12 weeks, in addition to usual care. A detailed description of the EULT programme is
provided in Chapter 5, and a completed TIDieR checklist34 is provided in Appendix 1, Table 27.
Therapists recorded data on the content of EULT sessions.
Usual care
Defining usual care is a challenge for any stroke rehabilitation trial. One of the current National
Institute for Health and Care Excellence (NICE) quality standards is that:
Patients with stroke should be offered a minimum of 45 minutes of each appropriate therapy that
is required, for a minimum of five days a week, at a level that enables the patient to meet their
rehabilitation goals for as long as they are continuing to benefit from therapy and as long as they are
able to tolerate it.
NICE39 © NICE 2013 Stroke Rehabilitation in Adults: Clinicial Guideline. Available from
www.nice.org.uk/guidance/cg162/resources/stroke-rehabilitation-in-adults-pdf-35109688408261.
All rights reserved. Subject to Notice of rights (www.nice.org.uk/terms-and-conditions#notice-of-rights).
NICE guidance is prepared for the National Health Service in England. All NICE guidance is
subject to regular review and may be updated or withdrawn. NICE accepts no responsibility
for the use of its content in this product/publication
For most stroke services, this is aspirational, and the majority of patients do not receive this intensity,
particularly after discharge from hospital or early supported discharge services.40 Patients with chronic
stroke are unlikely to receive ongoing rehabilitation in the longer term. Most services do not regularly
review patients to address unmet rehabilitation needs beyond 1 year.
Participants in all three randomisation groups received a trial ‘arm rehabilitation therapy log’ in
which they were asked to record any ‘usual’ upper limb rehabilitation that they received during the
course of the trial. Periodic text messages were sent to remind participants about completion of the
rehabilitation logs. In addition, participants in all three randomisation groups received regular trial
newsletters, which included requests to complete the rehabilitation logs.
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Outcome measures
Primary outcome
The primary outcome was upper limb functional recovery ‘success’ (assessed using ARAT)19 at 3 months
post randomisation (at the end of intervention period). The ARAT assesses upper limb function by
scoring the ability to complete a range of functional tasks. The scale is made up of 19 items in four
subscales (grasp, grip, pinch and gross movement), which are rated on a four-point ordinal scale ranging
from zero (can perform no part of the test) to three (performs test normally).19
The definition of upper limb functional recovery ‘success’ differed depending on baseline severity:
l ARAT baseline score of 0–7; ‘success’ is an improvement of ≥ 3 points
l ARAT baseline score of 8–13; ‘success’ is an improvement of ≥ 4 points
l ARAT baseline score of 14–19; ‘success’ is an improvement of ≥ 5 points
l ARAT baseline score of 20–39; ‘success’ is an improvement of ≥ 6 points.
A stepped approach was used because, although the minimal clinically important difference (MCID)
for the ARAT is 10% of its range (6 points41), a smaller treatment effect may be clinically beneficial in
those with severe initial upper limb functional limitation, who are likely to improve less than those with
more moderate limitation.
Secondary outcomes
Secondary outcomes at 3 and 6 months were upper limb function (measured using the ARAT19)
‘success’ (at 6 months); total ARAT score; upper limb impairment (measured using the FMA24); ADL
(measured using the Barthel ADL Index25); quality of life (measured using the SIS42 version 3.0); upper
limb pain (measured using a numeric rating scale27); resource use costs (an adaptation of the CSRI28,43);
and quality-adjusted life-years (QALYs), derived from the EQ-5D-5L.26
Upper limb functional recovery ‘success’ at 6 months
The same success criteria based on the baseline ARAT19 score used at 3 months were used to define
upper limb functional recovery ‘success’ at 6 months.
Total Action Research Arm Test score
A secondary analysis of ARAT used the numeric score, which ranges from 0 to 57.19 A higher score
indicates better upper limb function.
Action Research Arm Test subscales
The original plan was to analyse the subscales as numeric scores, and to compare means, but after
database lock for the final data set, it was realised that the data distribution for subscales was
U-shaped and almost binary, as participants mostly scored zero or full marks on each subscale. The
clinical team felt that a better approach was to create a binary variable for each ARAT subscale. For
this, if a participant scored 2 (‘completed test, but takes abnormally long time, or has great difficulty’)
or 3 (‘performs test normally’) for any of the items in that subscale, that participant was classified as
‘could complete at least one task’ for that subscale. Conversely, if a participant scored 0 (‘can perform
no part of the test’) or 1 (‘performs test partially’) for all parts of the subscale, that participant was
classified as ‘could not complete one task’ for that subscale. The rationale was that a comparison
should be made between participants who could complete a task fully and those who could not.
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The Fugl-Meyer Assessment total upper-extremity score
The FMA total upper-extremity score (score 0–126) assesses upper limb impairment by incorporating
the motor, sensory, range of motion and joint pain subscales.24 Each item is scored on a 3-point ordinal
scale (0–2 points per item):
l Motor function. This has 24 items, which include scoring of the active movement of the shoulder,
elbow, forearm, wrist and hand, and co-ordination and speed. The score for this subscale ranges
from 0 to 66.
l Sensation. This has six items and the score for this subscale ranges from 0 to 12.
l Range of motion and joint pain. This has 12 items, which are scored for each range of motion and
joint pain. The score for this subscale ranges from 0 to 48.
A higher FMA total upper-extremity score indicates less upper limb impairment.
Barthel Activities of Daily Living Index
The Barthel ADL Index consists of 10 items (bowels, bladder, grooming, toilet use, feeding, transfer,
mobility, dressing, stairs and bathing), and is calculated by summing up the individual items and ranges
from 0 to 20.25 A higher score indicates a better ability to complete ADL independently.
The Stroke Impact Scale
The SIS is a self-completion stroke-specific questionnaire to measure quality of life.42 There are 59 items
investigating nine dimensions (strength, hand function, mobility, ADL, emotion, memory, communication,
social participation and stroke recovery). Each item was scored on a 5-point scale (1–5). The dimension
and domain scores range from 0 to 100. A higher score implies a better quality of life.
Upper limb pain
Upper limb pain was measured using a numeric rating scale on which participants were asked to rate
their upper limb pain, with zero being no pain at all and 10 being ‘as painful as it could have been’.27
The EuroQol-5 Dimensions, five-level version, quality-adjusted life-years and
resource use
Participant responses to the EQ-5D-5L44 questionnaire, completed at baseline and at 3 and 6 months,
were used to derive QALYs. Utility values were estimated from the responses using health state utility
scores based on the UK population tariff,45,46 and mapped back to the EuroQol-5 Dimensions, three-
level version, valuation set.47 Costs incurred by the NHS and Personal Social Services (PSS) were
collected via the adapted CSRI28–30 resource use questionnaires completed at baseline and at 6 months.
Undertaking outcome assessments
Outcomes were assessed at 3 months (± 7 days) and 6 months (± 7 days) following randomisation, and
were undertaken in two stages.
Stage 1 was a self-completion postal questionnaire consisting of the SIS42 (at 3 and 6 months) and the
adapted CSRI28–30 resource use questions (at 6 months only).
Stage 2 was a face-to-face assessment with a researcher who was masked to the randomisation group.
The following data were collected: ARAT,19 FMA24 (total upper-extremity score), Barthel ADL Index,25
EQ-5D-5L,26 upper limb pain27 and adverse events. At the end of the 6-month stage 2 assessment,
participants were given a further self-completion questionnaire and were asked to return this by post.
This questionnaire contained time and travel resource use questions.48,49
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Staff training
All staff received trial-specific training at the start of their involvement, with refresher training provided
throughout the trial. Staff performing trial assessments (screening, baseline, outcomes) and delivering
trial interventions received training in these aspects. In addition, manuals describing delivery of the
interventions and instructions on how to perform the assessments were provided. Video demonstrations
of the ARAT and FMA were also prepared and made available for ongoing reference.
Masking
Owing to the nature of the interventions, it was not possible to mask participants or treating therapists
to treatment allocation. It was intended that stage 2 outcome assessments would be conducted by a
researcher masked to treatment allocation. At each outcome assessment, the researcher was asked to
record whether or not they had unintentionally become aware of treatment allocation in conversation
with a participant.
Trial withdrawal
No specific withdrawal criteria were preset. Participants could withdraw from the trial at any time and
for any reason. A reason for withdrawal was sought, but participants could withdraw without providing
an explanation.
Investigators, GPs, stroke physicians and therapists could also withdraw participants from the trial at
any time if they felt that it was no longer in their interest to continue, for example because of
intercurrent illness or adverse events. Participants were informed that data collected prior to
withdrawal would be used in the trial analysis, unless consent for this was specifically withdrawn.
Participants who wished to receive no further intervention were not withdrawn from trial follow-up
unless they specifically requested this.
Safety evaluation
The safety of robot-assisted training, EULT and usual care was evaluated by examining the occurrence
of all adverse events and serious adverse events (SAEs) in accordance with the National Research
Ethics Service guidance for non-Clinical Trials of an Investigational Medicinal Product.50
All adverse events were captured by including the following question in the outcome pro formas:
‘are there any new medical problems since the last study assessment?’.
Events considered to be SAEs were subsequently documented on a separate trial SAE form, and a
causality and expectedness assessment was performed. As trial investigators or other members of the
research team could become aware of SAEs at times other than at outcome assessment appointments,
the SAE form was also used to directly capture these events.
The standard definition for a SAE was used.51 A SAE is an untoward occurrence that:
l results in death
l is life-threatening
l necessitates hospitalisation, or prolongation of existing hospitalisation
l results in persistent or significant disability or incapacity
l consists of a congenital anomaly or birth defect
l is otherwise considered medically significant by the investigator.
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Data management
Trial data were collected on trial-specific paper case record forms, and subsequently entered onto an
online database by trial administrators at participating centres.
Sample size
The target sample size was 762 participants (254 participants per group). Responses from 216 participants
in each randomisation group would provide 80% power (significance level of 1.7% because of multiple
comparisons) to detect a 15% difference in upper limb function ‘success’ between each of the three pairs
of treatments (robot-assisted training, EULT and usual care). The target was inflated for 15% attrition,
subsequent to protocol publication. The baseline estimate of success was estimated as 30% from the
BoTULS trial,35,36 and a difference of between 45% and 30% corresponds to an odds ratio of 1.9.
Statistical analysis of primary and secondary outcome data
Analysis populations
All analyses were done in the intention-to-treat (ITT) population of all participants, in the group to
which they were assigned, who did not have missing data after simple imputation.
A secondary analysis comparing the primary outcome robot-assisted training and EULT was carried
out on a per-protocol (PP) analysis set, which removed participants who did not receive at least
20 sessions of therapy. This was based on evidence that 20 hours of repetitive task training improves
upper limb function.10 No definition of PP could be made for the usual care group, so no comparisons
were undertaken for this group.
The main analysis of the primary outcome was on all participants; however, we performed two
sensitivity analyses. The first was based on participants who completed their assessment visits within
3 months ± 14 days and 6 months ± 28 days. We have taken 3 months to be 91 days, and 6 months to
be 183 days, post randomisation date. The second sensitivity analysis excluded participants from the
analysis if they had a zero ARAT score at baseline, as such patients have a poor prognosis for recovery
of arm function.52
Missing data in the measurement scales
The pattern and extent of missing observations in all scales was examined to investigate both the extent
of missing data and whether it was missing at random or was informative. The number (percentage) of
participants for whom a whole or partial measure was missing was reported by measure.
Apart from the SIS, for which we followed the specific scale developer’s rules,42 where no more than
20% of questions were missing or uninterpretable on specific scales, the score was calculated by using
the median value of the respondent-specific completed responses on the rest of the scale to replace
the missing items (i.e. simple imputation).53
We planned that multiple imputation techniques would be considered if > 20% of participants had
missing values for the primary outcome, but these techniques were not necessary.
Analysis of primary outcome
The primary outcome was ‘success’ at 3 months based on the ARAT score.19
The primary outcome of ‘success’ at 3 months is reported descriptively by randomisation group and
overall as a proportion.
METHODS
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Logistic regression was used to compare ‘success’ between the three randomisation groups at
3 months, adjusting for time since stroke, baseline upper limb function (ARAT score) and trial centre.
A two-level logistic model (trial centre and participants) was used. We adjusted the coverage of the
CIs to account for the three paired comparisons between the randomisation groups. Because the trial
was powered on a significance level of 1.67%, we used 98.33% (100% – 1.67%) as the CI coverage.
We considered the trial centre as a fixed effect. We explored the possibility that participants in a
trial centre may be more alike in the treatment randomisation groups, owing to participants sharing
therapists in the robot-assisted training and EULT groups, but not in the usual care group. This is called
partial nesting, but accounting for this did not improve model fit; therefore, we did not include this in
the models reported here.54–56
Analysis of secondary outcomes
The secondary outcomes included upper limb functional recovery ‘success’ at 6 months, the ARAT total
score19 (numeric rather than ‘success’), ARAT subscales,19 upper limb impairment (FMA total upper-
extremity score24), ADL (Barthel ADL Index25), quality of life (SIS42) and upper limb pain (numeric rating
scale27) at 3 and 6 months.
The secondary outcome of ‘success’ at 6 months was analysed as described for the primary outcome,
and similarly for the binary version of the ARAT subscales.
All numeric secondary outcomes are reported at baseline (if collected) and at 3 and 6 months
descriptively by randomisation group as means and standard deviations (SDs). The secondary outcomes
were analysed at 3 and 6 months using linear regression, adjusting for time since stroke, baseline
score and trial centre. The baseline score used to adjust the analysis was the same scale; for example,
the baseline ARAT score was used to adjust for baseline in the model for the ARAT. The SIS was not
collected at baseline; therefore, no baseline score adjustment could be made. We adjusted the coverage
of the CIs to account for the three paired comparisons between the randomisation groups. Because
the trial was powered on a significance level of 1.67%, we have used 98.33% (100% – 1.67%) as the CI
coverage. We presented bias-corrected and accelerated CIs (100,000 bootstrap intervals) because of
the distribution of the data.
Exploratory subgroup analysis
The protocol included a subgroup analysis to consider the relationship between the severity of baseline
upper limb functional limitation and time since stroke on the effectiveness of the interventions.
The subgroup analyses examined trial centre and age, and are listed below. There was not sufficient
power to perform any formal subgroup analyses, so all analyses must be considered exploratory.
We performed subgroup analysis for the numeric ARAT score at 3 months across the following
subgroups:
l time since stroke (< 3 months, 3–12 months, > 12 months)
l baseline ARAT score (0, 1–7, 8–13, 14–19, 20–39, 40–57)
l trial centre
l age (< 55 years, 55–70 years, > 70 years).
When preparing the detailed statistical analysis plan, two further subgroup analyses were prespecified.
These were for the FMA motor score and the Barthel ADL Index at 3 months, but only for the time
since stroke categories. CIs were calculated using bias-corrected and accelerated bootstrap CIs
(100,000 samples).
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Descriptive analysis of the relationship between treatment received and total Action
Research Arm Test score
The total ARAT score at 3 and 6 months was plotted against the number of sessions attended, total
duration of therapy received, total number of therapy repetitions (EULT group only) and total robot
movement attempts (robot-assisted training group only) for the two intervention randomisation
groups. Zero was assumed for duration, therapy task repetitions and movement attempts for
participants who did not attend an appointment.
Safety
The proportion of participants with at least one SAE was reported by randomisation group and the
difference in proportions (98.33% CI) was calculated. The median number of SAEs per participant was
also calculated and the distribution of SAEs was compared across groups using the Mann–Whitney
U-test. The above was also completed for adverse events at 3 and 6 months.
Economic analysis
The economic evaluation consisted of a microcosting analysis, a within-trial economic evaluation and a
longer-term economic model.57 Methods are described in Chapter 8.
Parallel process evaluation
A two-stage process evaluation was conducted to understand (1) participants’ and health service
professionals’ experiences of robot-assisted training, EULT and usual care and (2) factors affecting the
implementation of the trial within and across trial sites. Methods are described in Chapter 7.
Ethics and regulatory issues
The trial sponsor was Newcastle upon Tyne Hospitals NHS Foundation Trust. The trial was conducted
in accordance with research governance framework for health and social care58 and good clinical
practice. Ethics approval was granted by the National Research Ethics Committee Sunderland
(reference number 13/NE/0274). Local NHS approvals were obtained from all participating NHS
organisations. Monitoring of trial conduct and data collection was performed by regular visits to all
participating trial centres. The trial was managed by a co-ordinating centre based at Newcastle
University, Newcastle upon Tyne, UK. An independent Data Monitoring Committee and Trial Steering
Committee were in place for the duration of the project.
Amendments made to the trial after it commenced
l Modification of the postal invitation procedure for potential participants by letter (from both
primary and secondary care). When the trial commenced, potential participants who were invited
by letter were asked to telephone their local trial team if they would like more information. The
response rate to these invitations was low; it was suggested that this was because the letter and
information sheet were too long, and that people may prefer to respond in writing initially. The
letter was revised, a short summary leaflet designed and a postal reply slip created. These revised
documents were then used for postal invitations. In addition, the option to re-contact potential
participants who did not respond to the initial invitation letter was introduced. This was by follow-up
letter or telephone call, according to local preference.
METHODS
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l Introduction of reminders to complete the trial arm rehabilitation logs. To attempt to promote
completion of the trial arm rehabilitation logs, regular reminders via text message were introduced.
l Provision of trial newsletters. Regular newsletters were introduced for participants during their
time in the trial. This was in response to noting that attrition was higher than anticipated, and aimed
to encourage retention in the trial.
l Modification of the parallel process evaluation. Several changes were made to the parallel
process evaluation:
¢ The initial protocol included interviewing a larger proportion of participants in the robot-assisted
training group. However, the need for equal data collection in both the robot-assisted training
and EULT groups became apparent, owing to their equivalent complexity. Therefore, the
requirement to interview more robot-assisted training group participants was removed.
¢ The participant interview time points for the second period of data collection (August 2016 to
April 2017) were changed from twice during the first 3 months to once during the first
3 months and once at around 6 months. This change was informed by the analysis of data collected
in the first period of data collection (February to June 2016). It allowed continued exploration of
views and experiences of treatments, but also additional exploration of the impact of therapy
following the end of treatment, plus participants’ experiences of trial participation (e.g. completing
trial documentation and outcome assessments).
¢ A review of the quantitative outcome assessment data (ARAT score at baseline and at 3 and
6 months) was added to the process evaluation for some participants. Comparison of quantitative
data with participants’ subjective experiences captured in the interview data aimed to inform
interpretation of the trial.
¢ The range of health service professionals to be interviewed was broadened. Rather than
interviewing only health service professionals who delivered therapy to RATULS trial participants
(as per the original trial protocol), other staff who were involved in the trial were included in
interviews. These included principal investigators, NIHR LCRN staff, local site trial co-ordinators
and trial administrators. This allowed more information to be captured about factors affecting the
implementation of the trial.
l Revision of recruitment target. In the original trial protocol, the target sample size was
720 participants, which included 10% attrition for the primary outcome. As the trial proceeded,
it became apparent that dropout was > 10%, and nearer to 15%. The target sample size was
therefore increased to 762 participants, to allow for 15% attrition.
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Chapter 3 Randomised controlled trial
results
Parts of this chapter have been reproduced from Rodgers et al.1 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Participant recruitment and randomisation
Between 14 April 2014 and 30 April 2018, 770 participants were recruited from the four trial centres,
and were randomised as follows: robot-assisted training, 257 participants; EULT, 259 participants; and
usual care, 254 participants.
Original predicted, revised predicted and actual cumulative recruitment are shown in Figure 1.
Recruitment predictions were revised in July 2016, when target recruitment was increased to
762 participants. Monthly recruitment by trial centre is tabulated in Appendix 2, Table 28.
Participant retention and follow-up
Participant flow through the trial is shown in a Consolidated Standards of Reporting Trials (CONSORT)
flow diagram (Figure 2).
Of the 257 participants randomised to robot-assisted training, 233 (91%) completed a 3-month
assessment and 223 (87%) completed a 6-month assessment. Of the 259 participants randomised to
EULT, 236 (91%) completed a 3-month assessment and 222 (86%) completed a 6-month assessment.
Of the 254 participants randomised to usual care, 207 (81%) completed 3-month assessment and
190 (75%) completed a 6-month assessment. There was a lower follow-up rate in the usual care
group and, therefore, differential attrition between randomisation groups. Seven participants did not
complete the ARAT at their 3-month assessment, but remained in the trial.
The numbers of participants who did not have assessments, and the reasons why, are reported in
Appendix 2, Table 29. There were 60 withdrawals by 3 months, and a further 22 withdrawals by
6 months. The main reasons given for withdrawal were not wanting to be randomised to usual care
[19/60 (32%) by 3 months], the burden of participation [19/60 (32%) by 3 months and 4/22 (18%) by
6 months] and being unwell [10/60 (17%) by 3 months and 6/22 (27%) by 6 months]. There were two
deaths before 3 months and a further two deaths before 6 months. Assessments were not conducted
for a further 32 people at 3 months and 49 people at 6 months. The main reasons for this were
non-response to attempts to arrange the assessment [14/32 (44%) at 3 months and 37/49 (76%) at
6 months], missing the assessment and non-response to attempts to re-arrange [6/32 (19%) at 3 months
and 5/49 (10%) at 6 months], and being unwell and unable to complete the assessment [8/32 (25%) at
3 months and 4/49 (8%) at 6 months].
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FIGURE 1 Predicted and actual cumulative recruitment. The initial recruitment target was 720 participants, to allow for 10% attrition, but the sample size was increased to
762 participants to allow for 15% attrition.
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Timing of participant outcome assessments
Of the 676 assessments scheduled for 3 months, 545 (81%) were carried out at 3 months ± 14 days;
the median time from randomisation was 96 days [interquartile range (IQR) 91–102 days]. Of the
635 assessments scheduled for 6 months, 575 (91%) were carried out at 6 months ± 28 days; the
median time from randomisation was 187 days (IQR 182–193 days) (Figure 3).
Missing data in the measurement scales
There were very few data missing across the scales, and simple imputation did not add many
participants to the analyses. For example, the ARAT total score was fully completed for 668 out of
708 (94%) of expected participants at 3 months; after simple imputation, only one more participant
was included, as this participant was the only one with missing data who had < 20% of items missing.
Assigned to robot-
assisted training
(n = 257)
• Withdrew, n = 17
• Died, n = 1
• Withdrew, n = 5
• Did not have
    3-month
    assessment, n = 6
• Did not have
    6-month
    assessment, n = 11
Had 3-month assessment
(n = 233)
 Had 6-month assessment
(n = 223)
 At 3 months
(n = 239)
 Enrolled
(n = 770)
 At 6 months
(n = 234)
Assigned to EULT
(n = 259)
• Withdrew, n = 12
• Died, n = 1
• Withdrew, n = 8
• Died, n = 2
• Did not have
    3-month
    assessment, n = 10
• Did not have
    6-month
    assessment, n = 14
Had 3-month assessment
(n = 236)
 Had 6-month assessment
(n = 222)
 At 3 months
(n = 246)
 At 6 months
(n = 236)
Assigned to
usual care
(n = 254)
• Withdrew, n = 31
• Withdrew, n = 9
• Did not have
    3-month
    assessment, n = 16
• Did not have
    6-month
    assessment, n = 24
Had 3-month assessment
(n = 207)
 Had 6-month assessment
(n = 190)
 At 3 months
(n = 223)
 At 6 months
(n = 214)
FIGURE 2 The CONSORT flow diagram.
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The number (percentage) of participants with no missing data on the measurement scales is reported
by measure and time point in Appendix 2, Tables 30–32. These tables also show how many participants
were included after simple imputation. As < 20% of participants were missing data on the primary
outcome after simple imputation, multiple imputation techniques were not used.
Participant baseline characteristics
Baseline demographics and stroke characteristics are shown in Tables 1 and 2; they appear balanced
across groups. The mean age of participants was 61 years (SD 13.5 years), and 468 out of 770 (60.8%)
participants were men. Most participants had experienced a cerebral infarction [613/770 (79.6%)]. The
median time from stroke to randomisation was 240 days (IQR 109–549 days), and participants had a mean
ARAT score of 8.4 points (SD 11.8 points), a mean FMA motor score of 18.1 points (SD 13.7 points) and a
mean Barthel ADL Index score of 14.4 points (SD 3.9 points). Typically, the ARAT score was low [median
3 points (IQR 0–11 points)] and the distribution was positively skewed. The upper limb rehabilitation
treatments that were being received at baseline are given in Appendix 2, Table 33. A total of 409 out of
768 (53.3%) participants were receiving physiotherapy and/or occupational therapy at the time of
randomisation.
0
–75 –50 50
Days from expected visit time
75 100 125 150–25 250
25
50
75
N
u
m
b
er
 o
f a
ss
es
sm
en
ts
100
125
150
(a)
0
–75 –50 50
Days from expected visit time
75 100 125 150–25 250
25
50
75
N
u
m
b
er
 o
f a
ss
es
sm
en
ts
100
125
150
(b)
FIGURE 3 Compliance with time of assessments at (a) 3 months and (b) 6 months. The vertical lines indicate the allowable
window of time within which the assessment could take place (± 14 days for 3 months and ± 28 days for 6 months).
RANDOMISED CONTROLLED TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
TABLE 1 Participant demographics, stroke characteristics and upper limb measures at baseline
Characteristic
Robot-assisted
training (N= 257) EULT (N= 259)
Usual care
(N= 254) Total (N= 770)
Sex, n (%)
Male 156 (60.7) 159 (61.4) 153 (60.2) 468 (60.8)
Female 101 (39.3) 100 (38.6) 101 (39.8) 302 (39.2)
Age at randomisation (years),
mean (SD)
59.9 (13.5) 59.4 (14.3) 62.5 (12.5) 60.6 (13.5)
Time from stroke to randomisation
(days), median (IQR)
233 (102–549) 258 (115–546) 242 (107–549) 240 (109–549)
Time from stroke to randomisation (months), n (%)
< 3 57 (22.2) 46 (17.8) 58 (22.8) 161 (20.9)
3–12 105 (40.9) 117 (45.2) 106 (41.7) 328 (42.6)
> 12 95 (37.0) 96 (37.1) 90 (35.4) 281 (36.5)
Arm affected by stroke, n (%)
Right 112 (43.6) 116 (44.8) 113 (44.5) 341 (44.3)
Left 145 (56.4) 143 (55.2) 141 (55.5) 429 (55.7)
Stroke type, n (%)
Cerebral infarction 197 (76.7) 202 (78.0) 214 (84.3) 613 (79.6)
Primary intracerebral
haemorrhage
58 (22.6) 56 (21.6) 38 (15.0) 152 (19.7)
Subarachnoid haemorrhage 2 (0.8) 1 (0.4) 2 (0.8) 5 (0.6)
NIHSS total score (0–42) n = 255 n= 259 n = 254 n= 768
Median (IQR) 5.0 (3.0–7.0) 5.0 (3.0–7.0) 5.0 (4.0–7.0) 5.0 (3.0–7.0)
Montreal Cognitive Assessment
(0–30)
n = 248 n= 250 n = 242 n= 740
Median (IQR) 24.0 (19.0–27.0) 24.0 (19.0–27.0) 24.0 (19.0–27.0) 24.0 (19.0–27.0)
Sheffield Screening Test for Acquired Language Disorders
Receptive skills score (0–11) n = 255 n= 258 n = 254 n= 767
Median (IQR) 8.0 (7.0–9.0) 8.0 (7.0–9.0) 8.0 (7.0–9.0) 8.0 (7.0–9.0)
Expressive skills score (0–9) n = 251 n= 258 n = 254 n= 763
Median (IQR) 11.0 (9.0–11.0) 11.0 (10.0–11.0) 11.0 (9.0–11.0) 11.0 (9.0–11.0)
Total score (0–20) n = 251 n= 258 n = 254 n= 763
Median (IQR) 19.0 (16.0–20.0) 19.0 (17.0–20.0) 19.0 (17.0–20.0) 19.0 (17.0–20.0)
Handedness,a n (%) n = 255 n= 259 n = 254 n= 768
Right 221 (86.7) 223 (86.1) 228 (89.8) 672 (87.5)
Left 34 (13.3) 35 (13.5) 25 (9.8) 94 (12.2)
Ambidextrous 0 (0.0) 1 (0.4) 1 (0.4) 2 (0.3)
Dominant hand affected by stroke,
n (%)
n = 255 n= 259 n = 254 n= 768
No (including ambidextrous) 141 (55.3) 131 (50.6) 132 (52.0) 404 (52.6)
Yes 114 (44.7) 128 (49.4) 122 (48.0) 364 (47.4)
NIHSS, National Institutes of Health Stroke Scale.
a It was not specified in the CRF whether or not the ‘handedness’ refers to before or after stroke.
Note
Three participants were randomised after their screening assessment, but before their baseline assessment.
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Primary outcome
The proportion of participants who achieved upper limb functional recovery ‘success’ at 3 months in
the ITT analysis was 103 out of 232 (44%) in the robot-assisted training group, 118 out of 234 (50%)
in the EULT group and 85 out of 203 (42%) in the usual care group (Table 3 and Figure 4). There was
little evidence of a statistically significant difference in the incidence of ‘success’ at 3 months when
comparing the robot-assisted training group with the usual care group [adjusted odds ratio (aOR) 1.2,
98.33% CI 0.7 to 2.0], the EULT group with the usual care group (aOR 1.5, 98.33% CI 0.9 to 2.5), or
the robot-assisted training group with the EULT group (aOR 0.8, 98.33% CI 0.5 to 1.3). Although the
unadjusted success rate was 8% higher in the EULT group than in the usual care group, the trial was
powered to detect a difference of 15% in success rates between groups. The results of both sensitivity
analyses and the PP analysis were consistent with the ITT analysis (see Table 3).
The secondary outcome results of upper limb functional recovery ‘success’ at 6 months are shown in
Table 3 and Figure 4. The number of participants who achieved upper limb functional recovery ‘success’
at 6 months in the ITT analysis was 103 out of 221 (47%) in the robot-assisted training group, 118 out
of 218 (54%) in the EULT group and 81 out of 185 (44%) in the usual care group; all groups showed
slight improvement from the 3-month assessment. The unadjusted success rate was 10% higher in the
EULT group than in the usual care group, but there was little evidence of a difference in the incidence
TABLE 2 Upper limb measures at baseline
Upper limb measure
Robot-assisted training
(N= 257)
EULT
(N= 259)
Usual care
(N= 254)
Total
(N= 770)
ARAT (0–57) n= 256 n = 259 n= 254 n = 769
ARAT total score
Mean (SD) 8.5 (11.9) 8.7 (11.9) 8.1 (11.5) 8.4 (11.8)
Median (IQR) 3.0 (0–12) 3.0 (0–13) 3.0 (0–11) 3.0 (0–11)
ARAT total score category
(0–57), n (%)
n= 256 n = 259 n= 254 n = 769
0–7 178 (69.5) 175 (67.6) 173 (68.1) 526 (68.4)
8–13 18 (7.0) 22 (8.5) 23 (9.1) 63 (8.2)
14–19 13 (5.1) 9 (3.5) 13 (5.1) 35 (4.6)
20–39 47 (18.4) 53 (20.5) 45 (17.7) 145 (18.9)
FMA
Motor function score (0–66) n= 255 n = 259 n= 254 n = 768
Mean (SD) 18.0 (13.1) 18.2 (14.1) 18.2 (13.9) 18.1 (13.7)
Range of motion and joint pain
score (0–48)
n= 254 n = 259 n= 254 n = 767
Mean (SD) 41.5 (6.1) 41.5 (6.2) 41.0 (6.6) 41.3 (6.3)
Sensation score (0–12) n= 253 n = 258 n= 252 n = 763
Mean (SD) 9.4 (3.2) 9.4 (3.3) 9.8 (2.9) 9.5 (3.1)
Total upper extremity score
(0–126)
n= 254 n = 259 n= 254 n = 767
Mean (SD) 68.9 (16.5) 69.0 (17.9) 68.9 (17.4) 68.9 (17.3)
Barthel ADL Index (0–20) n= 255 n = 259 n= 254 n = 768
Mean (SD) 14.5 (3.8) 14.3 (4.0) 14.4 (3.9) 14.4 (3.9)
Numeric pain scale (0–10) n= 253 n = 259 n= 254 n = 766
Mean (SD) 2.9 (3.2) 2.7 (3.0) 2.6 (3.1) 2.7 (3.1)
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TABLE 3 Comparison of upper limb functional recovery ‘success’ at 3 and 6 months between randomisation groups
Outcome
Robot-assisted
training EULT Usual care
OR (98.33% CI)
Robot-assisted training vs.
usual carea EULT vs. usual carea
Robot-assisted training vs.
EULTa
N n (%) N n (%) N n (%) Unadjusted Adjustedb Unadjusted Adjustedb Unadjusted Adjustedb
Primary outcome, 3 months
ITT 232 103 (44.4) 234 118 (50.4) 203 85 (41.9) 1.1 (0.7 to 1.8) 1.2 (0.7 to 2.0) 1.4 (0.9 to 2.2) 1.5 (0.9 to 2.5) 0.8 (0.5 to 1.2) 0.8 (0.5 to 1.3)
Sensitivity
analysis 1c
197 89 (45.2) 187 94 (50.3) 157 66 (42.0) 1.1 (0.7 to 1.9) 1.1 (0.6 to 2.0) 1.4 (0.8 to 2.3) 1.4 (0.8 to 2.4) 0.8 (0.5 to 1.3) 0.8 (0.5 to 1.4)
Sensitivity
analysis 2d
148 71 (48.0) 145 81 (55.9) 116 56 (48.3) 1.0 (0.5 to 1.8) 1.1 (0.6 to 2.2) 1.4 (0.7 to 2.5) 1.6 (0.8 to 3.1) 0.7 (0.4 to 1.3) 0.7 (0.4 to 1.4)
PP 222 97 (43.7) 219 112 (51.1) NA NA NA NA NA NA 0.7 (0.5 to 1.2) 0.7 (0.4 to 1.2)
Secondary outcomes, 6 months
ITT 221 103 (46.6) 218 118 (54.1) 185 81 (43.8) 1.1 (0.7 to 1.8) 1.2 (0.7 to 2.1) 1.5 (0.9 to 2.5) 1.6 (0.9 to 2.8) 0.7 (0.5 to 1.2) 0.8 (0.5 to 1.3)
Sensitivity
analysis 1c
200 91 (45.5) 203 110 (54.2) 163 71 (43.6) 1.1 (0.7 to 1.8) 1.3 (0.7 to 2.2) 1.5 (0.9 to 2.5) 1.6 (0.9 to 2.9) 0.7 (0.4 to 1.1) 0.8 (0.4 to 1.3)
Sensitivity
analysis 2d
139 72 (51.8) 136 84 (61.8) 109 55 (50.5) 1.1 (0.6 to 1.9) 1.3 (0.6 to 2.8) 1.6 (0.9 to 3.0) 1.9 (0.9 to 4.1) 0.7 (0.4 to 1.2) 0.7 (0.3 to 1.4)
PP 213 97 (45.5) 206 113 (54.9) NA NA NA NA NA NA 0.7 (0.4 to 1.1) 0.7 (0.4 to 1.2)
NA, not applicable; OR, odds ratio.
a A vs. B means that the OR is the odds of success for A compared with B.
b For the natural log of time since stroke, baseline ARAT score and trial centre.
c Participants were included only if the assessment took place within 3 months ± 14 days for the 3-month assessment and within 6 months ± 28 days for the 6-month assessment.
d Participants were excluded from the analysis if they had an ARAT score of zero at baseline.
Notes
The shaded boxes indicate the results of the primary comparison at 3 months.
Some are NA because a formal comparison to usual care would be biased.
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FIGURE 4 Upper limb functional recovery ‘success’ at 3 and 6 months for robot-assisted training, EULT and usual care.
(a) The proportion of participants achieving upper limb functional recovery ‘success’ by randomisation group; and
(b) pairwise comparisons of group upper limb functional recovery ‘success’ presented as ORs (98.33% CIs) (ITT population).
RT, robot-assisted training; UC, usual care.
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of ‘success’ at 6 months when comparing the robot-assisted training group with the usual care group
(aOR 1.2, 98.33% CI 0.7 to 2.1), the EULT group with the usual care group (aOR 1.6, 98.33% CI 0.9
to 2.8) or the robot-assisted training group with the EULT group (aOR 0.8, 98.33% CI 0.5 to 1.3).
The results of both sensitivity analyses and the PP analysis were consistent with the ITT analysis
(see Table 3).
Secondary outcomes
Robot-assisted training versus usual care
Action Research Arm Test total score
In the robot-assisted training group, the mean ARAT total scores were 8.5 points at baseline, 15.5 points
at 3 months and 16.5 points at 6 months. For the usual care group, the mean ARAT total scores were
8.1 points at baseline, 14.2 points at 3 months and 16.4 points at 6 months. There was little evidence
of a difference in the ARAT total score between these groups at 3 months [adjusted mean difference
(aMD) 1.4, 98.33% CI –1.1 to 3.8] and 6 months (aMD 1.0, 98.33% CI –1.9 to 3.7) (Table 4 and Figure 5).
The MCID for the ARAT total score is 6 points,59 so the changes in mean ARAT scores between baseline
and 3 months were consistent with a clinically meaningful difference on this scale for both groups, but
the differences between 3 and 6 months, and between groups at 3 and 6 months, were not. The results
of the ARAT subscales are given in Appendix 3, Table 34.
Fugl-Meyer Assessment total upper-extremity score
A similar pattern was seen in the mean FMA total upper-extremity scores, which were 68.9 points at
baseline, 76.6 points at 3 months and 78.2 points at 6 months in the robot-assisted training group.
By comparison, they were 68.9 points at baseline, 74.2 points at 3 months and 77.9 points at 6 months
in the usual care group. There was little evidence of a difference between these groups on this scale at
3 months (aMD 3.1, 98.33% CI –0.0 to 6.5) or at 6 months (aMD 1.6, 98.33% CI –1.8 to 5.2) (Table 5).
There is no published MCID for the FMA total upper-extremity score.
Fugl-Meyer Assessment motor function subscale
This pattern of improvement was also seen for the FMA motor function subscale. For the robot-
assisted training group, the mean scores were 18.0 points at baseline, 26.2 points at 3 months and
27.2 points at 6 months. In comparison, for the usual care group the mean scores were 18.2 points at
baseline, 24.2 points at 3 months and 26.3 points at 6 months. The robot-assisted training group had a
higher average FMA motor function subscale score than the usual care group at 3 months (aMD 2.8,
98.33% CI 0.7 to 5.0), and this difference was maintained at 6 months (aMD 2.5, 98.33% CI 0.1 to 5.1)
(Figure 6; see also Table 5). The MCID for this subscale is 4 points for acute stroke patients and 5.25
points for chronic stroke patients, which makes it difficult to interpret the results from a mixed patient
group.59 Further details and descriptive statistics for the ‘range of motion and joint pain’ and ‘sensation’
subscales are given in Table 5.
Barthel Activities of Daily Living Index
There was little change in the Barthel ADL Index score over time. In the robot-assisted training group,
the mean was 14.5, 15.5 and 15.6 points at baseline, 3 months and 6 months, respectively. This was
similar to the usual care group, in which the mean was 14.4, 15.3 and 15.3 points at baseline, 3 months
and 6 months, respectively. There was little evidence of a difference between these groups on this scale
at 3 months (aMD 0.2, 98.33% CI –0.4 to 0.8) or at 6 months (aMD 0.5, 98.33% CI –0.1 to 1.1) (Table 6).
The MCID on this scale is 1.85 units,59 and so the changes in the mean Barthel ADL Index scores
between baseline, 3 months and 6 months were not large enough to be consistent with a clinically
meaningful difference on this scale for both groups (i.e. robot-assisted training and usual care), nor were
the comparisons between group means at 3 or 6 months.
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TABLE 4 Comparison of the mean ARAT score at 3 and 6 months between randomisation groups
Time point
Robot-assisted training EULT Usual care
Mean difference (98.33% CI)
Robot-assisted training –usual
care EULT – usual care Robot-assisted training – EULT
n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) Unadjusted Adjusted
a
Unadjusted Adjusted
a
Unadjusted Adjusted
a
Baseline 256 8.5 (11.9) 3 (0–12) 259 8.7 (11.9) 3 (0–13) 254 8.1 (11.5) 3 (0–11) NA NA NA NA NA NA
3 months 232 15.5 (19.1) 5 (0–28) 234 17.3 (20.1) 5 (1–33) 203 14.2 (19.6) 3 (0–22) 1.2 (–3.3 to 5.7) 1.4 (–1.1 to 3.8) 3.0 (–1.6 to 7.5) 2.5 (0.0
b
to 5.1) –1.8 (–6.2 to 2.6) –1.2 (–3.6 to 1.2)
6 months 221 16.5 (19.7) 4 (0–29) 218 17.2 (19.9) 5 (0–36) 185 16.4 (21.3) 3 (0–34) 0.1 (–4.8 to 5.0) 1.0 (–1.9 to 3.7) 0.8 (–4.3 to 5.6) 0.3 (–2.6 to 3.0) –0.6 (–5.2 to 3.9) 0.7 (–1.8 to 3.3)
a For time since stroke (to the power of –0.5), baseline ARAT score and trial centre.
b This number is positive.
Note
Total score: 0–57.
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FIGURE 5 The ARAT total score at baseline and at 3 and 6 months for robot-assisted training, EULT and usual care.
(a) The ARAT total score by randomisation group; and (b) pairwise comparisons of the ARAT total score presented as
mean differences (98.33% CIs). RT, robot-assisted training; UC, usual care.
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TABLE 5 Comparison of the upper limb impairment (FMA score) at 3 and 6 months between randomisation groups
FMA and
time point
Robot-assisted
training EULT Usual care
Mean difference (98.33% CI)
Robot-assisted training –
usual care EULT – usual care Robot-assisted training – EULT
n Mean (SD) n Mean (SD) n Mean (SD) Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
Total upper-extremity score (0–126)
Baseline 254 68.9 (16.5) 259 69.0 (17.9) 254 68.9 (17.4)
3 months 232 76.6 (22.1) 234 77.8 (22.8) 202 74.2 (23.6) 2.4 (–2.9 to 7.6) 3.1 (–0.0 to 6.5) 3.6 (–1.8 to 8.9) 3.7 (0.5 to 6.8) –1.3 (–6.2 to 3.7) –0.5 (–3.4 to 2.6)
6 months 221 78.2 (22.8) 218 79.4 (24.1) 186 77.9 (23.2) 0.3 (–5.2 to 5.8) 1.6 (–1.8 to 5.2) 1.5 (–4.3 to 7.0) 1.8 (–1.8 to 5.3) –1.1 (–6.5 to 4.2) –0.2 (–3.6 to 3.4)
Motor function (0–66)
Baseline 255 18.0 (13.1) 259 18.2 (14.1) 254 18.2 (13.9)
3 months 232 26.2 (17.7) 234 27.1 (18.3) 202 24.2 (18.4) 2.0 (–2.2 to 6.2) 2.8 (0.7 to 5.0) 2.9 (–1.3 to 7.1) 3.0 (0.9 to 5.0) –0.9 (–4.8 to 3.1) –0.2 (–2.2 to 1.9)
6 months 221 27.2 (18.4) 217 28.2 (19.3) 186 26.3 (18.9) 0.9 (–3.6 to 5.3) 2.5 (0.1 to 5.1) 1.9 (–2.7 to 6.4) 2.4 (–0.2 to 4.8) –1.0 (–5.3 to 3.3) 0.1 (–2.3 to 2.7)
Range of motion and joint pain (0–48)
Baseline 254 41.5 (6.1) 259 41.5 (6.2) 254 41.0 (6.6)
3 months 232 40.8 (6.8) 234 41.2 (6.2) 204 40.0 (8.0)
6 months 221 41.5 (6.1) 218 41.6 (5.9) 186 41.6 (6.2)
Sensation (0–12)
Baseline 253 9.4 (3.2) 258 9.4 (3.3) 252 9.8 (2.9)
3 months 231 9.6 (3.1) 234 9.5 (3.0) 202 9.9 (2.9)
6 months 221 9.5 (3.0) 218 9.6 (2.9) 186 10.0 (2.7)
a For time since stroke (to the power of –0.5), baseline FMA score and trial centre.
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FIGURE 6 The FMA motor function subscale score at baseline and at 3 and 6 months for robot-assisted training, EULT
and usual care. (a) The FMA motor function subscale score by randomisation group; and (b) pairwise comparisons of the
FMA motor function subscale score presented as mean differences (98.33% CIs). RT, robot-assisted training; UC, usual care.
DOI: 10.3310/hta24540 Health Technology Assessment 2020 Vol. 24 No. 54
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Rodgers et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
27
TABLE 6 Comparison of the ADL (Barthel ADL Index scores) at 3 and 6 months between randomisation groups
Time
point
Robot-assisted
training EULT Usual care
Mean difference (98.33% CI)
Robot-assisted training –
usual care EULT – usual care Robot-assisted training – EULT
n Mean (SD) n Mean (SD) n Mean (SD) Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
Barthel ADL Index (0–20)
Baseline 255 14.5 (3.8) 259 14.3 (4.0) 254 14.4 (3.9)
3 months 233 15.5 (3.4) 236 15.9 (3.4) 207 15.3 (3.8) 0.2 (–0.6 to 1.0) 0.2 (–0.4 to 0.8) 0.6 (–0.2 to 1.5) 0.7 (0.2 to 1.2) –0.5 (–1.2 to 0.3) –0.5 (–1.0 to –0.0)
6 months 223 15.6 (3.4) 222 16.0 (3.5) 190 15.3 (3.7) 0.3 (–0.5 to 1.1) 0.5 (–0.1 to 1.1) 0.6 (–0.2 to 1.5) 0.9 (0.3 to 1.5) –0.4 (–1.2 to 0.4) –0.4 (–1.0 to 0.1)
a For time since stroke (to the power of –1), baseline Barthel ADL Index score and trial centre.
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Stroke Impact Scale
There was little change over time on any SIS subscale. The mean scores on the ADL subscale were
50.8 points at 3 months and 50.4 points at 6 months in the robot-assisted training group, but they
were 50.8 and 51.9 points at 3 and 6 months, respectively, in the usual care group. The results were
consistent with the Barthel ADL Index, in that they showed little evidence of a difference between
these groups at 3 months (aMD 0.7, 98.33% CI –4.2 to 5.8) or at 6 months (aMD –0.6, 98.33% CI –5.6
to 4.5) (Table 7). The MCID on this SIS subscale is 5.9 units,59 so the differences between groups were
not consistent with a clinically meaningful difference.
The mean scores on the SIS hand function subscale were 15.5 points at 3 months and 15.7 points at
6 months in the robot-assisted training group, but were 14.3 and 14.8 points at 3 and 6 months,
respectively, in the usual care group. There was also little evidence of a difference in hand function
between groups at 3 months (aMD 2.6, 98.33% CI –2.6 to 7.9) or 6 months (aMD 1.9, 98.33% CI
–3.6 to 7.5). The MCID on this SIS subscale is 17.8 units,59 so the results were not consistent with a
clinically meaningful difference.
The mean scores on the SIS mobility subscale were 61.6 points at 3 months and 61.7 points at 6 months
in the robot-assisted training group, but were 61.0 and 62.9 points at 3 and 6 months, respectively, in
the usual care group. As before, there was little evidence of a difference between groups for mobility at
3 months (aMD 1.3, 98.33% CI –4.3 to 6.9) or 6 months (aMD –0.5, 98.33% CI –6.0 to 5.1). However,
the MCID on this SIS subscale is 4.5 units,59 which was included in these CIs, so a clinically meaningful
difference between groups cannot be ruled out.
The mean scores on the SIS social participation subscale were 47.7 points at 3 months and 47.0 points
at 6 months in the robot-assisted training group, but were 47.1 and 49.2 points at 3 and 6 months,
respectively, in the usual care group. There was also little evidence of a difference at 3 months (aMD
0.5, 98.33% CI –5.2 to 6.2) or 6 months (aMD –2.2, 98.33% CI –8.2 to 3.9) between the robot-assisted
training group and the usual care group, as measured by the SIS. More details and descriptive statistics
for strength, emotion, memory, communication and stroke recovery are given in Table 7.
Robot-assisted training versus enhanced upper limb therapy
Action Research Arm Test total score
Both groups showed an improvement in ARAT total score from baseline to 3 months, but little
improvement thereafter. In the robot-assisted training group, the mean ARAT total score was 8.5 points
at baseline, 15.5 points at 3 months and 16.5 points at 6 months. In comparison, the mean ARAT total
score for the EULT group was 8.7 points at baseline, 17.3 points at 3 months and 17.2 points at 6 months.
There was little evidence of a difference in the ARAT total score between these groups at 3 months (aMD
–1.2, 98.33% CI –3.6 to 1.2) or at 6 months (aMD 0.7, 98.33% CI –1.8 to 3.3) (see Table 4 and Figure 5).
The MCID for ARAT total score is 6 points,59 so the changes in mean ARAT scores between baseline and
3 months were consistent with a clinically meaningful difference on this scale for both groups, but those
between 3 and 6 months, and between groups at 3 and 6 months, were not. The results of the ARAT
subscales are given in Appendix 3, Table 34.
Fugl-Meyer Assessment total upper-extremity score
There was a similar pattern in the FMA total upper-extremity score. The mean FMA total scores were
68.9 points at baseline, 76.6 points at 3 months and 78.2 points at 6 months in the robot-assisted
training group, and were 69.0, 77.8 and 79.4 points at baseline, 3 months and 6 months, respectively,
for the EULT group. There was little evidence of a difference between these groups on this scale at
3 months (aMD –0.5, 98.33% CI –3.4 to 2.6) or 6 months (aMD –0.2, 98.33% CI –3.6 to 3.4) (see Table 5).
There is no published MCID for the FMA total upper-extremity score.
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TABLE 7 Comparison of the quality of life (SIS scores) at 3 and 6 months between randomisation groups
SIS subscale and
time point
Robot-assisted training EULT Usual care
Mean difference (98.33% CI)
Robot-assisted training – usual
care EULT – usual care Robot-assisted training – EULT
n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) Unadjusted Adjusted
a
Unadjusted Adjusted
a
Unadjusted Adjusted
a
ADL (0–100)
3 months 220 50.8 (22.5) 48 (33–70) 223 55.9 (19.8) 55 (40–70) 194 50.8 (21.1) 50 (33–65) 0.0
b
(–5.1 to 5.2) 0.7 (–4.2 to 5.8) 5.1 (0.3 to 9.9) 5.6 (0.9 to 10.2) –5.1 (–10.0 to –0.3) –4.8 (–9.5 to –0.1)
6 months 212 50.4 (22.3) 50 (33–68) 216 52.5 (22.3) 50 (38–68) 179 51.9 (21.3) 53 (35–70) –1.4 (–6.7 to 3.9) –0.6 (–5.6 to 4.5) 0.6 (–4.7 to 5.8) 1.1 (–3.9 to 6.1) –2.0 (–7.2 to 3.1) –1.7 (–6.7 to 3.3)
Hand function (0–100)
3 months 219 15.5 (24.4) 0 (0–20) 223 21.4 (27.9) 5 (0–40) 193 14.3 (22.9) 0 (0–25) 1.3 (–4.3 to 6.8) 2.6 (–2.6 to 7.9) 7.2 (1.1 to 13.1) 7.9 (2.2 to 13.5) –5.9 (–11.9 to 0.1) –5.4 (–10.9 to 0.2)
6 months 213 15.7 (25.2) 0 (0–25) 216 18.4 (26.2) 0 (0–35) 179 14.8 (23.5) 0 (0–25) 0.9 (–5.0 to 6.8) 1.9 (–3.6 to 7.5) 3.6 (–2.4 to 9.5) 3.9 (–1.8 to 9.6) –2.7 (–8.6 to 3.3) –2.0 (–7.4 to 3.6)
Mobility (0–100)
3 months 219 61.6 (25.1) 64 (44–83) 223 66.4 (23.2) 69 (50–86) 192 61.0 (24.6) 61 (46–81) 0.6 (–5.3 to 6.5) 1.3 (–4.3 to 6.9) 5.4 (–0.1 to 11.1) 5.8 (0.4 to 11.2) –4.8 (–10.4 to 0.7) –4.5 (–9.9 to 0.9)
6 months 213 61.7 (24.8) 64 (44–83) 216 63.9 (23.7) 68 (47–83) 180 62.9 (23.8) 65 (44–83) –1.2 (–7.1 to 4.7) –0.5 (–6.0 to 5.1) 1.1 (–4.6 to 6.8) 1.4 (–4.1 to 6.8) –2.3 (–7.9 to 3.3) –1.9 (–7.3 to 3.5)
Social participation (0–100)
3 months 217 47.7 (24.7) 47 (29–66) 221 51.7 (23.0) 53 (38–69) 193 47.1 (23.7) 47 (31–63) 0.6 (–5.1 to 6.3) 0.5 (–5.2 to 6.2) 4.6 (–0.9 to 10.1) 4.7 (–0.7 to 10.1) –4.0 (–9.5 to 1.5) –4.2 (–9.6 to 1.3)
6 months 210 47.0 (25.9) 44 (25–66) 216 50.2 (24.4) 50 (31–69) 179 49.2 (23.8) 50 (31–63) –2.2 (–8.3 to 3.9) –2.2 (–8.2 to 3.9) 1.0 (–4.8 to 6.9) 1.2 (–4.7 to 7.0) –3.3 (–9.1 to 2.6) –3.4 (–9.2 to 2.4)
Strength (0–100)
3 months 220 43.8 (20.4) 44 (31–56) 220 48.1 (22.2) 50 (31–63) 193 40.1 (19.1) 38 (25–50)
6 months 213 40.9 (21.7) 38 (25–56) 216 44.3 (22.7) 44 (25–63) 176 40.3 (21.6) 38 (25–56)
Emotion (0–100)
3 months 220 68.3 (18.2) 69 (56–82) 222 69.9 (16.5) 69 (58–83) 194 67.4 (20.5) 67 (53–86)
6 months 211 66.9 (18.3) 67 (53–81) 216 68.3 (18.8) 69 (56–83) 179 67.4 (19.7) 69 (56–83)
Memory (0–100)
3 months 219 76.0 (22.4) 82 (61–96) 222 80.3 (18.8) 86 (68–96) 194 76.8 (22.2) 82 (61–96)
6 months 213 74.6 (22.7) 79 (58–93) 215 77.4 (21.2) 82 (64–96) 178 77.8 (23.4) 86 (64–96)
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TABLE 7 Comparison of the quality of life (SIS scores) at 3 and 6 months between randomisation groups (continued )
SIS subscale and
time point
Robot-assisted training EULT Usual care
Mean difference (98.33% CI)
Robot-assisted training – usual
care EULT – usual care Robot-assisted training – EULT
n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) Unadjusted Adjusted
a
Unadjusted Adjusted
a
Unadjusted Adjusted
a
Communication (0–100)
3 months 220 80.1 (23.4) 89 (68–100) 222 85.3 (20.5) 96 (79–100) 194 80.9 (24.3) 93 (68–100)
6 months 213 79.3 (21.7) 86 (68–100) 216 83.7 (22.7) 96 (75–100) 179 82.2 (22.5) 93 (71–100)
Stroke recovery (0–100)
3 months 217 47.9 (18.9) 50 (30–60) 223 50.3 (18.9) 50 (40–60) 190 45.2 (19.9) 50 (30–60)
6 months 213 51.4 (20.4) 50 (35–70) 215 50.9 (21.5) 50 (35–70) 180 48.5 (20.3) 50 (33–60)
a For transformed ‘time since stroke’ and trial centre. Time since stroke was to the power of –0.5 for all subscales except ADL and social participation, where –1 and 3 were used, respectively.
b This number is positive.
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Fugl-Meyer Assessment motor function subscale
The FMA motor function subscale scores also showed a similar pattern. The mean score changed from
18.0 points at baseline to 26.2 points at 3 months and 27.2 points at 6 months in the robot-assisted
training group, and was 18.2, 27.1 and 28.2 points at baseline, 3 months and 6 months, respectively,
in the EULT group. There was little evidence of a difference in this subscale between the two groups at
3 months (aMD –0.2, 98.33% CI –2.2 to 1.9) or 6 months (aMD 0.1, 98.33% CI –2.3 to 2.7). The MCID
for this subscale is 4 points for acute stroke patients and 5.25 points for chronic stroke patients59
(see Table 5 and Figure 6). Further details and descriptive statistics for ‘range of motion and joint pain’
and ‘sensation’ subscales are given in Table 5.
Barthel Activities of Daily Living Index
There was little change in the Barthel ADL Index score over time. In the robot-assisted training group,
the mean score was 14.5 points at baseline, 15.5 points at 3 months and 15.6 points at 6 months. In
comparison, the mean scores for the EULT group were 14.3, 15.9 and 16.0 points at baseline, 3 months
and 6 months, respectively. There was limited evidence that the EULT group participants fared better
than the robot-assisted training group participants when comparing ADL at 3 months (aMD –0.5,
98.33% CI –1.0 to –0.0), but there was no difference at 6 months (aMD –0.4, 98.33% CI –1.0 to 0.1)
(see Table 6). The MCID on this scale is 1.85 units,59 and so the changes in mean Barthel ADL Index
scores between baseline, 3 months and 6 months were not large enough to be consistent with a
clinically meaningful difference on this scale for both groups, nor were the comparisons between group
mean scores at 3 or 6 months.
Stroke Impact Scale
The mean scores on the SIS ADL subscale were 50.8 points at 3 months and 50.4 points at 6 months in
the robot-assisted training group, but were 55.9 and 52.5 points at 3 and 6 months, respectively, in the
EULT group. The scores of the ADL subscale of the SIS were consistent with the Barthel ADL Index
scores, in that they showed evidence that EULT group participants fared better than the robot-assisted
training group participants at 3 months (aMD –4.8, 98.33% CI –9.5 to –0.1), but there was no difference
at 6 months (aMD –1.7, 98.33% CI –6.7 to 3.3) (see Table 7). The MCID on this scale is 5.9 units,59 which
was included in the CI; therefore, a difference of this size cannot be ruled out at both time points.
The mean scores on the SIS hand function subscale were 15.5 points at 3 months and 15.7 points at
6 months in the robot-assisted training group, but were 21.4 and 18.4 points at 3 and 6 months,
respectively, in the EULT group. There was little evidence of a difference between the robot-assisted
training group and the EULT group in hand function at 3 months (aMD –5.4, 98.33% CI –10.9 to 0.2) or
6 months (aMD –2.0, 98.33% CI –7.4 to 3.6). The MCID on this scale is 17.8 units,59 so the results were
not consistent with a clinically meaningful difference (see Table 7).
The mean scores on the SIS mobility subscale were 61.6 points at 3 months and 61.7 points at 6 months
in the robot-assisted training group, but were 66.4 and 63.9 points at 3 and 6 months, respectively,
in the EULT group. Similarly, there was little evidence of a difference in mobility at 3 months (aMD
–4.5, 98.33% CI –9.9 to 0.9) or 6 months (aMD –1.9, 98.33% CI –7.3 to 3.5). The MCID on this scale is
4.5 units,59 which was included in these CIs, so a clinically meaningful difference cannot be ruled out.
Finally, the mean scores on the SIS social participation subscale were 47.7 points at 3 months and
47.0 points at 6 months in the robot-assisted training group, but were 51.7 and 50.2 points at 3
and 6 months, respectively, in the EULT group. There was little evidence of a difference in social
participation scores at 3 months (aMD –4.2, 98.33% CI –9.6 to 1.3) or 6 months (aMD –3.4, 98.33% CI
–9.2 to 2.4). More details and descriptive statistics for strength, emotion, memory, communication and
stroke recovery subscales are given in Table 7.
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Enhanced upper limb therapy versus usual care
Action Research Arm Test total score
In the EULT group, the mean ARAT total score was 8.7 points at baseline, 17.3 points at 3 months and
17.2 points at 6 months. In comparison, the mean ARAT total score for the usual care group was 8.1,
14.2 and 16.4 points at baseline, 3 months and 6 months, respectively. The EULT group participants
had better upper limb function than the usual care group participants at 3 months (aMD 2.5, 98.33% CI
0.0 to 5.1), but this difference was not maintained at 6 months (aMD 0.3, 98.33% CI –2.6 to 3.0) (see
Table 4 and Figure 5). The MCID for ARAT total score is 6 points,59 so the changes in mean ARAT scores
between baseline and 3 months were consistent with a clinically meaningful difference on this scale for
both groups, but the changes between 3 and 6 months, and between groups at 3 and 6 months, were
not. The results of the ARAT subscales are given in Appendix 3, Table 34.
Fugl-Meyer Assessment total upper-extremity score
In the EULT group, the mean FMA total upper-extremity score was 69.0 points at baseline, 77.8 points
at 3 months and 79.4 points at 6 months. In comparison, the mean scores for the usual care group
were 68.9, 74.2 and 77.9 points at baseline, 3 months and 6 months, respectively. The EULT group
participants had less upper limb impairment than the usual care group participants for the total score
at 3 months (aMD 3.7, 98.33% CI 0.5 to 6.8), but this difference was not maintained at 6 months
(aMD 1.8, 98.33% CI –1.8 to 5.3) (see Table 5). There is no published MCID for the FMA total upper-
extremity score.
Fugl-Meyer Assessment motor function subscale
In the EULT group, the mean score for the FMA motor function subscale was 18.2 points at baseline,
27.1 points at 3 months and 28.2 points at 6 months. In comparison, the scores for the usual care
group were 18.2, 24.2 and 26.3 points at baseline, 3 months and 6 months, respectively. The EULT
group had a higher average FMA motor function subscale score than the usual care group at 3 months
(aMD 3.0, 98.33% CI 0.9 to 5.0), but this difference was not maintained at 6 months (aMD 2.4, 98.33% CI
–0.2 to 4.8) (see Table 5 and Figure 6). The MCID for this subscale is 4 points for acute stroke patients
and 5.25 points for chronic stroke patients, which makes it difficult to interpret the results from a mixed
patient group.59 Further details and descriptive statistics for ‘range of motion and joint pain’ and
‘sensation’ subscales are given in Table 5.
Barthel Activities of Daily Living Index
In the EULT group, the mean scores for the Barthel ADL Index were 14.3 points at baseline, 15.9 points
at 3 months and 16.0 points at 6 months. In comparison, the mean scores for the usual care group were
14.4, 15.3 and 15.3 points at baseline, 3 months and 6 months, respectively. The EULT group performed
better than the usual care group when comparing ADL at 3 months (aMD 0.7, 98.33% CI 0.2 to 1.2)
and at 6 months (aMD 0.9, 98.33% CI 0.3 to 1.5) (see Table 6). The MCID on this scale is 1.85 units,59
and so the changes in the mean Barthel ADL Index scores between baseline, 3 months and 6 months
were not large enough to be consistent with a clinically meaningful difference on this scale for both
groups, nor were the comparisons between group mean scores at 3 and 6 months.
Stroke Impact Scale
The mean scores on the SIS ADL subscale were 55.9 points at 3 months and 52.5 points at 6 months
in the EULT group, but were 50.8 and 51.9 points at 3 and 6 months, respectively, in the usual care
group. When comparing ADL, the results were consistent with the Barthel ADL Index, in that they
showed evidence that EULT participants scored better than usual care participants (aMD 5.6, 98.33%
CI 0.9 to 10.2) at 3 months. This difference was not maintained at 6 months (aMD 1.1, 98.33% CI
–3.9 to 6.1) (see Table 7). The MCID on this scale is 5.9 units,59 which is included in the CI; therefore,
a difference of this size between groups cannot be ruled out at both time points.
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The mean scores on the SIS hand function subscale were 21.4 points at 3 months and 18.4 points at
6 months in the EULT group, but were 14.3 and 14.8 points at 3 and 6 months, respectively, in the usual
care group. There was evidence that the EULT group scored better than the usual care group at 3 months
(aMD 7.9, 98.33% CI 2.2 to 13.5), but not at 6 months (aMD 3.9, 98.33% CI –1.8 to 9.6). The MCID on
this scale is 17.8 units,59 so the results were not consistent with a clinically meaningful difference.
The mean scores on the SIS mobility subscale were 66.4 points at 3 months and 63.9 points at
6 months in the EULT group, compared with 61.0 and 62.9 points at 3 and 6 months, respectively, in
the usual care group. There was evidence that the EULT group scored better than the usual care group
at 3 months (aMD 5.8, 98.33% CI 0.4 to 11.2), but not at 6 months (aMD 1.4, 98.33% CI –4.1 to 6.8).
The MCID on this scale is 4.5 units,59 which was included in these CIs, so a clinically meaningful
difference cannot be ruled out.
The mean scores on the SIS social participation subscale were 51.7 points at 3 months and 50.2 points
at 6 months in the EULT group, compared with 47.1 and 49.2 points at 3 and 6 months, respectively, in
the usual care group. There was little evidence of a difference between the EULT and usual care groups
at 3 months (aMD 4.7, 98.33% CI –0.7 to 10.1) or 6 months (aMD 1.2, 98.33% CI –4.7 to 7.0). Descriptive
statistics for strength, emotion, memory, communication and stroke recovery are given in Table 7.
Upper limb pain
Upper limb pain scores varied little over time, or between groups. The proportion of participants reporting
upper limb pain in the arm affected by stroke at 3 months was 46% in the robot-assisted training group,
43% in the EULT group and 51% in the usual care group. The mean numeric pain score at 3 months was
2.5 points in the robot-assisted training group, 2.2 points in the EULT group and 2.7 points in the usual
care group (Table 8). There was little evidence of a difference at 3 months between the robot-assisted
training group and the usual care group (aMD –0.2, 98.33% CI –0.9 to 0.4), between the EULT group
and the usual care group (aMD –0.6, 98.33% CI –1.2 to 0.1) or between the robot-assisted training
group and the EULT group (aMD 0.3, 98.33% CI –0.3 to 0.9).
The proportion of participants reporting pain at 6 months was 44% in the robot-assisted training group,
45% in the EULT group and 39% in the usual care group. The mean numeric pain score at 6 months was
2.5 points in the robot-assisted training group, 2.5 points in the EULT group and 2.0 points in the usual
care group. There was little evidence of a difference at 6 months between the robot-assisted training
group and the usual care group (aMD 0.4, 98.33% CI –0.3 to 1.1), between the EULT group and the usual
care group (aMD 0.4, 98.33% CI –0.3 to 1.1) or between the robot-assisted training group and the EULT
group (aMD 0.0, 98.33% CI –0.7 to 0.7).
Pre-planned subgroup and exploratory analyses
Exploratory subgroup analysis
There was little evidence of a difference in the mean ARAT total score between pairs of randomisation
groups when looking at the subgroups of participants for time since stroke, baseline ARAT score, trial
centre and age (Table 9 and Figure 7). This was also the case for the FMA motor function subscale
score (Table 10 and Figure 8a–c) and the Barthel ADL Index score (Table 11 and Figure 8d–f), which
were examined by the time since stroke categories. Note that, by splitting the data across subgroups,
the sample size is reduced for any comparison, so the CIs are wide. The CI includes results that are
often consistent with a clinically meaningful difference (as per the MCID) on the scales, sometimes in
both directions.
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TABLE 8 Summary of upper limb pain (numeric rating scale scores) at 3 and 6 months, by randomisation group
Numeric
rating
scale and
time point
Robot-assisted
training EULT Usual care
Mean difference (98.33% CI)
Robot-assisted training –
usual care EULT – usual care Robot-assisted training – EULT
n Mean (SD) n Mean (SD) n Mean (SD) Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
Upper limb pain (0–10)b
Baseline 253 2.9 (3.2) 259 2.7 (3.0) 254 2.6 (3.1)
3 months 232 2.5 (3.2) 236 2.2 (2.9) 206 2.7 (3.2) –0.2 (–0.9 to 0.5) –0.2 (–0.9 to 0.4) –0.5 (–1.3 to 0.2) –0.6 (–1.2 to 0.1) 0.4 (–0.3 to 1.0) 0.3 (–0.3 to 0.9)
6 months 223 2.5 (3.2) 221 2.5 (3.2) 190 2.0 (2.9) 0.5 (–0.2 to 1.2) 0.4 (–0.3 to 1.1) 0.5 (–0.3 to 1.2) 0.4 (–0.3 to 1.1) 0.0c (–0.7 to 0.8) 0.0c (–0.7 to 0.7)
a For log(time since stroke), baseline upper limb pain score and trial centre.
b Zero is no pain and 10 is ‘as painful as it could be’.
c This number is positive.
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TABLE 9 Exploratory subgroup analysis of the total ARAT score (0–57)a
Subgroup
Robot-assisted training EULT Usual care Unadjusted mean difference (98.33% CI)
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR) n Mean (SD) Median (IQR)
Robot-assisted
training – usual care EULT – usual care
Robot-assisted
training – EULT
Time since stroke
< 3 months 47 25.6 (22.2) 23 (3–48) 39 34.2 (23.9) 46 (5–57) 50 22.4 (24.3) 7 (0–48) 3.1 (–8.2 to 14.4) 11.8 (–0.9 to 23.5) –8.7 (–20.2 to 3.6)
3–12 months 94 16.2 (19.8) 4 (0–29) 110 16.5 (19.1) 5 (3–30) 77 13.4 (18.5) 3 (0–21) 2.8 (–4.4 to 9.7) 3.1 (–3.9 to 9.4) –0.3 (–6.6 to 6.3)
> 12 months 91 9.5 (13.6) 3 (0–11) 85 10.5 (14.6) 3 (0–15) 76 9.6 (15.4) 3 (0–8) –0.2 (–6.0 to 5.0) 0.8 (–5.0 to 6.3) –1.0 (–6.2 to 4.0)
Baseline ARAT score
0 84 5.5 (12.1) 0 (0–4) 89 5.1 (12.0) 0 (0–3) 87 3.4 (10.6) 0 (0–3) 2.1 (–2.1 to 6.3) 1.7 (–2.3 to 5.9) 0.4 (–4.1 to 4.8)
1–7 77 6.5 (10.3) 3 (1–7) 69 10.3 (15.0) 4 (3–10) 51 7.7 (13.1) 3 (0–6) –1.1 (–7.3 to 3.5) 2.6 (–3.8 to 8.6) –3.7 (–9.3 to 1.0)
8–13 16 22.3 (15.6) 19 (11–29) 21 24.1 (14.7) 23 (14–29) 20 17.5 (13.7) 16 (8–22) 4.8 (–6.6 to 17.0) 6.6 (–4.5 to 16.7) –1.8 (–13.0 to 11.1)
14–19 12 32.8 (14.2) 29 (24–43) 7 38.9 (14.2) 38 (32–49) 11 34.2 (22.0) 33 (14–55) –1.3 (–18.7 to 18.1) 4.7 (–16.1 to 24.7) –6.0 (–20.3 to 12.7)
20–39 43 43.6 (11.0) 45 (34–54) 48 43.7 (11.9) 47 (33–54) 34 43.5 (12.3) 46 (36–53) 0.1 (–6.0 to 6.9) 0.2 (–6.1 to 6.9) –0.1 (–5.7 to 5.7)
Trial centre
1 65 16.2 (19.6) 5 (1–29) 70 18.7 (19.9) 7 (3–33) 57 16.2 (21.5) 4 (0–39) 0.1 (–9.0 to 8.7) 2.5 (–6.6 to 11.1) –2.4 (–10.5 to 5.7)
2 76 12.3 (18.2) 3 (0–17) 72 13.6 (20.0) 1 (0–25) 68 9.6 (17.0) 0 (0–10) 2.7 (–4.4 to 9.5) 4.0 (–3.6 to 11.5) –1.3 (–8.9 to 6.1)
3 34 19.7 (22.9) 6 (0–45) 28 26.1 (23.8) 20 (3–54) 30 24.1 (24.0) 18 (0–48) –4.4 (–18.3 to 9.7) 2.0 (–12.9 to 17.0) –6.4 (–20.6 to 7.9)
4 57 16.3 (16.9) 6 (3–28) 64 16.0 (17.9) 4 (3–32) 48 12.3 (15.4) 5 (3–16) 4.0 (–3.9 to 11.3) 3.7 (–4.1 to 11.0) 0.2 (–7.3 to 7.9)
Age
< 55 years 81 17.0 (20.8) 5 (1–29) 90 17.0 (19.8) 5 (3–30) 53 12.0 (19.1) 3 (0–14) 5.0 (–3.9 to 12.9) 5.0 (–3.7 to 12.5) 0.0b (–7.3 to 7.5)
55–70 years 97 14.3 (17.9) 5 (0–26) 84 16.6 (20.9) 3 (0–34) 83 11.3 (17.6) 3 (0–15) 3.1 (–3.5 to 9.3) 5.4 (–1.9 to 12.4) –2.3 (–9.3 to 4.6)
> 70 years 54 15.2 (18.6) 5 (0–28) 60 18.6 (19.9) 9 (2–34) 67 19.7 (21.4) 6 (0–39) –4.5 (–13.0 to 4.3) –1.1 (–9.7 to 7.8) –3.4 (–11.9 to 5.2)
a Comparison of the mean ARAT score at 3 months between trial randomisation groups and subgroups (time from stroke to randomisation, baseline ARAT score, trial centre
and age).
b This number is positive.
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FIGURE 7 Forest plots for the subgroup analysis of the unadjusted ARAT score by time since stroke, baseline ARAT
score, trial centre and age categories, comparing (a) robot-assisted training and usual care; (b) EULT and usual care;
and (c) robot-assisted training and EULT. RT, robot-assisted training; UC, usual care. (continued )
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Descriptive analysis of the relationship between treatment received and total Action
Research Arm Test score
Descriptive analysis between treatment received and total ARAT score was completed for the two
intervention groups. These data are shown in Chapters 4 and 5.
Masking of treatment allocation
At 3 months, the researchers conducting the outcome assessments reported that they became
aware of the treatment group allocation for 101 out of 676 (15%) participants with non-missing data
(see Appendix 4, Table 35). The rate in the robot-assisted training group, at 21%, was almost twice
that in the EULT group (12%) and the usual care group (12%). The researcher was correct in 86 out
of 94 (91%) cases; for 58 out of 101 (57%) cases, the researcher reported that the treatment was
known before the outcome assessment was completed (see Appendix 4, Table 36). Becoming aware of
the treatment group before outcome assessment was more common in the intervention groups than in
the usual care group [robot-assisted training group, 34/50 (68%); EULT group, 15/26 (58%); and usual
care group, 9/25 (36%)]. The results were similar at 6 months: the researchers thought that they knew
the allocation of 88 out of the 633 (14%) assessments that were undertaken, and awareness of the
treatment group before the outcome assessment was completed was also similar across the groups
[robot-assisted training group, 22/39 (56%); EULT group, 15/25 (60%); and usual care group, 15/24 (63%)]
(see Appendix 4, Tables 37 and 38).
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FIGURE 7 Forest plots for the subgroup analysis of the unadjusted ARAT score by time since stroke, baseline ARAT
score, trial centre and age categories, comparing (a) robot-assisted training and usual care; (b) EULT and usual care;
and (c) robot-assisted training and EULT. RT, robot-assisted training; UC, usual care.
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TABLE 10 Exploratory subgroup analysis of the mean FMA scorea
Time since
stroke
Robot-assisted training EULT Usual care Unadjusted mean difference (98.33% CI)
n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR)
Robot-assisted
training – usual care
EULT – usual
care
Robot-assisted
training – EULT
< 3 months 47 36.0 (19.8) 37 (16–55) 39 38.8 (21.0) 42 (21–58) 50 30.3 (22.3) 26 (6–51) 5.7 (–4.6 to 15.9) 8.5 (–2.7 to 19.2) –2.8 (–13.1 to 7.9)
3–12 months 94 26.4 (17.8) 23 (10–41) 110 26.4 (17.6) 23 (11–42) 76 24.0 (18.4) 17 (9–40) 2.3 (–4.5 to 8.9) 2.4 (–4.2 to 8.6) –0.0 (–5.9 to 6.0)
> 12 months 91 21.1 (14.2) 19 (8–30) 85 22.7 (15.7) 20 (10–32) 76 20.4 (14.2) 18 (8–29) 0.7 (–4.7 to 5.9) 2.3 (–3.3 to 8.0) –1.6 (–7.1 to 3.7)
a Comparison of the mean FMA motor score at 3 months between randomisation groups and subgroups.
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FIGURE 8 Forest plots for the subgroup analysis of the unadjusted FMA motor function subscale score and Barthel ADL
Index by time since stroke categories. (a) FMA, robot-assisted training vs. usual care; (b) FMA, EULT vs. usual care;
(c) FMA, robot-assisted training vs. EULT; (d) Barthel ADL Index, robot-assisted training vs. usual care; (e) Barthel ADL
Index, EULT vs. usual care; and (f) Barthel ADL Index, robot-assisted training vs. EULT. RT, robot-assisted training;
UC, usual care. (continued )
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Index, EULT vs. usual care; and (f) Barthel ADL Index, robot-assisted training vs. EULT. RT, robot-assisted training;
UC, usual care.
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TABLE 11 Exploratory subgroup analysis of the mean Barthel ADL Index scorea
Time since
stroke
Robot-assisted training EULT Usual care Unadjusted mean difference (98.33% CI)
n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR) n Mean (SD)
Median
(IQR)
Robot-assisted
training – usual care
EULT – usual
care
Robot-assisted
training – EULT
< 3 months 47 15.8 (3.3) 17 (15–18) 39 17.3 (2.8) 18 (15–20) 50 15.7 (4.1) 17 (13–19) 0.1 (–1.7 to 2.0) 1.6 (–0.1 to 3.4) –1.5 (–3.1 to 0.1)
3–12 months 95 15.6 (3.1) 16 (14–18) 110 15.6 (3.6) 16 (14–18) 80 14.9 (3.9) 16 (13–18) 0.7 (–0.5 to 2.0) 0.7 (–0.6 to 2.0) 0.0b (–1.1 to 1.2)
> 12 months 91 15.2 (3.8) 16 (13–18) 87 15.8 (3.2) 17 (14–18) 77 15.4 (3.5) 16 (13–18) –0.2 (–1.6 to 1.1) 0.4 (–0.9 to 1.7) –0.6 (–1.9 to 0.6)
a Comparison of the mean Barthel ADL Index score at 3 months between randomisation groups and subgroups.
b This number is positive.
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Participant safety data
Serious adverse events
Serious adverse events were reported for 39 out of 257 (15.2%) participants in the robot-assisted
training group (a total of 43 events), for 33 out of 259 (12.7%) participants in the EULT group (a total
of 42 events) and for 20 out of 254 (7.9%) participants in the usual care group (a total of 29 events).
The number of events per participant is shown in Table 12.
The number of participants with at least one SAE during the trial was 39 out of 257 (15.2%) in the
robot-assisted training group, 33 out of 259 (13.7%) in the EULT group and 20 out of 254 (7.9%) in
the usual care group. The difference in proportions between the robot-assisted training and usual care
groups was 7% (98.33% CI 0.2% to 14%); for the EULT and usual care groups, it was 5% (98.33% CI
–2% to 12%), and for the robot-assisted training and EULT groups it was 2% (98.33% CI –5% to 10%).
From these results, we can see that there is evidence of a larger proportion of participants in the
robot-assisted training group than in the usual care group reporting SAEs. There was little evidence
of a difference between the EULT and usual care groups, or between the robot-assisted training and
EULT groups.
The median number of SAEs was 0 (IQR 0–0) across all three groups. The p-values from Mann–Whitney
U-tests were 0.013 when comparing robot-assisted training with usual care, 0.08 when comparing EULT
with usual care and 0.4 when comparing robot-assisted training with EULT, which indicate that there
is evidence of a statistically significant difference between the robot-assisted training and usual care
groups (with SAEs being slightly less common in the usual care group), but not between the EULT
and usual care groups, or between the robot-assisted training and EULT groups (significance
level = 0.05/3 = 0.0167).
Details of reported SAEs are shown in Appendix 5, Table 39. The most common reason for an event to
be reported as a SAE was because it resulted in hospitalisation (robot-assisted training group, n = 32;
EULT group, n = 37; and usual care group, n = 25). None of the SAEs was considered to be related to
the trial intervention. Six events resulted in death (robot-assisted training group, n = 1; EULT group,
n = 4; and usual care group, n = 1). Note that, in the CONSORT flow diagram (see Figure 2), four
participants are reported to be deceased: one participant in the robot-assisted training group and three
participants in the EULT group. For two participants (EULT group, n = 1; usual care group, n = 1),
a SAE was initially reported during their involvement in the trial, but the date of death from this event
was after their involvement ceased.
A summary of the SAEs that resulted in death is presented in Appendix 5, Table 40. A summary of all
other SAEs is presented in Appendix 5, Table 41.
TABLE 12 Number of SAEs per participant
Number of SAEs
Participants, n (%)
Robot-assisted training (N= 257) EULT (N= 259) Usual care (N= 254)
0 218 (84.8) 226 (87.3) 234 (92.1)
1 35 (13.6) 28 (10.8) 14 (5.5)
2 4 (1.6) 3 (1.2) 3 (1.2)
3 0 (0) 1 (0.4) 3 (1.2)
4 0 (0) 0 (0.0) 0 (0)
5 0 (0) 1 (0.4) 0 (0)
Total events 43 42 29
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Non-serious adverse events
At 3 months, 38 out of 233 (16.3%) participants in the robot-assisted training group and 37 out of 236
(15.7%) participants in the EULT group in whom an assessment was carried out reported at least one
non-serious adverse event. For the usual care group, this number was 35 out of 207 (16.9%) participants.
At 6 months, 42 out of 223 (18.8%) participants in the robot-assisted training group and 46 out of
222 (20.7%) participants in the EULT group in whom an assessment was carried out reported at least
one non-serious adverse event. For the usual care group, this was 27 out of 190 (14.2%) participants.
There was little evidence of a difference in the proportion of participants with at least one adverse
event between the pairs of groups. The median number of adverse events was 0 (IQR 0–0) for all groups
at both time points. Full details of all non-serious events are shown in Appendix 5, Tables 42–44.
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Chapter 4 The robot-assisted training
programme
Introduction
This chapter includes a description of the robot-assisted training programme and details of delivery fidelity.
The robot-assisted training programme
Robot-assisted training used a MIT-Manus robotic gym system, which was available at each of the
four trial hub sites. The MIT-Manus robotic gym comprises three components: a shoulder–elbow
(InMotionARM robot), a wrist (InMotionWRIST robot) and a hand attachment (InMotionHAND robot).
The shoulder–elbow and wrist components are standalone robot units, whereas the hand component
is an attachment that fits onto the shoulder–elbow unit. The training programme was designed to be
progressive and challenging. Over the course of the programme, all participants progressed from
exercises that involved gross movements (e.g. shoulder–elbow movement) to exercises that involved
more complex movements (e.g. hand movement). A detailed description of the robot-assisted training
programme is provided in the following paragraph, and a completed TIDieR checklist34 is provided in
Appendix 1, Table 27.
The robot-assisted training programme aimed to provide therapy sessions three times per week for
12 weeks, predominantly in an outpatient setting (36 sessions in total). This was divided into 18 sessions
on the shoulder–elbow (± hand attachment) component and 18 sessions on the wrist robot component.
A session lasted for up to 1 hour, which included 45 minutes of face-to-face therapy for each individual
participant (the aim was to provide 27 hours of face-to-face therapy in total). Transport was arranged
by the local trial co-ordinator if required. A senior therapist (physiotherapist or occupational therapist)
undertook the initial training session on each robot unit (shoulder–elbow and wrist), and at the session
in which the hand attachment was introduced. The remaining therapy sessions were designed to be
delivered by a therapy assistant.
The 12-week robot-assisted training programme was divided into three consecutive blocks (Figure 9).
Block 1: 2 weeks
rhythmic training
Shoulder–elbow Alternate sessions Wrist
Block 2: 6 weeks
assist-as-needed training
Shoulder–elbow Alternate sessions Wrist
Block 3: 4 weeks
assist-as-needed training
Hand Alternate sessions Wrist
FIGURE 9 Summary of the robot-assisted training programme.
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Block 1 lasted for 2 weeks; the shoulder–elbow and wrist robot components were used on alternate
training sessions for three sessions each. Participants used the robot’s ‘playback protocol’, whereby the
arm (placed in the robot arm support) was moved rhythmically towards the flashing red targets that
appear sequentially on a clock face on the robot computer screen (Figure 10). This block allowed
participants to become gradually accustomed to robot-assisted training.
Block 2 lasted for 6 weeks; the shoulder–elbow and wrist robot components were used on alternate
training sessions for nine sessions each. Participants used the ‘adaptive protocol’, whereby the arm
(placed in the robot arm support) was ‘assisted as needed’ to reach the flashing red targets appearing
sequentially on the clock face.
For the final 4 weeks (block 3), the shoulder–elbow and wrist robot units were used on alternate
training sessions for six sessions each. In this block, if a participant was physically able to grasp the
hand attachment, then the hand attachment was introduced. If a participant was physically unable to
grasp the hand attachment, they continued the programme on the shoulder–elbow robot and did not
use the hand attachment. Participants who used the hand attachment in this block used the ‘adaptive
protocol’, whereby the arm is ‘assisted as needed’ by a robot to complete the exercises. On the wrist
robot, and if a participant was unable to use the hand attachment on the shoulder–elbow robot, the
‘random protocol’ was used. The ‘random protocol’ was ‘assisted as needed’ as participants attempt to move
towards flashing red targets on the clock face, but this time targets were presented in random order.
In addition to the robot training exercises described above, the robot-assisted training programme also
involved regular ‘robot evaluations’ whereby kinematics (i.e. related to the movement pattern) and
kinetics (i.e. related to the causes of movement) were measured by the robot. These were completed
every 2 weeks.
The robot-assisted training programme was prescriptive, in that every session had a defined number
and type of exercises that a participant should complete. Each exercise comprised a prespecified
number of movement attempts. Movement attempts were ‘assisted’ for playback, adaptive and random
protocols and ‘unassisted’ for robot evaluations.
The total number of potential movement attempts differed per session, as this depended on the robot
(shoulder–elbow robot alone, shoulder–elbow robot with hand attachment, or wrist robot) and the
training block. If a participant was able to use the hand attachment, the total number of possible
shoulder–elbow robot movement attempts over the 18 sessions was 20,060 (a mean of 1114 movement
attempts per session). For those participants who were unable to use the hand attachment, the number
of possible movement attempts was 19,496 (a mean of 1083 movement attempts per session).
There was no variation in training for the wrist robot; therefore, for each participant, the total number
possible of wrist robot movement attempts over 18 sessions was 19,196 (a mean of 1066 movement
FIGURE 10 Robot-assisted training clock face exercise. The small white circle is the cursor the patient attempts to move;
the large white circle is the target.
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attempts per session). Overall, the number of possible movement attempts for the robot-assisted training
programme was 38,692 for those participants unable to use the hand attachment and 39,256 for those
able to use the hand attachment (a mean 1075 and 1090 movement attempts per session, respectively).
All therapy movement attempts were ‘assisted’. The total possible number of ‘assisted’ movement
attempts for each participant on each robot was 17,280 over the 18 sessions (a total of 34,560 over
the 36 sessions and a mean of 960 movement attempts per session).
Robot evaluations were ‘unassisted’. The total possible number of ‘unassisted’ robot movement attempts
for each participant was 2216 (for those unable to use the hand attachment) or 2780 (for those able to
use the hand attachment) for the shoulder–elbow robot over the 18 sessions. The total possible number
of ‘unassisted’ movement attempts for each participant on the wrist robot was 1916 over the 18 sessions.
Over the 36 sessions, this equated to a total target of 4132 (for those unable to use the hand attachment)
or 4696 (for those able to use the hand attachment) ‘unassisted’ movement attempts.
Training was provided to senior therapists and therapy assistants who delivered the robot-assisted training
programme with updates throughout the trial. Six manuals provided guidance on intervention delivery.60
The first described the purpose, principles and structure of the robot-assisted training programme, as well
as staff roles and responsibilities; the second provided instructions on how to operate the MIT-Manus
robotic gym system. The remaining manuals provided guidance on how to conduct the robot-assisted
training programme on each robot component, with accompanying step-by-step flow charts to guide
trial staff.
Recording the robot-assisted training programme
Details from all sessions were recorded on the trial robots. This included the number of times a
participant used a trial robot, a participant’s duration on the robot and the number and type of
exercises practised. The anonymised data from the trial robots were uploaded to the Newcastle
University server. Data about non-attendance were recorded on the trial database.
Analysis of robot data
Descriptive analyses of numeric data were undertaken and presented as mean (SD) or median (IQR),
as appropriate. Categorical data are presented as n (%).
Fidelity of the robot-assisted training programme
A total of 257 participants were randomised to receive robot-assisted training. Two participants
withdrew from the trial before receiving any robot-assisted training, as they felt that it was too much
of a burden. Data for the remaining 255 (99%) participants were available.
A total of 255 out of 257 (99%) participants received at least one robot-assisted training session,
with 254 out of 257 (99%) of participants receiving one or more shoulder–elbow robot-assisted
training sessions and 243 out of 257 (95%) participants receiving one or more wrist robot-assisted
training sessions. Of the 254 participants who received training on the shoulder–elbow robot,
156 (61%) received training using the hand attachment.
Overall, 8026 out of a possible 9252 sessions (87%) were attended by participants. The number of
sessions attended for the wrist robot was lower [3812/4626 (82%)] than the number of shoulder–elbow
sessions attended [4214/4626 (91%)]. The median number of robot-assisted training sessions received
per participant was 35 (IQR 31–36 sessions), with a median of 18 sessions (IQR 16–18 session) on the
shoulder–elbow robot and 18 sessions (IQR 14–18 sessions) on the wrist robot. The most common
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reason for lack of attendance at sessions was because participants withdrew from the trial [429/1226
(35%) sessions that were not attended]. Details of reasons for all missed sessions can be found in
Appendix 6, Table 45.
The median total duration of training (time on robot) per participant over the 12-week intervention
period was 23 hours and 30 minutes (IQR 19 hours and 13 minutes to 25 hours and 47 minutes).
The median total duration of training per participant was similar on both robots [11 hours and
40 minutes (IQR 9 hours and 54 minutes to 12 hours and 54 minutes) on the shoulder–elbow robot
and 11 hours 56 minutes (IQR 9 hours and 35 minutes to 13 hours and 14 minutes) on the wrist].
The median duration of face-to-face training in each attended session was 41 minutes (IQR 35–47
minutes). Similarly, the median duration of face-to-face training in each attended session was similar
for both robots [40 minutes (IQR 34–46 minutes) on the shoulder–elbow robot and 42 minutes
(IQR 36–48 minutes) on the wrist robot].
In terms of movement attempts, participants achieved 15,002 out of 20,060 (75%) movement
attempts on the shoulder–elbow robot with the hand attachment, 11,141 out of 19,496 (57%) on the
shoulder–elbow robot without the hand attachment and 13,460 out of 19,196 (70%) on the wrist
robot. Over the entire robot-assisted training programme, the median total number of movement
attempts per participant was 27,407 (IQR 22,900–32,187 movement attempts). There was a median
of 808 movement attempts (IQR 668–1040 movement attempts) per participant, per attended session.
The numbers of movement attempts achieved for the shoulder–elbow robot (with and without the
hand attachment), the wrist robot and overall are shown in Appendix 6, Table 46.
Movement attempts by baseline Action Research Arm Test score and
time since stroke
The impact of baseline ARAT score and time since stroke on the number of assisted, unassisted and
total movement attempts was investigated. The predefined categories of baseline ARAT score of
0–7 and 20–39 were used, but, owing to the small numbers of participants randomised with baseline
ARAT scores in the ranges of 8–13 or 14–19, these two categories were combined. For time since
stroke, the pre-defined categories of < 3 months, 3–12 months and > 12 months were used.
Participants with the low baseline ARAT scores (0–7) achieved the lowest median total number of
movement attempts [25,368 (IQR 21,662–29,153)]. Participants with baseline ARAT score in the
ranges of 8–19 and 20–39 achieved median total movement attempts of 32,187 (IQR 27,745–36,624)
and 33,358 (IQR 29,704–38,348), respectively.
Time since stroke did not have an impact on the number of movement attempts achieved, with all
subgroups achieving a similar number. Participants for whom it was < 3 months since their stroke
achieved a median of 28,359 movement attempts (IQR 18,611–35,070 movement attempts), compared
with a median of 26,706 movement attempts (IQR 23,319–32,163 movement attempts) for those
for whom it was 3–12 months since their stroke, and a median of 27,412 movement attempts
(IQR 23,660–30,061 movement attempts) for participants for whom it was > 12 months since their
stroke. Appendix 6, Table 47, shows the number of assisted, unassisted and overall movement attempts
by baseline ARAT score and time since stroke for the shoulder–elbow and wrist robots.
Descriptive analysis of the relationship between treatment received
and total Action Research Arm Test score
The total ARAT score at 3 and 6 months was plotted against the number of sessions attended, total
duration of therapy received and total robot movement attempts. For participants who did not attend
an appointment, zero duration and zero movement attempts were assumed. There is little evidence of
an association between total ARAT score and amount of treatment received (Figure 11).
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FIGURE 11 Scatterplots for the robot-assisted training group for ARAT total score at 3 and 6 months. (a) Number of sessions
attended vs. ARAT score at 3 months; (b) total time on robot vs. ARAT score at 3 months; (c) total robot movement attempts
vs. ARAT score at 3 months; (d) number of sessions attended vs. ARAT score at 6 months; (e) total time on robot vs. ARAT
score at 6 months; and (f) total robot movement attempts vs. ARAT score at 6 months. (continued )
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FIGURE 11 Scatterplots for the robot-assisted training group for ARAT total score at 3 and 6 months. (a) Number of sessions
attended vs. ARAT score at 3 months; (b) total time on robot vs. ARAT score at 3 months; (c) total robot movement attempts
vs. ARAT score at 3 months; (d) number of sessions attended vs. ARAT score at 6 months; (e) total time on robot vs. ARAT
score at 6 months; and (f) total robot movement attempts vs. ARAT score at 6 months. (continued )
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FIGURE 11 Scatterplots for the robot-assisted training group for ARAT total score at 3 and 6 months. (a) Number of sessions
attended vs. ARAT score at 3 months; (b) total time on robot vs. ARAT score at 3 months; (c) total robot movement attempts
vs. ARAT score at 3 months; (d) number of sessions attended vs. ARAT score at 6 months; (e) total time on robot vs. ARAT
score at 6 months; and (f) total robot movement attempts vs. ARAT score at 6 months.
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Chapter 5 The enhanced upper limb
therapy programme
Parts of this chapter have been reproduced from Bosomworth et al.61 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Introduction
This chapter includes a description of the EULT programme and details of delivery fidelity, dose, goals
selected and goal achievement.
The enhanced upper limb therapy programme
The EULT programme consisted of repetitive functional task practice, directed towards achieving
participant-centred goals. The aim of the EULT programme was to promote long-term improvement in
arm function that was useful to individual participants by focusing on their personal goals, through
an intervention that was engaging and challenging, yet achievable. The intervention structure and
principles were standardised, while its application allowed tailoring to individuals’ goals and abilities.
A detailed description of the EULT programme is provided in this chapter, and a completed TIDieR
checklist34 is provided in Appendix 1, Table 27.
To ensure that this comparator was matched to the robot-assisted training in terms of frequency and
duration, the EULT programme aimed to provide therapy sessions three times per week for 12 weeks,
predominantly in an outpatient setting (36 sessions in total). A session lasted for up to 1 hour, which
included 45 minutes of face-to-face therapy for each individual participant (the aim was 27 hours
of face-to-face therapy in total). Transport was arranged by the local trial co-ordinator if required.
A senior therapist (physiotherapist or occupational therapist) undertook the initial therapy session and
reviewed the participant every 4 weeks. The remaining therapy sessions were designed to be delivered
by a therapy assistant.
At the start of their first session, participants were invited to identify personally relevant goals; these
were not prespecified, other than that they should involve a functional task involving the affected arm.
Participants were advised to select no more than four goals at each review session (up to 12 across
the EULT programme), based on previous work.62 Goals from previous arm rehabilitation studies were
prepared as examples to facilitate goal selection.35–38 The goal selection process was not formalised, but
was undertaken according to each senior therapist’s clinical judgement. In each session, participants
practised functional activities to work towards their goals. Activities could involve whole- or part-task
practice, at the discretion of the senior therapist. Whole-task activity practice consisted of practising all
of the components of the task in sequence. Part-task activity practice consisted of practising a specific
part of a task. Part-task practice was undertaken when a participant had difficulty with a specific part
of a task, as it enabled them to concentrate on this particular aspect while working towards completing
the task as a whole. The order in which activities were practised, and the time spent on each, were at
the discretion of the therapist and participant. Participants were encouraged to undertake as many
repetitions as possible in each session. There was no set target for the number of repetitions.
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At the start of each session, participants undertook a brief ‘warm-up’, consisting of focusing attention
on their affected arm, gently stretching soft tissues and mobilising joints to stimulate sensation and
proprioception, before commencing practice, which focused on an individual’s goals.
At therapy sessions 12 (end of week 4) and 24 (end of week 8), progress towards goals was reviewed
with a senior therapist. If a participant had achieved a goal, a new goal and a new activity to practise
were selected. If a participant found a goal or activity too challenging, or experienced other problems,
an alternative goal and activity were chosen. At the final therapy session, practice continued and
progress towards goals was reviewed with a senior therapist. Part of the session was also dedicated to
providing feedback to the participant about progress over the course of the programme and advice
about maintaining arm function in the longer term.
Training was provided to the senior therapists and therapy assistants who delivered the EULT programme,
with updates throughout the trial. In addition, three manuals provided guidance on intervention delivery.60
The first described the purpose, principles and structure of the EULT programme, as well as staff roles and
responsibilities; the second provided guidance on how to structure each session (including assessment,
warm-up and stretching, demonstration and education, progression, monitoring compensatory movements
and feedback). The third manual provided examples of soft tissue stretches prior to task practice, and an
overview of commonly selected goals, with accompanying step-by-step flow charts to guide and progress
practice of functional tasks, each with whole-task and part-task options.
Recording the enhanced upper limb therapy programme
The following were recorded: session attendance, duration of session, duration of face-to-face therapy
during a session, number of repetitions per task practised in each session, goals selected and type of
task practice (whole or part task), and goal achievement. In terms of task repetitions, for whole-task
practice, completion of the whole task counted as one task repetition, that is from the start position
to a ‘return to the start position’ or to completion of the task (if different from the start position).
For part-task practice, completion of the component of the part task counted as one task repetition.
Details about the goals selected were recorded at the initial therapy session and at the 4- and 8-week
review sessions by the senior therapists. Information about whether or not a participant had achieved
their goals (recorded as ‘yes’/‘no’, according to the senior therapist’s clinical judgement) was recorded
at the 4-, 8- and 12-week review sessions. A formal goal attainment scale was not used.
Analysis of enhanced upper limb therapy data
Descriptive analyses of numeric data were undertaken and are presented as mean (SD) or median
(IQR), as appropriate. Categorical data are presented as n (%).
Recorded goal descriptions were reviewed by a research physiotherapist and retrospectively coded into the
following categories, as defined by the Canadian Occupational Performance Measure (COPM):63 self-care,
productivity and leisure, and their respective subcategories and activity categories. An additional ‘other’
category was developed for when the described goal did not fit into one of the three COPM categories.
The ‘other’ subcategories were coded as generic pick up/grasp/reach/place object; range of movement; upper
limb strengthening; weight-bearing; and, when there was insufficient information to code a goal, unclassified.
Fidelity and dose of the enhanced upper limb therapy programme
A total of 259 RATULS trial participants were randomised to receive the EULT programme across the
four trial centres. Data for all 259 participants were uploaded to the trial database.
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Overall, 7877 of the 9324 (84%) total possible sessions were attended. A median of 34 sessions
(IQR 29–36 sessions), out of the possible 36, were attended, per participant. The most common reason
for lack of attendance at sessions was being unwell [406/1447 (28%) sessions that were not attended].
Reasons for all missed sessions can be found in Appendix 6, Table 45. Participants attended 941 out of
1036 (91%) possible senior therapist review sessions, with a median of four reviews (IQR 4–4 reviews)
per participant. The overall median time spent at therapy sessions by each participant was 30 hours
and 32 minutes (IQR 24 hours and 42 minutes to 34 hours and 5 minutes). The overall median duration
of face-to-face therapy at the sessions was 24 hours and 40 minutes (IQR 20 hours and 24 minutes
to 26 hours and 15 minutes) per participant. The median duration of each session was 60 minutes
(IQR 45–60 minutes). The median duration of face-to-face therapy in each session was 45 minutes
(IQR 45–45 minutes).
To further describe dose, the number of task repetitions was recorded. A median of 127 (IQR 70–190)
task repetitions were achieved per participant per session attended. Overall, a median of 4121
(IQR 2395–5727) task repetitions per participant were achieved across the EULT programme.
Goal selection and goal achievement
A median of 12 goals (IQR 9–12 goals) were selected per participant during the 12-week EULT
programme; the overall total was 2664 goals. Table 13 shows the goal choices and goal achievement in
the EULT programme. Further detail about the activities practised is given in Appendix 6, Table 48. The
most popular category of goal choice was ‘self-care’ [1449/2664 (54%)], followed by the ‘other’ category
[661/2664 (25%)], ‘productivity’ [374/2664 (14%)] and ‘leisure’ [180/2664 (7%)]. In the ‘self-care’ category,
the subcategory of ‘personal care’ was the most frequently selected, with 1283 out of 1449 (89%) goals.
Of the 1283 personal care goals, the majority [622 (48%)] related to eating whereas 254 out of 1283
(20%) related to dressing. All 374 goals in the productivity category related to household management,
with ‘cleaning’ and ‘cooking’ being chosen for 206 (55%) goals and 125 (33%) goals, respectively.
TABLE 13 Goal choices and goal achievement based on the COPM
Category
Goals in category, n/N (%)
Subcategory
Goals in subcategory, n/N (%)
Set Achieveda Set Achieveda
Leisure 180/2664 (7) 109/171 (64) Active recreation 16/180 (9) 10/14 (71)
Quiet recreation 71/180 (39) 41/69 (59)
Socialisation 93/180 (52) 58/88 (66)
Productivity 374/2664 (14) 211/351 (60) Household management 374/374 (100) 211/351 (60)
Paid/unpaid work 0/374 (0) –
Play/school 0/374 (0) –
Self-care 1449/2664 (54) 640/1354 (47) Community management 25/1449 (2) 19/23 (83)
Functional mobility 141/1449 (10) 65/136 (48)
Personal care 1283/1449 (89) 556/1195 (47)
Other 661/2664 (25) 327/625 (52) Pick up/grasp/reach/
place object
163/661 (25) 84/155 (54)
Range of movement 413/661 (62) 196/390 (50)
Upper limb strengthening 8/661 (1) 7/7 (100)
Unclassified 26/661 (4) 15/24 (63)
Weight-bearing 51/661 (8) 25/49 (51)
a Data not available for 163 out of 2664 goals.
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In the leisure category, the most popular subcategory was ‘socialisation’ [93/180 (52%)], with the activity
of ‘correspondence’ being chosen for 92 out of 93 (99%) of socialisation goals.
Despite the specification that goals should involve a functional task using the arm, the ‘other’ category
predominantly comprised impairment-based upper limb goals, with ‘range of movement’ being the most
commonly chosen category [413/661 (62%)]. Range of movement was the second most commonly
chosen goal overall. A total of 163 out of 661 (25%) goals in the ‘other’ category comprised generic
reach, grasp, pick-and-place activities; although these were functional, they were not specified sufficiently
to be allocated to any particular COPM category. There was insufficient information to subcategorise
26 out of 661 (4%) of the ‘other’ goals.
In terms of type of practice, participants predominantly used whole-task practice to work towards their
goals [2213/2664 (83%) whole task, 451/2664 (17%) part task].
Of the 2664 goals selected, goal achievement data were recorded for 2501 (94%) goals. In total, 1287
out of 2501 (51%) goals were achieved, ranging between 47% and 100% for each COPM subcategory
(see Table 13). A median of 5 goals (IQR 2–7 goals) were achieved per participant. Of the three most
commonly chosen goals, 234 out of 587 (40%) related to eating were achieved, 196 out of 390 (50%)
related to range of movement were achieved and 141 out of 242 (58%) related to dressing were achieved.
Goal selection and goal achievement by baseline Action Research Arm Test
score and time since stroke
The impact of baseline ARAT score and time since stroke on goal selection and goal achievement
was investigated. The predefined categories of baseline ARAT scores of 0–7 and 20–39 were used;
however, because of the small numbers of participants randomised with baseline ARAT scores in the
ranges of 8–13 and 14–19, these two subgroups were combined. For time since stroke, the predefined
categories of < 3 months, 3–12 months and > 12 months were used.
For all subgroups, the most commonly selected goal was self-care; however, goal achievement varied
according to baseline ARAT score and time since stroke (see Appendix 6, Table 49). Participants who had
the lowest baseline ARAT score (0–7) had the lowest goal achievement, with 684 out of 1637 (42%)
goals being achieved. For participants with a low baseline ARAT score, goals that related to personal
care, range of movement and functional mobility had low achievement rates. Participants who had
ARAT scores in the ranges of 8–19 or 20–39 had goal achievements of 201 out of 318 (63%) and
402 out of 546 (74%) goals, respectively. In terms of time since stroke, participants who were recruited
> 1 year after stroke had the lowest goal achievement, with 336 out of 882 (38%) of goals being
achieved. Those participants who had the lowest baseline ARAT score (0–7) and who were recruited
> 1 year after stroke had the lowest goal achievement, with only 167 out of 616 (27%) goals being
achieved. Participants randomised within between 3 and 12 months of their stroke achieved 616 out of
1176 (52%) goals, whereas those recruited < 3 months after stroke had the highest goal achievement,
with 335 out of 443 (76%) goals being achieved.
Descriptive analysis of the relationship between treatment received and
total Action Research Arm Test score
The total ARAT score at 3 and 6 months was plotted against the number of sessions attended, total
duration of therapy received and total number of therapy repetitions. For participants who did not
attend an appointment, zero duration and zero therapy repetitions were assumed. There is little
evidence of an association between total ARAT score and amount of treatment received (Figure 12).
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FIGURE 12 Scatterplots for the EULT group for ARAT total score at 3 and 6 months. (a) ARAT score at 3 months vs.
number of sessions attended; (b) ARAT score at 3 months vs. total session duration; (c) ARAT score at 3 months vs. total
therapy duration; (d) ARAT score at 3 months vs. total number of repetitions; (e) ARAT score at 6 months vs. number of
sessions attended; (f) ARAT score at 6 months vs. total session duration; (g) ARAT score at 6 months vs. total therapy
duration; (h) ARAT score at 6 months vs. total number of repetitions. (continued )
DOI: 10.3310/hta24540 Health Technology Assessment 2020 Vol. 24 No. 54
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Rodgers et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
57
0
0
20
40
60
(e)
10 20 30
Number of sessions attended
A
R
A
T
 t
o
ta
l s
co
re
 a
t 
6
 m
o
n
th
s
0
0
20
40
60
(f)
500 1000 1500 2000
Total session duration (minutes)
A
R
A
T
 t
o
ta
l s
co
re
 a
t 
6
 m
o
n
th
s
0
0
20
40
60
(g)
500 1000 1500 2000
Total therapy duration (minutes)
A
R
A
T
 t
o
ta
l s
co
re
 a
t 
6
 m
o
n
th
s
0
0
20
40
60
(h)
5000 10,000 15,000
Total number of repetitions
A
R
A
T
 t
o
ta
l s
co
re
 a
t 
6
 m
o
n
th
s
FIGURE 12 Scatterplots for the EULT group for ARAT total score at 3 and 6 months. (a) ARAT score at 3 months vs.
number of sessions attended; (b) ARAT score at 3 months vs. total session duration; (c) ARAT score at 3 months vs. total
therapy duration; (d) ARAT score at 3 months vs. total number of repetitions; (e) ARAT score at 6 months vs. number of
sessions attended; (f) ARAT score at 6 months vs. total session duration; (g) ARAT score at 6 months vs. total therapy
duration; (h) ARAT score at 6 months vs. total number of repetitions.
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Chapter 6 Usual post-stroke care:
arm rehabilitation therapy logs
Introduction
It was intended that all randomisation groups should continue to receive usual post-stroke care during
participation in the trial. Trial interventions (robot-assisted training and the EULT programme) were
delivered in addition to usual care. Trial involvement and/or randomisation group should not have had
an effect on the usual care received. This chapter provides a description of the usual post-stroke care
that trial participants reported that they received for their arm or hand, during their time in the trial.
What is usual care in the NHS?
The current NICE quality standard39 states that stroke patients in hospital or in the community should
receive a minimum of 45 minutes of therapy, 5 days per week, and that this therapy should continue
in the longer term, depending on a patient’s need. However, it is widely accepted that this is not
met, especially once patients are discharged from hospital or early supported discharge services.40
Furthermore, this guidance relates to all therapy; it does not distinguish upper limb rehabilitation from
other aspects of rehabilitation. There is no specific standard about the amount or content of upper
limb rehabilitation that should be provided post stroke.
Recording information about usual care arm therapy
All RATULS trial participants were given trial-specific arm rehabilitation therapy logs, and were asked
to record any upper limb rehabilitation, other than the robot-assisted training or the EULT programme,
that they received during the course of the trial. Two arm rehabilitation therapy logs were given to
each participant: the log for trial weeks 1–12 (the intervention period) was given to participants at the
baseline assessment and the log for trial weeks 13–24 (the follow-up period) was given to participants
at the 3-month outcome assessment. The logs were collected from participants at the 3- and 6-month
outcome assessment visits.
The bespoke self-completion logs were intended to be completed weekly. If a participant received
upper limb therapy that was not a trial intervention, they were asked to record the frequency, duration
and the type of therapy received. For type of therapy, participants, with help from their therapists,
were asked to select from the following categories: passive stretching, range of motion, functional
strengthening, weight-bearing through hand, trunk control, repetitive task-specific practice, personal
ADL, extended ADL or other. Participants were also asked to record whether or not they undertook
any self-practice upper limb exercises.
Usual care received by each randomisation group
Completion of the arm rehabilitation therapy logs
Of the 676 participants who attended a 3-month assessment, 445 (66%) returned a therapy log. There
was little variation in the return rate of the arm rehabilitation therapy logs between randomisation groups,
with 158 out of 233 (68%) in the robot-assisted training group, 159 out of 236 (67%) in the EULT group
and 128 out of 207 (62%) in the usual care group returning their arm rehabilitation therapy log for trial
weeks 1–12 (the intervention period).
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Of the 635 participants who completed the 6-month assessment, 345 (54%) returned a therapy log for
trial weeks 13–24 (the follow-up period): 118 out of 223 (53%) in the robot-assisted training group,
113 out of 222 (51%) in EULT group and 114 out of 190 (60%) in the usual care group.
Although some logs were returned, this did not mean that data were complete. Table 14 reports the
number of weeks that participants provided some data in the arm rehabilitation logs. Data completeness
was comparable for all randomisation groups for both time periods.
Content of usual care therapy received
Number of weeks therapy was received
In the arm rehabilitation therapy logs, each participant was asked each week, ‘have you had any
therapy for your arm or hand in the last 7 days?’. During the intervention period, answers to this
question were received for 1830 out of 1896 (97%) weeks in the robot-assisted training group,
1830 out of 1908 (96%) weeks in EULT group and 1476 out of 1536 (96%) weeks in the usual care
group. For weeks 13–24, data were available about the number of weeks for which therapy was
received for 1355 out of 1416 (96%) weeks in the robot-assisted training group, 1296 out of 1356
(96%) weeks in EULT group and 1317 out of 1356 (96%) weeks in the usual care group. Table 15 gives
the number of weeks that participants who returned their log stated that they received therapy for
their arm or hand outside the RATULS trial. When participants did not respond to this question, it was
assumed that no therapy was received.
For weeks 1–12, 65 out of 158 (41%) participants in the robot-assisted training group, 76 out of 159
(48%) in the EULT group and 75 out of 128 (59%) in the usual care group stated that they received
some usual care therapy for their arm or hand. However, only 18 out of 158 (11%) participants in the
robot-assisted training group, 18 out of 159 (11%) in EULT group and 27 out of 128 (21%) in the usual
care group stated that some usual care arm therapy was received for each of the 12 weeks. The usual
care group participants reported receiving usual care therapy for their arm or hand more often than
participants in the other two groups, with usual care arm therapy being received for a median of
4 weeks (IQR 0–11 weeks), compared with a median of 0 weeks for both the robot-assisted training
and EULT groups (IQR 0–7 weeks and IQR 0–8 weeks, respectively).
For weeks 13–24, 43 out of 118 (36%) participants in the robot-assisted training group, 57 out of 113
(50%) in the EULT group and 53 out of 114 (47%) in the usual care group stated that they received
some usual care arm therapy for their arm or hand. The number of participants who stated that therapy
was received for all 12 weeks was similar in all groups: 14 out of 118 (12%) in the robot-assisted
training group, 16 out of 113 (14%) in the EULT group and 16 out of 114 (14%) in the usual care group.
Amount of time that usual care arm therapy was received
If a participant received usual care arm therapy, they were asked to report the amount of time spent
on this therapy each week. Across all randomisation groups, 216 out of 445 (49%) participants
recorded that they received some usual care arm therapy during weeks 1–12. A total of 153 out of
345 (44%) participants recorded that they received some usual care arm therapy during weeks 13–24.
For weeks 1–12, 213 out of 216 (93%) participants provided data for both the number of days and the
amount of time spent on usual care arm therapy per week. For weeks 13–24, data were available for
133 out of 153 (86%) participants about the number of days and for 134 out of 153 (87%) participants
for the amount of time spent on usual care arm therapy per week. However, in all groups, and for both
time periods, the median number of days per week on which usual care arm therapy was provided was
0 days (IQR 0–1 days). Similarly, the median amount of time spent on usual care arm therapy per week
for all groups at both time points was 0 minutes; see Appendix 6, Table 50.
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TABLE 14 The number of weeks that participants who returned arm rehabilitation logs provided some data in the logs
Variable
Participants
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 158)
Weeks 13–24
(N= 118)
Weeks 1–12
(N= 159)
Weeks 13–24
(N= 113)
Weeks 1–12
(N= 128)
Weeks 13–24
(N= 114)
Number of weeks data were provided for, n (%)
1 0 (0) 1 (< 1) 2 (1) 0 (0) 0 (0) 1 (< 1)
2 0 (0) 0 (0) 1 (< 1) 0 (0) 1 (< 1) 0 (0)
3 0 (0) 1 (< 1) 1 (< 1) 0 (0) 0 (0) 1 (< 1)
4 1 (< 1) 0 (0) 0 (0) 1 (< 1) 1 (< 1) 0 (0)
5 1 (< 1) 1 (< 1) 0 (0) 1 (< 1) 2 (2) 0 (0)
6 2 (1) 0 (0) 2 (1) 1 (< 1) 0 (0) 0 (0)
7 1 (< 1) 0 (0) 0 (0) 1 (< 1) 2 (2) 1 (< 1)
8 2 (1) 2 (2) 1 (< 1) 0 (0) 1 (< 1) 1 (< 1)
9 1 (< 1) 4 (3) 0 (0) 0 (0) 1 (< 1) 3 (3)
10 3 (2) 0 (0) 5 (3) 4 (4) 2 (2) 2 (2)
11 5 (3) 2 (2) 11 (7) 2 (2) 4 (3) 9 (8)
12 142 (89) 107 (91) 136 (86) 103 (91) 114 (89) 96 (84)
Number of weeks therapy data was provided for each
participant who returned their therapy log, median (IQR)
12 (12–12) 12 (12–12) 12 (12–12) 12 (12–12) 12 (12–12) 12 (12–12)
Participants who returned their therapy log, n/N (%) 158/233 (68) 118/223 (53) 159/236 (67) 113/222 (50) 128/207 (62) 114/190 (60)
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TABLE 15 The number of weeks that participants stated that they received usual care arm or hand therapy for those participants who returned their arm rehabilitation therapy log
Variable
Participants
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 158)
(1896 weeks)
Weeks 13–24
(N= 118)
(1416 weeks)
Weeks 1–12
(N= 159)
(1908 weeks)
Weeks 13–24
(N= 113)
(1356 weeks)
Weeks 1–12
(N= 128)
(1536 weeks)
Weeks 13–24
(N= 114)
(1368 weeks)
Number of weeks participants stated that they received usual care therapy for their arm or hand, n (%)
0 93 (59) 75 (64) 83 (52) 56 (50) 53 (41) 61 (54)
1 2 (1) 4 (3) 9 (6) 6 (5) 3 (2) 5 (4)
2 4 (3) 5 (4) 8 (5) 2 (2) 2 (2) 2 (2)
3 3 (2) 3 (3) 5 (3) 9 (8) 2 (2) 8 (7)
4 4 (3) 6 (5) 1 (< 1) 6 (5) 6 (5) 4 (4)
5 2 (1) 1 (< 1) 3 (2) 4 (4) 5 (4) 2 (2)
6 2 (1) 1 (< 1) 6 (4) 3 (3) 4 (3) 2 (2)
7 9 (6) 1 (< 1) 2 (1) 2 (2) 7 (6) 3 (3)
8 5 (3) 0 (0) 8 (5) 3 (3) 3 (2) 3 (3)
9 7 (4) 1 (< 1) 3 (2) 1 (< 1) 5 (4) 3 (3)
10 4 (3) 3 (3) 5 (3) 4 (4) 3 (2) 0 (0)
11 5 (3) 4 (3) 8 (5) 1 (< 1) 8 (6) 5 (4)
12 18 (11) 14 (12) 18 (11) 16 (14) 27 (21) 16 (14)
Number of weeks participants stated they received usual care therapy for
their arm or hand, median (IQR)
0 (0–7) 0 (0–4) 0 (0–8) 1 (0–6) 4 (0–11) 0 (0–7)
Participants who stated that they received therapy for their arm or hand
during the 12-week period, n/N (%)
65/158 (41) 43/118 (36) 76/159 (48) 57/113 (50) 75/128 (59) 53/114 (47)
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Type of therapy received
Of those participants who recorded that they had received usual care arm therapy in weeks 1–12, 64
out of 65 (99%) in the robot-assisted training group, 75 out of 76 (99%) in the EULT group and 75 out
of 75 (100%) in the usual care group gave further information about the type of therapy received. For
weeks 13–24, 42 out of 43 (98%) participants in the robot-assisted training group, 56 out of 57 (98%)
in the EULT group and 49 out of 53 (93%) in the usual care group gave further information on the type
of therapy received. Table 16 gives the type of therapy that these participants received and details for
how many weeks each type of therapy was undertaken over the 12-week intervention period and the
12-week follow-up period.
For both time periods, there was little variation between the groups in the type of therapy undertaken;
the most common type of therapy received was passive stretching. For weeks 1–12, passive stretching
was undertaken for a median of 7 weeks (IQR 2–11 weeks) for the robot-assisted training group,
6 weeks (IQR 1–10 weeks) for the EULT group and 7 weeks (IQR 3–12 weeks) for the usual care group.
For weeks 13–24, although it was still the most common type of therapy received, the number of weeks
during which passive stretching was undertaken was reduced to a median of 4 weeks (IQR 1–11 weeks)
for the robot-assisted training group, 3 weeks (IQR 1–11 weeks) for the EULT group and 6 weeks
(IQR 2–11 weeks) for the usual care group for this time period.
The type of therapy received least was activities relating to extended ADL (e.g. cooking, cleaning).
During weeks 1–12, activities relating to extended ADL were undertaken for a median of 0 weeks in all
randomisation groups (IQR 0–3 weeks in the robot-assisted training group, IQR 0–2 weeks in the EULT
group and IQR 0–1 weeks in the usual care group). Similar results were obtained for weeks 13–24, with
this type of therapy being received for a median of 0 weeks in all randomisation groups (IQR 0–0 weeks
in the robot-assisted training group, IQR 0–1 weeks in the EULT group and IQR 0–2 weeks in the usual
care group). Details of the ‘other’ therapy specified by participants can be found in Appendix 6, Table 51.
Number of weeks self-practice was undertaken
In addition to the question about usual care arm therapy received, each week participants were asked
to respond yes/no to the following question: ‘Have you undertaken any self-practice exercises for your
arm or hand in the last 7 days?’.
For weeks 1–12, answers to this question were available for 1828 out of 1896 (96%) weeks for the
robot-assisted training group, 1823 out of 1908 (96%) weeks for the EULT group and 1451 out of
1536 (94%) weeks for the usual care group. For weeks 13–24, responses were available for 1336 out
of 1416 (94%) weeks for the robot-assisted training group, 1304 out of 1356 (96%) weeks for the
EULT group and 1305 out of 1356 (96%) weeks for the usual care group. Table 17 gives the number
of weeks that participants who returned their log stated that they completed any self-practice for their
arm or hand. When participants did not respond to the question about self-practice, it was assumed
that no self-practice was undertaken in those weeks.
The amount of reported self-practice was high for both time periods. For weeks 1–12, 136 out of 158
(86%) participants in the robot-assisted training group, 152 out of 159 (96%) in the EULT group and
120 out of 128 (94%) in the usual care group stated that they completed self-practice at some stage
during this time. For all groups, self-practice was undertaken for a median of 12 weeks (IQR 8–12 weeks
for the robot-assisted training group, IQR 10–12 weeks for the EULT group and IQR 10–12 weeks for the
usual care group). For weeks 13–24, self-practice was undertaken for a median of 12 weeks for all groups
(IQR 9–12 weeks for the robot-assisted training group, IQR 11–12 weeks for the EULT group and IQR
11–12 weeks for the usual care group), with 107 out of 118 (91%) participants in the robot-assisted
training group, 107 out of 113 (95%) in the EULT group and 107 out of 114 (94%) in the usual care
group stating that they completed self-practice at some stage during this time.
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TABLE 16 The type of therapy participants stated they received and for how many weeks each type of therapy was undertaken over the trial period
Type of therapy
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 524 weeks)
(64 participants)
Weeks 13–24
(N= 313 weeks)
(42 participants)
Weeks 1–12
(N= 533 weeks)
(75 participants)
Weeks 13–24
(N= 375 weeks)
(56 participants)
Weeks 1–12
(N= 645 weeks)
(75 participants)
Weeks 13–24
(N= 373 weeks)
(49 participants)
Passive stretching
Participants who received this type of therapy, n/N (%) 60/64 (94) 35/42 (83) 63/75 (84) 50/56 (89) 66/75 (88) 42/49 (86)
Weeks this type of therapy was undertaken, median (IQR) 7 (2–11) 4 (1–11) 6 (1–10) 3 (1–11) 7 (3–12) 6 (2–11)
Improving range of motion
Participants who received this type of therapy, n/N (%) 56/64 (86) 33/42 (79) 57/75 (76) 48/56 (86) 66/75 (88) 37/49 (76)
Weeks this type of therapy was undertaken, median (IQR) 7 (2–10) 4 (1–9) 5 (1–10) 4 (1–9) 7 (3–11) 4 (1–10)
Functional strengthening
Participants who received this type of therapy, n/N (%) 44/64 (69) 27/42 (64) 48/75 (64) 36/56 (64) 51/75 (68) 31/49 (63)
Weeks this type of therapy was undertaken, median (IQR) 3.5 (0–7) 1 (0–4) 1 (0–7) 4 (0–8) 2 (0–8) 2 (0–7)
Weight-bearing through hand
Participants who received this type of therapy, n/N (%) 38/64 (59) 18/42 (43) 41/75 (55) 29/56 (52) 45/75 (60) 24/49 (49)
Weeks this type of therapy was undertaken, median (IQR) 1.5 (0–7) 0 (0–2) 1 (0–6) 1 (0–4) 2 (0–4) 0 (0–3)
Trunk control
Participants who received this type of therapy, n/N (%) 32/64 (50) 16/42 (38) 32/75 (43) 25/56 (45) 35/75 (47) 24/49 (49)
Weeks this type of therapy was undertaken, median (IQR) 0.5 (0–5) 0 (0–2) 0 (0–4) 0 (0–3) 0 (0–4) 0 (0–4)
Repetitive task-specific practice
Participants who received this type of therapy, n/N (%) 43/64 (67) 22/42 (52) 42/75 (56) 29/56 (52) 48/75 (64) 25/49 (51)
Weeks this type of therapy was undertaken, median (IQR) 2.5 (0–7) 1 (0–5) 1 (0–8) 1 (0–5) 2 (0–7) 1 (0–5)
U
SU
A
L
P
O
ST
-ST
R
O
K
E
C
A
R
E
:
A
R
M
R
E
H
A
B
ILIT
A
T
IO
N
T
H
E
R
A
P
Y
LO
G
S
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
6
4
Type of therapy
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 524 weeks)
(64 participants)
Weeks 13–24
(N= 313 weeks)
(42 participants)
Weeks 1–12
(N= 533 weeks)
(75 participants)
Weeks 13–24
(N= 375 weeks)
(56 participants)
Weeks 1–12
(N= 645 weeks)
(75 participants)
Weeks 13–24
(N= 373 weeks)
(49 participants)
Personal ADL
Participants who received this type of therapy, n/N (%) 33/64 (52) 16/42 (38) 34/75 (45) 24/56 (43) 38/75 (51) 18/49 (37)
Weeks this type of therapy was undertaken, median (IQR) 1 (0–7) 0 (0–1) 0 (0–7) 0 (0–4) 1 (0–5) 0 (0–4)
Extended ADL
Participants who received this type of therapy, n/N (%) 25/64 (39) 8/42 (19) 23/75 (31) 14/56 (25) 21/75 (28) 16/49 (33)
Weeks this type of therapy was undertaken, median (IQR) 0 (0–3) 0 (0–0) 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–2)
Other
Participants who received this type of therapy, n/N (%) 17/64 (27) 14/42 (33) 27/75 (36) 22/56 (39) 29/75 (39) 21/49 (43)
Weeks this type of therapy was undertaken, median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–2) 0 (0–3) 0 (0–6)
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TABLE 17 The number of weeks that participants stated they completed any self-practice for their arm or hand, for those participants who returned their arm rehabilitation therapy log
Participants
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 158 participants)
(1896 weeks)
Weeks 13–24
(N= 118 participants)
(1416 weeks)
Weeks 1–12
(N= 159 participants)
(1908 weeks)
Weeks 13–24
(N= 113 participants)
(1356 weeks)
Weeks 1–12
(N= 128 participants)
(1536 weeks)
Weeks 13–24
(N= 114 participants)
(1368 weeks)
Number of weeks data were provided for, n (%)
0 22 (14) 11 (9) 7 (4) 6 (5) 8 (6) 7 (6)
1 0 (0) 4 (3) 2 (1) 0 (0) 0 (0) 1 (< 1)
2 0 (0) 0 (0) 3 (2) 3 (3) 1 (< 1) 1 (< 1)
3 3 (2) 2 (2) 0 (0) 0 (0) 0 (0) 1 (< 1)
4 5 (3) 2 (3) 3 (2) 0 (0) 1 (< 1) 0 (0)
5 3 (2) 0 (0) 0 (0) 1 (< 1) 5 (4) 1 (< 1)
6 5 (3) 3 (3) 3 (2) 3 (3) 0 (0) 2 (2)
7 1 (< 1) 2 (2) 3 (2) 4 (4) 3 (2) 2 (2)
8 2 (1) 2 (2) 3 (2) 3 (3) 4 (3) 1 (< 1)
9 2 (1) 6 (5) 7 (4) 2 (2) 5 (4) 5 (4)
10 7 (4) 2 (2) 9 (6) 5 (4) 8 (6) 5 (4)
11 17 (11) 11 (9) 20 (13) 9 (8) 11 (9) 7 (6)
12 91 (58) 73 (62) 99 (62) 77 (68) 82 (64) 81 (71)
Number of weeks
participants stated they
completed self-practice
for their arm or hand,
median (IQR)
12 (8–12) 12 (9–12) 12 (10–12) 12 (11–12) 12 (10–12) 12 (11–12)
Participants who stated
that they had completed
self-practice for their arm
or hand during the 12-week
period, n (%)
136 (86) 107 (91) 152 (96) 107 (95) 120 (94) 107 (94)
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Usual care arm therapy according to baseline arm function and
time since stroke
In clinical practice, the intensity of therapy usually decreases as time since stroke increases, and varies
according to severity of the upper limb neurological deficit. Therefore, to describe the therapy received
by participants in the usual care arm, the arm rehabilitation log data were analysed according to
participants’ baseline ARAT scores and time since stroke. The prespecified categories of baseline ARAT
score of 0–7 and 20–39 were used; however, because of the small numbers of participants randomised
with baseline ARAT scores in the ranges 8–13 and 14–19, these two categories were combined. For
time since stroke, the prespecified categories of < 3 months, 3–12 months and > 12 months were used.
Completion of the arm rehabilitation therapy logs
The return rate of the arm rehabilitation therapy log varied according to a participant’s baseline
ARAT score and time since stroke. Appendix 6, Tables 52 and 53, show the arm rehabilitation log data
analysed according to participants’ baseline ARAT scores and time since stroke over trial weeks 1–12
and 13–24, respectively. When participants did not respond to the question, it was assumed that no
usual care arm therapy/self-practice was undertaken in those weeks.
For those participants who attended a 3-month assessment, the lowest return rate was 9 out of
20 (45%) in the subgroup with a baseline ARAT score of between 8 and 19, and who were < 3 months
post stroke. The subgroup with the highest return rate was those participants who had a baseline
ARAT score of between 0 and 7 and were < 3 months post stroke [66/89 (74%)].
Fewer arm rehabilitation logs were returned at 6 months. However, there was still variation in the
return rate between subgroups. For those participants who attended the 6-month assessment, the
lowest return rate was 14 out of 30 (47%) in the subgroup with a baseline ARAT score of between
8 and 19 and who were > 12 months post stroke. The subgroup that had the highest return rate was
those participants who had a baseline ARAT score of between 20 and 39 and who were > 3 months
post stroke [19/31 (61%)].
Content of usual care therapy received
Number of weeks therapy was received
Regardless of a participant’s baseline ARAT score, those participants who were > 12 months post
stroke received the least therapy, with a total of 48 out of 166 (29%) of these participants stating
that they received usual care arm therapy in weeks 1–12; this proportion was 44 out of 122 (36%)
participants in weeks 13–24.
Time spent receiving usual care therapy
For weeks 1–12, participants who had a baseline ARAT score of between 8 and 19 and who were
< 3 months post stroke received the most usual care arm therapy. They received therapy on a median
of 1 day per week (IQR 0–4 days) and a median of 80 minutes therapy time per week (IQR 0–180 minutes).
For all subgroups during weeks 13–24, the median number of days per week on which usual care arm
therapy was received was zero, with a median therapy time of zero minutes per week.
Type of therapy received
With the exception of the subgroup with a baseline ARAT score of between 20 and 39, the most
common type of therapy received was passive stretching (> 80% of cases) over the intervention period.
For those with a baseline ARAT score of between 20 and 39 and who were < 3 months post stroke,
functional strength training, repetitive task-specific practice and personal ADL were equally as popular,
being received in 10 out of 13 (77%) cases. For the follow-up period, passive stretching was the most
common type of therapy received. Appendix 6, Tables 54 and 55, shows the type of therapy received
according to a participant’s baseline ARAT score and time since stroke over trial weeks 1–12 and 13–24.
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Number of weeks self-practice was undertaken
Levels of self-practice were high for both time periods and for all subgroups. For weeks 1–12, 408 out
of 445 (92%) participants stated that self-practice was undertaken; for weeks 13–24, 321 out of 345
(93%) participants stated that self-practice was undertaken. There was minimal variation in the amount
of self-practice undertaken between subgroups (see Appendix 6, Table 53).
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Chapter 7 Qualitative process evaluation
Introduction
Process evaluation can contribute to the interpretation of the results of a RCT of a complex intervention.64
Trial designs tend to prioritise the objective assessment of clinical outcomes, leaving the process of change
(the space between the provision of the intervention resources and the outcomes) unclear.34,65,66 Process
evaluation can lead to an understanding of participants’ experiences and responses to trial interventions
(acceptability), reflection on the mechanisms of impact of the intervention(s) and descriptions of the range
of individual and contextual factors that affect how the interventions are delivered during the trial. It can
also inform how interventions may need to be adapted and/or delivered in routine practice, after the trial,
if proven efficacious.
Qualitative reviews and meta-syntheses of patient experiences of recovery after stroke demonstrate
the multifaceted impact that stroke can have on a survivor, on their life after stroke and trajectories of
recovery.67–69 Rehabilitation for stroke patients is, therefore, a complex intervention. Often, interventions
are multicomponent, target different domains, use multiple outcome measures and depend on
engagement from both the participant and the health service professional delivering the treatment.
In line with the UK Medical Research Council’s guidance for the design and evaluation of complex
interventions,70 a qualitative process evaluation was conducted to explore the experiences and delivery
of two complex interventions (robot-assisted training and EULT) [both described in detail in Chapters 4
and 5, and using the TIDieR framework34 (see Appendix 1, Table 27)] and usual care for upper limb
rehabilitation following stroke.
The objectives of this qualitative study were to:
l seek the views and experiences of patients and health service professionals about the upper limb
rehabilitation that they have received or provided
l seek the views of patients and health service professionals about the factors that affected the
implementation of the trial.
Qualitative process evaluation design and methods
The study design comprised semistructured interviews with both patients and health service professionals,
conducted during two time periods (phases) in the trial (Figure 13). During phase 1, patients who were
randomised to receive an intervention were interviewed at baseline and at 3 months post randomisation
(at the end of the intervention period). During phase 2, different patients were interviewed at 3 months
(post intervention) and 6 months (follow-up) post randomisation. Interviews took place in two phases to
minimise the likelihood that reporting of the experiences of participants was unduly shaped by factors
relating to delivery of the trial at the time of interviewing, which can change over the course of the trial,
and to enable an iterative process of data collection and analysis between phases, providing scope to
follow up initial findings in greater depth and/or explore questions not targeted in interviews from
phase 1. The phase 1 interim analysis also informed phase 2; instead of interviewing patients at the
beginning and end of therapy, we interviewed them at the end of therapy and 3 months after completing
therapy (6 months post randomisation).This provided a post-intervention period of 3 months during which
patients could reflect on any perceived impacts of therapy, before we interviewed them.
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In both phases, patients who were randomised to receive a trial intervention (robot-assisted training or
EULT) were interviewed twice. This was to allow for exploration of changes in patients’ expectations and
experiences at different points during the therapy programme (and to provide more detailed follow-up
of emerging key issues at a participant’s second interview). In combination, the two data collection
phases allowed us to collect qualitative data corresponding to the three assessment time points in the
trial (baseline, 3 months and 6 months), without interviewing any patient more than twice.
Patients from the usual care group were interviewed only once to provide insight into the type of
therapy received outside the trial context. Different health service professionals were interviewed up
to two times in total, across phases 1 and 2.
Theoretical framework
This qualitative study was informed by normalisation process theory (NPT).71 NPT explains the work
undertaken by people to embed and implement new processes or technologies into routine practice.
This study used NPT to develop an understanding of how the RATULS trial was delivered, through
informing both data collection (interview topic guide) and analysis.
Study participants and recruitment
Patients and health service professionals were recruited from all open trial centres: the three trial
centres that had commenced trial recruitment for phase 1 (by February 2016) and all four trial centres
for phase 2 (from October 2016).
Patient study group
All participants in the trial were eligible to participate in the qualitative study. Selection for the
qualitative study was based on the timing of qualitative data collection in each of the two phases
and the timing of patients’ therapy programmes (see Figure 13). In phase 1, participants who had just
been randomised to the trial were invited to undertake a first interview during the first 4 weeks of
therapy. In phase 2, participants who were currently receiving therapy were invited to undertake a
first interview on completion of their therapy. The local trial co-ordinators or administrator were asked
to invite patients meeting these criteria, by providing them with an invitation letter and an expression
of interest form. Patients who returned their expression of interest form were contacted by the
researcher (NA) who further explained the study, ascertained whether or not the individual wanted to
participate and arranged a time and date for their first interview to take place. Interviews took place
Participant recruitment across the RATULS trial
April 2014 to April 2018
Phase 1
Recruited February 2016 to June 2016
Patient sample 1
(n = 23, interviews = 39)
Professional interviews
(n = 16)
Patient sample 2
(n = 21, interviews = 36)
Analysis
First
interview
Baseline
Second
interview
3 months
Second
interview
6 months
First
interview
3 months
Professional interviewsa
(n = 24)
Phase 2
Recruited October 2016 to April 2017
FIGURE 13 Qualitative process evaluation study design. a, Some health service professionals were interviewed twice (n= 5).
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at a patient’s home or at their local RATULS trial centre, according to patient preference. Written
informed consent was taken on the day of the initial interview and covered participation for both
interviews. Participants were clearly informed that they could withdraw from the qualitative study at
any point, without affecting their participation in the trial.
It was not possible to purposively select participants on the basis of patient characteristics in a trial
centre, because of the need for clustering interviews around specific time points in a patient’s therapy
programme, and to be able to conduct enough interviews in a single fieldwork trip to a region away
from the researcher’s base.
Health service professional study group
Health service professional interviewees primarily included the local principal investigators, trial
administrators and co-ordinators, and senior therapists and therapy assistants who delivered
the interventions. A small number of therapists who provided usual care, but who did not deliver the
RATULS trial interventions, were also interviewed. Trial co-ordinators at each site identified the appropriate
health service professionals and invited them to participate in the study. The trial co-ordinator provided
the contact details of potential participants to the researcher (NA), who then contacted the professional
and explained the study, and, if agreed by the participant, arranged a time and date for the interview to
take place. Written informed consent was taken on the day of interview.
Data collection: semistructured interviews
Patient interviews were conducted using semistructured interview guides that were developed and
adapted for robot-assisted training, EULT and usual care patient groups. These guides were also
adapted for the first and second interviews, as appropriate to the time points being covered in each of
the study phases. The topics covered in the interviews are detailed in Appendix 7, Table 56. The topic
guides for professionals were informed by NPT, but were not rigidly structured around it. Patient topic
guides focused more on therapy experiences. For the robot-assisted training and EULT groups, phase 1
data collection aimed to capture patients’ experiences of their stroke and rehabilitation to date, initial
expectations of therapy in the RATULS trial, their experiences of participating in their allocated treatment,
and their perceptions of the benefits and impacts of their allocated therapy. Based on phase 1 findings,
the phase 2 interview guide was extended to explore maintenance of perceived impacts and experiences
of participating in, and completing, the RATULS trial outcome assessments.
For usual care patients, in both study phases, interviews focused on their experiences of stroke
rehabilitation and life pre stroke, expectations and hopes for recovery, and their experiences of taking
part in the RATULS trial (including allocation to usual care).
In health service professional interviews, current provision of stroke rehabilitation was explored,
including what worked well, what did not work well or could be improved (for patients) and perceptions
of how the RATULS trial might advance research and practice in stroke rehabilitation. Professionals’ views
of the trial interventions were explored, based on experience for those who delivered the interventions,
and following provision of a description of the therapies for professionals who were not delivering the
trial interventions. For those health service professionals who delivered robot-assisted training and EULT,
views about how the interventions might be delivered in routine practice were also explored.
Data management and analysis
Interviews were transcribed verbatim. Transcripts were checked for completion and accuracy by the
researcher who conducted the interview (NA), and anonymised prior to sharing with the research
team for analysis. NVivo (QSR International, Warrington, UK) was used to facilitate data coding and
management. Thematic analysis72 was conducted by two researchers (NA and TF) initially, informed by
the framework approach.73 Both researchers independently read a selection of transcripts from interviews
from across the three trial randomisation groups (patient participants), and across trial centres (professional
participants) to code data and identify emergent themes. The researchers subsequently met to discuss their
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coding, share interpretations of the data and jointly develop a coding framework for application to
subsequent transcripts. A tentative thematic framework was developed based on these discussions, then
applied to a number of further transcripts to categorise the data and test its applicability. The framework
was refined as necessary through regular discussion between the two process evaluation researchers
(NA and TF), and with wider project team members as appropriate, and applied to all transcripts. Coded
data were summarised in data matrices (participant by theme) to facilitate a within- and cross-site
comparison. This process was undertaken separately for the data sets relating to patient interviews and
to professional participant interviews.
An additional exploratory analysis was undertaken with the quantitative data from two interview
participants from phase 2, to explore any correspondence between improvements (or otherwise) in
arm function as reported verbally during the qualitative interviews (at 3 and 6 months), with recorded
assessments for those patients on the ARAT,19 which was the primary outcome of the RATULS trial.
From each therapy group (robot-assisted training and EULT), the patients who made the greatest gain
in ARAT score across the trial (from baseline to 6 months) were selected for this analysis. We chose to
focus these case studies on highest number of ARAT points gained, as these participants seemed most
likely to have experienced noticeable changes that might be described in their qualitative interviews.
These case studies are therefore intended to be illustrative of improvement, in patients categorised as
having a successful trial outcome, as experienced subjectively, rather than representative of improvement
of all participants (which is beyond the scope of the analysis).
Results
Recruitment of participants to the qualitative study
A total of 79 patient and health service professional participants were interviewed across the two study
phases, resulting in 115 interviews (Table 18). The 44 patients who were interviewed represented all of
the patients who returned an expression of interest form for the interview study (and subsequently
consented to participate). This included 12 patients from the usual care randomisation group (interviewed
once only). All but one of the 32 patients from an intervention group were interviewed twice: one patient
was not able to be contacted for their second interview. Therefore, in total, 75 interviews were conducted
with patients in phase 1 (n = 39 participants) and phase 2 (n = 36 participants). Across the phases, time
1 (initial) interviews were a mean of 49 minutes’ duration (range 25–45 minutes), whereas time 2
(repeat) interviews were a mean of 43 minutes’ duration (range 14–88 minutes).
The key descriptive information about participants for guiding interpretation of results is provided
in Table 19. In the results section, patient participants will be referred to using the pseudonyms
presented in Table 19. These pseudonyms are used to attribute data excerpts, alongside their age,
TABLE 18 Summary of qualitative study participants
Process evaluation phase (n interviews)
1 2
First patient interviews l Robot-assisted training (n = 7)
l EULT (n= 9)
l Usual care (n= 7)
l Robot-assisted training (n= 7)
l EULT (n = 9)
l Usual care (n = 5)
Second patient interviews l Robot-assisted training (n = 7)
l EULT (n= 9)
l Robot-assisted training (n= 6)
l EULT (n = 9)
Professional interviews l Senior therapist (n = 10)
l Therapy assistant (n = 6)
l Senior therapist (n= 6)
l Therapy assistant (n = 5)
l RATULS trial staff (n= 13)
Total interviews 55 60
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TABLE 19 Characteristics of patients interviewed in qualitative process evaluation
Phase Pseudonym Age (years) Sex
Time since stroke
at first interview Randomisation group
1 Henry 67 Male 4 years Robot-assisted training
1 Michael 74 Male 17 months Robot-assisted training
1 Alexander 66 Male 1 month EULT
1 Josie 66 Female 1 month Robot-assisted training
1 Sarah 46 Female 8 months EULT
1 Louise 68 Female 10 months Robot-assisted training
1 Ian 53 Male 10 months EULT
1 David 65 Male 23 months Robot-assisted training
1 John 38 Male 4 years EULT
1 Sally 66 Female 14 months EULT
1 Edward 65 Male 1 month EULT
1 Jenny 56 Female 14 months EULT
1 Isla 52 Female 7 months Robot-assisted training
1 Stephen 82 Male 10 months Robot-assisted training
1 Timothy 52 Male 2 years EULT
1 Sebastian 62 Male 1 year EULT
2 Lisa 69 Female 4 months EULT
2 Gerard 66 Male 5 months EULT
2 Keith 79 Male 8 months Robot-assisted training
2 Jim 47 Male 15 months EULT
2 Colin 68 Male 20 months Robot-assisted training
2 Suzanne 44 Female 4 months EULT
2 Kevin 55 Male 7 months Robot-assisted training
2 Jack 58 Male 3 months EULT
2 Christopher 75 Male 3 months EULT
2 Jane 47 Female 2 months Robot-assisted training
2 Lynne 52 Female 9 months Robot-assisted training
2 Liam 48 Male 2 years Robot-assisted training
2 Graham 68 Male 4 years Robot-assisted training
2 Peter 37 Male 7 months EULT
2 Amanda 64 Female 1 year EULT
2 Susie 70 Female 22 months EULT
1 Nicola 70 Female 14 months Usual care
1 Alison 29 Female 5 years Usual care
1 Clive 73 Male 4 months Usual care
1 Micky 47 Male 6 months Usual care
continued
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time since stroke and randomisation group. For professionals, general professional category only is
provided, to preserve participants’ anonymity.
In total, 35 health service professionals were interviewed. Of those involved in the delivery of the trial
interventions (n = 14), five were physiotherapists, three were occupational therapists and six were
therapy assistants. Members of the research staff who were interviewed (n = 13) included the local
principal investigators, trial administrators, trial co-ordinators and the outcome assessors. An additional
seven therapists working in stroke rehabilitation at the trial centres, who did not provide the RATULS
trial intervention therapies, were interviewed: four physiotherapists, two occupational therapists and
one therapy assistant. As some staff (n = 5) were interviewed in both phases of the project, a total
of 40 interviews were conducted. The number of interviews per trial centre ranged from 4 to 12.
To protect anonymity of professional participants, a breakdown of professional categories by trial centre
is not provided (owing to small numbers), and information about trial centre is omitted.
Presentation of results
Results are reported in relation to three issues: patients’ experiences of robot-assisted training and
EULT, patients’ experiences of participating in the usual care randomisation group and factors affecting
the trial and the provision of robot-assisted training and EULT (drawing primarily on professional
participants’ data).
Patients’ experiences of robot-assisted training and enhanced
upper limb therapy
In this section, we describe the intervention participants’ experiences in terms of treatment acceptability
(attendance, intensity and duration), participation challenges, physical and functional impacts, and social
and psychological impacts, and we present case studies of participants who made large gains on the ARAT.
Treatment acceptability
Attendance
Patients who were randomised to receive one of the two RATULS trial interventions were invited to
attend treatment sessions three times per week, for 12 weeks. All patients interviewed travelled to
their treatment from their home. Travel was funded by the RATULS trial and organised by local staff
(when necessary). The majority of participants reported using this support, and considered it an
TABLE 19 Characteristics of patients interviewed in qualitative process evaluation (continued )
Phase Pseudonym Age (years) Sex
Time since stroke
at first interview Randomisation group
1 Harry 62 Male 6 months Usual care
1 Elaine 81 Female 5 months Usual care
1 Andrew 75 Male 2 months Usual care
2 Irene 62 Female 5 months Usual care
2 Glenn 72 Male 4 months Usual care
2 Joshua 66 Male 5 months Usual care
2 Matthew 84 Male 1 month Usual care
2 Gillian 64 Female 2 weeks Usual care
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important facilitator of trial participation. For example, when asked about the difficulties of
participating in the RATULS trial, a patient responded:
Maybe just getting there, but they had that boxed off because they had a taxi firm who used to send a
taxi over. [. . .] That’s never been a problem for me, but I think if they took that aspect of it away, it would
be really difficult.
Sarah, aged 46 years, 8 months post stroke, EULT
Other patients reported having a long commute to their treatment; for example, one patient drove an
hour each way, which they found tiring. Therefore, logistical considerations, such as the allocation of
treatment time (morning or afternoon) and ‘break’ days by trial centre staff, were also reported to be
important considerations that facilitated participation. Furthermore, some patients reported missing
treatment sessions because of other therapy appointments or commitments:
Well, that was difficult [organising appointments] because you had to work round with some of them
[other therapy appointments], and the other thing was that my mum has got Alzheimer’s and she stays
with my sister at the moment, but sometimes I have to look after her, so I had to cancel some of the
sessions and then go back.
Jack, aged 58 years, 3 months post stroke, EULT
Flexibility in the delivery of the treatment programmes enabled this participant and others (in exceptional
cases) to complete their missed sessions by slightly extending the duration of the treatment programme.
In summary, the transport and logistical support offered as part of the trial and flexibility in delivery of
the treatment programmes facilitated participation in, and compliance with, the RATULS trial treatments.
Intensity and duration
Both RATULS trial interventions were designed to provide repetitive practice in sessions that lasted up
to 1 hour. Patients participating in both robot-assisted training and EULT reported that the sessions
could be physically and mentally tiring:
When I’m doing an exercise for the first time, then I’m using more of my mind, so to speak. You’re not doing
remembered things; you’re having to re-train the muscle to pick up a comb and so forth, so to start with, it’s
more tiring. As you become more used to it, more skilled, then it becomes, ‘Ah, yes, I can get on with that’.
Ian, aged 53 years, 10 months post stroke, EULT
This patient describes how the physical effort of practising functional tasks (e.g. picking up a comb)
was also mentally tiring, as more cognitive processing was required, particularly in the early stages of
treatment. In comparison with the functional focus in the EULT programme, in robot-assisted training,
task practice was determined by a cursor on the screen. This type of activity was reported to be
mentally and physically tiring also:
Working on the robotic machine and trying to concentrate on doing it properly is quite [tiring] – I was
surprised how physically tiring the mental effort was.
Stephen, aged 82 years, 10 months post stroke, robot-assisted training
Patients discussed the fact that that robot-assisted training was particularly challenging when the
cursor moved randomly, rather than predictably, as they were unable to pre-empt and prepare for
the movement:
Then they became random, which was a wee bit more taxing on your brain.
Kevin, aged 55 years, 7 months post stroke, robot-assisted training
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Some patients linked their levels of fatigue during treatment to the effects of their stroke, as described
by this patient:
When I first started I still wasn’t very well, which I didn’t realise, because it was just exhausting, absolutely
exhausting. And I had given myself huge expectations, I wanted to do well, I wanted to be the best there was.
Isla, aged 52 years, 7 months post stroke, robot-assisted training
This patient explained that, for them, participation in the treatment was ‘absolutely exhausting’ as
they were still in the early stages of recovery post stroke. However, despite the physical and mental
challenge, in general, patients appeared motivated to support their recovery through participation in
such intensive treatments:
At the end of the day, I was only after a result in my arm. That was all I thought about before I went in
’til I came back out. When I was sitting ready to go in I would say, ‘Right, I’m going in here and I’m going
to do the best I can possibly do for my hand today’. That was always in my mind.
Kevin, aged 55 years, 7 months post stroke, robot-assisted training
All stroke survivors who were interviewed completed their 12-week programme, with the exception of
one (in the robot-assisted training group) who withdrew because of back pain, which made transferring
from their wheelchair to the treatment chair difficult.
In regards to treatment duration, some participants reported that they felt that they had made all the
progress that they could by the end of their treatment:
It was enough for me [treatment duration] and it was enough for [husband], I think, for driving there. But
I can’t say if I had done anything more . . . if I went for 15 weeks, would it . . . I don’t think it would have
done. It’s the [botulinum toxin] that’s done this bit.
Louise, 68 years, 10 months post stroke, robot-assisted training
In comparison with this participant, others felt that extending treatment duration would support further
recovery; for example, an individual in the EULT programme commented:
I thought I was just getting into it and it ended. I thought I was coming on and then it stops.
John, aged 38 years, 4 years post stroke, EULT
Similarly, a patient randomised to receive robot-assisted training noted:
Yes, definitely [they feel they would have continued to progress if treatment had continued] because on
different weeks we would discover new movements that were becoming available to me.
Liam, aged 48 years, 2 years post stroke, robot-assisted training
Others noted that extending treatment duration could support a ‘better goal’, and would help people
who might need longer to achieve their rehabilitation goals. Furthermore, some patients thought that
continued support was beneficial regardless of functional improvement:
The therapy they gave us was stretching and exercises and that, and that was good for the pain and the
stiffness. So if it had continued, that would have been great.
Sarah, aged 46 years, 8 months post stroke, EULT
In summary, patients found both robot-assisted training and EULT physically and mentally challenging,
but were motivated to complete their treatment to support their recovery. However, equally relevant
to patients in both therapy groups, individuals had different rehabilitation needs and some felt that
extending the treatment, or combining it with another type of intervention, may have been beneficial
to support their rehabilitation and recovery journey over the longer term.
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Participation challenges
The majority of patients interviewed completed their treatment programme. However, some reported
challenges with participating in their therapies. For example, some people became frustrated when
they were unable to complete a task:
I found that one [the wrist attachment] more tiring because I was trying [. . .] And she was saying,
‘Don’t try too hard. Just do what you can do, and we can see what . . .’ But I found that a bit frustrating,
because I couldn’t get it, you know.
Colin, aged 68 years, 20 months post stroke, robot-assisted training
Similarly, a patient in the EULT programme commented:
I was more frustrated than tired at some of the things that I couldn’t do. Like, you wanted to lift it and
lob it across the room and both the physio[therapist] and the OT [occupational therapist] knew you
were getting to a stage where, ‘This is not working. She’s just not doing it,’ and they just changed it to
something else. Just changed the task for that day. They didn’t stop it all together. You always went back
to it the next time you came.
Jenny, aged 56 years, 14 months post stroke, EULT
The patients described how their frustration was alleviated with help from the therapy staff, who
recommended taking a break, switching to a different task and trying again at their next therapy
session. For one participant, in the EULT programme, not being able to complete a task ‘correctly’
was exacerbated by their confusion over the purpose of the repetitive functional task practice:
Honestly, I don’t think it was explained enough about the point-scoring and whether you did it wrong or
right. I think you did it wrong, and the mentality is you get fed up with it because you’re doing it wrong
or you weren’t completing it right, or you’re taking too many clicks to do it and then you thought ‘well
what’s the point in asking me to do this if I can’t do it, get somebody else to do it’.
Jack, aged 58 years, 3 months post stroke, EULT
Having a meaningful and achievable goal was highlighted by another patient, who felt that a new goal
(putting on a jacket) had been ‘tacked on at the end’ (Sarah, aged 46 years, 8 months post stroke, EULT)
of their treatment, as they had not been able to achieve any of their original goals.
Alongside upper limb impairment, other post-stroke problems were reported to affect engagement in
therapy. For example, in the robot-assisted training programme, having to follow the cursor on the
computer screen caused difficulty for a patient with visual impairment; they explained:
When the ball went to 8:45 or 8:50, I didn’t see it, but now I know it’s there because I’m catching on to
where the ball’s going, I suppose you get used to it: ‘oh, it’s going over there next’. You know it’s going to
go left after a while and you’ve got to scan.
Louise, aged 68 years, 10 months post stroke, robot-assisted training
This patient described learning to scan the screen to observe the ball when it was moving into the area
of their visual field loss. This individual also described the impact of not recognising whether or not
their hand and wrist were moving correctly to follow the cursor on-screen, potentially because of
sensory/proprioceptive impairment. This patient’s husband accompanied them to their treatment and
explained developing a strategy whereby they called out ‘ceiling, floor, ceiling’, to help the participant
move in the appropriate direction.
In summary, although patients represented a motivated group, engagement in either type of therapy
could be difficult and frustrating if they were unable to complete the agreed tasks. Furthermore,
challenges that related to specific treatments were reported, including lack of clarity in the goal-setting
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process in EULT, and the impact of visual and cognitive impairments on completing the robot-assisted
training activities. These challenges were managed with support from the therapy staff and family,
or by the patients themselves, using strategies such as taking breaks and tailoring goals.
Physical and functional impacts
The primary aim of the robot-assisted training and EULT was to improve the upper limb function of
participants. Across both treatment programmes, the patients interviewed reported experiencing
physical and functional benefits, as one patient in the robot-assisted training programme explained:
Well, folding clothes up, I can use both hands. Making the bed, I can use both hands. Dusting I don’t,
I just use the left hand, and writing I need to use the left hand.
Josie, aged 66 years, 1 month post stroke, robot-assisted training
This patient highlights how she was now able to use two hands to perform some household tasks,
whereas she used her unaffected hand and arm only for other activities that required more complex
motor control.
A patient in the EULT programme reported:
This is a bit funny, but, before I came here, I had to get somebody to shave under my arms. I can do that
myself now. I can dry my hair and straighten my hair, I can do that myself using two hands instead of just
one hand, instead of getting someone else to do it.
Jenny, aged 56 years, 14 months post stroke, EULT
For this person, participation in the EULT programme had enabled her to regain independence in
personal tasks for which she had previously required support. This patient also explained that
the EULT programme was an opportunity to relearn how to use her affected hand to button a
shirt, as ‘I had just completely forgotten what this hand did.’ (Jenny, aged 56 years, 14 months
post stroke, EULT).
In other cases, physical impacts were linked to improved motor function (rather than ADL),
for example:
I am able to move it [my arm] more, mobility. Not necessarily function, although in terms of the tasks,
when I am there, doing the sessions, it works. I can just feel, and others can see, the ability to move it
more than I could before.
Amanda, aged 64 years, 1 year post stroke, EULT
Similarly, other patients reported changes in strength and sensation, being more aware of their
affected side, and reduced pain and stiffness, all of which were considered benefits of the interventions
even when they did not translate into improvement in ADL. However, in terms of satisfaction with
progress, although some patients reported being happy with the improvement made, others revealed a
more complex picture:
It’s a really tough question because we all want the silver bullet, don’t we? We all want to come out
with a fully functional bad arm. So, in that context, I wasn’t satisfied, but, in the slightly more realistic
context of ‘It’s neurological rehab[ilitation] that you were trying to deal with’, then, as far as the trial is
concerned, having come from absolutely no movement, to some functional use of my arm, then yes
pretty . . . Like I say, it depends where you start off, going in.
Liam, aged 48 years, 2 years post stroke, robot-assisted training
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This patient described how he compared his progress against his pre-stroke ability of having a fully
functional arm; however, he did accept that this expectation was unrealistic. Similarly, another patient
explained that he was happy with the progress that he had made while recognising that, for him, there
was still work to be done:
It’s got me to a level that I had some doubt I would get to, so I think it’s been beneficial in that way. It
has achieved what it was designed to do, I believe, to a large extent, to make life easier for me, and it has,
it’s done it. As I say, still recognising that I’ve got some way to go.
Alexander, aged 68 years, 1 month post stroke, EULT
Specifically, in the robot-assisted training programme, some patients discussed that, although the
robot-assisted training provided exercises for the shoulder, elbow and wrist, dexterity and finger
movement was not a focus of the therapy:
Partner: It’s brought your arm and wrist on. You’re probably expecting more from the fingers.
Louise, aged 68 years, 10 months post stroke, robot-assisted training: I certainly was [. . .] But then
I didn’t know what you had to do before I went.
Partner: But it is for the upper arm really, isn’t it?
This patient further reported that she had received botulinum toxin to support recovery of her hand
movement, and commented ‘if I could just get maybe, one-to-one physio[therapy] and get these fingers
working, I’ll be topped up’.
In summary, patients reported beneficial impacts on sensory and motor function, as well as pain, across
both treatment groups, with EULT in particular offering an opportunity for participants to ‘relearn’
how to perform specific tasks of value to them. Even so, although patients were generally satisfied
with the impacts experienced, not all therapy goals were fully achieved. Some participants discussed
their expectation for continued progress and, in some cases, the need to access alternate treatments to
those provided in the RATULS trial to support their recovery.
Social and psychological impacts
The interview schedule explored whether or not patients enjoyed the RATULS trial therapy programmes.
In response, they discussed social and psychological benefits of attending the treatments. For example,
a patient in the EULT programme discussed that she enjoyed interacting with the staff:
The staff are all lovely, they’re really nice, it’s good that you get a laugh, they’re all so friendly.
Jenny, aged 56 years, 14 months post stroke, EULT
The social benefits were not limited to EULT, as a patient in the robot-assisted training
programme commented:
I can talk to the girls. I socialise. They give me company.
Jane, aged 47 years, 2 months post stroke, robot-assisted training
Patients also described socialising with fellow participants, with whom they could share experiences.
For some patients, attending treatment was enjoyable as it simply gave them ‘hope’ for improvement:
Yes, I enjoyed coming in. [. . .] that was always in the back of my mind, ‘This next session I’m going to put
110% into and hopefully something will happen’. It was just hope.
Kevin, aged 55 years, 7 months post stroke, robot-assisted training
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Often, the RATULS trial offered an opportunity for further rehabilitation to patients who had been
discharged from NHS rehabilitation services. Another benefit of taking part in the trial, reported by
some patients, was increased independence, as a patient explained:
I think [. . .] for me, because I was travelling such a long way, [it] had other benefits as well as . . . I knew I
was going in for primarily upper limb work, but I was driving [. . .] The fact that I was staying away from
home obviously has helped, in terms of making me a bit more independent, and being aware of being able
to be independent again.
Liam, aged 48 years, 2 years post stroke, robot-assisted training
This patient drove themselves to their treatment, whereas others discussed travelling alone on public
transport, or by taxi (organised by the trial centre staff) without a family member, all of which were
reported to increase their confidence in their ability to act independently. Finally, participating in a
RATULS trial therapy programme was said to provide a sense of purpose in a patient’s day, ‘a reason to
get up and get dressed for’, as a patient explained:
You know, if I was to go over, if I was to go there, and at the end of these 3 months, if I haven’t achieved
anything, from a psychological perspective, then that was a winner, because that is exactly what I needed
at that time.
Isla, aged 52 years, 7 months post stroke, robot-assisted training
Although important to most people, having a sense of purpose was particularly significant to Isla, who
described having a busy work and social life prior to her stroke.
In summary, the RATULS trial focused on improvement in upper limb function; however, attending the
treatment sessions was reported to have social and psychological impacts that may have benefited the
recovery process of participants in both the EULT and robot-assisted training groups.
Case studies of patients making greatest gains on the Action Research Arm Test
In phase 2, patients had their second interview at 6 months post randomisation, allowing exploration
of maintenance of any improvements, progress or deterioration at around 3 months after finishing
therapy. Overall, of the 15 patients interviewed at both the 3- and 6-month time points, 13 felt that
they had maintained the physical and functional changes described at the time of their first interview.
Only one patient (robot-assisted training) felt that their arm function had deteriorated since completing
their treatment programme, despite continuing to exercise their affected arm. Here, we describe in more
detail the self-reported improvements of two phase 2 patients (one from each treatment group) who
made the highest gains in ARAT scores across the trial (Table 20).
The two participants (Jack and Jane) shared some characteristics. They were younger than the average
RATULS trial participant (mean age 62.5 years), had moderate rather than severe reduction in upper
limb function at their baseline assessment and were recruited early after their stroke. By 3 months, Jack
and Jane’s ARAT scores had improved by 28 and 27 points, respectively, and both had an ARAT score of
57 (the maximum score) at 6 months.
TABLE 20 Phase 2 case study participants’ assessments of ARAT scores
Participant Group Age (years)
Time from stroke
to randomisation
(months)
ARAT score (points)
Baseline
3-month
assessment
6-month
assessment
Jack EULT 58 3 26 54 57
Jane Robot-assisted
training
47 2 28 55 57
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On entering the trial, Jack reported that ‘[I] couldn’t open my hand or my fingers and my hand was
very sore, it was just, like, a lead weight.’ He discussed the fact that, through participation in EULT,
he was shown useful ‘techniques’ (e.g. how to button a shirt and tie shoelaces), and that his hand had
been strengthened through the exercise. However, he found participation in EULT ‘repetitive’ and
felt that the purpose of the repetitions was not fully explained to him. Further to this, he discussed,
‘they [the EULT exercises] were useful but some of them weren’t relevant to what I felt I should have
been focusing on’ and explained the impact on his motivation to participate in the therapy: ‘If you’re
doing something you’re not liking, you totally turn against it and you’re like, “that’s finished, I still can’t
do it and there’s no point” ’.
This experience highlights the importance of involving patients in the goal-setting process, so that they
are clear about, and happy with, the goals that they are working to achieve. Jack discussed, ‘one [goal]
I was thinking of that could have been included was some keyboard stuff that would be relevant to
what I’m doing.’ Using a computer keyboard was a skill that was relevant to his office-based job (pre
stroke) and he felt that incorporating it as a goal would have been more useful to him than buttoning
a shirt (a goal selected from examples provided to him at the start of his therapy). However, Jack did
explain that cooking-based goals (tasks personal to him) were introduced at his request later on in
the therapy. Despite improvement in his arm, Jack discussed that he had not been able to return to his
office-based job:
I don’t know if I could actually manage that [returning to work]. [. . .] I feel a lot better and it seems to be
improving all the time, but I still have the fatigue later on in the day, that kind of thing. It’s like that, that
it’s not possible, because everybody I know has asked about my hand itself, and it’s not just the hand,
it’s other things. I went to one of the doctors who specialises in strokes for talking, just like for the mind
side of it, how it affects your mind and stuff and how you can deal with that, and that was very useful.
Jack was uncertain whether or not he would ever return to his previous work, but explained that a
number of other stroke-related problems (e.g. fatigue and psychological impacts), for which he was
seeking help, were preventing his participation in this activity, highlighting the complex and
multifaceted nature of post-stroke recovery.
Jane participated in the robot-assisted training programme. On entering the trial, Jane reported that
she felt that she had a good range of movement in her arm, and had been independent in her ADL
since returning home from hospital. Jane commented that her hand and fingers were her main focus
for improvement and that she had volunteered for the trial in order to improve as quickly as possible.
In terms of participation in the robot-assisted training, Jane described:
Sometimes you feel like playing the games, really. When it is very easy when you reach something, you can
enjoy it, but when it is too tiring, I feel my brain was hot that time, sweaty. It’s been a long journey, sitting
there and start this.
Jane travelled independently (through choice) on public transport to the treatment, and, like some
others, described that robot-assisted training was tiring after the long commute. However, Jane also
reported that she felt that the commute was beneficial for her mobility and independence; robot-
assisted training provided stimulation for the mind as well as the arm, and she enjoyed the social
interaction that attending the treatment provided. Even so, Jane expressed some disappointment with
the treatment that she had received:
The only thing is the robot doesn’t do your finger [. . .] It doesn’t train your finger, only the wrist, big joint,
nothing to do with the delicate things [. . .] When I came here I really wanted that.
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Jane felt that robot-assisted training did not support recovery of dexterity, which was what she was
particularly keen to improve. Jane did report improvement in her fingers, but was unsure whether or
not to attribute it to the robot-assisted training:
My finger can open now after the robot. We don’t know if it’s because of the robot or it is natural really.
I also do some acupuncture as well. It’s all combination. My finger, big improvement really.
Further to this, Jane was the only participant to report a deterioration in her arm movement:
Before the robot, my arm fully, I can lift it above my head. I can do lots of things. After robot, because of
the pain, I can’t do anything.
Jane attributed her deterioration to completing her treatment sessions as quickly as possible
using her shoulder instead of her wrist, in some activities, to move the cursor on the screen.
In relation to this issue, Jane discussed the importance of having professional guidance available
during the treatment:
So [the professional] can say you didn’t use your wrist, [you] use your shoulder. They can tell that,
yes, straightaway, and have rest and do this. Do properly. Do the quality job not the quantity. I doing
quantity job really. I just want to finish this, finish and finish and finish and a good figure [score].
That’s wrong.
Jane felt that more professional instruction should be provided to promote ‘quality’ of movement over
speed of task completion and attempting to achieve a good score. Reassuringly, at Jane’s second
interview (around the time of her 6-month follow-up assessment), she reported that she had been able
to regain her shoulder movement through participation in a different (non-RATULS trial), therapist-
based, rehabilitation programme:
It’s fixed by [additional upper limb rehabilitation]. They gave me twice, I think, just physio[therapy].
They did this [lifting arm] and something, and it’s gone.
Therefore, although Jane represents a successful outcome in terms of the RATULS trial, from her
perspective, the treatment had a limited beneficial impact and was also attributed to a deterioration
in her ability to move her arm.
In summary, although these two patients improved their ARAT scores the most out of those interviewed
in phase 2, their self-reported experiences of recovery highlight that the impact of therapy is more
complex than the ARAT scores indicate. These participants were considered to have a successful outcome,
and, although they reported improvements in their upper limb function, a deterioration in range of
movement due to pain was attributed to the robot-assisted training, whereas, in the EULT programme,
the participant wanted to practise tasks personalised to them and more relevant to their daily life.
These case studies are illustrative, rather than representative of all patients’ experiences, but demonstrate
that functional improvement is only one component of recovery from stroke.
Experiences of participants allocated to usual care
Twelve participants who were randomised to receive usual care were interviewed. All had been discharged
from hospital; four were receiving ongoing rehabilitation from community-based NHS services, one of
whom was supplementing these services with a private physiotherapist. Two participants were accessing
ongoing physiotherapy solely through privately funded services. The most intensive rehabilitation received
was by Irene (aged 62 years, 5 months post stroke), who reported that she was visited three times a week
by a community stroke team. This team was providing therapy to improve Irene’s mobility and the use of
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her upper limb. The community team had also provided speech and language therapy, which had ended
when Irene felt that she was no longer making progress. Although the rehabilitation received by Irene
was comparable to either of the RATULS trial therapies in terms of number of visits (three times a
week), the focus was not solely on the upper limb.
In comparison with Irene, the least intensive therapy received was by Gillian (aged 64 years, 2 weeks
post stroke), who described attending one outpatient group at her local hospital every 3 weeks, where
she exercised her upper limb under the supervision of a physiotherapist.
The type and amount of upper limb rehabilitation received by usual care participants varied. Other
types of therapy undertaken at the time of the RATULS trial included mirror therapy, electrical
stimulation and botulinum toxin. From this small number of interviews, we can conclude that, although
it is unlikely that the other therapies and treatments were comparable to the RATULS trial therapy
programmes in the targeting of the upper limb, some participants in the usual care group of the trial
engaged in (NHS-provided and non-NHS-provided) activities to support their recovery after stroke.
Unsurprisingly, participants randomised to usual care expressed disappointment, particularly as they
had had a 66% chance of receiving additional treatment, and because of the length of the screening
process, which they felt had built their expectations of receiving treatment:
Then I was disappointed when, well my husband was as well. I don’t think we could quite believe it and,
you know, we’d been through all that and why didn’t we just get told that in January instead of waiting
all those weeks, ‘cause that was a long time to wait.
Nicola, aged 70 years, 14 months post stroke, usual care
It should be noted that two patients interviewed (Alison, aged 29 years, 5 years post stroke; and Clive,
aged 79 years, 4 months post stroke) reported that they were confused by the three randomisation
groups and thought that they would be receiving an intervention in time. These findings were reported
back to the trial centre teams, who called the participants to provide clarification on what allocation to
the usual care group entailed.
Factors affecting implementation of the Robot-Assisted Training for the
Upper Limb after Stroke trial
The RATULS trial was complex, evaluating two forms of upper limb rehabilitation; 770 participants,
across four trial centres, were recruited over a period of 49 months.
This section focuses on the processes that contributed to the successful delivery and completion of
the trial, from the perspective of therapists and trial staff involved in delivering the RATULS trial.
We include here, also, reference to professionals’ views about delivery of the different therapies
themselves. The results are framed around the constructs of NPT.71 NPT proposes that the embedding
of a practice or intervention, in other words ‘becoming normalised’, is dependent on four kinds of
work that must be undertaken: coherence (ways in which an intervention ‘makes sense’ and has clear
purpose and objective), cognitive participation (willingness and ability to commit the time and energy
needed to make it work), collective action (the resources, arrangements, skills, etc. required to make
an intervention work) and reflexive monitoring (formal and informal mechanisms for appraising the
process and outcomes of an intervention).
Coherence: did the Robot-Assisted Training for the Upper Limb after Stroke trial make
sense to those involved?
Staff involved in the RATULS trial had a clear and (mostly) shared sense of understanding about what
the trial aimed to achieve and what was involved for participants. Professionals who were interviewed
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attributed this to the early engagement of local staff and teams across the trial centres when the trial
was being planned, for example prior to submission of the funding application. They felt that this
enabled participating professionals to develop an understanding of the roles and experience needed to
support successful trial delivery before commencement of the trial. As illustrated by the following
comment from a trial co-ordinator, the complexity of the proposed trial was anticipated at the outset:
I involved the Head of Therapies as well and we, sort of, got together and we were just thinking first of all
about, ‘Can we do this? Can we actually do this? Is it feasible? Do we have the patients? Can we support
it financially?’ The result of those thoughts really was, ‘Yes, we can. We think we can’.
These very early discussions included the chief investigator (who was also the principal investigator at
one trial centre), senior research associate, principal investigators at trial centres 2 and 3, and other
key staff working at these trial centres. This early engagement was key to the successful running of the
RATULS trial, as explained by a trial co-ordinator:
Do you know what is different about this study? From the very, very beginning I felt that I was involved
in the setting up of the study. I felt that the trial team were engaging with me and involving me in
setting up the study and that was important. [. . .] That’s why I feel that it’s like my baby, because of that
I think.
This coherence-focused ‘groundwork’ involved engaging with therapy teams and other departments
to ensure that the trial centres had the necessary resources, including financial, therapy and an
appropriate patient population, to support the trial. Interviewees reported that, for the majority of
trial centres, those involved were able to make realistic judgements about the feasibility of delivering
the proposed trial. This ‘coherence work’ facilitated engagement and collaborative ‘troubleshooting’
throughout the duration of the trial.
Cognitive participation: how did those involved engage with the trial?
Jointly establishing the purpose, focus and feasibility of the RATULS trial at the outset facilitated cognitive
participation, which refers to the organised participation of individuals in the work of implementing
the trial, and their continued commitment to project delivery. Like many trials, participant recruitment
was challenging, and required co-ordinated investment in promoting recruitment to meet the trial
recruitment targets.74 Sustained commitment towards the common goals of co-ordinating and delivering
the trial was evident:
I sent a lot of e-mails out to [staff supporting the trial in the trial centre], with some quite clear, concise
information, and I re-sent it, with any difficulties we were having, every couple of months. I went to visit a
couple of hospitals: [city hospital name] and [community] hospital. I spoke to the community stroke team,
went up to the acute wards and the rehabilitation wards on a regular basis, just asking the therapists if
they had any patients, and made sure that they knew how to pass names on.
Senior therapist
I think having worked with the Stroke Research Network I knew a lot of the girls on the different sites.
So that was an advantage to start with. [. . .] I don’t think you can be successful without those networks
really. It’s something you’ve got to work at. Although you might do it initially to get them set up as a site,
then you can’t just leave it there. You have to keep working at that because people do forget and they do
have other trials.
Trial co-ordinator
From the trial management perspective, trial centre staff described a number of key activities that
were undertaken to maximise and maintain staff engagement across the duration of the trial. These
included routine updates about the trial from the co-ordinating centre, with information about
recruitment and data quality at each trial centre, and regular communication and face-to-face meetings
between all trial centres and the co-ordinating centre.
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The senior therapists at each trial centre, who were occupational therapists or physiotherapists, were
central to initiating and maintaining engagement with the trial processes. These professionals were
responsible for supporting the therapy assistants in the delivery of the trial treatment programmes.
Each trial centre consisted of a hub hospital, which contained the MIT-Manus robotic gym, and spoke
sites, which referred potential participants to the trial for screening. Spoke sites could be NHS trusts,
community stroke teams or primary care. The trial was thus founded on solid working relationships
across hub and spoke sites, and ongoing investment in sustaining those links.
Collective action: how was the work of the trial accomplished?
Trial interventions and assessments were mostly achieved as intended, according to the therapy and
trial protocols, respectively. How closely therapy was delivered according to the therapy protocols was
influenced by a number of factors. In this section, we outline ways in which patients and professionals
worked together during therapy. The concepts of interactional workability, skill-set workability and
contextual integration (that form elements of collective action) organise this section.
Interactional workability: getting the work of the trial to fit with existing practice
Here, interactional workability refers to the ease with which participants can incorporate the tasks
required of the trial as part of their work, including therapy delivery.71 There were logistical issues
relating to participant recruitment that needed to be considered. In some cases, lack of availability of a
hoist in the room with the robot meant that some patients were unable to participate in the trial, and
were therefore not randomised. With experience, solutions (e.g. checking with a patient before arrival)
were identified and adopted. If a patient had too much upper limb pain or muscle tone, they were also
not recruited at that time, but they could be put on a review list, so that, if their condition changed,
they could be recruited at a later date.
A number of process-related factors that affected the delivery of therapy programmes were also
described. In relation to robot-assisted training, technical factors, particularly breakdown of machines
or attachments, were reported to have some impact on therapy delivery. Machine breakdowns meant
that individuals could not use certain attachments for the robot on occasion. In addition, the hand
attachment was not able to be used by all participants, as some were unable to open their hand
sufficiently to grasp the attachment. In such instances, therapy staff described that providing robotic
therapy could be frustrating. In addition, some staff referred to differences in the degree of flexibility
that the therapies offered in terms of working with patients to achieve a better therapy outcome:
I suppose with the robot, you perhaps don’t always get the same quality of someone’s movement, because
they’re quite intent, you know, on moving the robot arm, however way they can, but perhaps not in the
best pattern of movement. But, whereas in the enhanced, we’ve got a bit more control over how they, sort
of, complete the task, perhaps.
Senior therapist
Patient-related factors that influenced the delivery of robot-assisted training, EULT or outcome
assessments included the following: missed treatment sessions, missed outcome assessments, frustration
experienced by some participants on being unable to make the arm movements required and participants
having difficulty assessing their own progress (particularly in the robot-assisted training group). Therapists
reported that, relative to robot-assisted training, EULT offered more opportunities for tailoring the
intervention to participants’ personal goals and abilities:
If you do enhanced therapy, you can just be more focused, on sort, of practising exercises that they find
important. For example, I don’t know, using a key board, or I had a patient who liked, before a stroke,
liked knitting or, so you can make it a bit more personalised.
Therapy assistant
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Trial staff used a number of approaches to maximise adherence to trial processes. Trial staff responded
to challenges relating to recruitment of participants by improving the telephone screening process to
gain a better understanding of patient eligibility for the trial by taking into account their practical and
other needs (e.g. requiring a hoist). To maximise retention, trial co-ordinators shared their experiences
to improve the explanations of trial processes during the consent procedure. The trial team/staff working
on the trial maximised recruitment and retention by, when appropriate, completing assessments over the
telephone, visiting patients at home and having contact about appointments made by staff with whom
they had already developed a relationship. Offers of appointment/referral for a patient to see a consultant
were made when appropriate.
Skill-set workability: aligning skills and knowledge to trial delivery
Skill-set workability refers to the compatibility between the requirements of the trial and the skills
and knowledge of those working in the trial.71 The RATULS trial co-ordinating centre team provided
training, including a set of detailed manuals, for all the health service professionals involved in the
delivery of the trial. This training included how to conduct the trial according to the trial protocol; how
to deliver the interventions; and how to conduct the screening, baseline and outcome assessments.
Most staff involved in delivering the trial had previous experience in either therapy delivery within or
outside the context of stroke care, or performing outcome assessments for stroke research studies.
In regards to the EULT delivery, a senior therapist commented:
You’re just learning about the protocol itself that [. . .] you set four treatment goals and normally in, in
clinical practice you would set goals, but you might not set four goals and you might not review them
every 4 weeks.
Senior therapist
For EULT, the therapy protocol, with additional structure (to set up to four goals, and timing of reviews)
is what appeared to distinguish it from what they might provide in an NHS setting. Regarding robot-
assisted training, some professionals were more apprehensive, as they had no experience of delivering
this type of treatment:
I think that was the thing that probably worried me more than the enhanced therapy, was the
fact that this was something that was unknown to me. That actually turned out to be much,
much simpler than I expected it to be, once you get the basics of what you’re doing, switching
everything on.
Therapy assistant
Most professionals explained that they quickly became familiar with robot-assisted training, and,
with experience, it was considered ‘less labour intensive’ for themselves as therapists than traditional
therapy. The professionals’ main responsibilities were to ensure that the patient was positioned
appropriately in the orthotic support, and to oversee their progress.
The outcome assessors were generally research nurses who were familiar with performing some of
the outcomes measures. However, they were not initially familiar with the ARAT and FMA scales.
In addition to initial and refresher training, advice was occasionally provided by trial therapists to help
the research nurses with interpretation of the terminology used in the measures.
Contextual integration: how were the resources organised to support delivery?
Contextual integration refers to the extent to which the tasks involved in delivering the trial are
supported by the organisation in which the work takes place.71 Although the resources allocated to
each trial centre to deliver the RATULS trial were equivalent, there was scope at a local level for trial
centres to organise their team structure to suit their local organisation’s structures and processes.
For example, in both robot-assisted training and EULT, four review sessions with a senior therapist
were allocated for an initial patient assessment when beginning the programmes and review of patient
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progress throughout the programmes. These sessions were always performed by a senior therapist
(physiotherapist or occupational therapist). However, at two trial centres, the senior therapists were
allocated directly to the RATULS trial – it constituted their main role. The other two trial centres
used NHS therapists who had allocated time to perform the initial patient assessment and reviews,
alongside treating other NHS patients. Involving several NHS therapists who had other responsibilities,
rather than trial-specific therapists, created some challenges in trial delivery:
Most of the therapists who were supposed to be doing [RATULS treatments] were on the rotation, the
ring rotation. So when that comes, you won’t be just [working in the] stroke department. It will be up
other departments, wherever you are going to allow them or give them the time to come and see the
patients, which we anticipated will be a little bit of a problem, as we found out.
Trial co-ordinator
The therapists who were interviewed treated stroke patients as their main clinical role, and they also
reported rotating between different specialties. These practices made allocating time to support
delivery of the RATULS trial therapy programmes challenging, particularly if they were rotated into
non-stroke services, where managers who were initially unaware of the trial may have been less
accommodating with therapists’ time.
Having dedicated administrative staff, as was the case in two trial centres with dedicated senior
therapists, was also key to smooth delivery of the trial. In these trial centres, the administrators acted
as a central point of contact for patients, professionals and the trial team, and supported the trial in
many ways. This allowed senior therapists and therapy assistants to dedicate their time to treatment
delivery. In other trial centres, administrative duties were allocated to the therapy assistants. Two
people covered this role in one trial centre, whereas, in another centre, an individual therapy assistant
was responsible for these tasks. The therapy assistant at this trial centre reported:
You do need, like, a dedicated team specifically just to RATULS. [. . .] I think you need at least three
people working on this study specifically, to just obtain the results, especially if you’ve got other
studies going on as well, you’d need to have a proper dedicated team so that I can recruit that many
and to have the right trained staff to do it and then, you know, also to do the data entries and
everything else.
Therapy assistant
At this trial centre, researchers attached to the RATULS trial (a trial co-ordinator and research
manager) worked across multiple projects, and the senior therapists were from the stroke service.
This therapy assistant was the professional who dedicated the most time to the trial; for this reason,
they were responsible for delivering the treatments (under supervision from the senior therapists),
organising travel on a patient’s behalf and inputting the assessment data into the central database.
The therapy assistant commented that recruiting to target would make delivering the RATULS trial
treatments at that trial centre unmanageable.
In summary, to achieve collective action in delivering the trial and its therapies, flexibility and
adaptation, both therapy- and outcome assessment-related, were sometimes necessary. Therapists
reported that delivering the components of the EULT programme according to the trial protocol did
not represent much change to their normal therapy practice. Although robot-assisted training was
a bigger change for them, and could be frustrating at times when machines or attachments were
unavailable, once trained, they were usually able to deliver therapy satisfactorily. Despite this, EULT
was seen to offer more flexibility in terms of meeting the rehabilitation goals of their patients. Insights
into these experiences allow anticipation for what adjustments and flexibility may be required for
successful delivery of the therapies in routine care.
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Reflexive monitoring: how was the trial kept on track?
Throughout the trial, processes were continually monitored, and adapted if appropriate. In terms of
supporting skills in undertaking trial assessments, this ongoing monitoring and support was key from
the perspective of one of the therapy assistants:
Because I was so new at the time, I couldn’t think of the questions to ask because I was still trying to
assess and it wasn’t until I got more and more settled in that I had more and more questions to ask, but it
was nice, I could just e-mail [co-ordinating centre] and it was quick and easy to just get that cleared up.
Therapy assistant
The RATULS trial co-ordinating centre was responsible for ongoing monitoring of recruitment and data
quality across trial centres. It also provided ongoing support to ensure that professionals across sites
were undertaking the trial as per protocol, for example co-ordinating centre staff visited sites regularly
and organised annual meetings attended by representatives of all trial centre teams to share learning
and experiences, and to refresh therapy and assessment procedures as part of ongoing training.
This ongoing work of assessing and responding to challenges as they emerged facilitated successful
delivery of the trial.
Discussion
This qualitative study was designed to help illuminate the complexities of the RATULS trial and its therapy
programmes, through in-depth exploration of patients’ and professionals’ experiences of participating
in the trial and of providing robot-assisted training and the EULT programme. Rehabilitation requires
the active participation of patients and professionals; therefore, any intervention’s success or failure
is partly shaped by their experiences and their engagement with the therapies provided. Participant
experiences provide important insight into the acceptability of the treatment, and challenges in
intervention delivery that can inform future implementers and decision-makers, and facilitate the
interpretation of the trial results.
Our study reports that robot-assisted training and EULT were generally acceptable to patients. Both
interventions were physically and mentally challenging and, in some cases, frustrating for patients,
when they struggled to complete a task. Some of these challenges were related to severity of the
stroke in general (e.g. fatigue, mobility issues and cognitive impairment), and of arm impairment in
particular, including sensory and proprioceptive impairment, as well as participants’ expectations of
themselves and the intervention. Support from RATULS trial staff, and the patients’ families in trying
to overcome these challenges was appreciated. Some patients expressed a wish for therapy to be
extended beyond 12 weeks to support their achievement of goals for their upper limb and ongoing
recovery more generally.
The RATULS trial reported that robot-assisted training and EULT did not improve upper limb function
(the primary outcome) after stroke, compared with usual care. However, improvement in impairment
was seen for both robot-assisted therapy and EULT, compared with usual care. Additional improvements
in ADL and mobility were found in the EULT group. This study explored patients’ self-reported impacts of
therapies. Patients who received either treatment reported physical improvements related to their upper
limb, and many reported that these improvements were maintained at 6 months. However, some of the
self-reported changes (e.g. better arm positioning, improved sensation and reduced stiffness) would not
have been captured by the trial outcome measures, and indicate a potential mismatch (or limited focus)
of objective assessments, relative to qualitative exploration of impacts of trialled interventions. This
mismatch has been reported previously and highlights the importance of capturing participants’ own
experiences of intervention impacts.75 In addition, although patients generally expressed some level of
satisfaction with physical improvements resulting from therapy, they self-assessed their progress with
reference to their more general hopes and expectations for complete recovery, which were focused on
regaining ‘before stroke’ capabilities and functioning.
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A more detailed analysis of two phase 2 interviewees’ (who achieved a ‘successful’ outcome according
to the RATULS trial criteria) experiences of therapy impact indicated that improvement is more complex
than assessment scores indicate. There is a need to ensure that patient and practitioner understandings
of therapy interventions are aligned as much as possible. Our findings highlight the importance of what
‘clinically assessed improvement’ means to patients, in terms of functionality and practical gains, and in
terms of what impacts of therapy they experience as valuable. This point was further emphasised, as
participants reported a range of positive impacts that crossed social and psychological domains, for
example social engagement and increased confidence that arose from taking part in a trial (but these
did not seem to be associated with the intervention content per se). These are additional benefits of
therapy that are important for patients in their recovery process, but that would not be expected to be
captured in measures included in a trial.
Although the RATULS trial demonstrated improvement in impairment following robot-assisted training,
those who received EULT additionally showed improvement in ADL. This was not surprising, given the
specificity of learning. In robot-assisted training, movements were stereotypical, identical and did not
involve everyday objects, and movement patterns were tightly controlled by the device. In contrast,
health-care professionals reported that the EULT programme offered more scope for working on a range
of activities that linked to patients’ personal goals, and they also felt that there was more opportunity
to monitor and facilitate motor control in this type of treatment. Activities could be varied, tailored and
progressed, and feedback could be used selectively; all of these are components for optimising skill
acquisition and transfer. Patients in the EULT group indicated that they valued some of the functional
goals they had achieved.
Some participants (in both intervention groups) were engaging in other treatments (e.g. botulinum toxin,
other forms of physiotherapy and other physical rehabilitation) outside the RATULS trial provision, as
were some participants in the usual care group. This was allowed in the protocol. Furthermore, some
participants in both groups expressed a need for therapy to be extended beyond 12 weeks, to support
their rehabilitation potential in their upper limb and more general recovery. This resonates with the
findings of a qualitative study of Australian stroke survivors’ (n = 19) and spouses’ (n = 9) perceptions
of upper limb recovery after stroke, that emphasised survivors’ approach as one of ‘keeping the door
open’ – maintaining hope for and continuing to work towards improvement.76
Although broader conclusions about the therapies cannot be made for patients collectively on the
basis of specific examples, our findings indicate that rehabilitation for upper limb recovery is complex,
with the arm often being only part of the picture and patients engaging in multiple treatments (when
possible) to achieve their rehabilitation potential. Effective engagement in upper limb therapy (both
robot-assisted training and EULT) is likely to be influenced by factors related to stroke, such as fatigue,
cognition and communication abilities, as well as emotional factors, motivation, self-efficacy and social
support. These factors also influence other aspects of a patient’s life that constitute rehabilitation, such
as participation in social activity and return to work. It must also be emphasised that, even for those
indicating good improvement from upper limb therapy, the end of treatment does not mean the end of
the recovery journey.
The second objective of this qualitative study was to identify factors affecting the implementation
of the trial, and the trial therapies, increasingly an important focus in process evaluation of complex
interventions.64 It is important to understand two different objects of implementation here: the trial
in its broader sense (which includes the therapies and delivery contexts, in combination with trial
processes) and the therapies themselves, which may be subsequently provided in routine service
provision in the absence of the trial. We used NPT to present the results about implementation of the
trial and the RATULS trial therapies in that context.71 The findings indicated that successful delivery of
the trial required continuous investment in NPT framed ‘work’ to maintain commitment, engagement
and reflection/adaptation to some of the trial processes, to achieve the tasks (primarily recruitment,
therapy delivery and data collection) required for the RATULS trial.
DOI: 10.3310/hta24540 Health Technology Assessment 2020 Vol. 24 No. 54
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Rodgers et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
89
Early engagement of trial centres in planning the trial enabled development of understanding of the
trial and of the therapies being delivered (shared by most trial centres) (coherence), which facilitated
engagement by staff (cognitive participation). In terms of achieving the work of the trial (collective
action), allocation of therapy staff (dedicated RATULS therapists when possible) was highly facilitative,
as was a level of flexibility in therapy provision and organisation (e.g. allowing patients to express
preferences for days of therapy). The level of support, monitoring and feedback from the co-ordinating
centre throughout the trial (regarding recruitment, completion of assessments, etc.) (reflexive monitoring)
ensured ongoing engagement of sites, staff and patients.
Findings suggest that both robot-assisted training and EULT could be delivered successfully in routine
service provision, if adequately resourced and optimally organised to allow for reasonable flexibility
in delivery. Apart from some frustrations expressed by staff in relation to robot equipment failures,
both therapies were acceptable to staff after adequate training in the treatment protocols.
Methodological reflections indicate key strengths, and some limitations, of this qualitative process
evaluation. This is a large qualitative study of a multicentre trial, providing experiential accounts of trial
participation and delivery from staff and patients across multiple time points during a patient’s trajectory
through the trial. Conducting the interviews in two phases allowed some iterative development of
fieldwork focus, based on issues arising during the trial (and from phase 1). This approach also enabled
coverage of three different time points during therapy (commencement, completion and maintenance),
while limiting the number of interviews for individual patients; in particular, the extent to which patients
felt that they had been able to maintain any impacts at 6 months (3 months after therapy completion)
could be explored in phase 2. As a qualitative process evaluation study, the absence of an observational
component to supplement (or triangulate) interview findings may be a limitation, in that we have focused
on participants’ accounts of therapy rather than having directly observed the sessions they spoke of.
Observational methods can be valuable, but also intrusive to those involved. If we had taken this approach
in the RATULS trial, it may have affected therapy negatively, for limited benefit in data collection. Other
data were collected during the trial to document therapy provision, which can be used for some level
of data triangulation, and these suggest that therapy was generally delivered as intended. The findings
from the subset of trial participants who took part in the qualitative process evaluation have highlighted
a range of experiences, and differing levels of engagement in therapy, that were able to be achieved
by patients with different needs, and at different points in their recovery process after stroke.
This suggests that adequate variability of participants in the trial was achieved.
Overall, the RATULS trial participants’ accounts of stroke were strongly aligned with the existing
qualitative literature concerning the multifaceted impacts of stroke,68,69,77 variable nature of recovery
over time76,78,79 and expression of hopes and expectations concerning fuller recovery over time.76,80
Participating in the RATULS trial was viewed by patients as an opportunity to extend or supplement
their recovery process, particularly in relation to upper limb rehabilitation. Some participants expressed
disappointment on being allocated to the usual care group. Participants who received robot-assisted
training and EULT tended to be highly motivated and engaged well with their therapies, and reported
a range of benefits that represented improvements.
From the perspective of professional staff who delivered the RATULS therapies, both therapies could
be delivered to patients as a 12-week programme, providing the necessary resources were available
and staff engagement was high, and provided there was scope to make adjustments to therapy delivery
to accommodate patient, therapist, equipment and organisation factors affecting therapy provision.
Provision of both robot-assisted training and EULT in routine care (beyond the RATULS trial) may be
more flexible in terms of delivery and organisation than was possible in the context of the trial, in
which adherence to therapy and trial protocols were of paramount importance. Routine provision of
these therapy treatments may differ, however, in ways that affect efficacy, and should be further
explored in this context.
QUALITATIVE PROCESS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
Conclusion
Participants in both the robot-assisted training and EULT groups generally found the therapies to be
acceptable, and were able to complete their therapy programmes. Not surprisingly, some challenges
were experienced by some participants relating to their upper limb capabilities and other stroke-related
limitations that affected their engagement in the programmes. Participants reported a range of benefits
from participating in either therapy programme, and many reported (self-judged) maintenance of some
of the benefits at 6 months.
Delivering the RATULS trial required continuous investment of effort by trial centres and the co-ordinating
centre, with high levels of engagement from the staff involved. At times, flexibility and adaptation of
some of the processes, within the constraints of the trial protocol, were necessary to support continued
engagement of patients and professionals. The findings of this qualitative process evaluation can
be used to inform the delivery of robot-assisted training and the EULT programme for upper limb
rehabilitation, for service provision beyond the RATULS trial.
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Chapter 8 Health economic evaluation
Introduction
The health economic evaluation undertaken as part of the RATULS trial assessed the relative
cost-effectiveness of the robot-assisted training using the MIT-Manus robotic gym, compared with the
EULT programme and usual care. This evaluation included a within-trial analysis and an extrapolation of
the results to estimate costs and outcomes beyond the time frame of the trial.
The analyses took the perspective of the UK NHS and PSS. A wider societal perspective was also
explored by analysing the costs borne by participants and their carers. These costs included out-of-
pocket expenses incurred for hospital admissions, GP visits and outpatient appointments and time
away from usual activities such as work, study or caring responsibilities.
This chapter includes the main results of the within-trial economic evaluation and the extrapolation
exercise beyond the trial time frame. For the within-trial analysis, the following outcome measures
are reported:
l NHS and PSS resource use
l health-care costs per participant to the NHS and PSS over 6 months for each area of resource use
l utility scores derived from responses to the EQ-5D-5L26 questionnaire at baseline and at 3 and 6 months
post randomisation
l average QALYs per participant at 6 months post randomisation
l incremental cost-effectiveness ratios (ICERs)
l cost-effectiveness acceptability curves (CEACs) to assess the probability of each of the interventions
being considered most cost-effective at different willingness-to-pay (WTP) thresholds for a gained QALY.
For the extrapolation exercise, the following outcome measures are reported
l average health-care costs per participant at 12 months post randomisation
l average QALYs per participant at 12 months post randomisation
l ICERs and CEACs derived by extrapolating costs and QALYs from the data observed during the trial.
Results are also reported for the prespecified per-protocol and sensitivity analyses. The sensitivity
analyses explored uncertainty surrounding the level of resource use and the assumed lifespan of the
MIT-Manus robotic gym.
A stochastic sensitivity analysis was carried out for all analyses to address potential variance in the
outcome measures.
Methods
The economic analysis was conducted following best-practice guidelines conforming to the Consolidated
Health Economic Evaluation Reporting Standards.81
Baseline resource use
A health service utilisation questionnaire was developed, adapted from the CSRI28–30 and administered
at baseline. Participants were asked about the care received in the 3 months before they joined the
trial. It included questions relating to residential care and nursing home stays, visits to accident and
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emergency (A&E) departments, outpatient appointments, day patient appointments, overnight
hospital stays and the use of GP and nursing services. To limit the response burden on participants,
data were not collected on the use of therapy services, medications or community-based health
care and social services.
This information was used to control for any imbalance in participant resource use at baseline.
Follow-up resource use
Information on resource use from baseline to 6 months’ follow-up was collected to derive the total
mean cost per participant for each randomised group.
NHS and Personal Social Services resource use
The main within-trial economic analysis considered costs to the NHS and the PSS, which were
measured at the 6-month follow-up. Data were collected via a health service utilisation questionnaire,
which was completed by participants at the 6-month follow-up. Participants were asked about the care
they received in the previous 6 months. The resource use areas considered were primary care, therapy
services, secondary care NHS services, social care, stays at residential and nursing home facilities, the
use of social services and community-based health care, and prescribed medications.
Costs to the participant and caregiver
Data on participant- and carer-related costs were collected via a time and travel questionnaire
distributed at the 6-month follow-up assessment. This questionnaire was completed by the participants
and their carers, who provided details about their out-of-pocket expenses relating to their most recent
GP and secondary care appointments. This included travel time, time spent at appointments, mileage,
parking and other transport-related costs. Details relating to the main activities that participants and
carers would otherwise be doing were also provided.
Derivation of costs from NHS and Personal Social Services perspective
Individual patient-level data on resource use of the NHS and PSS were collected via the health service
utilisation questionnaire. Intervention costs were based on information received from the trial and
procurement NHS teams. These data were combined with unit costs obtained from routine data
sources such as the data collected by the Personal Social Services Research Unit82 and the 2017/18
national schedule of reference costs.83 The costs considered were presented in 2018 Great British
pounds and categorised as follows:
l intervention costs
l follow-up costs
¢ primary care
¢ therapy and community-based services
¢ secondary care
¢ residential and nursing home care
¢ social services
¢ medication costs.
Intervention costs
Participants recruited to the trial could be allocated to one of two distinct interventions: robot-assisted
training or the EULT programme. As per protocol, both interventions had the same duration and staff
component as shown in Appendix 8, Table 57. The full duration of each therapy session was 60 minutes,
including 45 minutes of face-to-face therapy. In addition to staff time, capital costs were calculated for
robot-assisted training using the ‘equivalent annual cost’.57 This methodology is described in Appendix 8.
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Primary care costs
Consultations with GPs, nurses and calls to NHS Direct (now NHS 111) were all classified as primary
care costs. The health service utilisation questionnaire allowed participants to state whether consultations
had taken place at home, at the health centre or by telephone. Unit costs were obtained from Curtis and
Burns.82 (see Appendix 8, Table 58). An average cost per participant for each randomisation group was
then calculated.
Therapy and community-based services costs
Therapy services were classified as physiotherapy, occupational therapy, and speech and language
therapy (see Appendix 8, Table 59). Participants were asked to state whether these appointments
took place at the hospital, the GP’s surgery, their own home, or elsewhere. Appointments with
community-based health professionals (health visitor, geriatrician, psychiatrist, chiropodist, optician
and pharmacist) were also collected. It was assumed that all therapy services reported by participants
were NHS funded and excluded any private consultations.
Secondary care costs
The type of secondary costs captured in the health service utilisation questionnaire included:
l Emergency visits to A&E departments.
l Overnight stays in hospital. When reporting their overnight hospital stay, participants were also
asked whether this followed an emergency (A&E) or general ward admission. They were also asked
how long they stayed in hospital. Both of these factors influenced which unit costs were applied.
The cost of stays of ≥ 22 days was based on excess bed-days beyond 21 days following the criteria
used to define long-stay patients in acute hospitals by NHS England.84
l Planned outpatient appointments not resulting in an overnight stay.
l Planned day patient appointments. Participants were asked about the approximate length of their
hospital stay as a day patient (either half or full days), which determined which unit cost was applied.
Appendix 8, Table 60, provides details on unit costs and the different categories captured for secondary
care use.
Residential and nursing home care costs
Stays in nursing and residential care facilities captured the participants’ residential and nursing home
stays for the whole duration of the trial. Costs for this cost category were derived from Curtis and
Burns82 and are outlined in Appendix 8, Table 61.
Social services costs
Social services were categorised as home help received by participants in the areas of personal care,
household tasks or daily shopping (see Appendix 8, Table 62). The questionnaire also captured whether
participants were in receipt of Meals on Wheels. To minimise recall bias, participants were asked to
record the services received in the preceding week. This information was then multiplied by 24 (assuming
4 weeks in a month) to estimate the resource use for the full 6 months.
Medication costs
The cost of prescribed medication was included in the trial. Participants were asked to state the
medication name, dosage, frequency, and start and end dates. When all information was available,
the unit cost was taken from the British National Formulary (BNF)85 and multiplied by the total units
prescribed for the stated period. If dosage was missing or incorrect, the BNF standard recommendation
for the patient group was used. Prescription cost analysis86 was used in those cases for which it was
impossible to ascertain the intake duration or the format prescribed. In this case, it was assumed that
the participant had been issued one prescription for the most commonly prescribed format (e.g. dose,
mode of intake) for the 6-month period.
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Assessment of effects
The QALY was used in the cost-effectiveness analysis as the health outcome, as it is recommended by
NICE.87 QALYs were used to assess the health gain of participants over the 6-month trial period.
Estimation of quality-adjusted life-years
Health status was measured by the completion of the EQ-5D-5L questionnaire by participants at
baseline and at 3 and 6 months post randomisation. Data from the EQ-5D-5L questionnaires were
then used to derive utilities and QALYs for the cost–utility analysis.
Following NICE guidelines,88 responses to the EQ-5D-5L questionnaire were mapped to the EuroQol-5
Dimensions, three-level version (EQ-5D-3L), descriptive system to generate the utility values. These
utility values have a range of –0.594 (worse than death) to 1 (perfect health). The resulting QALYs
were calculated, applying the area-under-the-curve approach,89 using the utility values obtained at
baseline and at 3 and 6 months post randomisation.
Dealing with missing data
The base-case cost-effectiveness analysis included only those participants for whom we had some
data on costs and baseline EQ-5D-5L. Because data were found to be missing at random, multiple
imputation was used to estimate the missing utility values at 3 and 6 months. Truncated normal
regression was applied, controlling for age, sex and baseline ARAT score, to generate 10 different
utility scores at each time point for each participant. The average value of the 10 iterations was taken
and imputed in place of the missing utility value.
Because data on intervention costs were available for participants in each of two intervention groups,
the only participants with missing total costs belonged to the usual care group. A sensitivity analysis
was subsequently conducted to explore the effect on cost-effectiveness of applying multiple imputation
to missing total costs, controlling for age, sex and baseline ARAT score.
Cost-effectiveness analysis
The base-case economic analysis takes the form of a cost-effectiveness analysis, with QALYs gained at
6 months as the primary economic analysis outcome measure. Costs included in the analysis comprised
the intervention costs for the robot-assisted training and EULT programme groups and health service
use over the 6-month follow-up period for all randomised groups. All participants reporting at least
some costs (NHS, PSS or intervention) associated with their participation in the trial were included in
the analysis.
Time and travel costs have been analysed but were not included in the base-case analysis, as this took
an NHS and PSS perspective. These have been summarised and are described separately in Appendix 8,
Time and travel analysis. The differences in costs and effects between the randomisation groups were
calculated, formally tested for statistically significant differences using the ttest command in Stata®
15 (StataCorp LP, College Station, TX, USA), and presented in the form of an ICER. The ICER is
defined as the difference in costs divided by the difference in effects (in this case QALYs) between
two alternatives:
ICER = (CA –CB /QALYsA –QALYsB), (1)
where C is costs.
A regression analysis on costs and outcomes was conducted using seemingly unrelated regression.90
This approach involves the estimation of two linear regressions with their own dependent variable for
costs and QALYs and a different set of explanatory variables. Randomisation group, trial centre and
time since stroke were used as explanatory variables for both costs and QALYs. In addition, baseline
utility score was used as an explanatory variable for the QALY equation and total baseline costs were
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added as an explanatory variable to the costs equation. This analysis was conducted in Stata 15 using
the seemingly unrelated regression command sureg.
Results from the regression analysis were used to calculate the incremental cost per QALY gained for
the comparison between the randomised groups at 6 months. Pairwise comparisons of the interventions
were decided according to their cost (i.e. the least costly intervention was compared with the next least
costly). If a comparator was both more costly and less effective than the others (i.e. it is dominated),
then this comparator was dropped from any further cost-effectiveness comparisons.
Sensitivity analysis
Stochastic sensitivity analysis
The imprecision surrounding the estimates of costs, effects and cost-effectiveness was assessed by
conducting a non-parametric stochastic sensitivity analysis. This technique allows for the comparison
of arithmetic means without making assumptions about the distribution of costs and QALYs.
This approach involved drawing bootstrapped samples, with replacement, of the mean costs and mean
QALYs from the original trial data. This process was repeated 1000 times, calculating new mean costs
and mean QALYs. The number of replications was increased until the results were stable. The new
values generated from the bootstrapping exercise were used to calculate the differences in costs and
effects between groups.
The information generated from bootstrapping was then combined with a range of WTP values
(£0, £10,000, £20,000, £30,000 and £50,000) per QALY gained. This generated a CEAC, which graphically
represented and quantified the probability of each of the interventions being cost-effective at each of the
prespecified WTP values.
Deterministic sensitivity analysis
A deterministic sensitivity analysis was carried out to explore any uncertainties surrounding the level
of resource use and their impact on the cost-effectiveness of the interventions. No formal testing to
detect differences across groups was conducted as part of the sensitivity analysis. The following areas
of uncertainty were explored:
l Extreme value analysis – this scenario assumed that the reason participants had not completed
information on health-care resource use was because no health-care costs had been incurred.
The total costs for these individuals was hence changed to zero, and the impact of this change in
cost-effectiveness was assessed.
l Multiple imputation of total missing costs – the possibility that those participants with missing total
costs may have incurred some costs was also considered. Once the missing information analysis on
costs established that information was missing at random, truncated normal regression was applied
using age, sex and baseline ARAT score as covariates to generate 10 different total mean costs for
each participant. After exploring the total cost distribution for each randomisation group, the upper
limit was set at £25,000. The average value of the 10 iterations was taken and imputed in place of
the missing value.
l Increased useful life of the MIT-Manus robotic gym (7 years) – after seeking expert opinion, the
effect on costs, QALYs and cost-effectiveness was explored in the event that the useful life of the
robot could be extended from 5 to 7 years.
l Exclusion of physiotherapy visits – participants were asked to record the physiotherapy sessions
received during the 6-month follow-up period. To account for the risk of potentially ‘double-counting’
the therapy sessions received by participants as part of the trial, the sensitivity analysis explored
how excluding the physiotherapy sessions recorded in the health service utilisation questionnaire
would affect the results. All physiotherapy visits were excluded for those participants allocated to
both the robot-assisted training and the EULT programme groups.
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These analyses were combined with stochastic sensitivity analyses to minimise any uncertainty
surrounding the ICER.
Subgroup analysis
To explore the impact of time since stroke on the cost-effectiveness of the interventions, an exploratory
analysis was conducted for the subgroups outlined in the protocol. Three subgroups were prespecified
(< 3 months, 3–12 months and > 12 months). No formal testing to detect differences across
randomisation groups was included in the analysis.
Per-protocol analysis
A secondary cost-effectiveness analysis was conducted: removing from the data set those participants
who did not receive at least 20 sessions of therapy in the robot-assisted training and the EULT
programme groups. The cut-off point of 20 sessions is based on clinical evidence that 20 hours of
therapy leads to improvements on functional outcome.10 No formal testing to detect differences across
groups was conducted as part of the per-protocol analysis.
Economic model
An economic model was originally planned in order to consider the long-term costs and utilities that
each group of participants would probably experience over the course of their lifetime. The design and
type of the economic model was contingent on the results of the within-trial analysis and, hence, the
cost-effectiveness of the proposed interventions. Having examined the cost-effectiveness analysis (CEA)
base-case results, the modelling exercise was designed to extrapolate the mean QALYs at 6 months to
12 months based on the results of the trial. It was assumed that participants across all groups maintained
the same utility levels reported at the 6-month follow-up point.
Intervention costs and therapy-related costs (physiotherapy, occupational therapy, and speech and
language therapy) were assumed not to continue beyond the 6-month trial period. However, all
other levels of health-care resource use were assumed to remain constant and continue for an
additional 6 months.
The differences in mean costs and effects between the randomisation groups were calculated, with
differences across groups not being formally tested. The adjusted ICER at 12 months was derived after
regression analysis on costs and outcomes; this was conducted using seemingly unrelated regression.90
The same explanatory variables used in the base-case CEA were included. Choice of pairwise comparisons
was decided according to their cost. As in the base-case CEA, if a comparator was both more costly and
less effective than the others, it was dropped from any further cost-effectiveness comparisons.
A stochastic sensitivity analysis was conducted, drawing bootstrapped samples of mean costs and mean
QALYs 1000 times. Results from this analysis were then combined with the same WTP values as used
in the base-case CEA, generating a CEAC that represented the probability of the interventions being
cost-effective at each WTP value.
Results
Response rates
The response rates relating to participant-completed health economics questionnaires are outlined
in Appendix 8, Table 63. A progressive loss to follow-up was identified over the duration of the trial.
The pattern of non-response was similar across the intervention groups; however, the loss to follow-up
was more pronounced in the usual care group in both responses to the health service utilisation and
quality-of-life questionnaires. Completion of resource use data at baseline was 96% across all randomisation
groups. Overall, this decreased to 79% at 6 months, with 70% of participants in the usual care group
completing the health service utilisation questionnaire.
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Full completion of EQ-5D-5L at baseline was accomplished by 99% of participants. Completion rate
decreased to 88% at 3 months and 82% at 6 months. The highest number of non-respondents
belonged to the usual care group (see Appendix 8, Table 63).
Resource use
This section describes the use of health-care resources incurred by the three randomisation groups at
both baseline and the 6-month follow-up. Mean and median resource use, SDs and IQRs have been
reported. The information has been presented in two separate ways. First, the data were summarised
for those participants who reported that they had accessed health-care services (Table 21 and Appendix 8,
Table 64). Second, a summary (Table 22 and Appendix 8, Table 65) was created for all randomised groups at
each time point to examine the overall mean (SD) and median (IQR) values.
Missing data were excluded from the analysis. No formal testing was conducted to detect statistically
significant differences in resource use between randomisation groups.
Resource use at baseline
The information collected at baseline captured the resource use recorded by participants in the 3 months
prior to being randomised to the trial. Response rates were high across all randomisation groups.
Appendix 8, Table 64, shows the summary statistics for those participants who reported to have
accessed health-care services. Key differences are described below; for full details of access to services,
see Appendix 8, Response rates and health-care resource use.
For those who accessed GP and nursing services, there was no substantial variation between
randomisation groups. The only exception was the average number of home nurse visits received by
participants, which was higher in the usual care group. Large SDs indicate that there was considerable
variation in the number of nurse home visits for this group, with some individuals using services very
frequently, thereby inflating the mean.
Resource use in secondary care and residential and nursing home facilities was characterised by a
substantial variability in the level of resource use, as shown by the high SDs for each of the randomisation
groups. This was particularly noticeable in the number of nights in hospital reported by participants
admitted to hospital through either A&E or a non-emergency admission. For those participants staying
in residential care and nursing homes facilities, high mean and SD values were reported, indicating large
variation between individuals, with long-term residents inflating the mean across all groups.
Descriptive statistics for the randomisation groups as a whole are described in Appendix 8, Table 65.
This shows similar mean levels of resource use across all groups in primary care. Participants in the
robot-assisted training group reported the highest mean number of hospital nights after A&E admission,
followed by EULT and usual care.
Resource use at 6 months post randomisation
Participants reported on the level of health-care resource use over the 6 months of the trial. The type of
health care accessed by participants included primary, therapy and secondary services provided by the
NHS; stays at residential and nursing home facilities; and use of social services and community-based
health care. Table 21 summarises the level of resource use for those accessing NHS and PSS services.
General practitioner consultations and outpatient hospital visits were the most common health-care
services accessed by participants across all groups. This was followed by nurse consultations and
physiotherapy appointments.
Reported use of secondary care services was characterised by a high variability in all categories except
for day patient treatment and A&E visits. The highest mean values across all groups were found in
the reported number of overnight hospital stays. The mean number of nights spent in hospital after
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TABLE 21 Resource use at 6 months for participants reporting use of services via the health service utilisation questionnaire
Area of
resource
utilisation
Randomisation group
Robot-assisted training EULT Usual care
Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR)
GP
Surgery 124 2.98 (4.63) 2.00 (1.00–3.50) 120 2.59 (2.16) 2.00 (1.00–3.00) 106 2.90 (2.09) 2.00 (1.00–4.00)
Home 33 2.33 (1.73) 2.00 (1.00–3.00) 33 1.75 (0.93) 2.00 (1.00–2.00) 27 2.48 (2.48) 2.00 (1.00–3.00)
Telephone 51 2.17 (1.60) 2.00 (1.00–3.00) 43 1.91 (1.27) 1.00 (1.00–2.00) 29 1.75 (0.99) 1.00 (1.00–2.00)
Nurse
Surgery 62 1.98 (1.89) 1.00 (1.00–2.00) 53 1.96 (1.67) 1.00 (1.00–2.00) 49 3.10 (10.10) 1.00 (1.00–2.00)
Home 25 3.92 (4.74) 2.00 (1.00–4.00) 32 3.00 (3.26) 2.00 (1.00–3.50) 28 32.75 (107.52) 1.00 (1.00–5.00)
Telephone 8 2.12 (2.10) 1.00 (1.00–3.00) 7 1.57 (0.78) 1.00 (1.00–2.00) 5 1.4 (0.55) 1.00 (1.00–2.00)
NHS Direct 17 1.35 (0.86) 1.00 (1.00–1.00) 14 1.28 (0.61) 1.00 (1.00–1.00) 3 2.00 (1.73) 1.00 (1.00–4.00)
Physiotherapy
Hospital 57 8.03 (9.55) 4.00 (3.00–8.00) 62 10.18 (14.81) 4.50 (2.00–10.00) 41 11.04 (12.60) 6.00 (4.00–11.00)
Home 49 11.55 (14.92) 6.00 (3.00–20.00) 57 11.24 (12.02) 7.00 (3.00–16.00) 48 15.40 (18.25) 9.50 (4.50–20.00)
General
practice
surgery
6 4.67 (5.64) 2.50 (2.00–4.00) 14 6.00 (7.38) 3.00 (2.00–5.00) 8 11.00 (15.45) 7.00 (2.00–10.50)
Elsewhere 11 4.36 (4.94) 2.00 (1.00–10.00) 6 7.50 (8.69) 4.00 (2.00–10.00) 9 12.00 (17.68) 3.00 (1.00–12.00)
Occupational therapy
Hospital 22 6.13 (7.95) 2.50 (1.00–6.00) 20 13.00 (20.41) 5.50 (1.50–15.50) 13 7.61 (11.02) 2.00 (1.00–6.00)
Home 43 7.60 (9.86) 3.00 (2.00–8.00) 37 7.19 (7.88) 4.00 (2.00–10.00) 45 7.51 (12.71) 3.00 (2.00–7.00)
General
practice
surgery
1 1.00 (–) 1.00 (1.00–1.00) 1 2.00 (–) 2.00 (2.00–2.00) 1 3.00 (–) 3.00 (3.00–3.00)
Elsewhere 3 11.66 (5.77) 15.00 (5.00–15.00) 0 – (–) – (–) 0 – (–) – (–)
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Area of
resource
utilisation
Randomisation group
Robot-assisted training EULT Usual care
Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR)
Speech and language therapy
Hospital 16 7.56 (7.34) 4.00 (2.50–12.50) 18 7.22 (10.80) 2.00 (1.00–12.00) 14 11.57 (15.20) 7.00 (1.00–12.00)
Home 20 4.95 (4.58) 3.00 (2.00–7.00) 17 8.00 (12.04) 4.00 (2.00–10.00) 21 18.57 (41.83) 6.00 (2.00–18.00)
General
practice
surgery
0 – (–) – (–) 2 3.50 (3.53) 3.50 (1.00–6.00) 3 1.00 (0.00) 1.00 (1.00–1.00)
Elsewhere 3 3.33 (1.52) 3.00 (2.00–5.00) 1 10.00 (–) 10.00 (10.00–10.00) 1 6.00 (–) 6.00 (6.00–6.00)
A&E visits 45 1.58 (0.92) 1.00 (1.00–2.00) 49 1.63 (1.48) 1.00 (1.00–2.00) 30 1.40 (1.16) 1.00 (1.00–1.00)
Outpatient
appointments
110 3.16 (3.78) 2.00 (1.00–4.00) 100 3.06 (3.60) 2.00 (1.00–4.00) 83 3.14 (5.76) 2.00 (1.00–3.00)
Hospital nights
Admitted via
A&E
20 8.45 (13.64) 3.00 (2.00–8.00) 27 14.59 (34.48) 5.00 (1.00–10.00) 15 8.26 (9.74) 3.00 (1.00–18.00)
Not admitted
via A&E
7 7.71 (16.48) 1.00 (1.00–3.00) 5 1.20 (0.45) 1.00 (1.00–1.00) 6 7.50 (7.06) 5.50 (1.00–14.00)
Day patient treatment
Half day 12 1.42 (0.51) 1.00 (1.00–2.00) 13 1.54 (1.13) 1.00 (1.00–1.00) 7 1.43 (0.79) 1.00 (1.00 – 2.00)
Full day 6 1.00 (0.00) 1.00 (1.00–1.00) 4 1.25 (0.50) 1.00 (1.00–1.50) 1 1.00 (–) 1.00 (1.00–1.00)
Residential care 5 74.40 (68.00) 69.00 (30.00–90.00) 5 89.80 (75.87) 105.00 (16.00–136.00) 5 49.40 (45.82) 40.00 (7.00–90.00)
Nursing home 0 – (–) – (–) 1 180 (0.00) 180.00 (180.00–180.00) 3 181.67 (0.57) 182.00 (181.00–182.00)
Meals on Wheels 1 4.00 (–) 4.00 (4.00–4.00) 2 4.50 (3.53) 4.50 (2.00–7.00) 2 7.5 (9.19) 7.50 (1.00–14.00)
continued
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TABLE 21 Resource use at 6 months for participants reporting use of services via the health service utilisation questionnaire (continued )
Area of
resource
utilisation
Randomisation group
Robot-assisted training EULT Usual care
Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR)
Home help
Personal care 48 12.70 (8.79) 8.5 (7.00–21.00) 43 14.83 (9.75) 12.00 (7.00 – 28.00) 38 14.45 (7.92) 14.00 (7.00–21.00)
Household
tasks
21 7.47 (7.52) 7.00 (1.00–14.00) 18 8.05 (11.10) 2.00 (1.00–7.00) 18 10.28 (10.53) 7.00 (1.00–21.00)
Shopping 8 3.00 (2.56) 1.5 (1.00–5.50) 7 2.14 (2.19) 1.00 (1.00–2.00) 7 2.85 (2.85) 1.00 (1.00–7.00)
Health visitor 5 2.20 (2.17) 1.00 (1.00–2.00) 6 3.17 (4.40) 1.00 (1.00–3.00) 3 2.00 (1.00) 2.00 (1.00–3.00)
Geriatrician 2 3.50 (3.53) 3.50 (1.00–6.00) 3 1.67 (1.15) 1.00 (1.00–3.00) 0 – (–) – (–)
Psychiatrist 10 2.70 (2.11) 2.00 (1.00–3.00) 6 2.67 (2.06) 2.00 (1.00–4.00) 2 1.00 (0.00) 1.00 (1.00–1.00)
Psychologist 23 4.09 (5.00) 3.00 (1.00–4.00) 18 3.28 (2.37) 3.00 (1.00–4.00) 15 5.13 (6.66) 2.00 (1.00–6.00)
Chiropodist 50 2.32 (1.35) 2.00 (1.00–3.00) 38 2.16 (1.57) 2.00 (1.00–3.00) 39 1.97 (1.28) 2.00 (1.00–2.00)
Optician 41 1.26 (0.55) 1.00 (1.00–1.00) 42 1.17 (0.58) 1.00 (1.00–1.00) 42 1.33 (0.57) 1.00 (1.00–2.00)
Pharmacist 34 4.12 (4.46) 3.00 (1.00–6.00) 27 4.59 (4.69) 3.00 (1.00–6.00) 31 6.55 (8.52) 5.00 (2.00–6.00)
a Number of participants who answered ‘Yes’ to question.
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TABLE 22 Resource use at 6 months for participants completing the health service utilisation questionnaire
Area of resource utilisation
Randomisation group
Robot-assisted training EULT Usual care
Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR)
GP
Surgery 205 1.80 (3.88) 1.00 (0.00–2.00) 208 1.49 (2.08) 1.00 (0.00–2.00) 168 1.83 (2.17) 1.00 (0.00–3.00)
Home 209 0.37 (1.08) 0.00 (0.00–0.00) 213 0.27 (0.73) 0.00 (0.00–0.00) 174 0.38 (1.29) 0.00 (0.00–0.00)
Telephone 207 0.53 (1.22) 0.00 (0.00–0.00) 207 0.39 (0.96) 0.00 (0.00–0.00) 172 0.30 (0.77) 0.00 (0.00–0.00)
Nurse
Surgery 203 0.61 (1.39) 0.00 (0.00–1.00) 210 0.49 (1.19) 0.00 (0.00–1.00) 169 0.90 (5.58) 0.00 (0.00–1.00)
Home 206 0.47 (2.07) 0.00 (0.00–0.00) 213 0.45 (1.65) 0.00 (0.00–0.00) 170 5.39 (44.63) 0.00 (0.00–0.00)
Telephone 211 0.08 (0.56) 0.00 (0.00–0.00) 212 0.52 (0.31) 0.00 (0.00–0.00) 174 0.04 (0.25) 0.00 (0.00–0.00)
NHS Direct 211 0.11 (0.44) 0.00 (0.00–0.00) 213 0.08 (0.35) 0.00 (0.00–0.00) 174 0.03 (0.32) 0.00 (0.00–0.00)
Physiotherapy
Hospital 210 2.18 (6.10) 0.00 (0.00–1.00) 211 2.99 (9.23) 0.00 (0.00–2.00) 171 2.64 (7.72) 0.00 (0.00–0.00)
Home 205 2.76 (8.76) 0.00 (0.00–0.00) 207 3.10 (8.04) 0.00 (0.00–1.00) 170 4.35 (11.87) 0.00 (0.00–2.00)
General practice surgery 213 0.13 (1.16) 0.00 (0.00–0.00) 212 0.40 (2.63) 0.00 (0.00–0.00) 176 0.50 (3.85) 0.00 (0.00–0.00)
Elsewhere 212 0.23 (1.45) 0.00 (0.00–0.00) 213 0.21 (1.82) 0.00 (0.00–0.00) 175 0.62 (4.63) 0.00 (0.00–0.00)
Occupational therapy
Hospital 211 0.64 (3.14) 0.00 (0.00–0.00) 211 1.23 (7.23) 0.00 (0.00–0.00) 174 0.57 (3.53) 0.00 (0.00–0.00)
Home 210 1.56 (5.39) 0.00 (0.00–0.00) 209 1.27 (4.28) 0.00 (0.00–0.00) 173 1.95 (7.23) 0.00 (0.00–1.00)
General practice surgery 213 0.00 (0.07) 0.00 (0.00–0.00) 211 0.01 (0.14) 0.00 (0.00–0.00) 176 0.02 (0.23) 0.00 (0.00–0.00)
Elsewhere 212 0.16 (1.49) 0.00 (0.00–0.00) 211 0.00 (0.00) 0.00 (0.00–0.00) 176 0.00 (0.00) 0.00 (0.00–0.00)
Speech and language therapy
Hospital 213 0.57 (2.79) 0.00 (0.00–0.00) 213 0.65 (3.74) 0.00 (0.00–0.00) 173 0.94 (5.24) 0.00 (0.00–0.00)
Home 210 0.47 (2.00) 0.00 (0.00–0.00) 212 0.64 (3.97) 0.00 (0.00–0.00) 175 2.22 (15.42) 0.00 (0.00–0.00)
General practice surgery 212 0.00 (0.00) 0.00 (0.00–0.00) 213 0.03 (0.42) 0.00 (0.00–0.00) 176 0.02 (0.13) 0.00 (0.00–0.00)
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TABLE 22 Resource use at 6 months for participants completing the health service utilisation questionnaire (continued )
Area of resource utilisation
Randomisation group
Robot-assisted training EULT Usual care
Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR)
Elsewhere 213 0.05 (0.42) 0.00 (0.00–0.00) 213 0.47 (0.68) 0.00 (0.00–0.00) 175 0.03 (0.45) 0.00 (0.00–0.00)
A&E visits 213 0.33 (0.77) 0.00 (0.00–0.00) 214 0.37 (0.98) 0.00 (0.00 – 0.00) 178 0.24 (0.70) 0.00 (0.00 – 0.00)
Outpatient appointments 212 1.64 (3.14) 1.00 (0.00–2.00) 215 1.42 (2.88) 0.00 (0.00–2.00) 176 1.48 (4.24) 0.00 (0.00–2.00)
Hospital nights
Admitted via A&E 213 0.79 (4.77) 0.00 (0.00–0.00) 215 1.83 (12.95) 0.00 (0.00–0.00) 176 0.70 (3.59) 0.00 (0.00–0.00)
Not admitted via A&E 213 0.28 (3.09) 0.00 (0.00–0.00) 215 0.03 (0.19) 0.00 (0.00–0.00) 176 0.25 (1.81) 0.00 (0.00–0.00)
Day patient treatment
Half day 205 0.08 (0.35) 0.00 (0.00–0.00) 210 0.09 (0.46) 0.00 (0.00–0.00) 175 0.06 (0.32) 0.00 (0.00–0.00)
Full day 199 0.03 (0.17) 0.00 (0.00–0.00) 201 0.025 (0.18) 0.00 (0.00–0.00) 169 0.06 (0.07) 0.00 (0.00–0.00)
Residential care 213 1.75 (14.65) 0.00 (0.00–0.00) 215 2.08 (17.07) 0.00 (0.00–0.00) 177 1.39 (10.72) 0.00 (0.00–0.00)
Nursing home 213 0.00 (0.00) 0.00 (0.00–0.00) 216 0.83 (12.24) 0.00 (0.00–0.00) 177 3.08 (23.51) 0.00 (0.00–0.00)
Meals on Wheels 213 0.02 (0.27) 0.00 (0.00–0.00) 213 0.04 (0.49) 0.00 (0.00–0.00) 177 0.08 (1.05) 0.00 (0.00–0.00)
Home help
Personal care 211 2.89 (6.77) 0.00 (0.00–0.00) 210 3.04 (7.42) 0.00 (0.00–0.00) 173 3.17 (7.03) 0.00 (0.00–0.00)
Household tasks 213 0.74 (3.21) 0.00 (0.00–0.00) 212 0.68 (3.87) 0.00 (0.00–0.00) 175 1.06 (4.54) 0.00 (0.00–0.00)
Shopping 213 0.11 (0.74) 0.00 (0.00–0.00) 212 0.07 (0.53) 0.00 (0.00–0.00) 176 0.11 (0.76) 0.00 (0.00–0.00)
Health visitor 212 0.05 (0.45) 0.00 (0.00–0.00) 213 0.09 (0.85) 0.00 (0.00–0.00) 177 0.03 (0.28) 0.00 (0.00–0.00)
Geriatrician 212 0.03 (0.42) 0.00 (0.00–0.00) 213 0.02 (0.23) 0.00 (0.00–0.00) 177 0.00 (0.00) 0.00 (0.00–0.00)
Psychiatrist 212 0.13 (0.72) 0.00 (0.00–0.00) 213 0.75 (0.54) 0.00 (0.00–0.00) 175 0.01 (0.11) 0.00 (0.00–0.00)
Psychologist 209 0.45 (2.07) 0.00 (0.00–0.00) 211 0.28 (1.14) 0.00 (0.00–0.00) 176 0.44 (2.37) 0.00 (0.00–0.00)
Chiropodist 210 0.55 (1.19) 0.00 (0.00–0.00) 210 0.39 (1.06) 0.00 (0.00–0.00) 173 0.44 (1.02) 0.00 (0.00–0.00)
Optician 210 0.25 (0.56) 0.00 (0.00–0.00) 212 0.23 (0.53) 0.00 (0.00–0.00) 174 0.32 (0.64) 0.00 (0.00–0.00)
Pharmacist 211 0.66 (2.33) 0.00 (0.00–0.00) 207 0.60 (2.28) 0.00 (0.00–0.00) 174 1.16 (4.35) 0.00 (0.00–0.00)
a Number of participants who completed all or part of the questionnaire.
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admission via A&E was highest in the EULT group, followed by the robot-assisted training and usual
care groups. When admission to hospital was not via A&E, the robot-assisted training group displayed
the highest mean number of nights in hospital, followed by the EULT and usual care groups.
The use of community-based health care and social services was similar across all randomisation groups.
The reported use of a community pharmacist, however, suggests the highest variability among all
participants, with high SDs calculated for all groups. Table 22 shows that, overall, mean values were
similar across all randomisation groups for most areas of health-care resource use. The main differences
between groups were reported in the therapy services received, with the usual care group participants
being the highest users of home physiotherapy and speech and language therapy services.
Participants were also asked to report additional NHS and social services received during the trial
that were not captured by predefined questions in the questionnaire. The resource use and unit costs
of these additional services is summarised in Appendix 8, Tables 70–73.
Health-care costs
Cost information at baseline was used to adjust for any imbalance in resources and costs after
randomisation (see Appendix 8).
The costs collected at 6 months post randomisation were used to calculate incremental mean costs to
ascertain the cost-effectiveness of the interventions. Table 23 summarises the total costs per participant
for each cost category, as well as the mean total cost per randomisation group. The highest mean costs
per participant were associated with the use of social care services, which included stays in residential
and nursing home facilities and care assistance received at home. The average cost per participant
was higher in the usual care group in all categories except in secondary care and other NHS and
social services used by the participants. The addition of the intervention costs, however, reversed this
trend, making the mean cost per participant highest in the group receiving robot-assisted training.
Large SDs indicate that there was substantial variation in resource use between individuals across all
randomisation groups.
The mean difference in total costs between the usual care and robot-assisted training groups
was statistically significant, with usual care being, on average, £1601 less costly than robot-assisted
training (p < 0.001).
Quality-of-life outcomes
The utility scores derived from responses to the EQ-5D-5L questionnaires are shown in Table 24.
Response rates for the robot-assisted training and EULT randomisation groups were similar at all time
points. The number of responses for the usual care group was noticeably lower both at 3 and 6 months.
The utility values were similar across all groups. The highest mean utility increment occurs between
baseline and 3 months across all groups. The highest mean QALY was reported for the EULT group
(0.23), with the robot-assisted training and usual care groups yielding an equal mean QALY gained of
0.21 at 6 months. The mean difference in QALYs between each of the intervention groups (robot-assisted
training and EULT) and usual care was very small and was not statistically significant, with the 95% CIs
crossing zero.
Results from the within-trial economic evaluation
Incremental cost-effectiveness analysis
The unadjusted CEA shows that usual care was less costly than robot-assisted training and EULT, but
that usual care was less effective than EULT. There was no evidence of a difference in QALYs between
groups (Table 25). The deterministic results from the adjusted analysis show an ICER of £74,100 for
the EULT group, compared with usual care. Robot-assisted training was dominated by EULT as it was,
on average, both more costly and less effective, although this was not statistically significant.
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TABLE 23 Total costs (£) over 6 months including all participants with full economic data
Area of resource utilisation
Randomisation group
Robot-assisted training EULT Usual care
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Intervention costs 2872 (0) 2872 (2872–2872) 1399 (0) 1399 (1399–1399) – (–) – (–)
Primary care costs and community-based health care
(including therapy services)
743 (1031) 322 (96–748) 777 (1262) 326 (94–904) 1078 (1813) 514 (145–1194)
Social care 1410 (3146) 0 (0–322) 1541 (3943) 0 (0–0) 1890 (4281) 0 (0–1612)
Secondary care 733 (2247) 142 (0–704) 988 (4486) 142 (0–566) 668 (1880) 138 (0–138)
Medication costs 149 (302) 53 (26–139) 154 (273) 75 (27–186) 198 (347) 81 (32–220)
Other NHS and social services 727 (983) 339 (172–904) 790 (946) 525 (186–860) 307 (406) 171 (128–256)
Deceased participants 0 (0) 0 (0–0) 13,953 (4516) 13,451 (9709–18,700) – (–) – (–)
Mean total cost 5387 (4054) 3778 (2962–5854) 4451 (6033) 2245 (1596–4442) 3785 (5437) 1302 (503–4598)
Mean difference between usual care and robot-assisted
training (95% CI); p-value
–1601 (–2496 to –706); < 0.001
Mean difference between usual care and
EULT (95% CI); p-value
–665 (–1774 to 444); 0.239
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TABLE 24 Utility scores at baseline, 3 months and 6 months, and QALYs at 6 months
Robot-assisted training EULT Usual care
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR) n Mean (SD) Median (IQR)
Utility scores
Baseline EQ-5D-5L 254 0.36 (0.26) 0.38 (0.17–0.56) 259 0.39 (0.25) 0.41 (0.20–0.57) 254 0.37 (0.26) 0.39 (0.18–0.58)
3-month EQ-5D-5L 232 0.45 (0.27) 0.51 (0.26–0.67) 236 0.48 (0.24) 0.55 (0.32–0.67) 207 0.42 (0.29) 0.42 (0.21–0.64)
6-month EQ-5D-5L 223 0.46 (0.29) 0.54 (0.22–0.71) 222 0.50 (0.27) 0.57 (0.32–0.72) 190 0.46 (0.27) 0.53 (0.25–0.66)
QALYs at 6 months after multiple imputation 254 0.21 (0.12) 0.22 (0.14–0.30) 259 0.23 (0.10) 0.24 (0.16–0.30) 254 0.21 (0.11) 0.22 (0.15–0.28)
Mean difference in QALYs between usual care
and robot-assisted (95% CI); p-value
0.00 (–0.20 to 0.20); 0.995
Mean difference in QALYs between usual care
and EULT (95% CI); p-value
–0.02 (–0.35 to 0.00); 0.080
TABLE 25 Results from base-case and stochastic cost–utility analysis for robot-assisted training, EULT and usual care based on an ITT analysis
Randomisation group
Unadjusted mean (98.33% CI) Adjusted incremental (98.33% CI)
Adjusted
ICER (£)
Probability that each therapy is cost-effective at
WTP of
Cost (£) QALY QALY Cost (£) £0 £10,000 £20,000 £30,000 £50,000
Usual care 3785 (2801 to 4770) 0.21 (0.19 to 0.23) – 0.90 0.85 0.81 0.74 0.62
EULT 4451 (3548 to 5354) 0.23 (0.21 to 0.24) 0.010
(–0.005 to 0.025)
741
(–461 to 1943)
74,100 0.10 0.15 0.19 0.26 0.38
Robot-assisted training 5387 (4777 to 5996) 0.21 (0.19 to 0.23) Dominated
by EULT
0.00 0.00 0.00 0.00 0.00
Notes
Unadjusted analysis: costs – usual care, n = 178; EULT, n= 259; robot-assisted training, n = 257. QALYs – usual care, n = 254; EULT, n= 259; robot-assisted training, n = 257). Adjusted
analysis: usual care, n = 171; EULT, n = 254, robot-assisted training, n= 247.
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The results of the deterministic analysis do not reflect the statistical imprecision surrounding estimates
of cost-effectiveness. This is provided by the stochastic sensitivity analysis. The results from this
sensitivity analysis (Figure 14) suggest that there was approximately a 20% chance that EULT was cost-
effective at a £20,000 WTP threshold value, and the probability that EULT was cost-effective is never
> 40% over the range of WTP values considered. Robot-assisted training has a 0% chance of being
cost-effective at all the WTP values considered in the analysis.
Additional graphical representation of the bootstrapped incremental costs and QALYs for EULT and
robot-assisted training, compared with usual care, can be seen in Figures 15 and 16. Figure 15
represents a comparison between EULT and usual care, showing the bootstrapped incremental costs
and QALYs, taking usual care as the reference point. As seen in Table 25, the majority of bootstrapped
values show that EULT was more costly and more effective than usual care. The majority of these
bootstrapped points fall above the £20,000 WTP threshold line, confirming that EULT has a low
probability of being cost-effective except when society’s WTP for a QALY is very high.
For completeness, we have also graphically represented the bootstrapped incremental costs and QALYs
for robot-assisted training compared with usual care. Figure 16 shows how the majority of bootstrapped
values for robot-assisted training confirm that it was, on average, both more costly and as effective as
usual care. A very small number of bootstrapped values fall below the £20,000 WTP threshold line,
confirming that the probability of robot-assisted training being cost-effective is very close to zero, even
when society’s WTP for a QALY is higher than might normally be considered to be the case.
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FIGURE 14 Cost-effectiveness acceptability curve (base-case analysis): adjusted bootstrapped replications for CEA.
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Deterministic sensitivity analysis
The results of each scenario explored in the deterministic sensitivity analysis are detailed in Appendix 8,
Deterministic sensitivity analysis. Table 26 provides a summary of the main findings. Robot-assisted
training remains dominated in all the scenarios explored.
When missing costs were changed to zero, the resulting ICER between EULT and usual care increased
to £172,000 (see Appendix 8, Tables 74 and 75, and Figure 17). This increase was to be expected
because all participants with missing total costs belonged to the usual care group. By imputing zero for
missing costs, the mean costs for the usual care participants were reduced; hence, the ICER increased
when compared with EULT (see Appendix 8, Tables 76 and 77, and Figure 18).
Results from extending the life of the robotic gym are shown in Appendix 8, Tables 78 and 79, and
Figure 19. The lowest ICER resulted from the exclusion of physiotherapy sessions from the analysis
(£48,600) (see Appendix 8, Tables 80 and 81, and Figure 20).
Subgroup analysis
The results from the adjusted and unadjusted subgroup analysis are outlined in Appendix 8, Subgroup
analysis. Adjusted and unadjusted results suggest that robot-assisted training was, on average, more
costly and less effective than EULT across all subgroups considered. The ICER, therefore, relates to the
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FIGURE 16 Incremental costs and QALYs for robot-assisted training in relation to usual care.
TABLE 26 Results from adjusted sensitivity analysis
Sensitivity analysis
Incremental (98.33% CI)a
ICER (£)
Probability of EULT being
considered cost-effective
at a WTP of £20,000Cost (£) QALY
Extreme analysis 1892
(823 to 2961)
0.011
(–0.002 to 0.024)
172,000 0.00
Multiple imputation 550
(–503 to 1604)
0.011
(–0.002 to 0.024)
50,000 0.27
Useful life of robot extended
to 7 years
741
(–460 to 1943)
0.010
(–0.005 to 0.025)
74,100 0.19
Physiotherapy sessions excluded 486
(–702 to 1674)
0.010
(–0.005 to 0.025)
48,600 0.34
a Estimates based on adjusted analysis.
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comparison between EULT and usual care at all times. The highest ICER (£126,143) relates to those
participants who, at randomisation, had experienced a stroke between 1 and 5 years ago. The subgroup
of participants who were < 3 months post stroke at randomisation had the lowest ICER (£31,400).
The stochastic sensitivity analysis for this group suggests that EULT has a 41% probability of being
cost-effective at the £20,000 WTP threshold.
The subgroup analysis results seem to mimic those found in the base-case economic evaluation.
The results, however, need to be interpreted with caution because of the reduced sample size in
each subgroup.
Per-protocol analysis
Results from the per-protocol analysis are reported in Appendix 8, Per-protocol analysis. Both the
unadjusted and adjusted results suggest that robot-assisted training is, on average, more costly and
less effective than EULT, and more costly and slightly more effective than usual care.
The resulting ICER (£68,000) relates to the comparison of EULTwith usual care. The stochastic
sensitivity analysis suggests that EULT has a 17% probability of being cost-effective at the
£20,000 WTP threshold.
Results from the economic model
The development of the model was contingent on the CEA results. At the current £20,000 WTP
threshold, usual care had the highest probability of being cost-effective (81%) at 6 months. The economic
model explored the impact on the results if the data were extrapolated beyond the time frame of the trial
(see Appendix 8, Tables 94–96, and Figure 24).
The unadjusted analysis shows that mean total costs per participant were lowest in the EULT group
(£6892), followed by usual care (£6916) and robot-assisted training (£7538). The assumption that
utility scores at 12 months equalled those reported at 6 months resulted in the mean QALY results
mimicking those obtained in the base-case CEA. Participants in the EULT group had the highest
mean QALYs at 12 months (0.48), followed by usual care (0.47) and robot-assisted training (0.44).
These results indicate that there is no evidence of a difference in mean QALYs between groups
at 12 months.
The adjusted CEA, however, shows that usual care was £128 less costly than EULT. Even though
the point estimate of the unadjusted analysis showed that EULT was the least costly option, this is
no longer the case when the CEA controls for baseline costs. These increased costs in EULT are then
translated into a £6095 ICER for the comparison between EULT and usual care; however there is
only a 55% probability of EULT being considered cost-effective compared with usual care at the
£20,000 WTP value.
The base-case CEA results from the within-trial analysis precluded the need for a more complex economic
model at this stage. An important limitation of the economic model is that untested assumptions (based
on trial data) on both costs and QALYs have been made. Although costs may be estimated, there is no
evidence that utilities will remain constant between 6 and 12 months. This means that cost-effectiveness
from the extrapolated results must be interpreted with caution.
Changes to the mode of delivery of EULT and robot-assisted training may affect both costs and QALYs,
and could be explored in further research. However, effectiveness data on changes to EULT or robot-
assisted training delivery are not currently available and no sensible parameter values could have been
used to inform the model.
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Discussion
The main strength of this economic evaluation is that it was conducted alongside a rigorously run
pragmatic RCT and followed guidelines for best practice throughout.87,91 As a result, the economic
evaluation was based on individual patient data collected during the trial and benefited from small
numbers of missing health-care resource and quality-of-life data. Completion of baseline questionnaires
was close to 100% across all randomisation groups. Although response rates for the health service
utilisation questionnaire remained high at 6 months, at 79% overall, this decreased to 70% for participants
in the usual care group. This number of missing responses is, however, to be expected. To assess
the impact of the missing data, multiple imputation methods were applied in a sensitivity analysis.
The cost-effectiveness results obtained using the imputed variables were consistent with those from the
base-case analysis.
Self-reported quality-of-life data were collected at three points during the trial using the EQ-5D-5L
questionnaire.26 This enabled us to accurately measure QALY gains for participants across all groups
using the preference-based instrument recommended by NICE.88 One important strength is that
assessing quality of life in this way will enable cost-effectiveness comparisons not only for this patient
group, but across different disease areas. Following NICE guidance,88 responses to the EQ-5D-5L
questionnaire were mapped to the EQ-5D-3L descriptive system to generate the utility values.
A noteworthy limitation of the economic evaluation is associated with the time frame of the trial.
The within-trial economic evaluation assessed the cost-effectiveness of the interventions at 6 months.
A longer-term perspective would have been achieved through the development of the long-term full
economic model that was originally planned. However, given the results of the trial and the dominant
status of usual care, the development of this type of model was no longer considered appropriate. As
an alternative, a shorter-term model was conducted to derive cost-effectiveness results at 12 months.
The results, however, need to be interpreted with caution because of the restricted assumptions made
on both costs and utility values.
The economic evaluation fills a significant evidence gap, as no economic evaluation comparing robot-
assisted training with usual care had been conducted in the UK NHS setting before, to our knowledge.
A scoping review found little evidence of cost-effectiveness studies in the UK, and the only economic
evaluation assessing the cost-effectiveness of robot therapy was US based.18 Differences in the health-
care systems between both countries mean that, unlike our economic evaluation, the results from this
US study18 lack generalisability to the UK setting. Furthermore, there were differences in the therapy
received by the randomisation groups, which reduces the grounds for comparability with the care
received in the NHS.
The use of multiple sites across the UK contributed to the generalisability of the economic evaluation.
The analysis controlled for differences in trial centres, hence minimising the chance of obtaining biased
results from differences in costs and effects driven by location.
Overall, our economic evaluation was designed and conducted following NICE’s guidance for best
practice,87,91 which resulted in robust and generalisable results.
The results from the economic evaluation create opportunities for further research. In particular,
further analyses could explore the potential effect on both costs and QALYs of reconfigurations to
the delivery of EULT and robot-assisted training.
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Conclusion
The CEA results suggest that, on average, robot-assisted training was more costly than both EULT
and usual care, and that robot-assisted training was less effective than EULT and as effective as usual
care. EULT was, on average, more effective and more costly than usual care in both the adjusted
and unadjusted CEA. The balance of probabilities favoured usual care as the preferred upper limb
rehabilitation therapy over the range of WTP values considered for the participants included in the
trial. Focusing on society’s WTP for a QALY, the stochastic analysis suggests that the balance of
probabilities does not favour EULT as being cost-effective over any of the WTP values considered,
despite EULT being more effective than the other randomisation groups.
A subgroup analysis in which the participants were categorised according to time since stroke did not
change the direction of the cost-effectiveness results.
The lowest ICER (£48,600) between EULT and usual care in the sensitivity analysis was reported when
the costs of physiotherapy sessions were excluded. Extrapolating within-trial results to 12 months
produced the lowest ICER (£6095) for the comparison between EULT and usual care overall; however,
high uncertainty surrounds the assumptions made on costs and utilities for the 12-month period.
Further studies are needed to confirm if these results hold true.
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Chapter 9 Discussion
Parts of this chapter have been reproduced from Rodgers et al.1 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Parts of this chapter have been reproduced from Rodgers et al.92 Reprinted from The Lancet, 395,
Rodgers H, Bosomworth H, Van Wijck F, Krebs HI, Shaw L, Usual care: the big but unmanaged problem
of rehabilitation evidence – authors’ reply, 337–8, 2020, with permission from Elsevier.
Parts of this chapter have been reproduced from Bosomworth et al.61 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Key findings
Primary outcome: achievement of prespecified improvement in upper limb
function at 3 months
All groups showed improvement in upper limb function from baseline to 3 months. Upper limb
functional recovery ‘success’ at 3 months was achieved by 44% of participants who received robot-
assisted training, by 50% of participants who received the EULT programme and by 42% of participants
who received usual care. However, we found little evidence of a difference in improvement of upper
limb function at 3 months between stroke patients who were randomised to receive robot-assisted
training, patients who were randomised to receive an EULT programme of goal-orientated repetitive
functional task practice and patients who were randomised to receive usual care. The aOR comparing
robot-assisted training, using the MIT-Manus robotic gym, with usual care was 1.2 (98.33% CI 0.7
to 2.0). The aOR comparing the EULT programme with usual care was 1.5 (98.33% CI 0.9 to 2.5).
The aOR comparing the EULT programme with robot-assisted training was 0.8 (98.33% CI 0.5 to 1.3).
Secondary outcomes: upper limb function, upper limb impairment, activities of daily living,
quality of life and upper limb pain
The improvements seen in upper limb function from baseline to 3 months were maintained at 6 months
by all randomisation groups. Upper limb functional recovery ‘success’ at 6 months was achieved by
47% of participants who received robot-assisted training, by 54% of participants who received the EULT
programme and by 44% of participants who received usual care. There were no statistically significant
differences between the randomisation groups for ARAT ‘success’ at 6 months.
Although there was no statistically significant difference between the EULT programme and usual care
in upper limb functional recovery ‘success’, the absolute difference was 8% at 3 months and 10% at
6 months, in favour of the EULT programme. These differences may be considered important by some
patients and clinicians, but the trial was designed to detect a 15% difference between groups.
Of the many pre-planned comparisons of secondary outcomes, some indicated differences that might
be clinically important, as the MCID was within the 98.33% CI. Robot-assisted training improved upper
limb impairment, as measured by the FMA motor subscale at 3 months, when compared with usual
care; this difference was maintained at 6 months. However, this improvement did not translate into
improvement in upper limb function, ADL or quality of life. Indeed, robot-assisted training participants
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performed less well in ADL (Barthel ADL Index and SIS ADL subscale) at 3 months than those who
received the EULT programme.
Enhanced upper limb therapy led to clinically important and statistically significant improvements in upper
limb impairment, when compared with usual care at 3 months. EULT also led to clinically important and
statistically significant improvements in mobility and ADL, as measured by the SIS, when compared with
usual care at this time point. Statistically significant differences were found in favour of EULT in ADL
(Barthel ADL Index) and hand function, but these were not felt to be clinically important. No clinically
important differences were found between EULT and usual care, or robot-assisted training and EULT,
at 6 months on any outcome measure.
There was no difference in the proportion of participants reporting upper limb pain between
randomisation groups.
Subgroup analyses
No significant differences were found between the randomisation groups for upper limb function
measured by the mean ARAT score at 3 months for any of the prespecified exploratory analyses: time
since stroke, baseline ARAT score, trial centre and age. However, CIs were wide because of the smaller
sample size of the subgroups. No significant differences in upper limb impairment or ADL were found
between randomisation groups according to time since stroke.
Safety
More participants in the robot-assisted training group and the EULT group (15% and 13%, respectively)
had SAEs than those who received usual care (8%). None was attributable to an intervention and
the differences are probably because of a reporting bias, as participants who received an intervention
had regular contact with RATULS trial teams, and were therefore more likely to make them aware of
these events.
Health economic evaluation
The cost per participant over the 6-month trial duration was £5387 for those randomised to robot-
assisted training, £4451 for those randomised to the EULT programme and £3785 for those randomised
to usual care. Neither robot-assisted training nor EULT, when delivered with a 1 : 1 patient-to-therapist
ratio, would be considered cost-effective at the UK current level of WTP for a QALY (£20,000–30,000).
Robot Assisted Training for the Upper Limb after Stroke trial results in the
context of other studies
Robot-assisted training
The results of a 2017 systematic review93 of the effects of robot-assisted therapy for the upper
limb after stroke (38 trials, 1206 participants) are consistent with the results of the RATULS trial.
This review concluded that ‘effects on motor control are small and specific to the joints targeted by
robot-assisted training, whereas no generalisation is found to improvements in upper limb capacity’.93
However, the 2018 Cochrane systematic review94 of electromechanical and robot-assisted arm training
(45 trials, 1619 participants) reported significantly improved ADL scores (SMD 0.31, 95% CI 0.09 to
0.50) and arm function (SMD 0.32, 95% CI 0.18 to 0.46) at the end of the intervention period. Although
this review94 reported improvement in arm function, the widely used FMA motor subscale, a measure of
upper limb impairment, was classified as an arm function measure in the meta-analysis. Other measures
of arm function were the Chedoke–McMaster Stroke Assessment and the Wolf Motor Function Test. In
addition, the clinical importance of these differences is unclear as statistically significant results are not
discussed in relation to MCIDs. The review authors recommend that the results should be treated with
caution because of study heterogeneity and variation in the quality of the included studies.
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Another systematic review95 (10 trials, 362 participants) found no difference in arm impairment
or arm function when robot-assisted training was compared with the same intensity and duration of
conventional therapy.
The VA robotics trial17 is the largest trial (n = 127) included in the Cochrane review, and the RATULS
trial used the same intensity and duration of training. Participants were > 6 months post stroke and
had a FMA total upper-extremity score of between 7 and 38 at baseline. In the VA robotics trial,17
robot-assisted training improved upper limb impairment (FMA motor subscale24), compared with usual
care, and the impairment advantage did translate into significant upper limb functional improvements
(Wolf Motor Function Test96) and benefits in the SIS.42
The VA robotics trial17 reported that the average total cost of treatment over a 12-week intervention
period (the same duration and intensity of the RATULS trial) was US$5152 for robot-assisted training,
and US$7382 for intensive comparison therapy (p = 0.001).18 In the VA robotics trial,17 the base-case
analysis assumed that the MIT-Manus robotic gym was used by two patients simultaneously. At 36 weeks,
the total health-care costs were comparable for all three randomisation groups.
The REM_AVC trial97 was reported subsequent to the 2018 Cochrane review.94 This trial randomised
218 participants to receive robot-assisted training with an Armeo Spring device or self-rehabilitation of
the same frequency and duration, and found no difference between randomisation groups on the FMA.97
Enhanced upper limb therapy programme
The EULT programme, based on goal-orientated repetitive functional task practice, resulted in some
potentially clinically important benefits over usual care and improvements in upper limb impairments,
which translated into improvements in ADL. These results support some of the conclusions of the
2016 Cochrane review11 (33 trials, 1853 participants) that found that repetitive functional task practice
improved arm function (SMD 0.25, 95% CI 0.01 to 0.49), ADL (SMD 0.28, 95% CI 0.10 to 0.45) and
hand function (SMD 0.25, 95% CI 0.00 to 0.51). The measures of arm function were Motor Assessment
Scale – upper limb component; ARAT; Frenchay Arm Test; Wolf Motor Function Test; Functional Test
of the Hemiparetic Upper Extremity; Box and Block Test; and Southern Motor Group Assessment.
This review did not include the GRASP trial (103 participants), which found significant improvements in
upper limb function, grip strength and upper limb use in daily activities in favour of the intervention.98
The GRASP was a 4-week, largely self-administered, repetitive upper limb supplementary programme;
participants were randomised at a mean of 21 days post stroke and had a mean FMA score of 40.
Participants in the RATULS trial had considerably more severe upper limb impairment than those in the
GRASP trial; therefore, the findings cannot be compared.
Mechanisms of action of robot-assisted training and enhanced
upper limb therapy
Theories of neuroplasticity and motor learning99,100 support an approach to rehabilitation based on
repetitive practice of tasks.101,102 Both interventions were, therefore, underpinned by established
theories of motor learning, including the stages of learning103 and motor programme theory,100,104 to
structure the learning processes. Evidence from translational studies105,106 further supports the use of
progressive, repetitive training protocols. Further information can be found in the RATULS interventions
TIDieR table (see Appendix 1, Table 27).
It is important to consider why the improvements in impairment seen with robot-assisted training in the
RATULS trial did not translate into improved function. The RATULS trial provided integrated training
with all three components of the MIT-Manus robotic gym (shoulder–elbow robot, wrist robot and hand
attachment), which adapt to participants’ abilities (providing more/less assistance as required). The
robot-assisted training programme did not include grip or pinch activities. Participants trained specific
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movements of the affected arm in a spatially controlled manner, but it is possible that these did not
resemble movements in everyday activities and, therefore, improvements in motor control (as shown on
the FMA) did not transfer into ADL. Furthermore, there may have been a lack of guidance for participants
about making the best use of any improvement in impairment in day-to-day activities. These suggestions
are supported by data from the qualitative study, in which some interviewees commented that robot-
assisted training focused on achieving gross arm movements rather than delicate tasks.
A trial107 published in 2019 (45 participants) randomised participants to receive robot-assisted training
using the MIT-Manus robotic gym or robot-assisted training plus therapist-assisted transition-to-task
training. Both interventions were provided for 1 hour, three times per week, for 12 weeks. There was
no difference in the primary outcome: FMA score at 12 weeks. However, participants who received
robot-assisted training plus therapist-assisted transition-to-task training showed a statistically
significant improvement in motor performance (as measured by the Wolf Motor Function Test96) and
hand function (as measured by the SIS42) at 12 weeks, compared with those who received robot-
assisted training alone.
Many daily activities involve both upper limbs, including the hands, in bilateral (e.g. opening a drawer)
or bimanual (e.g. making a sandwich) co-ordinated action. Furthermore, daily activities (e.g. buttoning a
shirt) often involve a range of objects that require different types of grasp and/or manipulation. Such
activities involve diverse and complex patterns of behaviour involving sensory, perceptual, cognitive
and motor functions. This could explain why robot-assisted training resulted in a less favourable
outcome in self-reported ADL than the EULT programme, in which training specifically focused on
complex daily activities and functional tasks. The improvement in mobility seen following EULT would
also support this theory, as the EULT programme included tasks involving the upper limbs in balance
and sit-to-stand activities, which were not components of robot-assisted training. The EULT programme
may also have addressed learned non-use of the affected arm by encouraging participants to use their
arm in day-to-day activities; one participant who was interviewed in the qualitative study stated ‘I had
completely forgotten what this hand did’.
The results of the RATULS trial provide a further example of the specificity of learning.100 This is
also supported by the results of the NIHR HTA Clinical and cost-effectiveness of aphasia computer
treatment versus usual stimulation or attention control long term post-stroke (Big CACTUS) RCT,108
which found that, although patients with dysphasia due to stroke who undertook a self-managed
programme of computer exercises showed improved word-finding abilities, this did not translate into
improvement in general conversation ability.
The Robot-Assisted Training for the Upper Limb after Stroke trial interventions
Development and content of robot-assisted training and the enhanced upper
limb therapy programme
We have reported the development, content and delivery of robot-assisted training and the EULT
programme in accordance with international recommendations, enabling them to be replicated in
further research and/or clinical practice.34,109,110
There was robust development of the robot-assisted training and EULT programmes. Experts in both
robot-assisted training and EULT were involved in designing and delivering the training programmes.
Robot-assisted training was provided at the same frequency and duration as intended in the VA
Robotics trial,17 which also evaluated MIT-Manus robotic gym. The intensive comparative therapy in
the VA Robotics trial17 sought to replicate the form and intensity of upper limb movements provided
by the MIT-Manus. A strength of the RATULS trial is that robot-assisted training was compared with
an upper limb therapy programme, based on current evidence and best practice, and provided at the
same frequency and duration.
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The robot-assisted training programme was prescriptive in that every session had a defined number
and types of exercises a participant should complete. Although the MIT-Manus was able to assist as
needed, it employed a single approach independent of the phase of recovery or impairment level, that
is the programme was not tailored to the individual. In contrast, there was scope for tailoring in the
EULT programme, as it was based on individual goals selected by the participant and their therapist.
The therapists were also able to tailor the specifics of the activity practised [including the nature and
purpose of the task, any object(s) involved, specific joint movement(s), type and scheduling of practice,
and environmental conditions] to the ability of the participant. In clinical practice, there would probably
be further tailoring of the interventions.
Delivery of robot-assisted training and the enhanced upper limb therapy programme
Robot-assisted training was provided at a central hub, as this is the model that would probably be
used in clinical practice. The EULT programme was provided as a centralised rather than a local service
for logistical reasons.
Training programmes and manuals were provided to ensure that the interventions could be delivered
as per protocol. There was regular contact between those who provided the intervention and the
RATULS trial co-ordinating centre team to monitor progress and to address any queries. The qualitative
process evaluation found that therapists who provided robot-assisted training and the EULT programme
felt well supported throughout the trial and were able to provide the 12-week programmes as intended.
We have demonstrated that it is possible to report details about the interventions received by
participants within a large multicentre randomised controlled rehabilitation trial. Intervention delivery
was monitored throughout the trial, which contributed to high levels of fidelity.
Although the amount of therapy time is frequently reported in RCTs, information about how this time is
spent is poorly reported.50,111 Robot-assisted training participants undertook a median of 808 movement
attempts per session attended, which demonstrates the intensity of treatment that this therapy can
achieve. EULT participants achieved a median of 127 repetitions per session attended. Movement
attempts and repetitions are different units of measurement and they are not comparable; therefore,
we are not able to make direct comparisons about the intensity of repetitive practice between robot-
assisted training and the EULT programme using these measures.
Goal-setting is currently considered to be integral to best practice in stroke rehabilitation and is
recommended in national clinical guidelines;39 however, the evidence that this approach improves
clinical outcomes is limited and there appears to be no consensus about the optimum approach.112,113
It was decided not to use a formal goal-setting method [e.g. the COPM63 or the Goal-setting and Action
Planning (G-AP) framework114] in the RATULS trial, as it is not widely used in most UK centres.115
In the EULT programme, the three most commonly chosen goals were eating, improving range of
movement and dressing. The selection of range of movement as a goal is likely to reflect the level of
severe arm impairment in the trial population, and the difficulty of setting functional goals for these
participants. Although goal achievement varied, the overall proportion was low (51%). However,
participants who were < 3 months after stroke achieved the majority of their goals.
Goal selection in the EULT programme may have been overoptimistic, particularly for those with
severe arm activity limitation, which has a poor prognosis, and for those who were ≥ 3 months after
stroke, when spontaneous recovery tends to slow down.52 A key component of therapy is managing
expectations. Some patients with severe impairment and little chance of upper limb recovery may wish
to select aspirational rather than achievable goals, which may motivate, but may also lead to unrealistic
expectations and difficulty adjusting to the residual consequences of stroke.
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Usual care
The RATULS trial was a pragmatic trial; therefore, usual care was chosen as a comparator group.
Obtaining accurate information about the usual care that patients receive is a challenge to this type of
study, and the assumption that usual care is uniformly provided is rarely true.116 Although there are UK
guidelines about the amount of therapy that a stroke patient should receive, they refer to contact time
with a specific type of therapist (e.g. physiotherapist) rather than specifying the focus (e.g. upper limb)
or intensity of the intervention itself.117
Usual care records are not standardised and, often, basic information about content and dose is not
recorded. Collecting data about the upper limb therapy provided by a large number of individuals
from a range of services and organisations (stroke units, early supported discharge teams, community
rehabilitation teams, outpatient therapists from hub and spoke sites), many of whom were not directly
involved in the RATULS trial, was not feasible.2 In addition, some patients arranged private rehabilitation.
Therefore, participants were asked to record the usual care they received and to seek help if needed
from their therapist(s) to complete their log books. However, this approach has limitations, including
data completeness. Although the number of participants who returned a therapy log was low (66% at
3 months), there was little variation between randomisation groups for the number of log books
returned or the completeness of the logs returned, for example of those returned, > 80% had all
12 weeks completed.
The usual care logs in the RATULS trial indicated that the most common type of therapy undertaken
was passive stretching, whereas the least common was practising extended ADL. This finding
resonates to some extent with findings from a recent survey of upper limb treatment reported by
physiotherapists and occupational therapists across the UK.118 This survey reported that, although
there was considerable variation in treatments provided for stroke patients with severe upper limb
deficits, the most common were range of movement exercises, mirror-box therapy and functional
electrical stimulation. For those with less severe upper limb deficit, most interventions comprised
active, task-specific practice. In terms of dose, upper limb therapy was reportedly provided for an
average of 29 minutes, three times per week.118 However, this amount exceeds that of observational
studies of upper limb treatment.76,111,119
Recording, measuring and monitoring the treatment received by individuals, and reporting of the
rehabilitation services provided, should be integral to routine clinical practice and should not be
seen as an added burden.92 If this was achieved, these data could be available to research teams
(with appropriate information governance), and would greatly facilitate the reporting of usual care
in rehabilitation trials.
Disappointment about group allocation may have resulted in some usual care participants seeking
or being provided with additional therapy, or increasing the amount of self-practice exercises
undertaken, thereby introducing a competitive therapy bias. We did consider offering either robot-
assisted training or EULT to usual care participants following the 6-month outcome assessment,
but this was not feasible.
Methodological considerations
To our knowledge, the RATULS trial is the largest trial of upper limb robot-assisted rehabilitation
undertaken to date. The RATULS trial is the first multicentre trial with adequate statistical power
to compare robot-assisted training with both an evidence-based therapy programme of the same
frequency and duration and with usual care.
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Trial setting
The model of a central hub stroke service, where the MIT-Manus gym was based, supported by surrounding
hospital and community services, enabled the RATULS trial to recruit to target. A recruitment rate of
four participants per trial centre per month was achievable. Trial participants were willing to travel
to a central hub to take part in the RATULS trial. Transport by taxi to and from therapy sessions and
outcome assessments was provided if required, and this may have contributed to the high level of
attendance. The qualitative process evaluation supports this view.
Participants
We recruited participants from both the incident and prevalent populations of stroke patients.
We initially asked clinicians at hub and spoke sites to complete a screening log, but, as the trial
progressed, we abandoned the screening log as this became a disincentive for clinical teams to refer
potential participants. Stroke services, therapy services and self-referral were the main routes of referral.
Acute, subacute and chronic stroke patients were included, as there was no evidence from the
literature on repetitive task training that suggested excluding patients at any stage of recovery.10,120
Hebbian and non-Hebbian learning processes foster experience-dependent plasticity, and this process
may continue for several years post stroke.10,121,122 In addition, the subgroup analyses of time since
stroke in the Cochrane systematic reviews11,94 of robot-assisted training and repetitive task training
have found no evidence of an influence of time post stroke on functional outcomes, although the low
quality of the evidence should be acknowledged. We felt that the interventions were likely to be
offered to patients at all stages of recovery from stroke in clinical practice, as the current Royal
College of Physicians’ National Clinical Guideline for Stroke117 suggest that patients should receive
therapy for as long as they are continuing to benefit from it. Subgroup analyses of the RATULS trial
showed no clear effect of time on the relative effectiveness of the interventions, thereby supporting
previously published evidence and guidelines.10,11,94,117,120–122
The RATULS trial participants were younger (60 years) than the average stroke population in the UK
(75 years), and the proportion of males was higher (61% vs. 50%).40 Participants who are recruited to
stroke trials are usually younger and more likely to be male than the general stroke population.123
It is likely that the pragmatic inclusion criteria led to some participants who had little prospect of
recovery being recruited: 68% had severe upper limb functional limitation (ARAT score 0–7), which has
a poor prognosis for recovery.8 At the time the trial was designed, literature had been published about
predictors (including biomarkers) of motor recovery after stroke.124 Methods for testing the integrity
of the corticospinal tract, thought to be a predictor for upper limb recovery after stroke, involve use
of transcranial magnetic stimulation-induced motor-evoked potentials or magnetic resonance imaging.
As this was a pragmatic trial and these methods are not used in routine clinical practice in the UK,
biomarkers for testing corticomotor structure and function were not used in this trial. Currently, these
biomarkers are not used in NHS clinical practice.
Sample size
In determining the sample size of the RATULS trial, we estimated that 30% participants who were
randomised to receive usual care would achieve the primary outcome of upper limb functional recovery
‘success’ at 3 months. This figure was derived from data from the NIHR HTA BoTULS trial, which
evaluated the role of treating upper limb spasticity due to stroke with botulinum toxin type A.35,36
The proportion of usual care participants who achieved upper limb functional recovery ‘success’ in the
RATULS trial at 3 months was higher than expected, at 42%. The reason why usual care participants
improved more than anticipated is unclear. Most spontaneous upper limb recovery from stroke occurs
within the first 6 months and there is little measurable recovery beyond 12 months. Part of the
explanation may be that a lower proportion of RATULS trial participants (36%) were recruited beyond
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1 year after stroke than in the BoTULS trial (45%). Differences in baseline ARAT scores between trials
are unlikely to explain the increased upper limb functional recovery ‘success’ rate: in the RATULS trial,
the median baseline ARAT score was 3 points (IQR 0–11 points), and in the BoTULS trial, it was 3 points
(IQR 3–16 points).
Dose of therapy
It has been suggested that the dose of face-to-face therapy provided to robot-assisted training and
EULT participants was too low, and this may explain why we did not demonstrate any significant
benefit on the primary outcome when compared with usual care.125,126 The robot-assisted training dose
in this trial was based on the VA study.17 It was felt that the VA study results were promising in terms
of efficacy and efficiency and that the experiences of that trial should be built on. Therefore, the same
number of sessions (36 sessions of 45 minutes of face-to-face therapy) were provided. At the time of
designing the trial, there was no justification for increasing the amount of additional therapy and an
increase would have surpassed the limit possible to provide in the NHS. The EULT intervention was
dose-matched to the robot-assisted training intervention (in terms of total therapy time, session
duration and frequency).
In relation to the optimum therapy dose, there is a lack of clarity in the literature about how dose is
measured.127 Dose is a multifactorial concept that includes the frequency, intensity, duration and timing
of an intervention. Often, studies of dose in rehabilitation trials focus only on therapy time. However,
in the RATULS trial, we have been able to report the number of sessions attended, session duration,
duration of face-to-face therapy and the number of repetitions of tasks undertaken.
There is ongoing debate about the optimum amount of additional therapy time needed to improve arm
function after stroke. A 2014 meta-analysis10 found strong evidence that an additional 17 hours of
physiotherapy significantly improved a range of outcomes, including arm function, basic ADL and
quality of life after stroke. We are not aware of dose-finding studies for therapy time of robot-assisted
training. A 2016 Cochrane systematic review11 reported that repetitive task training significantly
improved arm and hand function, but there were no significant differences in outcomes between a
dose of at least 20 hours and smaller doses. A 2016 meta-analysis128 found a trend towards a positive
relationship between therapy dose and activity, with findings suggesting that a 240% increase in usual
care duration was required for a significant likelihood that activity limitations would improve. However,
this meta-analysis did not report findings for arm rehabilitation in isolation. A number of more recent
RCTs of upper limb therapy post stroke have also been neutral for their primary outcome.129–134 These
trials planned to deliver between 10 and 45 hours of additional upper limb therapy, with four trials
aiming to deliver an additional ≥ 30 hours.129,130,132,134
Three studies135–137 have reported benefits of high amounts of therapy time in upper limb therapy for
chronic stroke patients. However, none of these studies had a lower dose or usual care comparator.
An arm rehabilitation programme comprising 90 hours of repetitive task practice, in addition to other
modalities, found clinically and statistically significant improvements in upper limb impairment and
activity limitation.137 Two small studies135,136 provided upper limb repetitive practice for 300 hours to
patients with severe arm impairment, and reported benefits with this intensity of treatment. Although
these results are interesting, these interventions require further evaluation in robust, adequately
powered RCTs to demonstrate their feasibility, clinical effectiveness and cost-effectiveness.
To date, results from studies that aimed to determine the optimum dose in terms of repetitions have
been inconsistent and inconclusive. A Phase II single-blind, randomised, repetition dose–response study
evaluated a task-specific upper limb rehabilitation intervention comprising up to 32 hours of practice
for stroke survivors at least 6 months after stroke with mild to moderate arm impairment.138 Eighty-
five participants were randomised to undertake either 3200, 6400, 9600 or individualised maximum
repetitions. All groups improved, but there was no evidence of a repetition dose–response relationship.
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Outcomes
The outcome measures used in the RATULS trial are widely used in stroke rehabilitation trials and
have been shown to be valid, reliable and sensitive to change,139 although the ARAT has several
psychometric properties (e.g. floor and ceiling effects) that would benefit from further investigation.140
However, the primary outcome, derived from the ARAT score, was developed specifically for the
RATULS trial and further validation is needed. A stepped approach was used because, although
the MCID for the ARAT is 10% of its range (6 points41), a smaller treatment effect may be clinically
beneficial in those with severe initial upper limb functional limitation, who are likely to improve less
than those with more moderate limitation. The Lancet editorial about the main results of the RATULS
trial supports the choice of primary outcome measure: ‘Although not used previously, this approach
aimed to more sensitively capture meaningful change relative to the patient’s starting point, which
makes sense but needs further validation’.125
In 2017, the Stroke Recovery and Research Roundtable139 recommended outcome measures to be
included in stroke recovery trials for each domain of the World Health Organization’s (WHO’s)
International Classification of Functioning Disability and Health (ICF).141 These included the ARAT to
measure upper limb activity limitation,19 the FMA to measure body function and structure,24 and the
EuroQol-5 Dimensions (EQ-5D) to measure quality of life.44 All of these measures were included in
the RATULS trial. The consensus recommendation also included using the modified Rankin Scale142 to
measure global disability, which was not used in the RATULS trial. No consensus was reached about
measures of participation. Another expert panel has recommended outcome measures, including the
ARAT,19 FMA24 and SIS,42 to be used in motor function intervention trials.143
We have reported and interpreted our finding against published MCIDs, regardless of the robustness
of the evidence underpinning these values for stroke patients.59 Lack of methodological robustness
in studies to determine MCIDs and lack of patient and carer involvement in determining meaningful
differences can lead to methodological or interpretation problems with clinical trials.143–145 We
recommend that a consensus about reporting research to identify MCIDs is developed, which
could then be incorporated into Enhancing the QUAlity and Transparency Of health Research
(EQUATOR) guidance.146
Strengths, weaknesses and sources of bias
The RATULS trial findings are robust with a low risk of bias. The RATULS trial was undertaken and
reported in accordance with current best practice.146 The trial was conducted in line with a published
protocol, and the statistical analysis plan and health economics analysis plan were finalised prior to
data lock. All outcomes were analysed and reported according to these prespecified plans. One of the
strengths of the trial is the completeness and high quality of the data (with the exception of the usual
care therapy logs).
We have used the terms of impairment, upper limb function and ADL throughout this report because
these terms were used in the original NIHR commissioning brief and the RATULS trial protocol, rather
than WHO’s ICF.141
Randomisation was by an independent web-based service with allocation concealment. It was not
possible to mask trial participants to their randomisation group allocation and therapists who delivered
robot-assisted training and the EULT programme were not masked to the intervention group. The same
therapists and therapy assistants delivered both interventions at each trial centre. Outcome assessments
were intended to be collected by a researcher who was masked to treatment allocation. However,
outcome assessors reported that they were unmasked for 15% of outcome assessments at 3 months
and 14% of outcome assessments at 6 months.
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Overall attrition rates were acceptable, but the attrition rate was higher in the usual care group (19%)
than in the robot-assisted training and EULT groups (both 9%), and differential attrition is a potential
source of bias. Most of the withdrawals before 3 months in the usual care group were due to
disappointment with treatment allocation.
The strengths and weaknesses of the process evaluation and economic evaluation have been discussed
in Chapters 7 and 8, respectively.
Patient and public involvement
Our involvement with patient groups, clinical experience and research has consistently shown that
patients feel that stroke rehabilitation focuses on mobility rather than recovery of upper limb function.
Improving upper limb function has been identified as the fourth most important rehabilitation research
priority by stroke survivors, carers and clinicians.9
The Guidance for Reporting Involvement of Patients and Public 2147 was published in 2017, towards
the end of the RATULS trial recruitment period; therefore, we were unable to be fully compliant.
We have not systematically recorded how patient and carer involvement enhanced the research
process throughout the trial.
Stroke survivors were involved in developing the outline and full NIHR proposal. At the grant
application stage, the trial was presented to the NIHR Stroke Research Network (SRN) Lay Member
Panel and comments from the panel were incorporated into the application. Input was sought from
the North East SRN Patient and Carer Panel for the design and content of trial documents, including
the trial information sheets and consent forms, and to help to develop resources to train staff who
undertook trial assessments. Stroke survivors contributed to the development of the intervention
programmes used in the RATULS trial and ran through the programme with researchers. The programmes
were adjusted following their feedback.
One of the co-applicants is a stroke survivor and contributed to design, delivery and reporting of this
work. One of the members of the Trial Steering Committee had had a stroke and gave a patient
perspective about the trial.
Trial participants were sent newsletters throughout the trial and were sent a letter that included a lay
summary of the results of the trial, following publication of the main results in The Lancet.1 The results
of the trial have been presented and discussed with the NIHR Clinical Research Network: Stroke North
East Patient and Carer Panel (formerly the SRN Panel).
DISCUSSION
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Chapter 10 Conclusion
Parts of this chapter have been reproduced from Rodgers et al.1 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
The RATULS trial did not find evidence that a robot-assisted training programme using the MIT-Manus
robotic gym, as implemented in this trial, improved upper limb function following a stroke when
compared with an EULT programme based on goal-orientated repetitive functional task practice of the
same frequency and duration, or with usual care.
Some differences in secondary outcome measures suggest potential benefits for robot-assisted training
and the EULT programme that may have implications for clinical practice and future research: robot-
assisted training led to improvement in upper limb impairment, compared with usual care; the EULT
programme led to improvements in upper limb impairment, mobility and ADL, compared with usual
care. Both interventions were acceptable to participants and therapists. Neither robot-assisted training
nor the EULT programme as provided in the RATULS trial (1 : 1 patient-to-therapist ratio) were
cost-effective at the current UK WTP per QALY (£20,000–30,000).
Implications for health and social care
The results of the RATULS trial do not support the routine use of robot-assisted training using the
MIT-Manus robotic gym, as implemented in this trial, for patients with moderate or severe upper limb
functional limitation due to stroke.
The RATULS trial provides some evidence of the potential benefits of the EULT programme, although,
as delivered in this trial, it is unlikely to be cost-effective. Delivering EULT as group/classroom therapy
would lead to a reduction in costs, which has the potential to make EULT a cost-effective intervention.
However, the impact of this change on clinical effectiveness and QALYs is unknown and should
be explored.
Recommendations for further research
The RATULS trial has demonstrated that a large multicentre trial to evaluate robot-assisted
rehabilitation, which includes a clear description of the interventions received and high levels
of intervention fidelity, is achievable. An editorial in The Lancet entitled ‘Robot-assisted training
after stroke: RATULS advances science’125 was supportive of the trial, and we suggest that future
rehabilitation trials could build on our experience.
Future trials may wish to stratify patients into groups with differing probabilities of upper limb
recovery using techniques such as shoulder abduction and finger extension52 and/or advanced
neuroimaging and transcranial magnetic stimulation to improve the targeting of therapies towards
participants with the potential to respond.148 Ongoing biomarker research may help in patient selection
or treatment monitoring of future stroke rehabilitation trials.110 Future trials may also wish to consider
having a patient-reported outcome measure and one of the standard activity scales as co-primary
outcome measures.75 Future trials should be aligned with recommendations made by the Stroke
Recovery and Rehabilitation Roundtable.139,149
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Recording, measuring and monitoring the treatment received are important components of research,
clinical practice and audit. By following checklists and guidance to describe research interventions, the
content of rehabilitation interventions evaluated in clinical trials could be accurately reported.34,110,150
Unfortunately, collecting standardised minimum data about the usual care received remains a challenge
in many settings, especially when it is provided by many services in a single study centre.92 There
needs to be a culture change in the recording and reporting of usual care in clinical practice to enable
key data to be used to inform clinical practice and research.
The dose of therapy is an important component of any stroke rehabilitation trial. Therapy dose is a
multifactorial concept.127 Dosage can include the number of sessions attended, session frequency
and duration, duration of face-to-face therapy, and the number of repetitions of tasks undertaken.
Equally important is reporting of the type of therapeutic activities undertaken, and the way these
are progressed. There is converging evidence that more therapy may result in better outcomes,50
but, in future, adequately powered dose-finding studies of promising interventions, tailored to targeted
subgroups, are needed, that also take into account potential cost-effectiveness.
Despite the neutral primary outcome of the RATULS trial, robot-assisted training in upper limb
rehabilitation after stroke still has potential. Further research is needed to determine how improvement
in upper limb impairment seen with the MIT-Manus gym can be translated into meaningful improvement
in upper limb function and ADL. For example, trials could be designed whereby robot-assisted training
could be utilised at the start of an intervention session as a ‘primer’,151 with the aim to focus attention on
the affected arm, assist movement and generate sensory, proprioceptive and visual feedback. The EULT
intervention could then be utilised (in the same session or after a number of robotic sessions) to enable
translation of improved motor control into meaningful, daily activities.107,152
Robotics is a rapidly advancing field and a number of other innovative devices are available, some
of which may be suitable for home use. In some parts of the world, the clinical use of robots has
preceded evidence of effectiveness. It is important that there is partnership between developments
in bioengineering, neuroscience and clinical evaluation to optimise improvement in patient outcomes
and care.
CONCLUSION
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Appendix 1 Description of the Robot-
Assisted Training for the Upper Limb after
Stroke trial interventions using the
Template for Intervention Description and
Replication checklist
TABLE 27 The TIDieR34 checklist for the RATULS trial intervention treatments
Item
Intervention group
Robot-assisted training EULT
1. Brief name: ‘State the
intervention name’
Robot-assisted training EULT
2. Why: ‘What is the scientific basis
of the intervention in terms of the
rationale, theory or goal of the
intervention?’
The rationale for repetitive training is based on converging theories and
evidence from the following domains: motor control and learning,
neuroplasticity, translational research and clinical trials
The goal of both the robot-assisted training and the EULT programme was to
improve arm function. This can be conceptualised, at the behavioural level,
as a process of motor learning, which has been described as ‘a set of processes
associated with practice/experience leading to relatively permanent changes
in the capability for producing skilled action’100. Both interventions were
therefore underpinned by established theories of motor learning, including
the stages of learning103 and motor programme theory100,104 to structure the
learning processes. At the neuronal level, learning involves Hebbian122 and
non-Hebbian processes that foster experience-dependent plasticity.101,121,153,154
Evidence from translational studies105,106 further supports the use of progressive,
repetitive training protocols. Finally, clinical trial evidence supports the use of
repetitive functional task practice for upper limb recovery10,120
Rationale for robot-assisted training:
robot-assisted training enables
repetitive tasks to be undertaken in
a highly consistent and controllable
manner. Robot-assisted training
is based on the virtual trajectory
hypothesis155 and the conjecture
that movement is composed by
primitives of movement, in particular,
that movement is a composition of
discrete (submovements),156 rhythmic
(oscillations)157–159 and mechanical
impedance.160,161 A Cochrane systematic
review94 of electromechanical and
robot-assisted arm training after
stroke reported outcomes from a total
of 1619 patients who participated in
45 trials. Improvements in arm function
(SMD 0.32, 95% CI 0.18 to 0.46) and
ADL (SMD 0.31, 95% CI 0.09 to 0.50)
were found in patients who received
this treatment.94 Studies were
heterogeneous and varied in
their quality
Rationale for EULT: the EULT
programme was based on the motor-
learning theory described above,
as well as the established specificity
of learning principle, which purports
that practice is most effective if it
resembles the task and environment
of the target activity as closely as
possible.104 The converging theory
and evidence referred to above,
supplemented by literature on clinical
applications thereof,102,162 informed
the focus, structure and progression
of the skill acquisition process of the
EULT programme
continued
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TABLE 27 The TIDieR34 checklist for the RATULS trial intervention treatments (continued )
Item
Intervention group
Robot-assisted training EULT
Essential elements:
l Robotic device (i.e. MIT Manus)
l Repetitive practice of
standard tasks
l Increased intensity of training
(compared with usual care)
Standardised protocol
Essential elements:
l Use of everyday objects
l Repetitive functional task practice
l Participant-selected goals
l Increased intensity of training
Tailored progression
3. What materials: ‘What
information/materials were provided
to participants or the intervention
providers in order to deliver the
intervention? Information on where
to access these materials should also
be provided’
l MIT-Manus robotic gym system
was used [www.bioniklabs.com/
(accessed 5 September 2019)].
The robotic gym consists of three
robot components to train the
participant to use their upper limb:
¢ The shoulder–elbow robot
(InMotion ARM™ interactive
therapy system). The participant
moves their affected arm
radially in eight different
directions
¢ The wrist robot (InMotion
WRIST™ interactive therapy
system). The movements of the
participant’s wrist include
flexion/extension, abduction/
adduction and pronation/
supination
¢ The hand attachment
integrated onto the
shoulder–elbow robot
(InMotion HAND™). This
encourages whole-arm
movements that involve limb
transport and grasp/release
l Study-specific manuals describing
robot-assisted training were
produced and were used by staff
delivering therapy
l Study-specific documentation
was used by therapists to record
attendance at sessions. The robot
software recorded data on the
robot protocol used, duration
of the sessions and the type
of game played to allow for
calculation of upper limb
movement attempts undertaken
l Staff delivering the robot-assisted
training programme received
specific training
l The EULT programme consisted of
repetitive functional task practice
aimed at patient-centred goals. It
was developed from upper limb
therapy programmes used in
the BoTULS trial35–37 and the
Repetitive Arm Functional Tasks
after Stroke (RAFTAS) project38
l Study-specific manuals describing
EULT were produced and were
used by staff delivering therapy.
Included in the manual was a
list of potential goals and a
description of suggested activities
for each goal. Everyday items to
enable functional task practice
were provided
l Study-specific documentation was
used by therapists to record
session attendance, session
duration, the type and number of
goals, the type of activity practice
(whole task or part task) and
number of therapy repetitions of
each task at each session. Goal
attainment was documented at
each review session
l Staff delivering the EULT
programme received
specific training
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
142
TABLE 27 The TIDieR34 checklist for the RATULS trial intervention treatments (continued )
Item
Intervention group
Robot-assisted training EULT
4. What (procedures): ‘What were
the activities and/or procedures
needed to deliver the intervention?’
l The robot-assisted training
programme was divided into three
consecutive blocks in order to
integrate training with all three
robot components. Training
sessions on all robot components
consisted of a large number of
movement attempts (aiming for
> 700 per session) of point-to-
point movements
l Block 1: block 1 lasted for
2 weeks and employed alternate
training sessions with the
shoulder–elbow robot and the
wrist robot (three sessions on
each robot). The robots
rhythmically moved the
participant’s upper limb to reach
sequentially presented targets
l Block 2: block 2 lasted for
6 weeks and employed alternate
therapy sessions with the
shoulder–elbow and the wrist
robots (nine sessions on each
robot). The robots allowed the
participant to attempt to move
towards sequentially presented
targets unassisted, but assisted
if the participant needed help to
reach the target
l Block 3: block 3 lasted for
4 weeks and employed alternative
therapy sessions with the hand
attachment integrated on the
shoulder–elbow robot, and the
wrist robot (six sessions on each
robot). As in block 2, the robots
allowed the participant to attempt
to move towards the targets
unassisted, but assisted if the
participant needed help to reach
the target. For the therapy
sessions with the hand attachment
integrated on the shoulder–elbow
robot, targets were presented
sequentially. For the therapy
sessions with the wrist robot, the
targets were presented randomly
l Evaluations of robotic kinematics
(i.e. related to the movement
pattern) and kinetics (i.e. related
to the causes of movement) were
incorporated into every third
training session on each robot.
These evaluations monitored
participant performance and
were used to give feedback
and encouragement
l At the initial therapy session a
brief assessment of the
participant’s upper limb was
performed and up to four upper
limb rehabilitation goals of
importance to the participant
were agreed. The activities to
practise to achieve these goals
were subsequently determined.
Activities were divided into two
types: ‘whole task’ or ‘part task’.
Whole-task activity practice
consisted of practising all of the
components of the task in
sequence. Part-task activity
practice consisted of practising a
specific part of a task. Part-task
practice was appropriate if a
participant had difficulty with a
specific part of a task, as it
enabled them to focus on this
particular aspect while working
towards completing the task as a
whole. The order in which to
practise the activities and the
time spent on each activity was
at the discretion of the therapist
and participant according to the
participant’s rehabilitation
priorities. When appropriate,
participants could undertake a
brief warm-up consisting of gentle
stretching of the upper limb, prior
to practising the chosen activities
l At the second and subsequent
therapy sessions, following a brief
warm-up (if necessary), practice of
the selected activities continued,
with the order in which to practise
and time to spend on each activity
being at local discretion. At
therapy sessions 12 (end of week 4)
and 24 (end of week 8), progress
towards goals was reviewed. If the
participant had achieved a goal, a
new goal was set and a new activity
to practise was selected. If the
participant found a goal or activity
too challenging or they were
experiencing other problems,
an alternative was chosen.
l At the final therapy session
(36, end of week 12), practice of
activities continued but part of the
session was dedicated to ‘summing
up’, with feedback given to the
participant about progress over
the programme and advice about
maintaining upper limb function in
the longer-term
continued
DOI: 10.3310/hta24540 Health Technology Assessment 2020 Vol. 24 No. 54
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Rodgers et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
143
TABLE 27 The TIDieR34 checklist for the RATULS trial intervention treatments (continued )
Item
Intervention group
Robot-assisted training EULT
5. Who provided: ‘What was
the expertise and background of
the intervention providers and was
any intervention-specific training
required?’
l A senior therapist (physiotherapist
or occupational therapist) assessed
each participant at their initial
session on each robot to ensure
correct positioning and
familiarisation with robot. Therapy
assistants (NHS band 3 or above)
then delivered the robot-assisted
training programme with senior
supervision and support. A senior
therapist reviewed each
participant at their last robot-
assisted training session and
provided feedback
l All staff involved in the study
received study-specific training.
The senior therapists and therapy
assistants delivering the robot-
assisted training programme
received specific training in
this aspect
l A senior therapist (physiotherapist
or occupational therapist) assessed
each participant at their initial
therapy session and they jointly
selected up to four upper limb
rehabilitation goals and activities
to practise. Therapy assistants
(NHS band 3 or above) then
delivered the EULT programme
with senior supervision and
support. A senior therapist
reviewed the participant every
4 weeks to plan/adjust the
programme according to progress.
A senior therapist reviewed each
participant at their last EULT
session and provided feedback
l All staff involved in the study
received study-specific training.
The senior therapists and therapy
assistants delivering EULT received
specific training in this aspect
6. How: ‘What was the mode of
delivery of the intervention (e.g. face
to face, individually or in group)?’
1 : 1 face-to-face delivery 1 : 1 face-to-face delivery
7. Where: ‘In which location
was the intervention provided
(e.g. outpatients, hospital or patients
own home)?’
NHS hospital facilities: dedicated
therapy room
NHS hospital facilities: therapy gym
or dedicated therapy room
8. When and how much: ‘What was
the planned amount of intervention
delivered in terms of the number
of sessions, over what time period,
the duration of sessions and the
intensity/dose of delivery?’
The robot-assisted training
programme was provided for up to
45 minutes per day, 3 days per week,
for 12 weeks (a total of 36 therapy
sessions), in addition to usual NHS
care. One hour was allowed for each
therapy session to facilitate
preparation and set-up
The EULT programme was provided
for up to 45 minutes per day, 3 days
per week, for 12 weeks (a total of
36 therapy sessions), in addition to
usual NHS care. One hour was
allowed for each therapy session to
facilitate preparation and set-up
9. Tailoring: ‘Was the intervention
designed so that it was able to
be personalised or adapted to
an individual?’
l The use of the robot components
and order of blocks were
standardised for all participants
following the robot-assisted
training programme. The only
exception was in block 3 whereby
if a participant was unable to
use the hand attachment, the
shoulder–elbow robot was used
on the ‘assist-as-needed’ random
protocol (as described in section 4
in this table)
l The MIT-Manus robotic gym
system ‘assisted as needed’ based
on the specific performance of
each patient. The system is
designed to adjust the parameters
(i.e. robot power and initiation of
movement) as necessary during
the therapy
The EULT programme was based on
patient-centred goals. Up to four
goals could be chosen. A senior
therapist assessed/reviewed each
participant at baseline and at 4, 8 and
12 weeks, and planned/adjusted the
programme according to progress.
The therapists were also able to
tailor the specifics of each activity
practised to the ability of the
participant, taking into consideration
a range of upper limb parameters
(i.e. sensation and proprioception,
range of motion, strengths and
co-ordination), other functions
(including sitting balance, visuo-
spatial awareness, vision), as well as
the person’s cognitive and emotional
status, communication skills and level
of motivation
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TABLE 27 The TIDieR34 checklist for the RATULS trial intervention treatments (continued )
Item
Intervention group
Robot-assisted training EULT
10. Modifications: ‘Were there any
modifications/changes made to the
intervention during the study and,
if so, what were these changes?’
There were no modifications to the interventions
11. How well (planned): ‘What
were the methods used to assess,
maintain or improve intervention
adherence and fidelity during
the study?’
l Therapists/therapy assistants
completed a robot-assisted
training checklist to document
attendance at sessions
l The robot software recorded data
on the robot protocol used,
duration of the sessions and the
type of game played to allow
for calculation of upper limb
movement attempts undertaken
l Data from training sessions were
periodically reviewed to monitor
intervention adherence and
feedback was provided to therapy
staff delivering the intervention
l Therapists/therapy assistants
recorded session attendance,
session duration, the type and
number of goals, the type of
activity practice (whole task or part
task) and number of repetitions of
each task at each session. Goal
attainment was documented at
each review session
l Data from therapy sessions were
periodically reviewed to monitor
intervention adherence, and
feedback was provided to therapy
staff delivering the intervention
12. How well (actual): ‘Was
the intervention was delivered
as intended?’
See Chapter 4 for further information See Chapter 5 for further information
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Appendix 2 Recruitment, withdrawal and
missing data
TABLE 28 Recruitment by trial centre and overall
Month and year
Number of participants recruited
North Tyneside Glasgow Romford Northwick Park Total
April 2014 3 3 x x 6
May 2014 4 6 0 x 10
June 2014 5 5 6 x 16
July 2014 7 4 6 x 17
August 2014 4 4 5 x 13
September 2014 5 6 6 x 17
October 2014 3 4 7 x 14
November 2014 8 2 6 x 16
December 2014 3 0 4 x 7
January 2015 8 8 6 x 22
February 2015 2 6 5 x 13
March 2015 1 4 7 x 12
April 2015 8 5 6 2 21
May 2015 5 3 6 5 19
June 2015 5 4 5 3 17
July 2015 5 2 4 4 15
August 2015 6 4 3 0a 13
September 2015 9 4 6 0a 19
October 2015 3 4 6 1 14
November 2015 2 6 5 0 13
December 2015 4 0 3 3 10
January 2016 5 5 7 3 20
February 2016 2 6 4 6 18
March 2016 3 6 7 1 17
April 2016 3 4 5 8 20
May 2016 5 7 4 5 21
June 2016 2 4 2 1 9
July 2016 5 4 2 5 16
August 2016 6 9 6 4 25
September 2016 8 6 5 4 23
October 2016 5 5 6 4 20
continued
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TABLE 28 Recruitment by trial centre and overall (continued )
Month and year
Number of participants recruited
North Tyneside Glasgow Romford Northwick Park Total
November 2016 7 2 6 6 21
December 2016 2 1 3 1 7
January 2017 9 8 5 3 25
February 2017 3 7 6 3 19
March 2017 4 3 8 2 17
April 2017 6 3 4 2 15
May 2017 6 7 6 5 24
June 2017 5 7 6 6 24
July 2017 3 2 x 6 11
August 2017 6 9 x 1 16
September 2017 6 2 x 4 12
October 2017 5 5 x 2 12
November 2017 6 4 x 3 13
December 2017 2 1 x 2 5
January 2018 6 8 x 2 16
February 2018 6 2 x 1 9
March 2018 6 6 x 2 14
April 2018 5 5 x 7 17
Total 237 222 194 117 770
x, site not open.
a Recruitment at Northwick Park was suspended from 3 August 2015 until 20 October 2015 because of a delay in
wrist robot delivery.
TABLE 29 Reasons for non-completion of assessments at 3 and 6 months
Reason for withdrawal/assessment not conducted
Participants (n)
Robot-assisted training EULT Usual care Total
At 3 months
Assessment not conducted 6 10 16 32
Participant did not attend agreed scheduled appointment
and did not respond to attempts to rearrange
2 2 3 7
Participant did not respond to telephone/e-mail/postal
attempts to arrange assessment
2 5 7 14
Participant had a change in personal circumstances and
was unable to attend assessment
1 0 1 2
Participant refused to complete assessment – reason
unknown
0 1 0 1
Participant unwell and unable to do assessment 1 2 5 8
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TABLE 29 Reasons for non-completion of assessments at 3 and 6 months (continued )
Reason for withdrawal/assessment not conducted
Participants (n)
Robot-assisted training EULT Usual care Total
Died 1 1 0 2
Withdrawn 17 12 31 60
Participant did not wish to take part, as randomised to
usual care
0 0 20 20
Participant experienced pain during therapy sessions 0 1 0 1
Participant experienced upper limb pain 1 1 0 2
Participant found to be ineligible, diagnosis not stroke 1 0 1 2
Participant had a change in personal circumstances and
was unable to continue participation in the trial
2 0 0 2
Participant moved out of trial area 1 1 0 2
Participant refused to complete assessment – reason
unknown
0 1 0 1
Participant refused to continue participation in the trial
as they did not feel any improvement in arm
1 0 0 1
Participant refused to continue participation in the trial
as they felt that it was too much of a burden
4 6 9 19
Participant unwell and unable to continue participation in
the trial
7 2 1 10
Total number of withdrawals/assessment not conducted
at 3 months
24 23 47 94
At 6 months
Assessment not conducted 11 14 24 49
Participant did not attend agreed scheduled appointment
and did not respond to attempts to rearrange
2 1 2 5
Participant did not respond to telephone/e-mail/postal
attempts to arrange assessment
6 12 19 37
Participant had a change in personal circumstances and
was unable to attend assessment
1 0 0 1
Participant paperwork was lost 1 0 0 1
Participant refused to complete assessment – reason
unknown
0 0 1 1
Participant unwell and unable to do assessment 1 1 2 4
Died 0 2 0 2
Died before 3-month assessment 1 1 0 2
Withdrawn 5 8 9 22
Participant behaviour was inappropriate 0 1 0 1
Participant had a change in personal circumstances and
was unable to continue participation in the trial
0 0 1 1
Participant had problems with transport arrangements to
assessment
0 0 1 1
Participant moved out of trial area 0 1 0 1
continued
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TABLE 29 Reasons for non-completion of assessments at 3 and 6 months (continued )
Reason for withdrawal/assessment not conducted
Participants (n)
Robot-assisted training EULT Usual care Total
Participant refused to continue participation in the trial
(reason unknown)
2 3 1 6
Participant refused to continue participation in the trial
because they did not feel any improvement in arm
0 1 0 1
Participant refused to continue participation in the trial,
as they felt that it was too much of a burden
0 1 3 4
Participant unhappy with randomisation group 0 0 1 1
Participant unwell and unable to continue participation in
the trial
3 1 2 6
Withdrawn before the 3-month assessment 17 12 31 60
Total number of withdrawals/assessment not conducted
at 6 months
34 37 64 135
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
150
TABLE 30 Number and percentage of non-missing data for each measure at baseline
Measure
Robot-assisted training EULT Usual care
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number possible
to imputea
(% of expected)
ARAT
Grasp 257 256 (99.6) 259 259 (100.0) 254 254 (100.0)
Grip 257 256 (99.6) 259 259 (100.0) 254 254 (100.0)
Pinch 257 256 (99.6) 259 259 (100.0) 254 254 (100.0)
Gross movement 257 256 (99.6) 259 259 (100.0) 254 254 (100.0)
ARAT total score 257 256 (99.6) 259 259 (100.0) 254 254 (100.0)
Montreal Cognitive
Assessment
257 248 (96.5) 259 250 (96.5) 254 242 (95.3)
Sheffield Screening Test for Acquired Language Disorders
Receptive skills
score
257 255 (99.2) 259 258 (99.6) 254 254 (100.0)
Expressive skills
score
257 251 (97.7) 259 258 (99.6) 254 254 (100.0)
Total score 257 251 (97.7) 259 258 (99.6) 254 254 (100.0)
NIHSS 257 253 (98.4) 255 (99.2) 259 259 (100.0) 254 252 (99.2) 254 (100.0)
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TABLE 30 Number and percentage of non-missing data for each measure at baseline (continued )
Measure
Robot-assisted training EULT Usual care
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number possible
to imputea
(% of expected)
FMA
Motor function
score
257 255 (99.2) 259 259 (100.0) 254 254 (100.0)
Range of motion
and joint pain
score
257 254 (98.8) 259 259 (100.0) 254 254 (100.0)
Sensation score 257 253 (98.4) 259 258 (99.6) 254 252 (99.2)
Total upper-
extremity score
257 253 (98.4) 254 (98.8) 259 258 (99.6) 259 (100.0) 254 252 (99.2) 254 (100.0)
Barthel ADL Index 257 255 (99.2) 259 259 (100.0) 254 254 (100.0)
Numerical Pain
Scaleb
257 253 (98.4) 259 259 (100.0) 254 254 (100.0)
NIHSS, National Institutes of Health Stroke Scale.
a Using simple imputation.53 Numbers appear in this column only if extra data are added by the simple imputation.
b This is a single item and so imputation is not used.
A
P
P
E
N
D
IX
2
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
5
2
TABLE 31 Number and percentage of non-missing data for each measure at 3 months
Measure
Robot-assisted training EULT Usual care
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number
possible to
imputea (% of
expected)
ARAT
Grasp 239 232 (97.1) 246 234 (95.1) 223 203 (91.0)
Grip 239 232 (97.1) 246 234 (95.1) 223 203 (91.0)
Pinch 239 232 (97.1) 246 234 (95.1) 223 203 (91.0)
Gross movement 239 232 (97.1) 246 234 (95.1) 223 202 (90.6)
ARAT total score 239 232 (97.1) 246 234 (95.1) 223 202 (90.6) 203 (91.0)
FMA
Motor function
score
239 229 (95.8) 232 (97.1) 246 233 (94.7) 234 (95.1) 223 201 (90.1) 202 (90.6)
Range of motion
and joint pain
score
239 231 (96.7) 232 (97.1) 246 234 (95.1) 223 204 (91.5)
Sensation score 239 231 (96.7) 246 234 (95.1) 223 200 (89.7) 202 (90.6)
Total upper-
extremity score
239 227 (95.0) 232 (97.1) 246 233 (94.7) 234 (95.1) 199 (89.2) 202 (90.6)
Barthel ADL Index 239 233 (97.5) 246 236 (95.9) 223 207 (92.8)
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TABLE 31 Number and percentage of non-missing data for each measure at 3 months (continued )
Measure
Robot-assisted training EULT Usual care
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number
possible to
imputea (% of
expected)
SIS
Strength 239 217 (90.8) 220 (92.1) 246 219 (89.0) 220 (89.4) 223 193 (86.5)
Hand function 239 218 (91.2) 219 (91.6) 246 219 (89.0) 223 (90.7) 223 192 (86.1) 193 (86.5)
Mobility 239 217 (90.8) 219 (91.6) 246 216 (87.8) 223 (90.7) 223 184 (82.5) 192 (86.1)
ADL 239 212 (88.7) 220 (92.1) 246 215 (87.4) 223 (90.7) 223 191 (85.7) 194 (87.0)
Emotion 239 213 (89.1) 220 (92.1) 246 215 (87.4) 222 (90.2) 223 188 (84.3) 194 (87.0)
Memory 239 217 (90.8) 219 (91.6) 246 219 (89.0) 222 (90.2) 223 191 (85.7) 194 (87.0)
Communication 239 216 (90.4) 220 (92.1) 246 220 (89.4) 222 (90.2) 223 193 (86.5) 194 (87.0)
Social participation 239 183 (76.6) 217 (90.8) 246 176 (71.5) 221 (89.8) 223 148 (66.4) 193 (86.5)
Stroke recoveryb 239 217 (90.8) 246 223 (90.7) 223 190 (85.2)
Numerical Pain Scaleb 239 232 (97.1) 246 236 (95.9) 223 206 (92.4)
a Using simple imputation.53 Numbers appear in this column only if extra data are added by the simple imputation.
b This is a single item and so imputation is not used.
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TABLE 32 Number and percentage of non-missing data for each measure at 6 months
Measure
Robot-assisted training EULT Usual care
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number possible
to imputea (% of
expected)
ARAT
Grasp 234 221 (94.4) 236 218 (92.4) 214 185 (86.4)
Grip 234 221 (94.4) 236 218 (92.4) 214 185 (86.4)
Pinch 234 221 (94.4) 236 218 (92.4) 214 185 (86.4)
Gross movement 234 221 (94.4) 236 218 (92.4) 214 185 (86.4)
ARAT total score 234 221 (94.4) 236 218 (92.4) 214 185 (86.4)
FMA
Motor function
score
234 219 (93.6) 221 (94.4) 236 217 (91.9) 214 185 (86.4) 186 (86.9)
Range of motion
and joint pain
score
234 220 (94.0) 221 (94.4) 236 218 (92.4) 214 186 (86.9)
Sensation score 234 220 (94.0) 221 (94.4) 236 218 (92.4) 214 186 (86.9)
Total upper-
extremity score
234 218 (93.2) 221 (94.4) 236 217 (91.9) 218 (92.4) 214 185 (86.4) 186 (86.9)
Barthel ADL Index 234 223 (95.3) 236 222 (94.1) 214 190 (88.8)
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TABLE 32 Number and percentage of non-missing data for each measure at 6 months (continued )
Measure
Robot-assisted training EULT Usual care
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number after
imputationa
(% of expected)
Number
expected
Number with
complete-case
data (% of
expected)
Number possible
to imputea (% of
expected)
SIS
Strength 234 210 (89.7) 213 (91.0) 236 215 (91.1) 216 (91.5) 214 175 (81.8) 176 (82.2)
Hand function 234 210 (89.7) 213 (91.0) 236 214 (90.7) 216 (91.5) 214 177 (82.7) 179 (83.6)
Mobility 234 208 (88.9) 213 (91.0) 236 213 (90.3) 216 (91.5) 214 174 (81.3) 180 (84.1)
ADL 234 204 (87.2) 212 (90.6) 236 206 (87.3) 216 (91.5) 214 173 (80.8) 179 (83.6)
Emotion 234 203 (86.8) 211 (90.2) 236 210 (89.0) 216 (91.5) 214 170 (79.4) 179 (83.6)
Memory 234 210 (89.7) 213 (91.0) 236 212 (89.8) 215 (91.1) 214 175 (81.8) 178 (83.2)
Communication 234 209 (89.3) 213 (91.0) 236 213 (90.3) 216 (91.5) 214 174 (81.3) 179 (83.6)
Social participation 234 180 (76.9) 210 (89.7) 236 179 (75.8) 216 (91.5) 214 150 (70.1) 179 (83.6)
Stroke recoveryb 234 213 (91.0) 236 215 (91.1) 214 180 (84.1)
Numerical Pain Scaleb 234 223 (95.3) 236 221 (93.6) 214 190 (88.8)
a Using simple imputation.53 Numbers appear in this column only if extra data are added by the simple imputation.
b This is a single item and so imputation is not used.
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TABLE 33 Baseline upper limb rehabilitation treatments
Upper limb rehabilitation treatment Robot-assisted training (N= 257) EULT (N= 259) Usual care (N= 254) Total (N= 770)
Physiotherapy/occupational therapy (N) 255 259 254 768
No, n (%) 127 (49.8) 115 (44.4) 117 (46.1) 359 (46.7)
Yes, n (%) 128 (50.2) 144 (55.6) 137 (53.9) 409 (53.3)
Splints (N) 255 259 254 768
No, n (%) 181 (71.0) 184 (71.0) 180 (70.9) 545 (71.0)
Yes, n (%) 74 (29.0) 75 (29.0) 74 (29.1) 223 (29.0)
Shoulder brace (N) 255 259 254 768
No, n (%) 225 (88.2) 235 (90.7) 220 (86.6) 680 (88.5)
Yes, n (%) 30 (11.8) 24 (9.3) 34 (13.4) 88 (11.5)
TENS (N) 255 259 254 768
No, n (%) 235 (92.2) 241 (93.1) 237 (93.3) 713 (92.8)
Yes, n (%) 20 (7.8) 18 (6.9) 17 (6.7) 55 (7.2)
Antispasticity medication (N) 255 259 254 768
No, n (%) 223 (87.5) 213 (82.2) 213 (83.9) 649 (84.5)
Yes, n (%) 32 (12.5) 46 (17.8) 41 (16.1) 119 (15.5)
Botulinum toxin (N) 255 259 254 768
No, n (%) 234 (91.8) 228 (88.0) 234 (92.1) 696 (90.6)
Yes, n (%) 21 (8.2) 31 (12.0) 19 (7.5) 71 (9.2)
Unknown, n (%) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.1)
Other upper limb rehabilitation (N) 255 259 254 768
No, n (%) 244 (95.7) 241 (93.1) 242 (95.3) 727 (94.7)
Yes, n (%) 11 (4.3) 18 (6.9) 12 (4.7) 41 (5.3)
TENS, transcutaneous electrical nerve stimulation.
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Appendix 3 Analysis of the Action
Research Arm Test subscales
Robot-assisted training versus usual care
Both groups showed an improvement from baseline to 3 months, but little improvement thereafter,
with little difference between groups. In the robot-assisted training group, the proportion of participants
who could complete at least one task on the gross movement subscale was 33% at baseline, 43% at
3 months and 47% at 6 months. For the usual care group, these proportions were 31%, 39% and 41% at
baseline, 3 months and 6 months, respectively. There was little evidence of a difference in the proportions
for gross movement between these groups at 3 months (aOR 1.3, 98.33% CI 0.7 to 2.5) or 6 months
(aOR 1.7, 98.33% CI 0.9 to 3.2) (Table 34).
In the robot-assisted training group, the proportion of respondents who could complete at least one
task on the grasp subscale was 21% at baseline, 33% at 3 months and 38% at 6 months. For the usual
care group, these proportions were 17%, 27% and 31% at baseline, 3 months and 6 months, respectively.
There was little evidence of a difference in this proportion for grasp between these groups at 3 months
(aOR 1.6, 98.33% CI 0.7 to 3.2) or 6 months (aOR 1.8, 98.33% CI 0.9 to 3.8) (see Table 34).
In the robot-assisted training group, the proportion of participants who could complete at least one task
on the grip subscale was 24% at baseline, 37% at 3 months and 36% at 6 months. For the usual care
group, these proportions were 22%, 31% and 35% at baseline, 3 months and 6 months, respectively.
There was little evidence of a difference in this proportion for grip between these groups at 3 months
(aOR 1.9, 98.33% CI 0.9 to 4.0) or 6 months (aOR 1.2, 98.33% CI 0.5 to 2.4) (see Table 34).
In the robot-assisted training group, the proportion of participants who could complete at least one
task on the pinch subscale was 11% at baseline, 23% at 3 months and 24% at 6 months. For the usual
care group, these proportions were 12%, 21% and 26% at baseline, 3 months and 6 months, respectively.
There was little evidence of a difference in this proportion for pinch between these groups at 3 months
(aOR 1.6, 98.33% CI 0.8 to 3.3) or 6 months (aOR 1.0, 98.33% CI 0.5 to 2.1) (see Table 34).
Robot-assisted training verses enhanced upper limb therapy
Both groups showed an improvement from baseline to 3 months, but little improvement thereafter,
with small differences between groups. In the robot-assisted training group, the proportion of respondents
who could complete at least one task on the gross movement subscale was 33% at baseline, 43% at
3 months and 47% at 6 months. In the EULT group, these proportions were 36%, 47% and 49% at
baseline, 3 months and 6 months, respectively. There was little evidence of a difference in this proportion
for gross movement between these groups at 3 months (aOR 1.0, 98.33% CI 0.5 to 1.7) or 6 months
(aOR 1.1, 98.33% CI 0.6 to 2.0) (see Table 34).
In the robot-assisted training group, the proportion of respondents who could complete at least one
task on the grasp subscale was 21% at baseline, 33% at 3 months and 38% at 6 months. In the EULT
group, these proportions were 22%, 35% and 34% at baseline, 3 months and 6 months, respectively.
There was little evidence of a statistically significant difference in this proportion for grasp between
these groups at 3 months (aOR 0.9, 98.33% CI 0.5 to 1.8) or 6 months (aOR 1.8, 98.33% CI 0.9 to 3.5)
(see Table 34).
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TABLE 34 Comparison of those who could complete at least one task with those who could not on the ARAT subscales at 3 and 6 months between trial randomisation groups
ARAT subscale
Time
point
Robot-assisted
training EULT Usual care
OR (98.33% CI)
Robot-assisted training vs.
usual care EULT vs. usual care
Robot-assisted training vs.
EULT
N n (%) N n (%) N n (%) Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
Gross
movement
Baseline 256 85 (33.2) 259 94 (36.3) 254 78 (30.7) NA NA NA NA NA NA
3 months 232 100 (43.1) 234 110 (47.0) 203 80 (39.4) 1.2 (0.7 to 1.9) 1.3 (0.7 to 2.5) 1.4 (0.9 to 2.2) 1.4 (0.8 to 2.6) 0.9 (0.5 to 1.3) 1.0 (0.5 to 1.7)
6 months 221 103 (46.6) 218 107 (49.1) 185 76 (41.1) 1.3 (0.8 to 2.0) 1.7 (0.9 to 3.2) 1.4 (0.9 to 2.2) 1.5 (0.8 to 2.9) 0.9 (0.6 to 1.4) 1.1 (0.6 to 2.0)
Grasp Baseline 256 55 (21.5) 259 58 (22.4) 254 43 (16.9) NA NA NA NA NA NA
3 months 232 77 (33.2) 234 83 (35.5) 203 55 (27.1) 1.3 (0.8 to 2.2) 1.6 (0.7 to 3.2) 1.5 (0.9 to 2.4) 1.6 (0.8 to 3.4) 0.9 (0.6 to 1.4) 0.9 (0.5 to 1.8)
6 months 221 83 (37.6) 218 75 (34.4) 185 57 (30.8) 1.4 (0.8 to 2.2) 1.8 (0.9 to 3.8) 1.2 (0.7 to 2.0) 1.0 (0.5 to 2.2) 1.1 (0.7 to 1.8) 1.8 (0.9 to 3.5)
Grip Baseline 256 61 (23.8) 259 58 (22.4) 254 55 (21.7) NA NA NA NA NA NA
3 months 232 85 (36.6) 234 91 (38.9) 203 62 (30.5) 1.3 (0.8 to 2.1) 1.9 (0.9 to 4.0) 1.4 (0.9 to 2.4) 2.4 (1.1 to 5.1) 0.9 (0.6 to 1.4) 0.8 (0.4 to 1.5)
6 months 221 79 (35.7) 218 90 (41.3) 185 65 (35.1) 1.0 (0.6 to 1.7) 1.2 (0.5 to 2.4) 1.3 (0.8 to 2.1) 1.8 (0.8 to 3.7) 0.8 (0.5 to 1.3) 0.7 (0.3 to 1.3)
Pinch Baseline 256 29 (11.3) 259 32 (12.4) 254 30 (11.8) NA NA NA NA NA NA
3 months 232 54 (23.3) 234 58 (24.8) 203 42 (20.7) 1.2 (0.7 to 2.0) 1.6 (0.8 to 3.3) 1.3 (0.7 to 2.2) 1.6 (0.8 to 3.3) 0.9 (0.5 to 1.5) 1.0 (0.5 to 1.9)
6 months 221 53 (24.0) 218 58 (26.6) 185 49 (26.5) 0.9 (0.5 to 1.5) 1.0 (0.5 to 2.1) 1.0 (0.6 to 1.7) 1.1 (0.6 to 2.3) 0.9 (0.5 to 1.5) 0.9 (0.5 to 1.8)
NA, not applicable; OR, odds ratio.
a For time since stroke–0.5, baseline ARAT and trial centre.
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In the robot-assisted training group, the proportion of respondents who could complete at least one
task on the grip subscale was 24% at baseline, 37% at 3 months and 36% at 6 months. In the EULT
group, these proportions were 22% at baseline, 39% at 3 months and 41% at 6 months. There was
little evidence of a difference in this proportion for grip between these groups at 3 months (aOR 0.8,
98.33% CI 0.4 to 1.5) or 6 months (aOR 0.7, 98.33% CI 0.3 to 1.3) (see Table 34).
In the robot-assisted training group, the proportion of respondents who could complete at least one
task on the pinch subscale was 11% at baseline, 23% at 3 months and 24% at 6 months. In the EULT
group, these proportions were 12% at baseline, 25% at 3 months and 27% at 6 months. There was
little evidence of a difference in this proportion for pinch between these groups at 3 months (aOR 1.0,
98.33% CI 0.5 to 1.9) or 6 months (aOR 0.9, 98.33% CI 0.5 to 1.8) (see Table 34).
Enhanced upper limb therapy versus usual care
Both groups showed an improvement from baseline to 3 months, but little improvement thereafter,
with occasional small differences between groups. In the EULT group, the proportion of respondents
who could complete at least one task on the gross movement subscale was 36% at baseline, 47% at
3 months and 49% at 6 months. In the usual care group, these proportions were 31%, 39% and 41% at
baseline, 3 months and 6 months, respectively. There was little evidence of a difference in this rate
for gross movement between these groups at 3 months (aOR 1.4, 98.33% CI 0.8 to 2.6) or 6 months
(aOR 1.5, 98.33% CI 0.8 to 2.9) (see Table 34).
In the EULT group, the proportion of respondents who could complete at least one task on the grasp
subscale was 22% at baseline, 35% at 3 months and 34% at 6 months. For the usual care group, these
proportions were 17%, 27% and 31% at baseline, 3 months and 6 months, respectively. There was little
evidence of a difference in this proportion for grasp between these groups at 3 months (aOR 1.6,
98.33% CI 0.8 to 3.4) or 6 months (aOR 1.0, 98.33% CI 0.5 to 2.2) (see Table 34).
In the EULT group, the proportion of respondents who could complete at least one task on the grip
subscale was 22% at baseline, 39% at 3 months and 41% at 6 months. In the usual care group, these
proportions were 22%, 31% and 35% at baseline, 3 months and 6 months, respectively. There was
evidence of a difference in the ARAT grip subscale at 3 months (aOR 2.4, 98.33% CI 1.1 to 5.1);
however, this was not present at 6 months (aOR 1.8, 98.33% CI 0.8 to 3.7) (see Table 34).
In the EULT group, the proportion of respondents who could complete at least one task on the pinch
subscale was 12% at baseline, 25% at 3 months and 27% at 6 months. In the usual care group, these
proportions were 12%, 21% and 26% at baseline, 3 months and 6 months, respectively. There was
little evidence of a difference in this proportion for pinch in the EULT group compared with the usual
care group at 3 months (aOR 1.6, 98.33% CI 0.8 to 3.3) or at 6 months (aOR 1.1, 98.33% CI 0.6 to 2.3)
(see Table 34).
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Appendix 4 Masking data
TABLE 35 Masking of the researcher conducting the outcome assessment at 3 months
Did you know the participant’s
treatment group?
Robot-assisted
training (N= 239) EULT (N= 246)
Usual care
(N= 223)
Overall
(N= 708)
n 233 236 207 676
No, n (%) 183 (78.5) 210 (89.0) 182 (87.9) 575 (85.1)
Yes, n (%) 50 (21.5) 26 (11.0) 25 (12.1) 101 (14.9)
TABLE 36 Awareness of randomisation group at 3 months
Question
Robot-assisted
training (N= 50) EULT (N= 26)
Usual care
(N= 25)
Overall
(N= 101)
Which group did you think they
were in? (n)
47 23 24 94
Robot-assisted training, n (%) 44 (94) 1 (4) 0 (0) 45 (48)
EULT, n (%) 1 (2) 21 (91) 3 (13) 25 (27)
Usual care, n (%) 2 (4) 1 (4) 21 (88) 24 (26)
Did the group given match the patient’s
actual group? (n)
47 23 24 94
No, n (%) 3 (6) 2 (9) 3 (13) 8 (9)
Yes, n (%) 44 (94) 21 (91) 21 (88) 86 (91)
Was treatment known before the
outcome assessment? (n)
50 26 25 101
No, n (%) 16 (32.0) 11 (42.0) 16 (64.0) 43 (42.6)
Yes, n (%) 34 (68.0) 15 (58.0) 9 (36.0) 58 (57.4)
Did you know the treatment group before starting
the outcome assessment because you werea (n)
Involved in randomisation 34 15 9 58
No, n (%) 24 (71) 3 (20) 2 (22) 29 (50)
Yes, n (%) 10 (29) 12 (80) 7 (78) 29 (50)
Involved in provision of robot-assisted
training or EULT (n)
34 15 9 58
No, n (%) 13 (38) 15 (100) 7 (78) 35 (60)
Yes, n (%) 21 (62) 0 (0) 2 (22) 23 (40)
Involved in/aware of treatment discussions (n) 34 15 9 58
No, n (%) 22 (65) 3 (20) 7 (78) 32 (55)
Yes, n (%) 12 (35) 12 (80) 2 (22) 26 (45)
Involved in arranging transport (n) 34 15 9 58
No, n (%) 33 (97) 14 (93) 9 (100) 56 (97)
Yes, n (%) 1 (3) 1 (7) 0 (0) 2 (3)
continued
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TABLE 36 Awareness of randomisation group at 3 months (continued )
Question
Robot-assisted
training (N= 50) EULT (N= 26)
Usual care
(N= 25)
Overall
(N= 101)
Other (n) 34 15 9 58
No, n (%) 32 (94) 13 (87) 9 (100) 54 (93)
Yes, n (%) 2 (6) 2 (13) 0 (0) 4 (7)
Did you become aware of the treatment group during the outcome assessment becausea
The participant made a comment (n) 16 11 16 43
Yes, n (%) 16 (100) 11 (100) 16 (100) 43 (100)
Other (n) 50 25 25 100
No, n (%) 50 (100) 25 (100) 25 (100) 100 (100)
a Multiple reasons could have been selected.
TABLE 37 Masking of the researcher conducting the outcome assessment at 6 months
Did you know the participant’s
treatment group?
Robot-assisted
training (N= 234) EULT (N= 236)
Usual care
(N= 214)
Overall
(N= 684)
n 223 220 190 633
No, n (%) 184 (82.5) 195 (88.6) 166 (87.4) 545 (86.1)
Yes, n (%) 39 (17.5) 25 (11.4) 24 (12.6) 88 (13.9)
TABLE 38 Awareness of randomisation group at 6 months
Question
Robot-assisted
training (N= 39) EULT (N= 25)
Usual care
(N= 24)
Overall
(N= 88)
Which group were they in? (n) 39 24 24 87
Robot-assisted training, n (%) 36 (92) 3 (13) 0 (0) 39 (45)
EULT, n (%) 3 (8) 19 (79) 2 (8) 24 (28)
Usual care, n (%) 0 (0) 2 (8) 22 (92) 24 (28)
Does the group given match the
patient’s group? (n)
39 24 24 87
No, n (%) 3 (8) 5 (21) 2 (8) 10 (11)
Yes, n (%) 36 (92) 19 (79) 22 (92) 77 (89)
Was treatment known before the outcome
assessment? (n)
39 25 24 88
No, n (%) 17 (44) 10 (40) 9 (38) 36 (41)
Yes, n (%) 22 (56) 15 (60) 15 (63) 52 (59)
Did you know the treatment group before starting the outcome assessment because you werea
Involved in randomisation (n) 22 15 15 52
No, n (%) 13 (59) 4 (27) 3 (20) 20 (38)
Yes, n (%) 9 (41) 11 (73) 12 (80) 32 (62)
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TABLE 38 Awareness of randomisation group at 6 months (continued )
Question
Robot-assisted
training (N= 39) EULT (N= 25)
Usual care
(N= 24)
Overall
(N= 88)
Involved in provision of robot-assisted training
or EULT (n)
22 15 15 52
No, n (%) 9 (41) 11 (73) 15 (100) 35 (67)
Yes, n (%) 13 (59) 4 (27) 0 (0) 17 (33)
Involved in/aware of treatment discussions (n) 22 15 15 52
No, n (%) 12 (55) 4 (27) 12 (80) 28 (54)
Yes, n (%) 10 (45) 11 (73) 3 (20) 24 (46)
Involved in arranging transport (n) 22 15 15 52
No, n (%) 22 (100) 15 (100) 14 (93) 51 (98)
Yes, n (%) 0 (0) 0 (0) 1 (7) 1 (2)
Other (n) 22 15 15 52
No, n (%) 19 (86) 12 (80) 13 (87) 44 (85)
Yes, n (%) 3 (14) 3 (20) 2 (13) 8 (15)
Did you become aware of the treatment group during the outcome assessment becausea
The participant made a comment (n) 17 10 9 36
No, n (%) 1 (6) 0 (0) 0 (0) 1 (3)
Yes, n (%) 16 (94) 10 (100) 9 (100) 35 (97)
Other (n) 38 25 24 87
No, n (%) 38 (100) 25 (100) 24 (100) 87 (100)
a Multiple reasons could have been selected.
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Appendix 5 Patient safety data
TABLE 39 Reasons why medical events were considered to be SAEs
Reason
Participants experiencing SAEs, n (%)
Robot-assisted training
(N= 43) EULT (N= 42)
Usual care
(N= 29)
Event resulted in deatha 1 (2.3) 4 (9.5) 1 (3.4)
Event was life-threatening 3 (7.0) 0 (0.0) 0 (0.0)
Event resulted in admission to hospital
or prolongation of hospitalisation
32 (74.4) 37 (88.1) 25 (86.2)
Event resulted in persistent or
significant disability or incapacity
1 (2.3) 0 (0.0) 3 (10.3)
Event was ‘otherwise considered
significant’ by the investigator
6 (14.0) 1 (2.4) 0 (0.0)
a For two participants (EULT, n= 1; usual care, n = 1), a SAE was initially reported during their involvement in the trial,
but the date of death from this event was after their involvement ceased.
Note
Mann–Whitney U-test on the number of SAEs per participant for robot-assisted training versus usual care, p = 0.013;
robot-assisted training versus EULT, p = 0.40; and EULT versus usual care, p = 0.08.
TABLE 40 Summarised SAEs that resulted in death
SAE Robot-assisted training EULT Usual care
Neurological 0 1 1
Glioblastoma multiformea 0 0 1
New strokea 0 1 0
Respiratory 0 1 0
Pneumonia 0 1 0
Urinary tract 0 2 0
Metastatic renal carcinoma 0 1 0
Urosepsis 0 1 0
Miscellaneous 1 0 0
Suicide 1 0 0
Total 1 4 1
a These events commenced during trial involvement, but date of death was after trial end.
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TABLE 41 Summarised SAEs that did not result in death
SAE
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Cardiovascular 5 5 2 2 0 0
Aortic aneurysm
rupture
1 0 0
Elective carotid
endarterectomy
0 1 0
Hypotension 1 0 0
Non-ST-elevation
myocardial infarction
1 0 0
Paroxysmal atrial
fibrillation
1 0 0
Possible angina 0 1 0
Vasovagal collapse 1 0 0
Endocrine 0 0 1 1 1 1
Amiodarone-induced
thyrotoxicosis
0 1 0
Hyperglycaemia 0 0 1
Ear, nose and throat 0 0 1 1 0 0
Elective vocal cord
medialisation
0 1 0
Gastrointestinal 4 4 6 7 1 1
Bleeding oesophageal
ulcers
0 1 0
Elective endoscopy for
diarrhoea
1 0 0
Elective hernia repair 1 0 0
Elective
transoesophageal
echo
0 0 1
Gallstone pancreatitis 0 2 0
Gallstones 0 1 0
Gastritis 0 1 0
Pancreatitis 1 0 0
Perirectal bleeding 0 1 0
Small-bowel obstruction 0 1 0
Typhoid 1 0 0
Gynaecological 0 0 1 1 0 0
Elective hysteroscopy 0 1 0
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TABLE 41 Summarised SAEs that did not result in death (continued )
SAE
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Musculoskeletal 4 4 6 6 3 3
Arthritis 0 1 0
Elective toe fusion 1 0 0
Fracture – clavicle 0 0 1
Fracture – humerus 1 0 0
Fracture – neck of
femur
0 2 1
Fracture – rib 0 1 0
Fracture – wrist 1 0 0
Lumbar L3 or L4 disc
prolapse
1 0 0
Muscle spasm –
leg/back
0 1 0
Prosthetic hip
replacement
0 1 0
Worsening rheumatoid
arthritis
0 0 1
Neurological 14 14 5 5 7 7
Decompensation of
stroke
0 1 1
Elective cranioplasty 1 0 0
Headache due to
intracranial air from
cranioplasty
1 0 0
Likely new stroke 0 0 1
New stroke 2 1 1
Non-convulsive status
epilepticus
1 0 0
Seizure 8 3 3
Traumatic left subdural
haematoma
1 0 0
Worsening stroke
symptoms from
focal seizure
0 0 1
Respiratory 4 4 3 3 6 7
Bronchitis 0 1 0
Elective admission for
investigation of sleep
apnoea
1 0 0
Influenza 0 0 1
Parapneumonic effusion 0 0 1
continued
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TABLE 41 Summarised SAEs that did not result in death (continued )
SAE
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Pneumonia 2 0 4
Pulmonary emboli 1 2 0
Pulmonary oedema 0 0 1
Urinary tract 3 3 3 4 3 3
Elective biopsy of
bladder lesion
0 0 1
Epididymo-orchitis 0 0 1
Hyperkalaemia and
renal acidosis
0 1 0
Urinary retention 0 1 1
Urinary tract infection/
urosepsis
3 2 0
Miscellaneous 8 8 8 8 5 6
Abdominal pain (cause
unknown)
1 0 0
Acute kidney injury
(cause unknown)
1 0 0
Deep-vein thrombosis
and chest infection
0 1 0
Diarrhoea (cause
unknown)
0 1 1
Diarrhoea and acute
kidney injury (cause
unknown)
0 0 1
Diarrhoea and nausea
secondary to
pembrolizumab
0 0 1
Elective axillary lipoma
excision
0 0 1
Infected cranioplasty 0 0 1
Fall (mechanical) 1 0 0
Fall (possible post
stroke seizure)
0 1 0
Head injury 1 0 0
Infected foot following
injury
0 1 0
Intoxication and
pneumonia
0 1 0
Likely viral illness 1 0 0
Pneumonia and seizure 0 0 1
Pyrexia (cause
unknown)
1 0 0
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At 3 months, 38 out of 233 (16.3%) participants in the robot-assisted training group and 37 out of
236 (15.7%) participants in the EULT group in whom an assessment was carried out reported at least
one non-serious adverse event. For the usual care group, this was 35 out of 207 (16.9%) participants.
The difference in proportions between the robot-assisted training and usual care groups was –1%
(98.33% CI –10% to 8%); for the EULT and usual care groups, the difference was –1% (98.33% CI
–10% to 8%); and for the robot-assisted training and EULT groups, the difference was 1% (98.33% CI
–8% to 9%). There was little evidence of a difference in the proportion of participants with at least
one adverse event between the pairs of groups. The median number of adverse events was 0 (IQR 0–0).
The p-values from the Mann–Whitney U-tests were 0.9 when comparing robot-assisted training with
usual care, 0.7 when comparing EULT with usual care and 0.8 when comparing robot-assisted training
with EULT, which indicates that there was little evidence of a difference between the pairs of groups.
TABLE 41 Summarised SAEs that did not result in death (continued )
SAE
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Scald/burn 0 1 0
Transient difficulty
walking (cause
unknown)
0 1 0
Urosepsis and infective
endocarditis
1 0 0
Vertigo 0 1 0
Worsening stroke
symptoms (cause
unknown)
1 0 0
Note
When SAE reports documented more than one clinical event (e.g. intoxication and pneumonia), the main event/reason
for hospitalisation is the event summarised. When the main event appeared unclear, adjudication took place to agree
the event to summarise.
TABLE 42 Number of non-serious adverse events per participant
Number of adverse
events per participant
Participants, n (%)
3 months 6 months
Robot-assisted
training
(N= 233)
EULT
(N= 236)
Usual care
(N= 207)
Robot-assisted
training
(N= 223)
EULT
(N= 222)
Usual care
(N= 190)
0 195 (83.7) 199 (84.3) 172 (83.1) 181 (81.2) 176 (79.3) 163 (85.8)
1 33 (14.2) 34 (14.4) 32 (15.5) 40 (17.9) 41 (18.5) 23 (12.1)
2 3 (1.3) 3 (1.3) 3 (1.4) 2 (0.9) 3 (1.4) 4 (2.1)
3 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9) 0 (0.0)
4 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total events (n) 46 40 38 44 53 31
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At 6 months, 42 out of 223 (18.8%) participants in the robot-assisted training group and 46 out of
222 (20.7%) participants in the EULT group in whom an assessment was carried out reported at least
one non-serious adverse event. For the usual care group, this was 27 out of 190 (14.2%) participants.
The difference in proportions between the robot-assisted training and usual care groups was 5%
(98.33% CI –5% to 14%); for the EULT and usual care groups, the difference was 7% (98.33% CI –3%
to 16%); and for the robot-assisted training and EULT groups, the difference was –2% (98.33% CI
–11% to 8%). There was little evidence of a difference in the proportion of participants with at least
one adverse event between the pairs of groups. The median number of adverse events was 0 (IQR 0–0)
for all groups. The p-values from the Mann–Whitney U-tests were 0.2 when comparing robot-assisted
training with usual care, 0.1 when comparing EULT with usual care and 0.6 when comparing robot-
assisted training with EULT, which indicate little evidence of a difference between the pairs of groups.
TABLE 43 Summarised non-serious adverse events reported at the 3-month assessment
Adverse event
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Cardiovascular 0 0 0 0 2 2
Heart palpitations 0 0 1
Pacemaker fitting 0 0 1
Dental 1 1 0 0 0 0
Tooth infection 1 0 0
Dermatological 1 1 0 0 3 3
Blisters on foot 0 0 1
Cyst on leg 0 0 1
Eczema 1 0 0
Leg ulcer 0 0 1
Endocrine 2 2 2 2 1 1
Diabetes mellitus 2 1 1
Hyperglycaemia 0 1 0
Ear, nose and throat 1 1 0 0 2 2
Ear infection 1 0 0
Oral thrush 0 0 1
Possible ear infection 0 0 1
Eye 0 0 1 1 1 1
Problems with eyes 0 1 0
Stye removal 0 0 1
Gastrointestinal 3 3 5 5 2 2
Abdominal pain and
diarrhoea
0 1 0
Abnormal liver function 0 1 0
Constipation 1 0 0
Diarrhoea 0 0 2
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TABLE 43 Summarised non-serious adverse events reported at the 3-month assessment (continued )
Adverse event
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Hernia 0 2 0
Infection at percutaneous
endoscopic gastrostomy
0 1 0
Reflux 1 0 0
Scope for assessment of
banding
1 0 0
Gynaecological 0 0 1 1 0 0
Fibroid 0 1 0
Musculoskeletal 9 9 5 6 5 5
Arthritis – knee 0 0 1
Foot problems 1 0 0
Fracture – ankle 0 1 0
Fracture – foot 0 1 0
Fracture – shoulder 1 1 0
Frozen shoulder 3 1 0
Osteoporosis 1 0 0
Podiatry referral 1 0 0
Possible arthritis 0 0 1
Shoulder pain 2 1 1
Tendonitis in arm 0 0 1
Trapped nerves in
shoulder
0 0 1
Upper limb pain 0 1 0
Neurological 1 1 5 5 5 5
Memory loss 0 0 1
Neuropathic pain 0 1 0
Seizure(s) 1 4 4
Psychiatric 2 2 3 3 2 2
Depression 2 3 1
Panic attacks 0 0 1
Respiratory 3 3 6 6 2 2
Chest infection 2 5 2
Possible new diagnosis
of chronic obstructive
pulmonary disease
0 1 0
Cough 1 0 0
continued
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TABLE 43 Summarised non-serious adverse events reported at the 3-month assessment (continued )
Adverse event
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Urinary tract 3 3 1 1 5 5
Bladder infections 0 0 1
Haematuria 1 0 0
Incontinence 0 0 2
Urinary frequency 0 0 1
Urinary retention 1 0 0
Urinary tract infection 1 1 0
Water retention 0 0 1
Miscellaneous 19 20 10 10 8 8
Abscess on back 1 0 0
Allergic reaction 0 1 0
Blackout 1 0 0
Bone flap reinserted
(on head)
1 0 0
Commenced on new
medication for blood
pressure and bladder
control
1 0 0
Change in drugs 0 0 1
Curling toes 1 0 0
Dog bite 0 0 1
Double vision 1 0 0
Drug side effects 2 1 0
Fall 6 2 2
High cholesterol 0 0 1
Joint/muscle/back pain 2 3 0
Lightheaded 0 1 0
No details provided 0 0 1
Swallowing problems 0 1 1
Swelling of foot 0 0 1
Swelling of legs 1 0 0
Swollen ankles 2 0 0
Toenail removal 1 0 0
Vertigo 0 1 0
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TABLE 44 Summarised non-serious adverse events reported at the 6-month assessment
Adverse event
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Cardiovascular 2 2 0 0 2 2
High blood pressure 0 0 1
Hypotension 2 0 0
Palpitations 0 0 1
Dermatological 2 2 6 6 2 2
Eczema 0 1 0
Forehead lesion (cause
unknown)
0 0 1
Itch 1 1 0
Infected toe 0 0 0
Leg rash 0 1 0
Leg ulcers 0 2 0
Lesion on face removed 0 1 0
Rash 1 0 1
Ear 0 0 2 2 0 0
Ear pain 0 1 0
Ears syringed 0 1 0
Endocrine 1 1 2 2 0 0
Diabetes mellitus 1 0 0
Menopause symptoms 0 1 0
Thyroid eye disease 0 1 0
Ear, nose and throat 1 1 1 1 0 0
Oral thrush 0 1 0
Potential throat cancer 1 0 0
Eye 0 0 0 0 2 2
Cataracts 0 0 1
Ophthalmologist review –
no further information
0 0 1
Gastrointestinal 5 5 3 3 2 2
Constipation 1 0 0
Diarrhoea 0 0 1
Diarrhoea and vomiting 0 1 0
Gastroscopy 1 0 0
Haemorrhoids 1 0 0
continued
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TABLE 44 Summarised non-serious adverse events reported at the 6-month assessment (continued )
Adverse event
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Hernia 1 1 0
Irritable bowel
syndrome
0 0 1
Piles 1 0 0
Rectal bleeding 0 1 0
Haematological 1 1 1 1 0 0
Low blood count 1 1 0
Musculoskeletal 5 5 7 7 5 5
Arthritis 1 0 1
Fracture – fingers 1 1 0
Fracture – foot 1 0 1
Fracture – humerus 0 1 0
Fracture – knuckles 0 1 0
Fracture – leg 0 0 1
Fracture – rib 0 1 0
Fracture – wrist 1 0 0
Frozen shoulder 0 2 0
Injured hand in car door 1 0 0
Orthotic appointments 0 0 1
Polymyalgia 0 1 0
Pre-operative
assessment for knee
replacement
0 0 1
Neurological 5 5 5 5 4 4
Foot drop 1 0 0
Migraine 0 1 0
Nerve impingement 0 1 0
Neuropathy 0 0 1
Pins and needles in
affected arm
1 0 0
Seizure(s) 3 3 3
Psychiatric 2 2 2 2 1 1
Depression 1 1 0
Panic attacks 0 1 0
Psychiatric assessment –
no further information
1 0 0
Stress 0 0 1
APPENDIX 5
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TABLE 44 Summarised non-serious adverse events reported at the 6-month assessment (continued )
Adverse event
Robot-assisted training EULT Usual care
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Participants who
experienced the
event (n)
Total
number
of events
Respiratory 2 2 6 6 1 1
Asbestosis 1 0 0
Chest infection 1 1 0
Chronic obstructive
pulmonary disease
0 2 0
Cough 0 0 1
Coughing blood 0 1 0
Pneumonia 0 1 0
Shortness of breath 0 1 0
Urinary tract 3 3 4 4 0 0
Incontinence 1 0 0
Urinary tract infection 2 4 0
Miscellaneous 15 15 13 14 11 12
Bloating and
uncomfortable
0 0 1
Chest pain (no cause
documented)
1 0 0
Collapse 0 1 0
Cut finger 1 0 0
Dizziness 0 1 0
Double vision 1 0 0
Drug side effects 1 0 0
Fall 3 2 4
Headaches 1 0 0
Head injury 1 1 0
Ingrowing toenail 2 0 1
Joint/muscle/back pain 2 6 5
No details given 0 1 0
Restless leg syndrome 0 1 0
Swallowing problems 1 0 1
Swelling of legs 0 1 0
Unwell (no further
details)
1 0 0
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Appendix 6 Randomisation group data
TABLE 45 Reasons for missed robot-assisted training and EULT sessions
Reason for missed session
Robot-assisted training EULT
Number of
participants
Number of
missed sessions
Number of
participants
Number of
missed sessions
Adverse weather conditions 0 0 3 5
Did not attend (reason unknown) 23 132 23 96
Fatigue 3 15 5 14
Participant being discharged from
hospital at time of therapy
1 1 6 9
Participant at work 0 0 3 4
Participant cancelled session (reason
unknown)
0 0 7 27
Participant cancelled session (family
emergency)
2 2 2 5
Participant could not tolerate three
sessions per week
3 31 1 23
Participant could not tolerate the
wrist robot
3 41 0 0
Participant died 1 32 0 0
Participant forgot appointment 2 2 9 10
Participant had another appointment 29 69 54 115
Participant moved area 1 8 1 35
Participant on holiday 6 15 21 117
Participant overslept 0 0 2 3
Participant unhappy with
randomisation group
0 0 1 31
Participant unwell 52 341 67 406
Participant unable to leave house
because of access problems
1 1 2 26
Participant working away from home 0 0 2 50
Personal circumstances 5 54 12 88
Problems with transport to
appointment
14 22 32 70
Robot out of order 1 1 0 0
Shoulder pain 5 62 2 4
Therapy slot unavailable (e.g. bank
holiday)
7 14 20 27
Withdrew 15 429 11 282
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TABLE 46 The number of movement attempts for the shoulder–elbow robot (with and without hand attachment), the wrist robot and overall
Variable
Number of
shoulder–elbow
movement
attempts per
training session
Total number of
shoulder–elbow
movement
attempts
Number of
shoulder–elbow
movement attempts
per training session
(no hand attachment)
Total number of
shoulder–elbow
movement
attempts (no hand
attachment)
Number
of wrist
movement
attempts
per training
session
Total number
of wrist
movement
attempts
Overall total
number of
movement
attempts per
training session
Overall total
number of
movement
attempts
Participants
(n)
156 156 98 98 243 243 255 255
Median
(IQR)
840 (672–1024) 15,002
(13,065–17,007)
804 (488–1024) 11,141
(6751–14,583)
796
(668–1132)
13,460
(11,236–16,220)
808 (668–1040) 27,407
(22,900–32,187)
Target
movement
attempts
achieved,
n/N (%)
840/1114 (75) 15,002/20,060
(75)
804/1083 (74) 11,141/19,496 (57) 796/1066
(75)
13,460/19,196
(70)
808/1090 (74) 27,407/39,256
(70)
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TABLE 47 The number of assisted and unassisted movement attempts by baseline ARAT score and time since stroke for the shoulder–elbow and wrist robot, and overall total
Baseline
ARAT score
(n participants)
Time since
stroke (n
participants) Value
Number of
assisted shoulder-
elbow movement
attempts
Number of
unassisted
shoulder-elbow
movement
attempts
Total number of
shoulder-elbow
movement
attempts
Number of
assisted wrist
movement
attempts
Number of
unassisted
wrist movement
attempts
Total number of
wrist movement
attempts
Overall number
of assisted
movement
attempts
Overall number
of unassisted
movement
attempts
Overall total
number of
movement
attempts
ARAT score of
0–7 (n= 177)
≤ 3 months
(n= 38)
n 37 37 37 35 35 35 38 38 38
Median (IQR) 11,666
(7056–14,025)
1682
(1012–2119)
13,520
(8230–16,166)
11,640
(8672–14,200)
1084
(592–1768)
12,988
(9508–15,536)
21,475
(16,344–27,794)
2522
(1583–3795)
24,436
(18,367–31,228)
> 3–12 months
(n= 68)
n 68 68 68 66 66 66 68 68 68
Median (IQR) 10,734
(9016–13,065)
1775
(1390–2124)
12,378
(10,535–14,952)
11,296
(9578–13,094)
1648
(1014–1873)
12,948
(10,845–14,809)
21,660
(19,443–25,194)
3333
(2221–3951)
25,386
(21,710–28,998)
> 12 months
(n= 71)
n 71 71 71 69 69 69 71 71 71
Median (IQR) 11,538
(9888–12,960)
1910
(1608–2288)
13,719
(11,566–15,066)
10,760
(9672–12,080)
1672
(1386–1844)
12,341
(10,982–13,820)
22,016
(20,020–24,776)
3516
(3024–3995)
25,628
(23,108–28,836)
ARAT score of
8–19 (n= 31)
≤ 3 months
(n= 6)
n 6 6 6 6 6 6 6 6 6
Median (IQR) 14,681
(10,173–16,268)
2264
(1656–2388)
17,223
(12,193–18,790)
17,688
(13,558–18,640)
2106
(775–2216)
19,794
(14,333–20,935)
32,881
(25,873–33,426)
4761
(2561–4831)
37,411
(29,219–37,958)
> 3–12 months
(n= 14)
n 14 14 14 14 14 14 14 14 14
Median (IQR) 13,048
(11,760–14,364)
2143
(1760–2492)
15,442
(13,733–16,324)
14,192
(11,944–16,960)
1778
(1521–1984)
15,966
(13,432–19,142)
28,060
(23,686–31,710)
3995
(3462–4404)
32,028
(27,341–35,827)
> 12 months
(n= 11)
n 11 11 11 11 11 11 11 11 11
Median (IQR) 12,880
(10,722–14,497)
2316
(1956–2420)
15,285
(13,064–16,917)
13,560
(7552–16,380)
1928
(1508–2088)
15,592
(8788–18,364)
27,120
(22,754–29,260)
4252
(3968–4420)
31,540
(26,966–33,593)
ARAT score of
20–39 (n= 47)
≤ 3 months
(n= 13)
n 12 13 13 10 10 10 12 13 13
Median (IQR) 14,747
(10,804–16,772)
2234
(1304–2596)
17,101
(10,712–19,152)
16,968
(14,006–19,848)
1744
(1056–2216)
19,054
(15,595–21,926)
30,975
(26,288–35,092)
3821
(2430–4612)
33,723
(23,908–38,637)
> 3–12 months
(n= 22)
n 22 22 22 20 20 20 22 22 22
Median (IQR) 13,560
(10,245–15,553)
2037
(1612–2511)
15,744
(11,837–17,628)
15,316
(12,604–19,274)
2048
(1545–2171)
17,388
(14,557–21,267)
27,980
(22,670–34,418)
3966
(3049–4677)
31,909
(26,171–38,463)
> 12 months
(n= 12)
n 12 12 12 12 12 12 12 12 12
Median (IQR) 14,841
(11,870–17,745)
2176
(1928–2316)
17,442
(14,138–20,152)
15,328
(13,138–19,800)
1998
(1829–2215)
17,404
(14,981–21,942)
29,695
(27,638–34,352)
4365
(3978–4730)
33,871
(31,556–39,015)
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TABLE 48 The COPM goal choice, activities and goal achievement in the EULT programme
Category
Number of goals
set in category/
total number of
goals set (%)
Number of goals
achieved in
category/number
of goals set
in category
(for which there
is achievement
data) (%)a Subcategory
Number of goals
set in subcategory/
total number of
goals set in
category (%)
Number of goals
achieved in
subcategory/
number of goals
set in subcategory
(for which there
is achievement
data) (%)a
Activity
category
Number of goals
set in activity
category/total
number of
goals set in
subcategory (%)
Number of goals
achieved in activity
category/number of
goals set in activity
category (for which
there is achievement
data) (%)a
Leisure 180/2664 (7) 109/171 (64) Active
recreation
16/180 (9) 10/14 (71) Outings 0/16 (0) 0/0 (0)
Sports 16/16 (100) 10/14 (71)
Travel 0/16 (0) 0/0 (0)
Quiet
recreation
71/180 (39) 41/69 (59) Crafts 4/70 (6) 3/4 (75)
Hobbies 63/70 (90) 35/62 (56)
Reading 3/70 (4) 3/3 (100)
Socialisation 93/180 (52) 58/88 (66) Correspondence 92/93 (99) 57/87 (66)
Parties 0/93 (0) 0/0 (0)
Telephone calls 0/93 (0) 0/0 (0)
Visiting 1/93 (1) 1/1 (100)
Productivity 374/2664 (14) 211/351 (60) Household
management
374/374 (100) 211/351 (60) Cleaning 206/374 (55) 100/189 (53)
Cooking 125/374 (33) 81/121 (67)
DIY 11/374 (3) 9/11 (82)
Laundry 19/374 (5) 13/19 (68)
Using light
switches
13/374 (3) 8/11 (73)
Paid/unpaid
work
0/374 (0) N/A Finding/keeping
a job
0/0 (0) 0/0 (0)
Volunteering 0/0 (0) 0/0 (0)
Play/school 0/374 (0) N/A Homework 0/0 (0) 0/0 (0)
Play skills 0/0 (0) 0/0 (0)
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Category
Number of goals
set in category/
total number of
goals set (%)
Number of goals
achieved in
category/number
of goals set
in category
(for which there
is achievement
data) (%)a Subcategory
Number of goals
set in subcategory/
total number of
goals set in
category (%)
Number of goals
achieved in
subcategory/
number of goals
set in subcategory
(for which there
is achievement
data) (%)a
Activity
category
Number of goals
set in activity
category/total
number of
goals set in
subcategory (%)
Number of goals
achieved in activity
category/number of
goals set in activity
category (for which
there is achievement
data) (%)a
Self-care 1449/2664 (54) 640/1354 (47) Community
management
25/1449 (2) 19/23 (83) Finances 19/25 (76) 16/17 (94)
Shopping 0/25 (0) 0/0 (0)
Transportation 6/25 (24) 3/6 (5)
Functional
mobility
141/1449 (10) 65/136 (48) Indoor 42/141 (30) 24/40 (60)
Outdoor 7/141 (5) 4/7 (57)
Transfers 92/141 (65) 37/89 (42)
Personal care 1283/1449 (89) 556/1195 (47) Bathing 166/1283 (13) 79/150 (53)
Child care 4/1283 (< 1) 0/3 (0)
Dressing 254/1283 (20) 0/1 (0)
Eating 622/1283 (48) 234/587 (40)
Grooming 74/1283 (6) 32/69 (46)
Hygiene 161/1283 (13) 70/142 (49)
Medication 1/1283 (< 1) 0/1 (0)
Other 661/2664 (25) 327/625 (52) Pick up/grasp/
reach/place
object
163/661 (25) 84/155 (54) N/A
Range of
movement
413/661 (62) 196/390 (50)
Upper limb
strengthening
8/661 (1) 7/7 (100)
Unclassified 26/661 (4) 15/24 (63)
Weight-bearing 51/661 (8) 25/49 (51)
DIY, do it yourself; N/A, not applicable.
a Data not available for 163 out of 2664 goals.
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TABLE 49 Goal choices and goal achievement according to baseline ARAT score and time since stroke in the EULT programme
Baseline
ARAT score
(n participants)
Time since stroke
(n participants)
Number of goals set for
each time since stroke
subgroup/total number
of goals set for ARAT
subgroup (%)
Number of goals achieved
in each time since stroke
subgroup/number of goals
set for each time since stroke
subgroup (for which there is
achievement data) (%)a Category
Number of goals set
in category for that
subgroup/total
number of goals set
for that subgroup (%)
Number of goals achieved
in category for that
subgroup/number of goals
set in category for that
subgroup (for which there
is achievement data) (%)a
0–7 (n= 175) < 3 months
(n = 26)
262/1759 (15) 175/240 (73) Leisure 18/262 (15) 17/18 (76)
Productivity 22/262 (8) 15/22 (68)
Self-care 118/262 (45) 76/107 (71)
Other 104/262 (40) 71/94 (76)
3–12 months
(n = 79)
823/1759 (47) 342/781 (44) Leisure 27/823 (3) 11/26 (42)
Productivity 142/823 (17) 75/133 (56)
Self-care 480/823 (58) 178/454 (39)
Other 174/823 (21) 78/168 (46)
> 12 months
(n = 70)
674/1759 (38) 167/616 (27) Leisure 16/674 (2) 2/14 (14)
Productivity 91/674 (17) 29/80 (36)
Self-care 361/674 (54) 77/332 (23)
Other 206/674 (31) 59/190 (31)
8–19 (n= 31) < 3 months
(n = 5)
48/333 (14) 36/41 (88) Leisure 3/48 (6) 3/3 (100)
Productivity 6/48 (13) 4/5 (80)
Self-care 24/48 (50) 16/19 (84)
Other 15/48 (31) 13/14 (93)
3–12 months
(n = 13)
136/333 (41) 72/128 (56) Leisure 8/136 (6) 3/7 (43)
Productivity 10/136 (7) 8/10 (80)
Self-care 95/136 (70) 46/89 (52)
Other 23/136 (17) 15/22 (68)
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Baseline
ARAT score
(n participants)
Time since stroke
(n participants)
Number of goals set for
each time since stroke
subgroup/total number
of goals set for ARAT
subgroup (%)
Number of goals achieved
in each time since stroke
subgroup/number of goals
set for each time since stroke
subgroup (for which there is
achievement data) (%)a Category
Number of goals set
in category for that
subgroup/total
number of goals set
for that subgroup (%)
Number of goals achieved
in category for that
subgroup/number of goals
set in category for that
subgroup (for which there
is achievement data) (%)a
> 12 months
(n = 13)
149/333 (45) 93/149 (62) Leisure 10/149 (7) 7/10 (70)
Productivity 19/149 (13) 16/19 (84)
Self-care 78/149 (52) 45/78 (58)
Other 42/149 (28) 25/42 (60)
20–39 (n = 53) < 3 months
(n = 15)
168/572 (29) 124/162 (77) Leisure 29/168 (17) 26/27 (96)
Productivity 26/168 (15) 17/25 (68)
Self-care 77/168 (46) 54/74 (73)
Other 36/168 (21) 27/36 (75)
3–12 months
(n = 25)
274/572 (48) 202/267 (76) Leisure 61/274 (22) 38/59 (64)
Productivity 48/274 (18) 39/47 (83)
Self-care 134/274 (49) 130/104 (80)
Other 31/274 (11) 21/31 (68)
> 12 months
(n = 13)
130/572 (23) 76/117 (65) Leisure 8/130 (6) 6/8 (75)
Productivity 10/130 (8) 8/10 (80)
Self-care 82/130 (63) 44/71 (62)
Other 30/130 (23) 18/28 (64)
a Data not available for 163 out of 2664 goals.
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TABLE 50 The number of days and how much time per week participants spent on therapy for their arm and hand for those participants who returned their arm rehabilitation therapy log
Question Value
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 1896 weeks)
(N= 158
participants)
Weeks 13–24
(N= 1416 weeks)
(N= 118
participants)
Weeks 1–12
(N= 1908 weeks)
(N= 159
participants)
Weeks 13–24
(N= 1356 weeks)
(N= 113
participants)
Weeks 1–12
(N= 1536 weeks)
(N= 128
participants)
Weeks 13–24
(N= 1368 weeks)
(N= 114
participants)
On how many days per week
have participants received
therapy for their arm or hand?
n 1884 weeks
(157 participants)
1412 weeks
(110 participants)
1881 weeks
(158 participants)
1353 weeks
(110 participants)
1529 weeks
(127 participants)
1367 weeks
(106 participants)
Median
(IQR)
0 (0–1) 0 (0–0) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
How much time (minutes)
per week has been spent in
therapy for their arm or hand?
n 1884 weeks
(157 participants)
1401 weeks
(109 participants)
1883 weeks
(158 participants)
1350 weeks
(110 participants)
1519 weeks
(127 participants)
1367 weeks
(106 participants)
Median
(IQR)
0 (0–20) 0 (0–0) 0 (0–30) 0 (0–30) 0 (0–60) 0 (0–30)
Note
If a participant stated, or if it was assumed, that no usual care arm therapy was received in a week, then the number of days and the amount of time spent on therapy for that week
was added as zero.
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TABLE 51 The type of therapy participants stated they received when they selected ‘other’ as type of therapy
‘Other’ therapy
Participants, n (%)
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 524 weeks)
(N= 64 participants)
Weeks 13–24
(N= 313 weeks)
(N= 42 participants)
Weeks 1–12
(N= 533 weeks)
(N= 75 participants)
Weeks 13–24
(N= 375 weeks)
(N= 56 participants)
Weeks 1–12
(N= 645 weeks)
(N= 75 participants)
Weeks 13–24
(N= 373 weeks)
(N= 49 participants)
Acupuncture 1 (2) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Aquafit 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
Balance work 0 (0) 0 (0) 0 (0) 0 (0) 5 (7) 0 (0)
Bobath 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
Botulinum toxin
injection
1 (2) 0 (0) 1 (1) 3 (4) 0 (0) 1 (1)
Compression splint 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Co-ordination 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Core stability 1 (2) 0 (0) 0 (0) 0 (0) 2 (3) 0 (0)
Driving 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Electrical stimulation 3 (5) 2 (3) 5 (7) 3 (4) 6 (8) 3 (4)
Exercise – non-specific 0 (0) 1 (2) 0 (0) 1 (1) 2 (3) 2 (3)
Fatigue/cognitive
management strategies
1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Gait re-education 2 (3) 0 (0) 3 (4) 0 (0) 2 (3) 1 (1)
Guitar and keyboard
practice
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1)
Gym 2 (3) 4 (6) 2 (3) 0 (0) 0 (0) 1 (1)
Hand putty 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
continued
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TABLE 51 The type of therapy participants stated they received when they selected ‘other’ as type of therapy (continued )
‘Other’ therapy
Participants, n (%)
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 524 weeks)
(N= 64 participants)
Weeks 13–24
(N= 313 weeks)
(N= 42 participants)
Weeks 1–12
(N= 533 weeks)
(N= 75 participants)
Weeks 13–24
(N= 375 weeks)
(N= 56 participants)
Weeks 1–12
(N= 645 weeks)
(N= 75 participants)
Weeks 13–24
(N= 373 weeks)
(N= 49 participants)
Hydrotherapy 0 (0) 0 (0) 1 (1) 1 (1) 1 (1) 1 (1)
Knitting 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Massage 0 (0) 0 (0) 1 (1) 0 (0) 1 (1) 1 (1)
Mirror box 2 (3) 0 (0) 2 (3) 0 (0) 2 (3) 1 (1)
Physiotherapy session 1 (3) 3 (5) 2 (3) 1 (1) 3 (4) 1 (1)
Playing piano 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Playing tennis 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Proprioceptive
neuromuscular
facilitation
1 (3) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Putting on ankle brace 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Reaching work 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 3 (4)
Reflexology 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (1)
Reiki 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Rowing machine
and/or pulleys
0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Saebo (Saebo, Inc.,
Charlotte, NC, USA)
1 (3) 0 (0) 2 (3) 2 (3) 2 (3) 3 (4)
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‘Other’ therapy
Participants, n (%)
Robot-assisted training EULT Usual care
Weeks 1–12
(N= 524 weeks)
(N= 64 participants)
Weeks 13–24
(N= 313 weeks)
(N= 42 participants)
Weeks 1–12
(N= 533 weeks)
(N= 75 participants)
Weeks 13–24
(N= 375 weeks)
(N= 56 participants)
Weeks 1–12
(N= 645 weeks)
(N= 75 participants)
Weeks 13–24
(N= 373 weeks)
(N= 49 participants)
Sensory work 2 (3) 1 (2) 1 (1) 1 (1) 2 (3) 0 (0)
Soft tissue release 0 (0) 0 (0) 1 (1) 0 (0) 1 (1) 0 (0)
Specific muscle
strengthening
0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
Splinting (application) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
Splint made 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
Strengthening
(non-specific)
0 (0) 0 (0) 1 (1) 1 (1) 0 (0) 0 (0)
Suspension therapy 0 (0) 0 (0) 1 (1) 1 (1) 0 (0) 0 (0)
Swimming 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Technology 1 (2) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
TheraBand (TheraBand,
Akron, OH, USA)
1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
TheraBand and putty 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Uria splint 3 (5) 1 (2) 1 (1) 1 (1) 2 (3) 0 (0)
Unknown 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (3)
Various activities
(not specified)
0 (0) 0 (0) 3 (4) 1 (1) 1 (1) 3 (4)
Visualisation 0 (0) 1 (2) 0 (0) 0 (0) 1 (1) 0 (0)
Weight-bearing 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Writing 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (1)
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TABLE 52 Arm rehabilitation therapy log data for weeks 1–12, analysed by baseline ARAT score and time since stroke
Baseline
ARAT score
(n participants)
Time since
stroke at
baseline (n
participants)
Participants who, n/N (%) Number
of weeks
participants
stated that
they received
therapy for their
arm or hand,
median (IQR);
n participants
On how many
days per week
did participants
receive therapy
for their arm or
hand, median
(IQR); n weeks
How much time
(minutes) per
week has been
spent in therapy
for their arm or
hand, median
(IQR); n weeks
Participants
who stated
that they had
completed
self-practice
for their arm
or hand during
the 12-week
period, n/N (%)
Number
of weeks
participants
stated that they
completed self-
practice for their
arm or hand,
median (IQR);
n participants
Attended
the 3-month
assessment
Returned their arm
rehabilitation log
Stated that
they received
therapy for
their arm or
hand during
the 12-week
period
0–7 (n= 526) < 3 months
(n= 105)
89/105 (85) 66/89 (74) 51/66 (49) 10 (2–12);
66 participants
1 (0–4);
790 weeks
40 (0–135);
790 weeks
60/66 (91) 12 (10–12);
66 participants
3–12 months
(n= 232)
201/232 (99) 132/201 (66) 70/132 (53) 1 (0–9);
132 participants
0 (0–1);
1582 weeks
0 (0–35);
1573 weeks
123/132 (93) 12 (11–12);
132 participants
> 12 months
(n= 189)
172/189 (91) 120/172 (70) 37/120 (31) 0 (0–3);
120 participants
0 (0–0);
1432 weeks
0 (0–0);
1433 weeks
109/120 (91) 12 (9–12);
120 participants
8–19 (n= 98) < 3 months
(n= 23)
20/23 (87) 9/20 (45) 7/9 (78) 12 (1–12);
9 participants
1 (0–4);
108 weeks
80 (0–180);
108 weeks
8/9 (89) 12 (12–12);
9 participants
3–12 months
(n= 40)
34/40 (85) 18/34 (53) 6/18 (33) 0 (0–7);
18 participants
0 (0–0);
216 weeks
0 (0–0);
216 weeks
15/18 (83) 12 (12–12);
18 participants
> 12 months
(n= 35)
33/35 (94) 22/33 (66) 6/22 (27) 0 (0–3);
22 participants
0 (0–0);
261 weeks
0 (0–0);
261 weeks
19/22 (86) 12 (8–12);
22 participants
20–39 (n = 145) < 3 months
(n= 39)
32/39 (82) 20/32 (63) 14/20 (70) 7 (0–8);
20 participants
0 (0–2);
222 weeks
0 (0–71);
220 weeks
20/20 (100) 12 (11–12);
20 participants
3–12 months
(n= 70)
61/70 (87) 34/61 (56) 20/34 (59) 2 (0–8);
34 participants
0 (0–1);
404 weeks
0 (0–56);
406 weeks
33/34 (97) 12 (8–12);
34 participants
> 12 months
(n= 36)
34/36 (94) 24/34 (71) 5/24 (21) 0 (0–0);
24 participants
0 (0–0);
279 weeks
0 (0–0);
279 weeks
21/24 (88) 11 (4–12);
24 participants
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TABLE 53 Arm rehabilitation therapy log data for weeks 13–24, analysed by baseline ARAT score and time since stroke
Baseline
ARAT score (n
participants)
Time since
stroke at
baseline (n
participants)
Participants who, n/N (%)
Number of
weeks
participants
stated that
they received
therapy for their
arm or hand,
median (IQR);
n participants
On how many
days per week
did participants
receive therapy
for their arm or
hand, median
(IQR); n weeks
How much
time (minutes)
per week has
been spent in
therapy for
their arm or
hand, median
(IQR); n weeks
Participants
who stated
that they had
completed
self-practice
for their arm
or hand during
the 12-week
period, n/N (%)
Number of
weeks
participants
stated that they
completed self-
practice for
their arm or
hand, median
(IQR); n
participants
Attended
the 6-month
assessment
Returned
their arm
rehabilitation
log
Stated that
they received
therapy for
their arm or
hand during
the 12-week
period
0–7 (n= 526) < 3 months
(n = 105)
80/105 (76) 45/80 (56) 32/45 (71) 3 (0–7);
45 participants
0 (0–1);
539 weeks
0 (0–45);
539 weeks
41/45 (91) 12 (8–12);
45 participants
3–12 months
(n = 232)
190/232 (82) 103/190 (54) 45/103 (44) 0 (0–8);
103 participants
0 (0–1);
1233 weeks
0 (0–30);
1233 weeks
98/103 (95) 12 (11–12);
103 participants
> 12 months
(n = 189)
163/189 (86) 89/163 (55) 35/89 (39) 0 (0–9);
89 participants
0 (0–1);
1068 weeks
0 (0–25);
1068 weeks
79/89 (89) 12 (7–12);
89 participants
8–19 (n= 98) < 3 months
(n = 23)
21/23 (91) 10/21 (48) 3/10 (30) 0 (0–3);
10 participants
0 (0–0);
120 weeks
0 (0–0);
120 weeks
8/10 (80) 11 (7–12);
10 participants
3–12 months
(n = 40)
33/40 (83) 19/33 (58) 6/19 (32) 0 (0–3);
19 participants
0 (0–0);
228 weeks
0 (0–0);
227 weeks
18/19 (95) 12 (12–12);
19 participants
> 12 months
(n = 35)
30/35 (86) 14/30 (47) 4/14 (29) 0 (0–6);
14 participants
0 (0–0);
168 weeks
0 (0–0);
168 weeks
14/14 (100) 12 (8–12);
14 participants
20–39
(n = 145)
< 3 months
(n = 39)
30/39 (77) 17/30 (57) 9/17 (53) 1 (0–5);
17 participants
0 (0–0);
204 weeks
0 (0–0);
204 weeks
17/17 (100) 12 (12–12);
17 participants
3–12 months
(n = 70)
57/70 (81) 29/57 (51) 14/29 (48) 0 (0–4);
29 participants
0 (0–0);
345 weeks
0 (0–0);
346 weeks
28/29 (97) 12 (12–12);
29 participants
> 12 months
(n = 36)
31/36 (86) 19/31 (61) 5/19 (26) 0 (0–4);
19 participants
0 (0–0);
227 weeks
0 (0–0);
213 weeks
18/19 (95) 12 (9–12);
19 participants
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TABLE 54 The type of therapy participants stated they received and for how many weeks each type of therapy was undertaken over weeks 1–12
Type of therapy
Baseline ARAT score
0–7 (n= 157) 8–19 (n= 19) 20–39 (n= 38)
< 3 months
(N= 51)
3–12 months
(N= 70)
> 12 months
(N= 36)
< 3 months
(N= 7)
3–12 months
(N= 6)
> 12 months
(N= 6)
< 3 months
(N= 13)
3–12 months
(N= 20)
> 12 months
(N= 5)
Passive stretching
Participants who received this
type of therapy, n/N (%)
48/51 (94) 63/70 (90) 29/36 (81) 7/7 (100) 6/6 (100) 6/6 (100) 9/13 (69) 17/20 (85) 4/5 (80)
Weeks this type of therapy was
undertaken, median (IQR)
10 (4–12) 7 (2–10) 6 (1–10) 10 (4–10) 5 (1–10) 7 (4–10) 1 (0–7) 3 (1–9) 5 (2–8)
Improving range of motion
Participants who received this
type of therapy, n/N (%)
49/51 (96) 59/70 (84) 25/36 (69) 6/7 (86) 5/6 (83) 5/6 (83) 9/13 (69) 17/20 (85) 4/5 (80)
Weeks this type of therapy was
undertaken, median (IQR)
10 (5–12) 6 (2–10) 5 (0–9) 7 (1–12) 7 (1–10) 7 (3–10) 4 (0–8) 5 (2–8) 4 (1–7)
Functional strengthening
Participants who received this
type of therapy, n/N (%)
35/51 (69) 41/70 (59) 21/36 (58) 6/7 (86) 4/6 (67) 5/6 (83) 10/13 (77) 18/20 (90) 3/5 (60)
Weeks this type of therapy was
undertaken, median (IQR)
4 (0–9) 1 (0–7) 1 (0–6) 6 (1–12) 8 (0–11) 7 (1–10) 2 (1–6) 4 (1–7) 2 (0–5)
Weight-bearing through hand
Participants who received this
type of therapy, n/N (%)
34/51 (67) 40/70 (57) 17/36 (47) 3/7 (43) 1/6 (17) 5/6 (83) 6/13 (46) 13/20 (70) 4/5 (80)
Weeks this type of therapy was
undertaken, median (IQR)
3 (0–10) 1 (0–5) 0 (0–4) 0 (0–6) 0 (0–0) 6 (2–10) 0 (0–4) 2 (0–4) 3 (1–4)
Trunk control
Participants who received this
type of therapy, n/N (%)
30/51 (59) 31/70 (44) 15/36 (42) 3/7 (43) 1/6 (17) 4/6 (67) 5/13 (38) 7/20 (35) 3/5 (60)
Weeks this type of therapy was
undertaken, median (IQR)
1 (0–6) 0 (0–6) 0 (0–4) 0 (0–7) 0 (0–1) 2 (0–7) 0 (0–3) 0 (0–4) 2 (0–4)
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Type of therapy
Baseline ARAT score
0–7 (n= 157) 8–19 (n= 19) 20–39 (n= 38)
< 3 months
(N= 51)
3–12 months
(N= 70)
> 12 months
(N= 36)
< 3 months
(N= 7)
3–12 months
(N= 6)
> 12 months
(N= 6)
< 3 months
(N= 13)
3–12 months
(N= 20)
> 12 months
(N= 5)
Repetitive task-specific practice
Participants who received this
type of therapy, n/N (%)
36/51 (71) 37/70 (53) 22/36 (61) 6/7 (86) 2/6 (33) 4/6 (67) 10/13 (77) 13/20 (65) 3/5 (60)
Weeks this type of therapy was
undertaken, median (IQR)
5 (0–10) 1 (0–5) 2 (0–9) 11 (1–12) 0 (0–5) 6 (0–9) 2 (1–7) 2 (0–6) 2 (0–3)
Personal ADL
Participants who received this
type of therapy, n/N (%)
30/51 (59) 29/70 (41) 21/36 (58) 4/7 (57) 3/6 (50) 3/6 (50) 10/13 (77) 12/20 (60) 2/5 (40)
Weeks this type of therapy was
undertaken, median (IQR)
5 (0–12) 0 (0–3) 0 (0–2) 1 (0–12) 1 (0–1) 2 (0–7) 3 (1–6) 2 (0–3) 0 (0–5)
Extended ADL
Participants who received this
type of therapy, n/N (%)
24/51 (47) 16/70 (23) 6/36 (17) 2/7 (29) 2/6 (33) 3/6 (50) 6/13 (46) 8/20 (40) 2/5 (40)
Weeks this type of therapy was
undertaken, median (IQR)
0 (0–5) 0 (0–0) 0 (0–0) 0 (0–4) 0 (0–2) 1 (0–5) 0 (0–4) 0 (0–3) 0 (0–4)
Other
Participants who received this
type of therapy, n/N (%)
12/51 (24) 27/70 (39) 21/36 (58) 1/7 (14) 2/6 (33) 5/6 (83) 4/13 (31) 4/20 (20) 1/5 (20)
Weeks this type of therapy was
undertaken, median (IQR)
0 (0–0) 0 (0–2) 0 (0–6) 0 (0–0) 0 (0–5) 6 (1–10) 0 (0–3) 0 (0–0) 0 (0–1)
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TABLE 55 The type of therapy participants stated they received and for how many weeks each type of therapy was undertaken over weeks 13–24
Type of therapy
Baseline ARAT score
0–7 (n= 157) 8–19 (n= 19) 20–39 (n= 38)
< 3 months
(N= 51)
3–12 months
(N= 70)
> 12 months
(N= 36)
< 3 months
(N= 7)
3–12 months
(N= 6)
> 12 months
(N= 6)
< 3 months
(N= 13)
3–12 months
(N= 20)
> 12 months
(N= 5)
Passive stretching
Participants who received this type
of therapy, n/N (%)
28/31 (90) 36/43 (84) 29/33 (89) 3/3 (100) 5/6 (83) 3/4 (75) 8/9 (89) 12/14 (86) 3/4 (75)
Weeks this type of therapy was
undertaken, median (IQR)
3 (2–7) 7 (2–12) 6 (1–12) 4 2 (1–6) 9 (2–11) 4 (1–9) 2 (2–5) 3 (1–7)
Improving range of motion
Participants who received this type
of therapy, n/N (%)
28/31 (90) 36/43 (84) 22/33 (67) 2/3 (67) 4/6 (67) 3/4 (75) 7/9 (78) 13/14 (93) 3/4 (75)
Weeks this type of therapy was
undertaken, median (IQR)
4 (2–8) 5 (2–11) 3 (0–10) 2 3 (0–6) 5 (1–9) 4 (1–9) 3 (2–10) 5 (1–7)
Functional strengthening
Participants who received this type
of therapy, n/N (%)
23/31 (74) 25/43 (58) 19/33 (58) 2/3 (67) 3/6 (50) 4/4 (100) 6/9 (67) 9/14 (64) 3/4 (75)
Weeks this type of therapy was
undertaken, median (IQR)
3 (0–6) 2 (0–8) 1 (0–4) 2 1 (0–3) 6 (3–9) 3 (0–8) 2 (0–5) 6 (1–10)
Weight-bearing through hand
Participants who received this type
of therapy, n/N (%)
14/31 (45) 21/43 (43) 15/33 (45) 1/3 (33) 3/6 (50) 3/4 (75) 5/9 (56) 6/14 (43) 3/4 (75)
Weeks this type of therapy was
undertaken, median (IQR)
0 (0–3) 0 (0–4) 0 (0–4) 0 1 (0–2) 9 (5–11) 3 (0–7) 3 (0–3) 3 (1–9)
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Type of therapy
Baseline ARAT score
0–7 (n= 157) 8–19 (n= 19) 20–39 (n= 38)
< 3 months
(N= 51)
3–12 months
(N= 70)
> 12 months
(N= 36)
< 3 months
(N= 7)
3–12 months
(N= 6)
> 12 months
(N= 6)
< 3 months
(N= 13)
3–12 months
(N= 20)
> 12 months
(N= 5)
Trunk control
Participants who received this type
of therapy, n/N (%)
14/31 (45) 14/43 (33) 17/33 (52) 2/3 (67) 2/6 (33) 4/4 (100) 4/9 (44) 5/14 (36) 3/4 (75)
Weeks this type of therapy was
undertaken, median (IQR)
0 (0–2) 0 (0–3) 1 (0–7) 0 0 (0–1) 9 (5–11) 0 (0–4) 0 (0–1) 2 (0–3)
Repetitive task-specific practice
Participants who received this type
of therapy, n/N (%)
18/31 (58) 23/43 (53) 14/33 (42) 2/3 (67) 3/6 (50) 4/4 (100) 4/9 (44) 6/14 (43) 2/4 (50)
Weeks this type of therapy was
undertaken, median (IQR)
2 (0–6) 1 (0–5) 0 (0–3) 1 0 (0–5) 6 (3–8) 0 (0–5) 0 (0–6) 3 (0–9)
Personal ADL
Participants who received this type
of therapy, n/N (%)
15/31 (48) 15/43 (35) 10/33 (30) 1/3 (33) 3/6 (50) 2/4 (50) 4/9 (44) 6/14 (43) 2/4 (50)
Weeks this type of therapy was
undertaken, median (IQR)
0 (0–4) 0 (0–3) 0 (0–1) 0 1 (0–2) 3 (0–8) 0 (0–7) 0 (0–4) 0 (0–6)
Extended ADL
Participants who received this type
of therapy, n/N (%)
10/31 (32) 10/43 (23) 7/33 (21) 1/3 (33) 1/6 (17) 1/4 (25) 2/9 (22) 4/14 (29) 2/4 (50)
Weeks this type of therapy was
undertaken, median (IQR)
0 (0–2) 0 (0–0) 0 (0–0) 0 0 (0–1) 0 (0–6) 0 (0–3) 0 (0–1) 3 (0–5)
Other
Participants who received this type
of therapy, n/N (%)
7/31 (23) 19/43 (44) 18/33 (55) 1/3 (33) 2/6 (33) 3/4 (75) 1/9 (11) 4/14 (29) 2/4 (50)
Weeks this type of therapy was
undertaken, median (IQR)
0 (0–0) 0 (0–3) 1 (0–9) 0 0 (0–2) 4 (0–6) 0 (0–0) 0 (0–1) 1 (0–9)
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Appendix 7 Qualitative parallel process
evaluation supplementary data
TABLE 56 Summary of topics of patient interviews by randomisation group and time point since stroke
Start of therapy (baseline)
End of therapy (3 months post
randomisation)
Three months post therapy
(6 months post randomisation)
Robot-assisted
training and EULT
Phase 1 only:
l Stroke event and life
pre stroke
l Expectations and ideas
of ‘good’ recovery
l Experience of taking
part in the RATULS trial
l Experiences of the
RATULS trial therapy
l Expectations, likes/
dislikes, logistics,
barriers/facilitators,
impacts and benefits
l Rehabilitation
experience outside
the RATULS trial
(previous/current)
Phase 1 interviews:
l First interview recap
l Rehabilitation –
perceived progress
l Self-assessment of impacts –
(benefits/declines; attribution to
the RATULS trial treatment or
other factors)
l Own approach to
rehabilitation/therapy
l Perceived wider applicability of
the RATULS trial therapy (other
patients; NHS)
l Post-RATULS trial rehabilitation –
hopes and plans
Phase 2 only: recap since first
interview, including –
l Physical and functional
impacts reported
l Maintenance of impacts
including continuing
formal (therapist-led) and
non-formal rehabilitation
post RATULS
trial – hopes, plans, barriers
and facilitators
l Reflection on benefits/
difficulties of engaging
in RATULS trial therapy
l Perceived wider applicability
of RATULS therapy (other
patients; NHS)Phase 2 interviews: as for phase 1,
first interview with additional
questioning on –
l Robot-assisted training or
EULT – specific issues that
emerged in phase 1 interviews
l Study processes – completing
therapy log and other
assessments, communication with
trial team post randomisation
Usual care topic
guides
Phase 1 interviews:
l Stroke event and life pre stroke
l Expectations and ideas of ‘good’ recovery
l Experience of taking part in the RATULS trial (and allocation to usual care arm)
l Rehabilitation experience outside the RATULS trial (previous/current)
Phase 2 interviews: as above, with additional probing about study processes –
l completing therapy log and other assessments, and communication with trial team
post randomisation
Professionals –
RATULS
interventions
Phase 1 interviews:
l Involvement in the RATULS trial and initial thoughts on the therapies
l Experiences of providing the RATULS trial therapies (robot-assisted training and EULT)
l Expectations of how the therapies might benefit patients
l Current stroke rehabilitation provision locally and how the RATULS trial differs
l Perceptions of how the RATULS trial therapies may/may not be delivered as routine provision
l Perceived utility of the RATULS trial for advancing research and practice in stroke rehabilitation
l Key priority areas for improving stroke service provision
continued
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TABLE 56 Summary of topics of patient interviews by randomisation group and time point since stroke (continued )
Start of therapy (baseline)
End of therapy (3 months post
randomisation)
Three months post therapy
(6 months post randomisation)
Phase 2 interviews: as for phase 1, with more detailed probing on the conduct and delivery of
the trial –
l patient recruitment processes, challenges/solutions; organisation of therapy locally; assessment
completions; participant withdrawals
Repeated interviews: followed similar topic list, focusing on changes since previous interview and
omitting questions that are not required again
Professionals –
usual care
Both phase 1 and phase 2:
l Description of standard stroke rehabilitation provision locally
l What works well/does not work/could be improved (for patients)
l Views about the RATULS trial therapies (robot-assisted training and EULT) after
providing description
l Perceived utility of the RATULS trial for advancing research and practice in stroke rehabilitation
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Appendix 8 Health economic evaluation
supplementary data
Unit costs
TABLE 57 Staff costs associated with the delivery of the intervention in the robot-assisted training and EULT groups
Item Unit Cost (£) Reference Code/page Notes
Therapy assistant –
band 3 mid-point
1 hour 25.70 aCurtis and Burns
201782
Page 203 l Overheads Curtis and Burns82 2017
£22,615. Assumed 1604 annual working
hours. Added to hourly rate to account
for cost for using therapy room
l Payscale band 3 mid-point £18,608
l Calculation:
(£22,615 + £18,608)/1604 = £25.70
Senior therapist –
band 6 mid-point
15 minutes 11.25 aCurtis and Burns
201782
Page 203 l Hourly rate = £45.00
l Calculation: £45.00/60 × 15 = £11.25
Administrator –
band 3 mid-point
5 minutes 0.79 NHS Employers’
Agenda for
Change payscales
2018163
l Hourly rate = £9.52
l Calculation: £9.52/60 × 5 = £0.79
a Unit price inflated to 2018 prices using the Bank of England inflator.164
TABLE 58 Unit costs: primary care
Item Unit Cost (£) Source and comments Page
GP consultations
GP visit at surgery 9.22 minutes per
appointment
38.00 l aCurtis and Burns 201782
l Including direct care staff costs (with
qualification costs)
162
GP home visit 23.4 minutes per
appointment
96.44 l aCurtis and Burns 201782 for GP visit time,
unit cost and reimbursement of travel costs
l aCurtis and Burns 2015165 for average travel
time and reimbursement of travel costs
l Time for home visit assumed to be 23.4 minutes
(11.4 time spent in patient’s home + 12 minutes’
travel time). Travel costs are reimbursed at
56p per mile; assuming a 30mph speed limit;
6 miles will be travelled in 12 minutes, so an
average of £3.36 has been added to the GP
home visit cost
l 164 (201782)
l 176 (2015165)
GP home visit
travel time
6 miles per visit 3.36 l aCurtis and Burns 2015165
l Travel costs are reimbursed at 56p per mile;
assuming a 30mph speed limit; 6 miles will be
travelled in 12 minutes, totalling £3.36 per visit,
on average
176
GP telephone
consultation
4 minutes 14.80 l aCurtis and Burns 201782
l Average time of GP-led telephone triage per
intervention = 4 minutes
164
continued
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TABLE 58 Unit costs: primary care (continued )
Item Unit Cost (£) Source and comments Page
Nurse consultations
Nurse visit at
surgery
15.5 minutes 10.85 l aCurtis and Burns 201782 used for hourly rate
(with qualifications)
l aCurtis and Burns 2015165 used for average
direct patient contact
l 15.5 minutes spent, on average, on patient
consultation, at cost of £42.00 per hour
l Cost per minute: £42 / 60= £0.70
l Calculation: 0.70 × 15.5 = £10.85
l 160 (201782)
l 176 (2015165)
Nurse home visit 25 minutes 17.50 l aCurtis and Burns 201782 used for hourly rate
(with qualifications), at cost of £42.00 per hour.
Cost per minute: £42 / 60= £0.70
l aCurtis and Burns 2015166 used for average
direct patient contact and time for specialist
nurse home visit
l 25 minutes spent, on average, on patient visit
l Calculation: 0.70 × 25= £17.50
l 160 (201782)
l 189 (2013166)
Nurse home visit
travel time
6 miles 3.36 l aCurtis and Burns 2015165
l Assumed same travel costs as for GP visits.
Travel costs are reimbursed at 56p per mile;
assuming a 30mph speed limit, 6 miles will be
travelled in 12 minutes, totalling £3.36 per visit,
on average
176
Nurse telephone
consultation
6.56 minutes 7.90 l aCurtis and Burns 201782
l Cost per intervention (including other costs)
l Average time of nurse-led telephone triage per
intervention – average time = 6.56 minutes
164
Other
NHS Direct/
NHS 111
Per call 12.26 aUniversity of Sheffield. 2012167 174
a Unit price inflated to 2018 prices using the Bank of England inflator.164
TABLE 59 Unit costs: therapy and community-based services
Item Unit Cost (£) Reference Code/page Notes
Physiotherapy
Hospital
appointment
Per
appointment
55 National schedule
of reference costs –
year 2017–1883
Code 650 Total outpatient attendances
(physiotherapy). Total cost
column
Home
appointment
Per 1-hour
appointment
36 aCurtis and Burns
2014168
Page 179 No information for home
visits. Hourly cost (including
training) for community
physiotherapist
Appointment at
general practice
surgery
Per 1-hour
appointment
33 aCurtis and Burns
201782
Page 155 Based on a band 5 health-care
professional salary cost per
working hour
Appointment
elsewhere
Per 1-hour
appointment
33 aCurtis and Burns
201782
Page 155 Based on a band 5 scientific
and professional salary cost
per working hour
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TABLE 59 Unit costs: therapy and community-based services (continued )
Item Unit Cost (£) Reference Code/page Notes
Occupational therapy
Hospital
appointment
Per
appointment
73 National schedule
of reference costs –
year 2017–1883
Code 651 Total outpatient attendances
(physiotherapy). Total cost
column
Home
appointment
Per 1-hour
appointment
45 aCurtis and Burns
201782
Page 177 Based on the hourly cost
(including training) of
community occupational
therapist
Appointment at
general practice
surgery
Per 1-hour
appointment
33 aCurtis and Burns
201782
Page 155 Based on a band 5 scientific
and professional salary cost
per working hour
Appointment
elsewhere
Per 1-hour
appointment
33 aCurtis and Burns
201782
Page 155 Based on a band 5 scientific
and professional salary cost
per working hour
Speech and language therapy
Hospital
appointment
Per
appointment
104 National schedule
of reference costs –
year 2017–1883
Code 652 Total outpatient attendances
(speech and language
therapy). Total cost column
Home
appointment
Per 1-hour
appointment
36 aCurtis and Burns
2014168
Page 181 No information for home
visits. Hourly cost (including
training) for community
speech and language
therapist
Appointment at
general practice
surgery
Per 1-hour
appointment
33 aCurtis and Burns
201782
Page 155 Based on a band 5 scientific
and professional salary cost
per working hour
Appointment
elsewhere
Per 1-hour
appointment
33 aCurtis and Burns
201782
Page 155 Based on a band 5 scientific
and professional salary cost
per working hour
Community-based health-care professionals
Health visitor Per 1-hour
appointment
76 aCurtis and Burns
2015165
Page 171 Hourly cost (including
qualification) per hour
of patient-related work.
It includes travel cost/
transport costs, training
course conferences, etc.
Geriatrician Per 1-hour
appointment
87 aCurtis and Burns
201782
Pages 154 and 155 Assumed to be consultant
level at band 8c – hourly
rate
Psychiatrist Per
consultation
157 National schedule
of reference costs –
year 2017–1883
Code 722 Assumed to be non-
admitted face-to-face
attendance to liaison
psychiatry consultation
Psychologist Per 1-hour
appointment
138 aCurtis and Burns
2014168
Page 183 Hourly rate per hour of
client contact of a clinical
psychologist in the
community
Chiropodist Per 1-hour
appointment
32 aCurtis and Burns
2014168
Page 182 Hourly rate for a community
chiropodist/podiatrist
continued
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TABLE 59 Unit costs: therapy and community-based services (continued )
Item Unit Cost (£) Reference Code/page Notes
Optician Per 1-hour
appointment
33 aCurtis and Burns
201782
Page 154 and
155, and www.
nhsemployers.org/
your-workforce/pay-
and-reward/job-
evaluation/national-
job-profiles/allied-
health-professionals
(accessed 5 December
2018)
Assumed band 5 scientific and
professional (optometrist) –
hourly rate
Pharmacist Per 1-hour
appointment
71 aCurtis and Burns
2014168
Page 184 Hourly rate for direct patient
contact for a community
pharmacist
a Unit price inflated to 2018 prices using the Bank of England inflator.164
TABLE 60 Unit costs: secondary care
Item Unit Cost (£) Reference Code/page Notes
A&E visit Per visit 138 National schedule
of reference costs –
year 2017–1883
Code T01NA – T04NA Weighted average of all
A&E visits (non-stay)
Outpatient
appointment
Per visit 137 aCurtis and Burns
201782
Page 110 Weighted average of all
hospital outpatients
attendances
Hospital overnight
stay (A&E
admission)
Per night 450 National schedule
of reference costs –
year 2017–1883
Code AA35A – AA35F Average cost for all non-
elective stroke-related
hospital stay (up to 21 days)
Hospital overnight
stay (A&E
admission)
Per night 317 National schedule
of reference costs –
year 2017–1883
Code AA35A – AA35F
(non-elective: excess
bed-days)
Average cost for all non-
elective stroke-related
excess bed-days (> 21 days)
Hospital overnight
stay (Non-A&E
admission)
Per night 437 National schedule
of reference costs –
year 2017–1883
Code AA35A – AA35F
(elective inpatient)
Average cost for all elective
stroke-related hospital stay
(up to 21 days)
Hospital overnight
stay (Non-A&E
admission)
Per night 337 National schedule
of reference costs –
year 2017–1883
Code AA35A – AA35F
(elective: excess
bed-days)
Elective: excess bed-days
(EL_XS)
Day patient
treatment
Per half day 140 National schedule
of reference costs –
year 2017–1883
Code OPROC Weighted average of all
outpatient procedures
Day patient
treatment
Per full day 742 National schedule
of reference costs –
year 2017–1883
Code AA22C – YR67B Weighted average of all
day cases
a Unit price inflated to 2018 prices using the Bank of England inflator.164
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Response rates and health-care resource use
TABLE 61 Unit costs: residential and nursing home care
Item Unit Cost (£) Reference Code/page Notes
Residential care Per week 813 aCurtis and
Burns 201782
Page 35 Mean cost per week of local authority
own-provision residential care for
older people
Nursing home Per week 762 aCurtis and
Burns 201782
Page 33 Mean cost per week made out of
standard NHS nursing care contribution
to PSS expenditure
a Unit price inflated to 2018 prices using the Bank of England inflator.164
TABLE 62 Unit costs: social services
Item Unit Cost (£) Reference Code/page Notes
Meals on wheels Per meal 6.60 aCurtis and
Burns 2013166
Page 127 Information available only on the PSSRU
2012/13 average cost of £6.60 for the
local authority and £5.00 for the
independent sector
Home help: personal
care
Per hour 26 aCurtis and
Burns 201782
Page 37 Average standard hourly rate for services
provided in-house. Duration of home visit
assumed to be 30 minutes
Home help: shopping Per hour 26 aCurtis and
Burns 201782
Page 37 Average standard hourly rate for services
provided in-house. Duration of average
visit assumed to be 30 minutes
Home help:
household tasks
Per hour 26 aCurtis and
Burns 201782
Page 37 Average standard hourly rate for services
provided in-house. Duration of home visit
assumed to be 30 minutes.
PSSRU, Personal Social Services Research Unit.
a Unit price inflated to 2018 prices using the Bank of England inflator.164
TABLE 63 Response rates for economic data
Data response rates
Robot-assisted
training (N= 257) EULT (N= 259) Usual care (N= 254) Total participants (N= 770)
n % n % n % n %
Health service utilisation (fully or partially completed)
Baseline 248 96 254 98 240 94 742 96
6 months 214 83 219 85 178 70 611 79
EQ-5D-5L (fully completed)
Baseline 254 99 259 100 254 100 767 99
3 months 232 90 236 91 207 81 675 88
6 months 223 87 222 86 190 75 635 82
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TABLE 64 Resource use at baseline for participants reporting use of services via the health service utilisation questionnaire
Area of resource
utilisation
Robot-assisted training EULT Usual care
Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR)
GP surgery 104 2.34 (2.52) 2.00 (1.00–3.00) 129 1.51 (0.88) 1.00 (1.00–2.00) 107 1.79 (1.04) 2.00 (1.00–2.00)
GP home 35 1.31 (0.90) 1.00 (1.00–1.00) 27 1.78 (2.45) 1.00 (1.00–1.00) 34 1.44 (0.82) 1.00 (1.00–2.00)
GP telephone 38 1.74 (1.13) 1.00 (1.00–2.00) 41 1.46 (0.81) 1.00 (1.00–2.00) 35 1.34 (0.64) 1.00 (1.00–2.00)
Nurse surgery 42 1.36 (1.01) 1.00 (1.00–1.00) 49 1.45 (1.31) 1.00 (1.00–1.00) 48 1.46 (1.01) 1.00 (1.00–1.50)
Nurse home 34 2.56 (3.12) 1.00 (1.00–2.00) 32 3.00 (6.68) 1.00 (1.00–2.50) 37 11.03 (24.70) 2.00 (1.00–4.00)
Nurse telephone 11 1.91 (1.44) 1.00 (1.00–3.00) 4 1.75 (1.50) 1.00 (1.00–2.50) 6 1.33 (0.81) 1.00 (1.00–1.00)
NHS Direct 19 1.05 (0.23) 1.00 (1.00–1.00) 14 1.07 (0.27) 1.00 (1.00–1.00) 10 1.40 (0.97) 1.00 (1.00–1.00)
A&E visits 69 1.24 (0.82) 1.00 (1.00–1.00) 60 1.28 (1.21) 1.00 (1.00–1.00) 53 1.23 (0.54) 1.00 (1.00–1.00)
Outpatient
appointments
113 2.26 (2.40) 2.00 (1.00–3.00) 109 1.98 (1.75) 1.00 (1.00–2.00) 98 2.31 (2.43) 1.00 (1.00–2.00)
Hospital nights after
being admitted via A&E
66 26.5 (29.27) 15.5 (3.00–37.00) 62 23.87 (21.68) 20.5 (7.00–36.00) 55 39.36 (27.58) 41.00 (14.00–60.00)
Hospital nights, not
admitted via A&E
3 74.00 (16.37) 70.00 (60.00–92.00) 9 27.89 (37.22) 5.00 (2.00–61.00) 10 30.30 (30.90) 26.00 (3.00–45.00)
Day patient treatment
(half day)
4 1.25 (0.50) 1.00 (1.00–1.50) 6 1.50 (0.55) 1.50 (1.00–2.00) 8 1.75 (1.16) 2.50 (1.00–2.50)
Day patient treatment
(full day)
10 4.10 (9.80) 1.00 (1.00–1.00) 6 8.5 (11.66) 1.00 (1.00–22.00) 4 1.00 (0.00) 1.00 (1.00–1.00)
Residential care 2 36.00 (43.84) 36.00 (5.00–67.00) 2 90.5 (0.70) 90.5 (90.00–91.00) 3 71.66 (31.75) 90.00 (35.00–90.00)
Nursing home 3 60.33 (51.33) 90.00 (1.00–90.00) 4 26.75 (42.58) 8.00 (1.50–52.00) 4 45.50 (30.34) 90.50 (60.00–91.00)
a n = number of participants who answered ‘Yes’ to question.
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TABLE 65 Resource use at baseline for participants completing health service utilisation questionnaire
Area of resource utilisation
Robot-assisted training EULT Usual care
Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR) Users (n)a Mean (SD) Median (IQR)
GP surgery 244 0.99 (2.01) 0.00 (0.00–1.00) 251 0.78 (0.99) 1.00 (0.00–1.00) 238 0.81 (1.13) 0.00 (0.00–1.00)
GP home 247 0.19 (0.57) 0.00 (0.00–0.00) 250 0.19 (0.97) 0.00 (0.00–0.00) 236 0.21 (0.59) 0.00 (0.00–0.00)
GP telephone 244 0.27 (0.77) 0.00 (0.00–0.00) 251 0.24 (0.63) 0.00 (0.00–0.00) 239 0.20 (0.53) 0.00 (0.00–0.00)
Nurse surgery 243 0.23 (0.66) 0.00 (0.00–0.00) 249 0.28 (0.81) 0.00 (0.00–0.00) 240 0.29 (0.74) 0.00 (0.00–0.00)
Nurse home 246 0.35 (1.45) 0.00 (0.00–0.00) 249 0.38 (2.57) 0.00 (0.00–0.00) 237 1.72 (10.45) 0.00 (0.00–0.00)
Nurse telephone 246 0.85 (0.49) 0.00 (0.00–0.00) 251 0.03 (0.27) 0.00 (0.00–0.00) 239 0.03 (0.24) 0.00 (0.00–0.00)
NHS Direct 244 0.08 (0.29) 0.00 (0.00–0.00) 251 0.06 (0.25) 0.00 (0.00–0.00) 240 0.06 (0.34) 0.00 (0.00–0.00)
A&E visits 246 0.35 (0.70) 0.00 (0.00–1.00) 253 0.30 (0.80) 0.00 (0.00–0.00) 238 0.27 (0.57) 0.00 (0.00–0.00)
Outpatient appointments 248 1.02 (1.97) 0.00 (0.00–1.00) 253 0.85 (1.50) 0.00 (0.00–1.00) 240 0.94 (1.92) 0.00 (0.00–1.00)
Hospital nights after being admitted
via A&E
248 7.05 (19.05) 0.00 (0.00–1.00) 253 5.84 (14.82) 0.00 (0.00–0.00) 239 3.05 (21.17) 0.00 (0.00–0.00)
Hospital nights, not admitted
via A&E
248 0.99 (8.36) 0.00 (0.00–0.00) 2.53 0.99 (8.41) 0.00 (0.00–0.00) 239 1.45 (8.78) 0.00 (0.00–0.00)
Day patient treatment (half day) 238 0.02 (0.17) 0.00 (0.00–0.00) 247 0.04 (0.24) 0.00 (0.00–0.00) 236 0.06 (0.37) 0.00 (0.00–0.00)
Day patient treatment (full day) 244 0.17 (2.05) 0.00 (0.00–0.00) 247 0.21 (2.11) 0.00 (0.00–0.00) 232 0.017 (0.13) 0.00 (0.00–0.00)
Residential care 248 0.29 (4.26) 0.00 (0.00–0.00) 254 0.71 (8.01) 0.00 (0.00–0.00) 240 0.90 (8.49) 0.00 (0.00–0.00)
Nursing home 248 0.73 (8.06) 0.00 (0.00–0.00) 254 0.42 (5.71) 0.00 (0.00–0.00) 239 1.26 (10.28) 0.00 (0.00–0.00)
a n = number of participants who completed all or part of the questionnaire.
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Allocation of capital costs
The MIT-Manus robotic gym costs included purchased capital investment and maintenance fees.
Costs associated with the institution’s estate and facilities were included in the salary costs of the
staff delivering the therapy. No additional storage facilities were identified as the robotic gyms were
installed in the therapy room. The allocation of these capital costs was conducted following the
‘equivalent annual cost’57 methodology. This method allowed us to convert the initial capital cost into
an annual sum that equals the resources invested plus their opportunity cost.
The equivalent annual cost of each robot session was calculated under the following assumptions:
l Robot usage: 35 average number of sessions per week (seven sessions held on an 8-hour day).
l Weeks per year that the MIT-Manus robotic gym system is in use: 52 weeks.
l Useful lifespan of the MIT-Manus robotic gym system is 5 years.
l Training costs are not included as they are not considered to drive any differences in costs between
randomisation groups.
l The capital cost of the robotic gym was spread over its lifespan (5 years).
l A discount factor of 3.5% was applied to account for the individual’s time preference for costs to be
incurred later rather than sooner. This follows guidance for best practice.
The following table illustrates this method, incorporating the initial purchasing cost of £1,000,000, and
£15,000 annual fees.
Equivalent annual cost or equivalent annuity
Year Discount factor at 3.5%a Equivalent annual cost of £263,084b (£)
1 0.9662 272,292
2 0.9335 138,487
3 0.9019 93,904
4 0.8714 71,625
5 0.8420 58,268
a Discount factor (Dn)= 1(1 + r)n, where r = discounting rate (e.g. 3.5%).
b Equivalent annual cost (An) = r/(1 –Dn).
Cost of robot per session Cost (£)
Capital
Opportunity cost of the capital (£58,268 × 5) 291,340
Annual cost of robotic gym 58,268
Annual cost of robotic gym per week (assume 52 weeks) 1121
Cost of robot per session – assuming an average of seven sessions per day 32
Maintenance
Annual maintenance costs 16,234
Maintenance costs per week (52 weeks) 312
Maintenance costs per session (35 sessions in 1 week) 8.92
Total robotic gym cost per session (capital+maintenance) 41.00
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Time and travel analysis
Methods
Participants were asked to complete a time and travel questionnaire relating to their most recent
health-care appointments over the previous 6 months. The questionnaire was divided into four distinct
sections covering hospital admissions, outpatient appointments, GP visits and personal help or care.
Information on work status and income was also collected to quantify the monetary cost of time spent
at health-care appointments.
The questionnaire captured data on the type of health-care appointment, mode and cost of transport,
mileage and length of journey. In addition, participants reported whether or not they had been
accompanied by a relative or carer, the time they had spent at the appointment and the type of activity
themselves or their relative/carer would have been doing instead.
Response rates
Table 66 summarises the responses rates for the different sections of the time and travel questionnaire
by randomised group.
Responses to each of the sections were low across all randomisation groups. Information relating to
hospital admission was poorly completed, with only 14% of participants, overall, providing any information.
This percentage was higher when participants were asked about their outpatient appointments, GP visits
and the personal help received, with responses rates increasing to 51%, 54% and 47%, respectively.
The number of participants completing all sections of the questionnaire was much lower (Table 67).
Only 6% of all participants taking part in the study completed all sections of the questionnaire, with
those allocated to robot-assisted training having the lowest response rate (5%). However, not all
sections were required to be completed by participants.
TABLE 66 Completion of time and travel questionnaire per section
Area of
resource
utilisation
Robot-assisted
training (N= 257) EULT (N= 259) Usual care (N= 254) Total (N= 770)
Answered (n)
% of
total n Answered (n)
% of
total n Answered (n)
% of
total n Answered (n)
% of
total n
Hospital
admission
35 14 37 14 33 13 105 14
Outpatient
appointments
145 57 134 52 114 45 393 51
GP visits 146 57 150 58 122 48 418 54
Personal help 120 47 134 52 108 42 362 47
TABLE 67 Full completion of time and travel questionnaire
Robot-assisted
training (N= 257) EULT (N= 259) Usual care (N= 254) Total (N= 770)
Answered (n) % of total n Answered (n) % of total n Answered (n) % of total n Answered (n) % of total n
13 5 18 7 16 6 47 6
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Owing to these low responses, a full economic analysis of the costs incurred by participants and carers
was deemed to be inappropriate. However, a further descriptive analysis to identify any potential
variation in health-care visits that might influence differences in time and travel costs between groups
was conducted, and is summarised in Tables 68 and 69.
Results
To ascertain whether time and travel costs may have been incurred by participants, a descriptive
analysis of health-care visits as reported in the health service utilisation questionnaire was conducted.
The focus was on those health-care visits that required participants to travel to hospital or the general
practice surgery, as detailed in Table 68.
Robot-assisted training participants reported the highest number of outpatient appointments and GP
visits. Participants in the EULT group reported the highest number of full-day patient visits and A&E
visits/admissions. Responses from the usual care group indicated that they were the heaviest users of
therapy services and nurse consultations at the general practice services.
The information outlined in Table 68 was further aggregated into secondary care (excluding A&E),
secondary care (including A&E) and primary care appointments. It was assumed that all secondary care
admissions (excluding A&E) incurred similar costs to participants and carers, as would all health-care
visits taking place at the general practice services. A&E visits and admissions may be less reliant on
public transport and involve higher use of ambulance, private vehicles or taxi travel.
A one-way analysis-of-variance test was conducted to determine whether or not differences in the numbers
of visits/appointments between randomisation groups were statistically significant. The p-values reported
in Table 69 show that no statistically significant differences between randomisation groups were detected
for any of the analysed categories (secondary care excluding A&E, A&E visits and admissions, and primary
care appointments at general practice surgery). It is expected that a complete time and travel analysis
would not change the cost-effectiveness results, with usual care still expected to yield the lowest travel cost
due to the low number of secondary care visits and A&E admissions.
TABLE 68 Number of health-care visits/appointments
Number of visits/appointments
Robot-assisted
training EULT Usual care
Total (n) Mean (SD) Total (n) Mean (SD) Total (n) Mean (SD)
A&E visits 71 0.33 (0.76) 80 0.37 (0.98) 42 0.24 (0.71)
Outpatient appointments 348 1.36 (2.93) 306 1.19 (2.69) 261 1.05 (1.05)
Hospital admission via A&E 24 1.26 (0.56) 29 1.07 (0.27) 18 1.20 (0.56)
Hospital admission not via A&E 8 1.00 (0.00) 5 1.00 (0.00) 10 1.66 (1.21)
Day patient treatment (half day) 17 0.08 (0.35) 20 0.09 (0.09) 10 0.06 (0.32)
Day patient treatment (full day) 6 0.03 (0.17) 5 0.02 (0.18) 1 0.01 (0.08)
GP at surgery 370 1.80 (3.87) 311 1.50 (2.08) 308 1.83 (2.17)
Nurse at general practice surgery 123 0.61 (1.39) 104 0.49 (1.19) 152 0.89 (5.58)
Therapy visits at general practice surgery 29 0.13 (1.16) 93 0.43 (2.40) 94 0.53 (3.86)
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Other NHS and social services reported
TABLE 69 Health-care visits (secondary and primary care)
Number of visits/
appointments
Robot-assisted
training EULT Usual care
One-way ANOVA
analysis (p-value)Total Mean (SD) Total Mean (SD) Total Mean (SD)
Secondary care (excluding
A&E visits and admissions)a
379 1.48 (3.00) 336 1.31 (2.81) 282 1.14 (3.68) 0.478
Primary care appointments at
general practice surgeryb
522 2.45 (4.60) 508 2.36 (3.91) 554 3.15 (7.30) 0.296
Hospital visits and admission
via A&E
95 0.44 (1.02) 109 0.50 (1.14) 60 0.33 (0.94) 0.279
ANOVA, analysis of variance.
a Includes outpatient appointments, day patient appointments (half day and full day) and non-A&E hospital admissions.
b Includes GP, nurse, physiotherapy, occupational therapy and speech and language therapy visits taking place at the
general practice surgery.
TABLE 70 Resource use and unit costs for robot-assisted training group (other NHS and social services reported)
Item Users (n) Unit Cost (£) Reference Code/page Notes
Robot-assisted training (n = 13)
Brain operation:
surgery to correct
malformation
1 Per
hospital
stay
576 National schedule
of reference costs –
year 2017–1883
Codes AA24C
to AA24H
Weighted average of all
brain tumours or cerebral
cysts (short stay)
Dietitian 1 Per visit 86 National schedule
of reference costs –
year 2017–1883
Code A03 Community Health
Services
Ear, nose and
throat
1 Per visit 105 National schedule
of reference costs –
year 2017–1883
Code 120 Outpatient attendance –
consultant-led unit cost
Early Supported
Discharge Team
1 Per visit 91 National schedule
of reference costs –
year 2017–1883
Code SCRT Unit price for Stroke
Community Rehabilitation
Teams
Emergency
outpatient dental
treatment
1 Per visit 97 National schedule
of reference costs –
year 2017–1883
Code M01C Emergency dental service,
attendance
Social worker 2 Per hour 82 aCurtis and Burns
201782*
Page 174 Hourly cost relating to
patient-related work of a
social worker
Spasticity clinic 1 Per visit 91 National schedule
of reference costs –
year 2017–1883
Code SCRT Unit price for Stroke
Community Rehabilitation
Teams
Splint fitted 1 Per
procedure
140 National schedule
of reference costs –
year 2017–1883
Code OPROC Weighted average for
outpatients procedures
Upper limb
rehabilitation
1 Per visit 91 National schedule
of reference costs –
year 2017–1883
Code SCRT Unit price for Stroke
Community Rehabilitation
Teams
continued
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TABLE 70 Resource use and unit costs for robot-assisted training group (other NHS and social services reported)
(continued )
Item Users (n) Unit Cost (£) Reference Code/page Notes
Stroke specialist 1 Per visit 226 National schedule
of reference costs –
year 2017–1883
Code
WF01A/328
Outpatient attendance –
consultant-led unit cost
STARRS 1 Per visit 91 National schedule
of reference costs –
year 2017–1883
Code SCRT Unit price for Stroke
Community Rehabilitation
Teams
STARRS, Short-Term Assessment, Rehabilitation and Reablement Service.
a Unit price inflated to 2018 prices using the Bank of England inflator.
TABLE 71 Resource use and unit costs for the EULT group (other NHS and social services reported)
Item Users (n) Unit Cost (£) Reference Code/page Notes
EULT (n = 11)
Acupuncture 1 Per FCE 246 National schedule
of reference costs –
year 2017–1883
Code AB23Z Unit price for acupuncture
for pain management
Adult care service 1 Per hour 82 aCurtis and Burns
201782
Page 174 Hourly cost relating to
patient-related work of a
social worker
Anticoagulant clinic 2 Per visit 49 National schedule
of reference costs –
year 2017–1883
Code
WF01A/324
Average unit cost for
anticoagulant service
Arthritis special
nurse
1 Per visit 28 National schedule
of reference costs –
year 2017–1883
Code N07AF Unit cost for one-to-one
specialist nurse (arthritis)
taken from Community
Health Services section
Care provided
morning and night
1 Per
30-minute
visit
13 www.nhsemployers.org/
pay-pensions-and-
reward/agenda-for-
change/pay-scales-
1819/hourly-1819
N/A Home help personal
2 × 30 minutes. Each
visit assumed to last
30 minutes
Dentist 1 Per hour 127 aCurtis and
Burns 201782
Page 165 Unit price per hour of
patient contact (NHS
dentist – performer –
only)
Gynaecologist 1 Per visit 144 National schedule
of reference costs –
year 2017–1883
Code 502 Outpatient attendance –
consultant-led unit cost
Keyworker from
CPN
1 Per hour 44 aCurtis and
Burns 201782
Page 185 Community psychiatric
nurse. Unit price for NHS
Community Mental
Health Teams
Orthotics 2 Per visit 86 National schedule
of reference costs –
year 2017–1883
Code 658 Outpatient attendance –
consultant-led unit cost
Podiatrist 1 Per visit 62 National schedule
of reference costs –
year 2017–1883
Code 653 Outpatient attendance –
consultant-led unit cost
Sleep therapy 1 Per FCE 625 National schedule of
reference costs –
year 2017–1883
Code AA43A-
B/DZ18D-G
Weighted average
short-stay sleep therapies
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TABLE 71 Resource use and unit costs for the EULT group (other NHS and social services reported) (continued )
Item Users (n) Unit Cost (£) Reference Code/page Notes
Warfarin clinic at
Renfrew Health
Centre
1 Per visit 91 National schedule
of reference costs –
year 2017–1883
Code SCRT Unit price for Stroke
Community Rehabilitation
Teams
Wigton Community
Hospital –
physiotherapy
and to help
with walking
1 Per visit 55 National schedule
of reference costs –
year 2017–1883
Code 650 Unit cost physiotherapy –
hospital outpatient
attendance data
Counsellor 1 Per hour 82 aCurtis and
Burns 201782
Page 174 Hourly cost relating to
patient-related work of a
social worker
CPN, community psychiatric nurse; N/A, not applicable.
a Unit price inflated to 2018 prices using the Bank of England inflator.
TABLE 72 Resource use and unit costs for the usual care group (other NHS and social services reported)
Item Users (n) Unit Cost (£) Reference Code/page Notes
Usual care (n = 11)
Audiology 1 Per visit 94 National schedule
of reference costs –
year 2017–1883
Code 84 Outpatient attendance –
consultant-led unit cost
Dentist 1 Per hour 127 aCurtis and
Burns 201782
Page 165 Unit price per hour of
patient contact (NHS
dentist – performer – only)
Diabetic podiatrist 1 Per visit 62 National schedule
of reference costs –
year 2017–1883
Code 653 Outpatient attendance –
consultant-led unit cost
Hearing
assessment
2 Per FCE 128 National schedule
of reference costs –
year 2017–1883
Code CA37B Audiometry or hearing
assessment (≥ 19 years)
Orthotics 1 Per visit 86 National schedule
of reference costs –
year 2017–1883
Code 658 Outpatient attendance –
consultant-led unit cost
Neurologist 1 Per visit 171 National schedule
of reference costs –
year 2017–1883
Code 400 Outpatient attendance –
consultant-led unit cost
Talking changes 1 Per visit 44 aCurtis and
Burns 201782
Page 185 Unit price for NHS
Community Mental
Health Teams
Social services 2 Per hour 82 aCurtis and
Burns 201782
Page 174 Hourly cost relating to
patient-related work of a
social worker
Eye hospital 1 Per visit 125 National schedule
of reference costs –
year 2017–1883
Code 662 Outpatient attendance –
consultant-led unit cost
a Unit price inflated to 2018 prices using the Bank of England inflator.
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TABLE 73 Total health-care costs per participant at baseline
Resource use
Robot-assisted training EULT Usual care
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR) n Mean (SD) Median (IQR)
Primary care costs 247 74 (10) 39 (0–103) 252 66 (12) 39 (0–79) 240 96 (246) 39 (0–101)
Social care 248 117 (1039) 0 (0–0) 254 133 (1153) 0 (0–0) 240 249 (1530) 0 (0–0)
Secondary care 248 3369 (7659) 142 (0–1032) 254 2986 (6537) 142 (0–1270) 240 4130 (8183) 142 (0–1610)
Total average cost 248 3559 (7667) 295 (78–1261) 254 3184 (6429) 239 (50–1524) 240 4475 (8370) 267 (50–3456)
Health-care costs per participant at baseline
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Deterministic sensitivity analysis
A deterministic sensitivity analysis was carried out to explore any uncertainty surrounding the level
of resource use and its impact on the cost-effectiveness of the interventions. The following areas of
uncertainty were explored:
l missing resource total cost assumed to be zero
l multiple imputation of total missing costs
l increased useful life of robot (7 years)
l exclusion of physiotherapy visits.
A stochastic sensitivity analysis was carried out in each scenario to address potential variance in the
outcome measures resulting from the deterministic analysis. Bootstrapping techniques were employed
to minimise any uncertainty surrounding the incremental cost-effectiveness ratio.
The results of the stochastic sensitivity analysis are presented through CEACs with various threshold
values of the WTP for a QALY. The base-case unadjusted results are presented alongside in each of the
costs summary tables for ease of comparison.
Extreme sensitivity analysis
The base-case analysis left all missing total cost information as missing. This section explores the effect
on the CEA results of changing this missing information to zero.
Because all instances of missing information occurred in the usual care group, the mean cost for this
group decreased (Table 74). As the mean QALYs remain the same, this has affected the resulting ICER
between EULT and usual care in the adjusted analysis, increasing it to £172,000 (see Table 75).
The mean costs for the robot-assisted training group appear to be higher than those reported in the
usual care group, and robot-assisted training remains dominated by EULT.
After bootstrapping the results, usual care had almost a 100% probability of being cost-effective at all
WTP values considered (Table 75 and Figure 17).
Multiple imputation of missing total costs
Multiple imputation was used to deal with the missing data relating to total costs. Once the missing
information analysis on costs established that information was missing at random, truncated normal
regression was applied using age, sex and baseline ARAT score as covariates to generate 10 different
total mean costs for each participant. After exploring the total cost distribution for each randomised
group, the upper limit was set at £25,000. The average value of the 10 iterations was taken and
imputed in place of the missing value.
TABLE 74 Total cost per participant at 6 months with missing costs changed to zero
Robot-assisted training (n= 257) EULT (n= 259) Usual care (n= 254)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Total cost per participant (£) at 6 months (missing costs changed to zero)
5387 (4054) 3778 (2962–5854) 4451 (6032) 2545 (1596–4442) 2652 (4868) 617 (0–2682)
Total cost per participant (£) at 6 months (base-case results)
5387 (4054) 3778 (2962–5854) 4451 (6033) 2245 (1596–4442) 3785 (5437) 1302 (503–4598)
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TABLE 75 Cost-effectiveness results: extreme sensitivity analysis (n= 741)
Randomisation
group
Unadjusted analysis,
cost (£) (98.33% CI)
Adjusted analysis,
incremental cost (£)
(98.33% CI)a
Unadjusted
analysis, QALYs
(98.33% CI)
Adjusted analysis,
incremental QALYs
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 240) 2653 (1916 to 3389) – 0.21 (0.19 to 0.23) – 1.00 1.00 1.00 1.00 0.99
EULT (n= 254) 4451 (3548 to 5354) 1892 (823 to 2961) 0.23 (0.21 to 0.24) 0.011 (–0.002 to 0.024) 172,000 0.00 0.00 0.00 0.00 0.01
Robot-assisted
training (n= 247)
5387 (4777 to 5996) – 0.21 (0.19 to 0.23) Dominated by EULT 0.00 0.00 0.00 0.00 0.00
a Estimated based on adjusted analysis (n = sureg n).
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The results in Table 76 show that the mean costs of usual care increased, compared with the base case,
although usual care remains the least costly option. This increase in mean costs is to be expected, as all
the missing total costs related to participants in the usual care group. Consequently, the resulting ICER
from the comparison between EULT and usual care decreased to £50,000 (Table 77). The probability
of EULT being cost-effective at £50,000 is 51%.
Robot-assisted training remains dominated by EULT as it is, on average, more costly and less effective
than usual care.
Useful life of robot
The effects on costs, QALYs and cost-effectiveness were explored in the event that the useful life of
the robotic gym could be extended from 5 to 7 years. Extending the life of the robotic gym resulted
in a reduction of the mean capital costs per patient and, hence, a lower mean total cost for the
robot-assisted training group (Table 78) than in the base-case analysis.
An increase in the useful life of the robotic gym did not move the robot-assisted training away from its
dominated status in the cost-effectiveness analysis. There was no evidence of a difference in mean
total costs between randomisation groups because all CIs overlap.
As no changes have been made to the mean costs of usual care and EULT, the resulting adjusted ICER
is the same as that in the base-case analysis (£74,100). The probability of robot-assisted training being
cost-effective (Table 79 and Figure 19) is similar to that of the base-case analysis (see Table 25).
Exclusion of physiotherapy sessions
To account for the risk of potential double-counting, the sensitivity analysis explored how excluding
the physiotherapy sessions recorded in the health service utilisation questionnaire would affect the
results. All physiotherapy visits were excluded for those participants allocated to the robot-assisted
training and EULT groups.
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FIGURE 17 Cost-effectiveness acceptability curve (extreme sensitivity analysis).
TABLE 76 Total cost per participant at 6 months, after multiple imputation
Robot-assisted training (n= 257) EULT (n= 259) Usual care (n= 254)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Total cost per participant (£) at 6 months (multiple imputation)
5387 (4054) 3778 (2962–5854) 4451 (6032) 2545 (1596–4442) 4019 (4624) 2807 (795–2808)
Total cost per participant (£) at 6 months (base-case results)
5387 (4054) 3778 (2962–5854) 4451 (6033) 2245 (1596–4442) 3785 (5437) 1302 (503–4598)
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TABLE 77 Cost-effectiveness results: multiple imputation of missing total costs (n = 741)
Randomisation
group
Unadjusted analysis,
cost (£) (98.33% CI)
Adjusted analysis,
incremental cost (£)
(98.33% CI)a
Unadjusted
analysis, QALYs
(98.33% CI)
Adjusted analysis,
incremental QALYs
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 240) 4019 (3320 to 4718) – 0.21 (0.19 to 0.23) – 0.87 0.81 0.73 0.63 0.49
EULT (n= 254) 4451 (3548 to 5354) 550 (–503 to 1604) 0.23 (0.21 to 0.24) 0.011 (–0.002 to 0.024) 50,000 0.13 0.19 0.27 0.37 0.51
Robot-assisted
training (n= 247)
5387 (4777 to 5996) – 0.21 (0.19 to 0.23) Dominated by EULT 0.00 0.00 0.00 0.00 0.00
a Estimated based on adjusted analysis (n = sureg n).
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The exclusion of physiotherapy sessions resulted in lower mean costs for both the robot-assisted
training and EULT groups (Table 80). Despite this reduction, robot-assisted training remains dominated
by EULT, with usual care still remaining the least costly option. Nonetheless, there was no evidence of
a difference in costs between randomisation groups.
The reduction in the mean total costs for the EULT group led to a decrease in the resulting ICER,
to £48,600 (Table 81). The results plotted on the CEAC (Figure 20) show that, although usual care
remains cost-effective at all WTP levels, EULT has a 51% probability of being cost-effective at the
£50,000 WTP value.
Subgroup analysis
Time since stroke: subgroup analysis
The mean total costs for each group are outlined in Table 82. The participants who were randomised
3–12 months post stroke have higher associated mean costs. Mean QALYs at 6 months (Table 83) are
the same across all groups.
Time since stroke (< 3 months post stroke)
This subgroup analysis includes all the participants who were randomised to the trial < 3 months post
stroke. The mean costs and QALYs were analysed for this subgroup and are summarised in Tables 84
and 85. Total mean costs were highest for participants in the robot-assisted training group, and mean
QALYs were highest in the EULT group. Usual care remained the lowest-cost therapy, with the lowest
mean QALYs per participant.
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FIGURE 18 Cost-effectiveness acceptability curve: multiple imputation of missing total costs.
TABLE 78 Total cost per patient at 6 months: useful life of robot extended to 7 years
Robot-assisted training (n= 257) EULT (n= 259) Usual care (n= 178)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Total cost per participant (£) at 6 months (extended life of robot)
5085 (4054) 3476 (2660–5552) 4451 (6032) 2245 (1595–4442) 3785 (5437) 1302 (503–4598)
Total cost per participant (£) at 6 months (base-case results)
5387 (4054) 3778 (2962–5854) 4451 (6033) 2245 (1596–4442) 3785 (5437) 1302 (503–4598)
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TABLE 79 Cost-effectiveness results: useful life of robot extended to 7 years (n= 672)
Randomisation
group
Unadjusted analysis,
cost (£) (98.33% CI)
Adjusted analysis,
incremental cost (£)
(98.33% CI)a
Unadjusted analysis,
QALYs (98.33% CI)
Adjusted analysis,
incremental QALY
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 171) 3785 (2801 to 4770) – 0.21 (0.19 to 0.23) – 0.90 0.85 0.80 0.73 0.62
EULT (n= 254) 4451 (3548 to 5354) 741 (–460 to 1943) 0.23 (0.21 to 0.24) 0.010 (–0.005 to 0.025) 74,100 0.10 0.15 0.19 0.26 0.37
Robot-assisted
training (n= 247)
5084 (4476 to 5694) – 0.21 (0.19 to 0.23) Dominated by EULT 0 0.00 0.01 0.01 0.01
a Estimated based on adjusted analysis (n = sureg n).
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Robot-assisted training remained dominated by EULT. However, the adjusted ICER between usual care
and EULT was much lower than the one reported in the base-case analysis (£31,400 vs. £74,100). EULT
is increasingly likely to become cost-effective as WTP values increase (at least over the range shown),
with EULT having a 50% chance of being cost-effective at the £30,000 threshold value (Table 86 and
Figure 21). Robot-assisted training had virtually zero probability of being considered cost-effective over
the range of WTP values shown.
Time since stroke (3–12 months post stroke)
The effect on cost-effectiveness of being 3–12 months post stroke at randomisation was included in
this analysis. Overall, mean costs remained highest for the robot-assisted training group (Table 87),
whereas the highest mean QALY per participant was associated with EULT (Table 88). The delivery of
robot-assisted training sessions was associated with higher costs and lower QALYs; hence, it was
dominated by the usual care and EULT groups. The adjusted cost-effectiveness comparison between
usual care and EULT yielded an ICER of £79,400, with usual care being cost-effective at all WTP values
presented (Table 89 and Figure 22).
Time since stroke (> 12 months post stroke)
Participants who were > 12 months post stroke at randomisation were included in this analysis.
As in the previous subgroup analyses, the robot-assisted training group had the highest mean costs
(Table 90). Mean QALYs were, on average, lowest in participants in the usual care group (Table 91).
The cost-effectiveness comparison remained between the usual care and EULT groups because
robot-assisted training is dominated by EULT. The resulting ICER of £126,143 was higher than ICERs
from the previous subgroup and base-case analyses, with usual care being cost-effective at all WTP
thresholds (Table 92 and Figure 23).
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FIGURE 19 Cost-effectiveness results: useful life of robot extended to 7 years (n = 672).
TABLE 80 Total cost per participant at 6 months: physiotherapy sessions excluded
Robot-assisted training (n= 257) EULT (n= 259) Usual care (n= 178)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Total cost per participant (£) at 6 months – (physiotherapy sessions excluded)
5191 (3971) 3497 (2943–5537) 4202 (5942) 2159 (1521–3972) 3785.47 (5437) 1302 (503–4598)
Total cost per participant (£) at 6 months (base-case results)
5387 (4054) 3778 (2962–5854) 4451 (6033) 2245 (1596–4442) 3785 (5437) 1302 (503–4598)
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TABLE 81 Cost-effectiveness results: physiotherapy sessions excluded (n = 672)
Randomisation
group
Unadjusted analysis,
cost (£) (98.33% CI)
Adjusted analysis,
incremental cost (£)
(98.33% CI)a
Unadjusted analysis,
QALYs (98.33% CI)
Adjusted analysis,
incremental QALY
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 171) 3785 (2801 to 4770) – 0.21 (0.19 to 0.23) – 0.80 0.75 0.66 0.61 0.49
EULT (n= 254) 4201 (3312 to 5091) 486 (–702 to 1674) 0.23 (0.21 to 0.24) 0.010 (–0.005 to 0.025) 48,600 0.20 0.25 0.34 0.39 0.51
Robot-assisted
training (n= 247)
5191 (4595 to 5788) – 0.21 (0.19 to 0.23) Dominated by EULT 0.00 0.00 0.00 0.00 0.00
a Estimated based on adjusted analysis (n = sureg n).
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FIGURE 20 Cost-effectiveness acceptability curve: physiotherapy sessions excluded.
TABLE 82 Total cost (£) per participant across all time since stroke groups
< 3 months (n= 140) 3–12 months (n= 294) > 12months (n= 260)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
4382 (4429) 2873 (1880–5458) 5301 (6114) 3151 (1783–6638) 3995 (4475) 2887 (1506–4489)
TABLE 83 Total QALYs per participant across all time since stroke groups
< 3 months (n= 161) 3–12 months (n= 294) > 12months (n= 260)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
0.22 (0.11) 0.23 (0.16–0.30) 0.22 (0.11) 0.23 (0.14–0.30) 0.22 (0.12) 0.23 (0.15–0.31)
TABLE 84 Total cost (£) per participant (< 3 months post stroke)
Robot-assisted training (n= 57) EULT (n= 46) Usual care (n= 37)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
5485 (4734) 3865 (2979–5989) 3863 (3645) 2604 (1835–4460) 3328 (4568) 1159 (552–2873)
TABLE 85 Total QALYs per participant (< 3 months post stroke)
Robot-assisted training (n= 57) EULT (n= 46) Usual care (n= 37)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
0.22 (0.10) 0.22 (0.16–0.30) 0.24 (0.11) 0.24 (0.19–0.31) 0.21 (0.11) 0.23 (0.17–0.27)
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TABLE 86 Cost-effectiveness results: time since stroke (< 3 months post stroke) (n = 133)
Randomisation
group
Unadjusted analysis,
cost (£) (98.33% CI)
Adjusted analysis,
incremental cost (£)
(98.33% CI)a
Unadjusted
analysis, QALYs
(98.33% CI)
Adjusted analysis,
incremental QALY
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 35) 3328 (1443 to 5213) – 0.21 (0.17 to 0.25) – 0.77 0.69 0.59 0.50 0.39
EULT (n= 45) 3863 (2527 to 5199) 628 (–1650 to 2905) 0.24 (0.20 to 0.28) 0.020 (–0.01 to 0.06) 31,400 0.22 0.31 0.41 0.50 0.61
Robot-assisted
training (n= 53)
5485 (3938 to 7032) – 0.22 (0.19 to 0.25) Dominated by EULT 0.00 0.00 0.00 0.00 0.00
a Estimated based on adjusted analysis (n = sureg n).
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Per-protocol analysis
A total of 58 participants were identified as not having received at least 20 sessions of therapy and
were therefore removed from the data set, reducing the sample size to 712. Thirty participants had
been allocated to the EULT group and 28 to the robot-assisted training group.
Results from the cost-effectiveness analysis for the per-protocol analysis (Table 93) show how the
unadjusted mean costs for both the robot-assisted training and EULT groups increased slightly
compared with the base-case analysis (see Table 25). The unadjusted mean QALYs for the robot-
assisted training group also increased, and they were higher than those reported for the usual care
group (0.22 vs. 0.21). Usual care remains the least costly option, followed by EULT and robot-assisted
training. The calculated ICER compares usual care with EULT. The resulting ICER is £68,000, compared
with £74,100 ICER in the base-case analysis. The probability of EULT being cost-effective was never
> 40% over the range of WTP values presented.
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FIGURE 21 Cost-effectiveness results: time since stroke (< 3 months post stroke) (n = 133).
TABLE 87 Total cost (£) per participant (3–12 months post stroke)
Robot-assisted training (n= 105) EULT (n= 117) Usual care (n= 72)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
5790 (4198) 3975 (2925–7103) 5084 (7528) 2463 (1556–4680) 4943 (5937) 2692 (833–6635)
TABLE 88 Total QALYs per participant (3–12 months post stroke)
Robot-assisted training (n= 104) EULT (n= 117) Usual care (n= 106)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
0.20 (0.12) 0.22 (0.12–0.30) 0.23 (0.09) 0.24 (0.16–0.29) 0.21 (0.11) 0.23 (0.14–0.30)
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TABLE 89 Cost-effectiveness results: time since stroke (3–12 months post stroke) (n = 285)
Randomisation
group Cost (£) (98.33% CI)
Incremental cost (£)
(98.33% CI)a QALYs (98.33% CI)
Incremental QALYs
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 69) 4943 (3228 to 6658) – 0.21 (0.19 to 0.24) – 0.64 0.61 0.59 0.57 0.52
EULT (n= 115) 5084 (3393 to 6774) 397 (–1816 to 2609) 0.23 (0.20 to 0.25) 0.005 (–0.01 to 0.03) 79,400 0.33 0.36 0.37 0.39 0.43
Robot-assisted
training (n= 101)
5790 (4793 to 6786) – 0.20 (0.18 to 0.23) Dominated by usual
care and EULT
0.03 0.03 0.04 0.04 0.05
a Estimated based on adjusted analysis (n = sureg n).
A
P
P
E
N
D
IX
8
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
2
2
4
0
P
ro
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
0.00
0.20
0.40
0.60
0.80
1.00
Usual care
EULT
Robot-assisted
training
10,000 20,000 30,000
Ceiling ratio (£)
40,000 50,000
FIGURE 22 Cost-effectiveness acceptability curve: time since stroke (3–12 months post stroke).
TABLE 90 Total cost (£) per participant (> 12 months post stroke)
Robot-assisted training (n= 95) EULT (n= 96) Usual care (n= 69)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
4882 (3385) 3676 (3005–5377) 3961 (4735) 2136 (1529–3960) 2823 (5160) 1007 (231–2579)
TABLE 91 Total QALYs per participant (> 12 months post stroke)
Robot-assisted training (n= 95) EULT (n= 96) Usual care (n= 90)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
0.22 (0.13) 0.24 (0.11–0.30) 0.23 (0.11) 0.23 (0.15–0.31) 0.21 (0.12) 0.21 (0.13–0.31)
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TABLE 92 Cost-effectiveness results: time since stroke (> 12 months post stroke) (n= 254)
Randomisation
group Cost (£) (98.33% CI)
Incremental cost (£)
(98.33% CI)b QALYs (98.33% CI)
Incremental QALYs
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 67) 2823 (1299 to 4348) – 0.21 (0.18 to 0.24) – 0.89 0.87 0.84 0.80 0.72
EULT (n= 94) 3961 (2783 to 5138) 883 (–677 to 2444) 0.23 (0.20 to 0.25) 0.007 (–0.01 to 0.03) 126,143 0.11 0.12 0.15 0.19 0.24
Robot-assisted
training (n= 93)
4822 (4036 to 5728) – 0.22 (0.18 to 0.25) Dominated by EULT 0.00 0.00 0.01 0.01 0.04
a Estimated based on adjusted analysis (n = sureg n).
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FIGURE 23 Cost-effectiveness acceptability curve: time since stroke (> 12 months post stroke).
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TABLE 93 Per-protocol cost-effectiveness analysis for the comparison of usual care, EULT and robot-assisted training, based on the within-trial analysis (n = 672)
Randomisation
group
Unadjusted analysis,
cost (£) (98.33% CI)
Adjusted analysis,
incremental cost (£)
(98.33% CI)a
Unadjusted
analysis, QALYs
(98.33% CI)
Adjusted analysis,
incremental QALYs
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 171) 3785 (2801 to 4770) – 0.21 (0.19 to 0.23) – 0.92 0.88 0.83 0.75 0.61
EULT (n= 227) 4551 (3596 to 5501) 816 (–421 to 2054) 0.23 (0.21 to 0.25) 0.012 (–0.004 to 0.028) 68,000 0.08 0.12 0.17 0.25 0.39
Robot-assisted
training (n= 221)
5595 (4929 to 6261) – 0.22 (0.20 to 0.24) Dominated by EULT 0.00 0.00 0.00 0.00 0.00
a Estimated based on adjusted analysis (n = sureg n).
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Model results
TABLE 94 Total costs (£) per participant (model): extrapolation of trial data to 12 months
Robot-assisted training (n= 257) EULT (n= 259) Usual care (n= 178)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
7538 (7901) 4245 (3048 to 8162) 6892 (11,644) 2951 (1738 to 6254) 6916 (10,568) 2260 (835 to 7284)
TABLE 95 Total QALYs per participant (model): extrapolation of trial data to 12 months
Robot-assisted training (n= 254) EULT (n= 259) Usual care (n= 254)
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
0.44 (0.25) 0.47 (0.28–0.63) 0.48 (0.23) 0.53 (0.35–0.63) 0.45 (0.22) 0.47 (0.31–0.59)
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TABLE 96 Results from modelled cost–utility analysis for robot-assisted training, EULT and usual care
Randomisation
group Cost (£) (98.33% CI)
Incremental cost (£)
(98.33% CI)a QALYs (98.33% CI)
Incremental QALYs
(98.33% CI)a ICER (£)
Probability of each therapy being considered
cost-effective at different threshold values
for society’s WTP
£0 £10,000 £20,000 £30,000 £50,000
Usual care (n= 67) 6916 (5003 to 8830) – 0.45 (0.41 to 0.48) – 0.48 0.42 0.35 0.29 0.23
EULT (n= 94) 6892 (5149 to 8635) 128 (–2460 to 2204) 0.48 (0.44 to 0.51) 0.021 (–0.06 to 0.20) 6095 0.40 0.48 0.55 0.62 0.69
Robot-assisted
training (n= 93)
7538 (6350 to 8725) – 0.44 (0.40 to 0.48) Dominated by EULT
and usual care
0.12 0.10 0.10 0.09 0.08
a Estimated based on adjusted analysis (n = sureg n).
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FIGURE 24 Cost-effectiveness results: model.
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